Contents

Original Papers

Effects of a Web-based Weight Management Education Program on Various Factors for Overweight and Obese Women: Randomized Controlled Trial (e42402)
Yunmin Han, Hoyong Sung, Geonhui Kim, Yeun Ryu, Jiyeon Yoon, Yeon Kim. 3

Cloud-Based Machine Learning Platform to Predict Clinical Outcomes at Home for Patients With Cardiovascular Conditions Discharged From Hospital: Clinical Trial (e45130)
Phillip Yang, Alokkumar Jha, William Xu, Zitao Song, Patrick Jamp, Jeffrey Teuteberg. 18

Formative Perceptions of a Digital Pill System to Measure Adherence to Heart Failure Pharmacotherapy: Mixed Methods Study (e48971)
Peter Chai, Jenson Kaithamattam, Michelle Chung, Jeremiah Tom, Georgia Goodman, Mohammad Hasidianda, Tony Barnes, Muthiah Vaduganathan, Benjamin Scirica, Jeffrey Schnipper. 32

Association of Arterial Stiffness With Mid- to Long-Term Home Blood Pressure Variability in the Electronic Framingham Heart Study: Cohort Study (e54801)
Xuzhi Wang, Yuankei Zhang, Chathurangi Pathiravasan, Nene Ukonu, Jian Rong, Emelia Benjamin, David McManus, Martin Larson, Ramachandran Vasan, Naomi Hamburg, Joanne Murabito, Chunyu Liu, Gary Mitchell. 45

Accurate Modeling of Ejection Fraction and Stroke Volume With Mobile Phone Auscultation: Prospective Case-Control Study (e57111)
Martin Huecker, Craig Schutzman, Joshua French, Karim El-Kersh, Shahab Ghaifghazi, Ravi Desai, Daniel Frick, Jarred Thomas. 57

Cardiac Rehabilitation During the COVID-19 Pandemic and the Potential for Digital Technology to Support Physical Activity Maintenance: Qualitative Study (e54823)
Linda Park, Serena Chi, Susan Pitsenbarger, Julie Johnson, Amit Shah, Abdelaziz Elaggar, Julia von Oppenfeld, Evan Cho, Arash Harzand, Mary Whooley. 68

Feasibility of Using Text Messaging to Identify and Assist Patients With Hypertension With Health-Related Social Needs: Cross-Sectional Study (e54530)
Aryn Kormanis, Selina Quinones, Corey Obermiller, Nancy Denizard-Thompson, Deepak Palakshappa. 91

Comparing the Efficacy of Targeted and Blast Portal Messaging in Message Opening Rate and Anticoagulation Initiation in Patients With Atrial Fibrillation in the Preventing Preventable Strokes Study II: Prospective Cohort Study (e49590)
Alok Kapoor, Parth Patel, Soumya Chennupati, Daniel Mbusa, Hammed Sadiq, Sanjeev Rampam, Robert Leung, Megan Miller, Kevin Vargas, Patrick Fry, Mary Lowe, Christina Catalano, Charles Harrison, John Catanzaro, Sybil Crawford, Anne Smith. 99
Physical Activity, Heart Rate Variability, and Ventricular Arrhythmia During the COVID-19 Lockdown: Retrospective Cohort Study (e51399)  
Sikander Texiwala, Russell de Souza, Suzette Turner, Sheldon Singh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111

User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study (e52576)  
Sigridur Björnsdottir, Hildigunnur Ulfasdottir, Elias Gudmundsson, Kárlrun Sveinsdottir, Ari Isberg, Bartosz Dobies, Gudlaug Akerlie Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Björnsdottir, Sigurdr Sigurdsson, Saemundur Oddsson, Vilmundur Gudnason. . . . 115

Cognitive Behavioral Therapy for Symptom Preoccupation Among Patients With Premature Ventricular Contractions: Nonrandomized Pretest-Posttest Study (e53815)  
Björn Liliequist, Josefin Särnholm, Helga Skuladóttir, Eva Ólafsdóttir, Brjánn Ljóttsson, Frieder Braunschweig. . . . . . . . . . . . . . . . . . . . . . . . . . . . 130

Factors That Influence Patient Satisfaction With the Service Quality of Home-Based Teleconsultation During the COVID-19 Pandemic: Cross-Sectional Survey Study (e51439)  
Guangxia Meng, Carrie McAiney, Ian McKillop, Christopher Perlman, Shu-Feng Tsao, Helen Chen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145

A Multidisciplinary Assessment of ChatGPT’s Knowledge of Amyloidosis: Observational Study (e53421)  
Ryan King, Jamil Samaan, Yee Yeo, Yuxin Peng, David Kunkel, Ali Habib, Roxana Ghashghaiei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162

Use of Machine Learning for Early Detection of Maternal Cardiovascular Conditions: Retrospective Study Using Electronic Health Record Data (e53091)  
Nawar Shara, Roxanne Mirabal-Beltran, Bethany Talmadge, Noor Falah, Maryam Ahmad, Ramon Dempers, Samantha Crovatt, Steven Eisenberg, Kelley Anderson. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170

The Effect of an AI-Based, Autonomous, Digital Health Intervention Using Precise Lifestyle Guidance on Blood Pressure in Adults With Hypertension: Single-Arm Nonrandomized Trial (e51916)  
Jared Leitner, Po-Han Chiang, Parag Agnihotri, Sujit Dey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179

Review

Persuasive Systems Design Trends in Coronary Heart Disease Management: Scoping Review of Randomized Controlled Trials (e49515)  
Eunice Agyei, Akon Ekpezu, Harri Oinas-Kukkonen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78

JMIR Cardio 2024 | vol. 8 | p.2
Effects of a Web-based Weight Management Education Program on Various Factors for Overweight and Obese Women: Randomized Controlled Trial

Yunmin Han1, MSc; Hoyong Sung2, PhD; Geonhui Kim3, PhD; Yeun Ryu1, MSc; Jiyeon Yoon4, MSc; Yeon Soo Kim1, MD, PhD

1Department of Physical Education, Seoul National University, Seoul, Republic of Korea
2Department of Military Kinesiology, Korea Military Academy, Seoul, Republic of Korea
3Department of Aviation Sports, Korea Air Force Academy, Cheongju, Republic of Korea
4Department of Kinesiology, Iowa State University, Ames, IA, United States

Corresponding Author:
Yeon Soo Kim, MD, PhD
Department of Physical Education
Seoul National University
Seoul, Gawnak Gu, Gawankro 1
71-1, 408
Seoul, 08826
Republic of Korea
Phone: 82 2 880 7894
Email: kys0101@snu.ac.kr

Abstract

Background: Mediated diet and exercise methods yield effective short-term weight loss but are costly and hard to manage. However, web-based programs can serve many participants, offering ease of access and cost-efficiency.

Objective: This study aimed to compare the effectiveness of a web-based weight management program through web-based education alone (MINE) or combined with tailored video feedback (MINE Plus) with a control (CO) group.

Methods: This intervention included 60 Korean women with overweight and obesity (BMI ≥ 23 kg/m²) aged 19 years to 39 years old. We randomly allocated 60 participants to each of 3 groups: (1) MINE group (web-based education video and self-monitoring app), (2) MINE Plus group (web-based education video, self-monitoring app, and 1:1 tailored video feedback), and (3) CO group (only self-monitoring app). Web-based education included nutrition, physical activity, psychological factors, medical knowledge for weight loss, goal setting, and cognitive and behavioral strategies. Tailored feedback aimed to motivate and provide solutions via weekly 10-minute real-time video sessions. The intervention lasted 6 weeks, followed by a 6-week observation period to assess the education's lasting effects, with evaluations at baseline, 6 weeks, and 12 weeks. A generalized linear mixed model was used to evaluate time and group interactions.

Results: In the intention-to-treat analysis including all 60 participants, there were significant differences in weight change at 6 weeks in the MINE and MINE Plus groups, with mean weight changes of –0.74 (SD 1.96) kg (P=.03) and –1.87 (SD 1.8) kg (P<.001), respectively, while no significant change was observed in the CO group, who had a mean weight increase of 0.03 (SD 1.68) kg (P=.91). After 12 weeks, changes in body weight were –1.65 (SD 2.64) kg in the MINE group, –1.59 (SD 2.79) kg in the MINE Plus group, and 0.43 (SD 1.42) kg in the CO group. There was a significant difference between the MINE and MINE Plus groups (P<.001). Significant group x time effects were found for body weight in the MINE and CO groups (P<.001) and in the MINE Plus and CO groups (P<.001), comparing baseline and 12 weeks. Regarding physical activity and psychological factors, only body shape satisfaction and health self-efficacy were associated with improvements in the MINE and MINE Plus groups (P<.001).

Conclusions: This study found that the group receiving education and tailored feedback showed significant weight loss and improvements in several psychological factors, though there were differences in the sustainability of the effects.

Trial Registration: Korea Disease Control and Prevention Agency (KDCA) KCT0007780: https://cris.nih.go.kr/cris/search/detailSearch.do/22861
Introduction

Obesity is linked to a wide range of diseases and increases the risk of morbidity and mortality [1]. In South Korea, there has been a steady yearly increase in the obesity trend, from 29.7% in 2009 to 36.3% in 2019 [2]. The social and economic burdens of obesity on health care systems worldwide are significant, with costs associated with obesity-related diseases continuing to rise [3]. Addressing obesity effectively not only improves individual health outcomes but also reduces these broader economic impacts [4]. As a result, this trend has led to a growing medical burden, which has become a significant social issue [5]. It has become an ongoing public health concern due to its increasing prevalence each year [6]. Furthermore, it is associated with a high risk of metabolic syndrome and chronic diseases such as type 2 diabetes, high blood pressure, and cardiovascular disease [7,8]. Studies have shown that people with obesity have a lower quality of life than those who do not [9], causing mental health problems such as an increased risk of depression [10]. Therefore, maintaining a healthy weight is essential to prevent physical and psychological health problems.

Treatments for obesity encompass various strategies, including psychological management. Research has shown that behavior modification programs targeting weight loss not only lead to significant weight reduction but also a decrease in depression [11]. Furthermore, studies focusing on the psychological aspects of weight loss, such as depression, anxiety, and quality of life, reveal that women with overweight or obesity are more likely to view their body image pessimistically than men [12,13]. Addressing these psychological challenges through obesity education and management programs grounded in social cognitive theory has been proven effective [14].

Over the years, various weight loss programs, including behavioral therapies, have been carried out to address obesity [15,16]. Exercise and nutrition are usually addressed by experts face to face in most conventional weight loss studies. Recently, web-based research has become increasingly popular due to its ability to save time, costs, and human resources compared with previous face-to-face research. However, these studies have several limitations, such as participants needing more motivation, data collection problems, and low attrition rates [17]. The sustainability of health behaviors postintervention is critical for long-term weight management success. Exploring strategies to maintain and support these behaviors beyond the intervention period is essential, underscoring the importance of follow-up and continued engagement [18]. Moreover, digital transformation in the exercise and medical sectors has become increasingly inevitable due to advancements in artificial intelligence and digital health care. The digital era has accelerated the growth of the online home training and telemedicine market [19]. Therefore, more studies are needed to increase the sample size, include various target groups, and confirm continuous effects to overcome the limitations.

According to a meta-analysis of behavioral change programs, study duration has varied from 2 weeks to 78 weeks (mean 26 weeks). However, given that only 5 of the 35 digital-based studies included a follow-up period, the number of studies with such periods was very limited [20]. Furthermore, studies that did not include goal setting and feedback showed low research quality. Therefore, to emphasize the effectiveness of behavioral change programs, high-quality research with feedback and goal setting is needed [21].

The primary aim of this study was to compare the weight loss effects of web-based education and feedback among 3 groups (2 interventions and 1 control) over a given period and to determine whether participants could implement what they learned and achieve weight loss. The second aim was to compare whether the effects of physical activity and psychological factors persisted in these groups during the observation period.

Methods

Recruitment and Participants

Participants in this study were recruited from Seoul National University students and staff members through advertisements (eg, email, flyers, and social media). The advertisements included information on the purpose of the study, data collection methods, and benefits offered to participants. According to the Korean Society for the Study of Obesity, a BMI of 23 kg/m² to 24.9 kg/m² is considered overweight, a BMI of 25 kg/m² to 29.9 kg/m² is considered first-degree obesity, a BMI of 30 kg/m² to 34.9 kg/m² is considered second-degree obesity, and a BMI ≥35 kg/m² is defined as severe obesity [22]. Eligible participants were young women aged 19 years to 39 years, with a BMI ≥23 kg/m² according to Asian standards, who were able to listen to and write Korean, and who could use the Internet and smartphone devices.

Exclusion criteria were a loss of more than 10% of body weight in the past 6 months, previous obesity surgery, and pregnancy. People diagnosed with severe mental illness or cardiovascular metabolism or who were receiving medication that could affect weight loss were also excluded. All participants submitted their informed consent before enrollment.

Interventions

The web-based program carried out in this study is referred to as “MINE,” which is a combination of “Mind,” “Medicine,” “Nutrition,” and “Exercise.” Participants received necessary education on weight loss in all 4 of these fields (Figure 1).
This program does not force physical activity on the participants nor interfere with their diet. Instead, through education and feedback as the intervention, it aims to change behavior to achieve weight loss by empowering the participants to make better choices on their own. The group that received only web-based education was called “MINE,” the group that received web-based education and tailored feedback was called “MINE Plus,” and the waiting list group was called “Control” (Figure 2).

The sample size was calculated using GPower version 3.1. The significance level was .05, the effect size was 0.25, and the power was 0.8. The minimum number of participants was 42, the dropout rate was set at approximately 20% based on previous studies [23], and the number of participants was set at 60 and randomly assigned to 3 groups. We asked the participants to send their self-monitoring records once a week. However, there was no compulsion to send data even if the data were insufficient. The behavior change strategy was composed by incorporating the basic concepts of personalized cognitive behavioral therapy for obesity that were previously researched, as well as goal setting, social support, action planning, coping planning, and self-monitoring, which are frequently used in eHealth interventions. This information was integrated and utilized in conjunction with the education content and feedback [24,25]. The education content was divided into exercise, nutrition, psychology, and medical areas to establish knowledge and behavioral change strategies necessary for weight loss. Educational materials were produced by referring to previous scientifically proven studies and were verified by qualified experts in the field. The web-based education videos lasted 15 minutes to 20 minutes; details are shown in Table 1. In addition, these videos were delivered via video links and materials for each week through chat rooms organized by the groups.
Table 1. Educational content order and topics.

<table>
<thead>
<tr>
<th>Number</th>
<th>Educational sessions</th>
<th>Field</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Setting my diet</td>
<td>Nutrient</td>
</tr>
<tr>
<td>2</td>
<td>Setting my workout</td>
<td>Exercise</td>
</tr>
<tr>
<td>3</td>
<td>How to control my appetite</td>
<td>Psychology</td>
</tr>
<tr>
<td>4</td>
<td>Understanding fat burning system</td>
<td>Medicine</td>
</tr>
<tr>
<td>5</td>
<td>Healthy nutrients vs worst nutrients</td>
<td>Nutrient</td>
</tr>
<tr>
<td>6</td>
<td>Understanding the benefits of exercise</td>
<td>Exercise</td>
</tr>
<tr>
<td>7</td>
<td>Dealing with other people’s perceptions and getting rid of stress</td>
<td>Psychology</td>
</tr>
<tr>
<td>8</td>
<td>Understanding the digestive system</td>
<td>Medicine</td>
</tr>
<tr>
<td>9</td>
<td>Practical diet recipes</td>
<td>Nutrient</td>
</tr>
<tr>
<td>10</td>
<td>How to exercise at home or the workplace</td>
<td>Exercise</td>
</tr>
<tr>
<td>11</td>
<td>How to deal with eating out and appointments</td>
<td>Psychology</td>
</tr>
<tr>
<td>12</td>
<td>Understanding the endocrine system and metabolism related to weight control</td>
<td>Medicine</td>
</tr>
<tr>
<td>13</td>
<td>Making your own sustainable diet plan</td>
<td>Nutrient</td>
</tr>
<tr>
<td>14</td>
<td>Making your own sustainable exercise goals</td>
<td>Exercise</td>
</tr>
<tr>
<td>15</td>
<td>Establishing long-term weight management strategies based on social cognitive theory</td>
<td>Psychology</td>
</tr>
<tr>
<td>16</td>
<td>Developing a self-check list and a plan for improving health indicators</td>
<td>Medicine</td>
</tr>
</tbody>
</table>

The feedback was based on the protocol of the web-based weight loss program called “POWeR” developed by Dennison et al [26] and a social cognitive theory strategy for obesity treatment developed by Dalle Grave et al [24]. Before proceeding with the feedback, basic lifestyle and weight loss experience information was collected through an online survey. The survey included information such as usual mealtimes, meal volume, sleep, health information, weight loss history, difficulties with losing weight, and personal goals. The feedback schedule was then implemented by entering the ID at the desired time through the online form and entering the Zoom video conference at the indicated time. Coaching sessions were conducted once a week, lasting approximately 15 minutes to 20 minutes each. Both groups (MINE and MINE Plus) received weekly educational materials and alarm messages about watching and practicing educational videos through group chat rooms. After receiving education, it was considered that the education was completed by submitting quizzes related to the content. In addition, a smart electronic weighing scale was provided as a research incentive. Of the 2 groups who did not receive feedback during the observation period, the MINE group received feedback, and the control group received educational videos and feedback after the end of the follow-up period.

Outcomes

The study lasted for a total of 12 weeks, consisting of a 6-week intervention period followed by a 6-week follow-up period. Participants’ demographic data included age, marital status, and education level. The main outcome was to confirm the results related to body weight change at 6 weeks and 12 weeks after baseline. The secondary outcome was to confirm the level of physical activity, eating attitudes, satisfaction with body shape, and health self-efficacy.

The participants were examined in the laboratory after signing a consent form. Height, body weight, body composition, waist circumference, and blood pressure (BP) were measured. Height was measured using a BSM230 (Biospace), and weight and body fat were measured using an InBody 720 (Biospace). Participants were advised to avoid heavy meals, water, and intense physical activity for at least 2 hours before undergoing the InBody measurement to minimize potential measurement bias. Waist circumference was marked in centimeters using a tape measure from the middle of the lower rib to the upper iliac. For the BP measurement, an arm cuff for adults was placed around the left upper arm (Watch BP 03, Microlife AG). After measuring BP twice at rest, the average of the 2 values was calculated for the final BP index. We conducted 4 surveys after collecting the basic physical information. Physical activity was measured using the Global Physical Activity Questionnaire (GPAQ) and calculated as metabolic equivalents (METs) [27]. In addition, the Eating Attitudes Test-26 (EAT-26), developed by Garner and Garfinkel [28], was used to measure attitudes toward eating, while the Body Shape Questionnaire (BSQ), developed by Cooper et al [29], was used to measure satisfaction with body shape. In addition, the Self-Rated Abilities for Health Practices (SRAHP) scale developed by Becker et al [30] was used as a measure of health self-efficacy [30]. Validity and reliability were verified for all questionnaires translated into Korean [31-33].

The EAT score was obtained by subtracting 65 points from the total score. A tendency for eating problems is assumed if the final score is 18 or higher, while a severe eating problem is
considered to exist if the final score is 25 or higher [33]. The BSQ is a 32-point to 192-point scale, with higher scores indicating a greater sense of obesity and lower overall satisfaction with body shape [29,34]. The SRAHP is a 24-point to 96-point scale, with higher scores indicating a greater sense of self-efficacy regarding one's health [30,31]. After the measurements were completed, participants were randomly allocated to the groups through a lottery. Precautions for participation in the study were delivered orally.

The same methods and questionnaires were used for every measurement. In addition, a program satisfaction survey on web-based education programs was conducted, and tailored feedback was provided on the intermediate measurement after the intervention. The survey included satisfaction with the overall program, satisfaction with personal feedback, and recommendations for the program (see Multimedia Appendix 1); it was modified by referring to the satisfaction survey in the preliminary study developed by Yip et al [35].

Statistical Analysis

Intention-to-treat analysis was performed for all outcomes at 6 weeks and 12 weeks. To determine differences in the variables, we set the time (baseline, 6 weeks, 12 weeks) as the repeated factors for body weight, body composition, blood pressure, physical activity, mental health score, and physical health score.

The Shapiro-Wilk normality test for each group was performed. Only the MINE Plus group did not show a normal distribution ($P<.01$). Therefore, for variables that did not have a normal distribution, such as body weight, BMI, waist circumference, and physical activity, a generalized linear mixed model was used to fit log-transformed data [36]. A linear mixed model method was used for the remaining variables satisfying the normality test [37]. These methods set fixed and random effects, and the interaction effect of time and group on the outcome was confirmed as outcomes of the variables. All statistical analyses were conducted using R studio (version 4.0.3). The mean and SD were calculated using descriptive statistical analysis, and the significance level was set at $P<.05$.

Ethical Considerations

The study received approval from the international review board at Seoul National University, Seoul, South Korea (SNU IRB NO. 2109/002-007). All participants provided written consent to participate, with a clear process established for medical referral and reporting any potential harm arising from their participation. The research also emphasized privacy and confidentiality protection for human subjects by ensuring that all study data were either anonymous or de-identified, accompanied by a brief description of the protective measures in place. To safeguard the privacy and confidentiality of participants, additional details on these protections were provided. As compensation for their involvement, participants received a smart scale valued at approximately US $20.

Results

Participant Characteristics

Of the 88 participants, 28 were excluded because their BMI did not exceed 23 kg/m$^2$ or they did not meet the inclusion criteria (Figure 3). A total of 60 people were assigned to the 3 groups, 20 per group, through random allocation; for their characteristics, see Table 2. All 60 participants were analyzed using the intention-to-treat method. In addition, missing values for unmeasured participants and participants who dropped out were analyzed as the last measured data through the last observation carried forward method [38].
Figure 3. Flow diagram of participants through the trial.

- Assessed for eligibility (n=88)
  - Excluded (n=28) Did not meet inclusion criteria
  - Randomized (n=60)
    - Wait list control (n=20)
      - 6 weeks
        - Lost to follow-up (n=1)
        - 1 COVID-19
      - 12 weeks
        - Lost to follow-up (n=1)
        - 1 fracture
        - 20 included in intention-to-treat analysis
    - MINE (only online education; n=20)
      - 6 weeks
        - Lost to follow-up (n=3)
        - 2 schedule
        - 1 panic disorder
      - 12 weeks
        - Lost to follow-up (n=0)
        - 20 included in intention-to-treat analysis
    - MINE Plus (online education + feedback; n=20)
      - 6 weeks
        - Lost to follow-up (n=3)
        - 1 lost contact
        - 1 pregnancy
        - 1 major depression
      - 12 weeks
        - Lost to follow-up (n=0)
        - 20 included in intention-to-treat analysis
Table 2. Baseline characteristics of participants (N=60).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MINE(^a) (n=20), mean (SD)</th>
<th>MINE Plus(^b) (n=20), mean (SD)</th>
<th>Control (n=20), mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29.7 (5.44)</td>
<td>28.2 (3.75)</td>
<td>30.3 (5.06)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>65.82 (7.23)</td>
<td>70.64 (13.07)</td>
<td>66.2 (7.08)</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>25.3 (2.09)</td>
<td>26.5 (4.11)</td>
<td>25.2 (2.00)</td>
</tr>
<tr>
<td>Body fat percentage (%)</td>
<td>36.8 (4.59)</td>
<td>38.5 (5.98)</td>
<td>36.5 (4.68)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>84.0 (6.21)</td>
<td>86.9 (9.81)</td>
<td>84.6 (6.54)</td>
</tr>
</tbody>
</table>

### Blood pressure (mm Hg)

- **Systolic**
  - MINE\(^a\): 117 (10.63)
  - MINE Plus\(^b\): 114 (7.98)
  - Control: 117 (10.98)
- **Diastolic**
  - MINE\(^a\): 74 (8.03)
  - MINE Plus\(^b\): 72 (6.44)
  - Control: 76 (10.44)
- **Resting heart rate (bpm)**
  - MINE\(^a\): 78 (13.22)
  - MINE Plus\(^b\): 75 (10.31)
  - Control: 82 (11.29)
- **Physical activity (METs\(^c\)/week)**
  - MINE\(^a\): 1717 (1368)
  - MINE Plus\(^b\): 1246 (1226)
  - Control: 1853 (2153)
- **EAT-26\(^d\)**
  - MINE\(^a\): 6.79 (16.84)
  - MINE Plus\(^b\): 10.53 (12.64)
  - Control: 6.84 (17.89)
- **BSQ\(^e\)**
  - MINE\(^a\): 110.55 (32.96)
  - MINE Plus\(^b\): 116.63 (26.48)
  - Control: 118.79 (27.56)
- **SRAHP\(^f\)**
  - MINE\(^a\): 70.88 (12.53)
  - MINE Plus\(^b\): 74.02 (11.74)
  - Control: 72.88 (10.66)

\(^a\)MINE: only online education.
\(^b\)MINE Plus: online education + tailored feedback.
\(^c\)MET: metabolic equivalent.
\(^d\)EAT-26: Eating Attitudes Test-26 (Korean version).
\(^e\)BSQ: Body Shape Questionnaire (Korean version).
\(^f\)SRAHP: Self-Rated Abilities of Health Practices (Korean version).

### Weight Loss

From baseline to week 6, the MINE group showed a significant mean weight reduction of –0.74 (SD 1.96) kg \((P=.03)\), the MINE Plus group showed a significant mean weight reduction of –1.87 (SD 1.8) kg \((P<.001)\), and the control group showed a mean weight increase of 0.03 (SD 1.68) kg \((P=.91)\;\text{Figure 4}\). From week 6 to week 12, the mean weight reduction was –0.91 (SD 2.2) kg \((P<.001)\) for the MINE group, while the mean increases in weight were 0.28 (SD 1.72) kg \((P=.24)\) for the MINE Plus group and 0.41 (SD 1.42) kg \((P=.23)\) for the control group. Comparing the baseline with week 12, the MINE group showed a total mean reduction of –1.65 (SD 2.64) kg \((P<.001)\), while the MINE Plus group showed a significant mean weight reduction of –1.59 (SD 2.79) kg \((P<.001)\). In contrast, the control group showed a mean weight increase of 0.43 (SD 1.42) kg \((P=.27)\). From baseline to Week 12, waist circumference significantly decreased by a mean –2.02 (SD 4.47) cm \((P<.001)\) in the MINE group and –2.2 (SD 3.58) cm \((P<.001)\) in the MINE Plus group, but the decrease of a mean –0.17 (SD 3.72) cm in the control group was not significant \((P=.82)\).

**Figure 4.** Mean changes in (A) body weight and (B) waist circumference at baseline, 6 weeks, and 12 weeks, with \(P\) values for differences from baseline at 6 weeks and 12 weeks. MINE: only online education; MINE Plus: online education + tailored feedback.
The interaction between time and group for weight change was not significant from baseline to week 12 after the intervention in the MINE and MINE Plus groups \((P=.30; \text{Figure 5})\). The MINE and control groups did not show any interaction effect until week 6 of the intervention \((P=.11)\), although there was a significant effect \((P<.001)\) compared with week 12 (see Multimedia Appendix 2). The MINE Plus and control groups showed a significant interaction effect when comparing baseline with week 6 and baseline with week 12 \((P<.001)\), but this was absent from week 6 to week 12 \((P=.98)\).

**Figure 5.** Comparison of (A) body weight and (B) waist circumference interaction effects between time and groups, with the \(P\) values for the differences between groups from baseline to 12 weeks. MINE: only online education; MINE Plus: online education + tailored feedback.

**Physical Activity Changes**
Physical activity was calculated as the percentage of participants meeting the minimum amount of physical activity recommended by the World Health Organization (600 METs/week) [39]. No significant changes in physical activity levels were observed in any group during the postmeasurement and follow-up periods (Table 3).
Table 3. Differences in weight, waist circumference (WC), physical activity, and psychological factors between groups (N=60).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MINE&lt;sup&gt;b&lt;/sup&gt; (n=20)</th>
<th>P value</th>
<th>MINE Plus&lt;sup&gt;b&lt;/sup&gt; (n=20)</th>
<th>P value</th>
<th>Control (n=20)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight at baseline (kg), mean (SD)</td>
<td>65.82 (7.23)</td>
<td>.91</td>
<td>70.64 (13.07)</td>
<td>.001</td>
<td>66.2 (7.08)</td>
<td>.01</td>
</tr>
<tr>
<td>Weight changes (kg), mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>−0.74 (1.96)</td>
<td>.03</td>
<td>−1.87 (1.8)</td>
<td>.001</td>
<td>0.03 (1.68)</td>
<td>.91</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>−0.91 (2.2)</td>
<td>&lt;.001</td>
<td>0.28 (1.72)</td>
<td>.24</td>
<td>0.41 (1.16)</td>
<td>.23</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>−1.65 (2.64)</td>
<td>&lt;.001</td>
<td>−1.59 (2.79)</td>
<td>&lt;.001</td>
<td>0.43 (1.42)</td>
<td>.27</td>
</tr>
<tr>
<td>WC at baseline (cm), mean (SD)</td>
<td>84.0 (6.21)</td>
<td></td>
<td>86.9 (9.81)</td>
<td>.24</td>
<td>84.6 (6.54)</td>
<td>.01</td>
</tr>
<tr>
<td>WC changes (cm), mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>−1.39 (3.57)</td>
<td>.02</td>
<td>−1.95 (2.83)</td>
<td>&lt;.001</td>
<td>−0.09 (2.52)</td>
<td>.93</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>−0.63 (3.31)</td>
<td>.29</td>
<td>−0.25 (2.2)</td>
<td>.71</td>
<td>−0.08 (3.13)</td>
<td>.89</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>−2.02 (4.47)</td>
<td>&lt;.001</td>
<td>−2.2 (3.58)</td>
<td>&lt;.001</td>
<td>−0.17 (3.72)</td>
<td>.82</td>
</tr>
<tr>
<td>Physical activity at baseline (≥600 METs&lt;sup&gt;d&lt;/sup&gt;)&lt;sup&gt;e&lt;/sup&gt;, n (%)</td>
<td>16 (80)</td>
<td></td>
<td>13 (65)</td>
<td>.72</td>
<td>14 (70)</td>
<td>.01</td>
</tr>
<tr>
<td>Physical activity changes (%)&lt;sup&gt;f&lt;/sup&gt;, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>−15 (1.83)</td>
<td>.13</td>
<td>0 (2.29)</td>
<td>.60</td>
<td>−5 (1.97)</td>
<td>.60</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>10 (2.24)</td>
<td>.31</td>
<td>0 (2.29)</td>
<td>.77</td>
<td>0 (2.29)</td>
<td>.97</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>5 (1.97)</td>
<td>.81</td>
<td>0 (1.62)</td>
<td>.62</td>
<td>−5 (1.97)</td>
<td>.58</td>
</tr>
<tr>
<td>EAT-26&lt;sup&gt;f,g&lt;/sup&gt; at baseline</td>
<td>6.79 (16.84)</td>
<td></td>
<td>10.53 (12.64)</td>
<td>.22</td>
<td>6.84 (17.89)</td>
<td>.97</td>
</tr>
<tr>
<td>EAT-26 changes, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>4.95 (10.44)</td>
<td>.07</td>
<td>3.3 (10.95)</td>
<td>.22</td>
<td>−0.1 (9.64)</td>
<td>.97</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>−0.3 (15.3)</td>
<td>.91</td>
<td>1.25 (8.88)</td>
<td>.64</td>
<td>0.5 (8.26)</td>
<td>.85</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>4.65 (18.73)</td>
<td>.09</td>
<td>4.55 (12.65)</td>
<td>.09</td>
<td>0.4 (9.68)</td>
<td>.88</td>
</tr>
<tr>
<td>BSQ&lt;sup&gt;h,i&lt;/sup&gt; at baseline, mean (SD)</td>
<td>110.55 (32.96)</td>
<td></td>
<td>116.63 (26.48)</td>
<td>.22</td>
<td>118.79 (27.56)</td>
<td>.97</td>
</tr>
<tr>
<td>BSQ changes, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>−10.45 (29.03)</td>
<td>.02</td>
<td>−10.35 (20.07)</td>
<td>.03</td>
<td>0.7 (18.43)</td>
<td>.88</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>−2.25 (13.64)</td>
<td>.62</td>
<td>0.3 (13.29)</td>
<td>.62</td>
<td>2.25 (13.88)</td>
<td>.62</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>−12.7 (33.67)</td>
<td>.006</td>
<td>−10.05 (16.99)</td>
<td>.03</td>
<td>2.95 (13.9)</td>
<td>.52</td>
</tr>
<tr>
<td>SRAHP&lt;sup&gt;j,k&lt;/sup&gt; at baseline, mean (SD)</td>
<td>70.88 (12.53)</td>
<td></td>
<td>74.02 (11.74)</td>
<td>.09</td>
<td>72.88 (10.66)</td>
<td>.97</td>
</tr>
<tr>
<td>SRAHP changes, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline to postintervention</td>
<td>5.65 (9.83)</td>
<td>.003</td>
<td>7.2 (8.68)</td>
<td>&lt;.001</td>
<td>1.8 (6.83)</td>
<td>.34</td>
</tr>
<tr>
<td>Postintervention to follow-up</td>
<td>1.1 (9.9)</td>
<td>.56</td>
<td>0.25 (6.54)</td>
<td>.89</td>
<td>2.05 (5.95)</td>
<td>.28</td>
</tr>
<tr>
<td>Baseline to follow-up</td>
<td>6.75 (12.34)</td>
<td>&lt;.001</td>
<td>7.45 (7.49)</td>
<td>&lt;.001</td>
<td>3.85 (5.63)</td>
<td>.04</td>
</tr>
</tbody>
</table>

<sup>a</sup>MINE: only online education.
<sup>b</sup>MINE Plus: online education + feedback.
<sup>c</sup>Not applicable.
<sup>d</sup>MET: metabolic equivalent.
<sup>e</sup>The minimum World Health Organization recommended amount of 600 METs minutes per week.
<sup>f</sup>EAT: Eating Attitudes Test.
<sup>g</sup>Higher scores indicate more negative eating attitudes.
<sup>h</sup>BSQ: Body Shape Questionaire.
<sup>i</sup>Higher scores indicate lower satisfaction.
<sup>j</sup>SRAHP: Self-Rated Abilities of Health Practices.
<sup>k</sup>Higher scores indicate better self-efficacy.
Psychological Factor Changes

After 12 weeks, the EAT-26 scores increased by 4.65 (SD 18.73; P=.09) for the MINE group, 4.55 (SD 12.65; P=.09) for the MINE Plus group, and 0.4 (SD 9.68; P=.88) for the control group. After 12 weeks, the BSQ scores decreased by –12.7 (SD 33.67; P=.006) for the MINE group and –10.05 (SD 16.99; P=.03) for the MINE Plus group but increased by 3.85 (SD 5.63; P=.04) for the control group, which means the MINE and MINE Plus groups experienced greater satisfaction with their body shape. By 6 weeks, the BSQ scores for the MINE and MINE Plus groups had significantly decreased by –10.45 (SD 29.03; P=.02) and –10.35 (SD 20.07; P=.03), respectively. However, there was no significant decrease from 6 weeks to 12 weeks, the period during which there was no intervention. The SRAHP scores increased by 6.75 (SD 12.34; P<.001) for the MINE Plus group and 7.45 (SD 7.49; P<.001) for the control group after 12 weeks. After the intervention, the SRAHP scores for both the MINE and MINE Plus groups increased significantly, by 5.65 (SD 9.83; P=.003) and 7.2 (SD 8.68; P<.001), respectively, but did not increase significantly until 12 weeks after the intervention.

Discussion

Principal Findings

This study confirmed changes in weight loss and psychological factors for women with overweight and obesity aged in their 20s and 30s through a web-based, weight-related, behavioral change program. Both the MINE group, who received only web-based education, and the MINE Plus group, who received web-based education and feedback, showed significant weight loss. Regarding psychological factors, significant positive changes were observed only in body shape satisfaction and health management self-efficacy.

Of the 60 participants in this study, 54 completed the postintervention and follow-up measurements, resulting in a dropout rate of ~10%. Mobile- or web-based, health-related interventions are usually reported to have high dropout rates [25]. According to a systematic literature review by Kelders et al [40], the median duration of web-based health interventions was 10 weeks, and the mean adherence rate for web-based trial participants was 55%. However, the proportions of participants who received the education and submitted quizzes were 68% in the MINE group and 84% in the MINE Plus group (Multimedia Appendix 3). This showed higher compliance than that observed in previous studies, due to continuous motivation and the accessibility of educational content. Therefore, this study shows that even web-based experimental studies can have low dropout rates.

Comparison With Previous Work

Compared with previous studies, a study by Baer et al [23] showed an average weight loss of –3.1 (95% CI –3.7 to –2.5) kg over 12 months in an integrated intervention group with online programs and health managers. In addition, studies based on other online platforms and coaching programs showed an average weight loss of –1.57 (95% CI –1.92 to –1.22) kg over 24 weeks [15]. In this study, the average 12-week loss in the intervention groups was –1.65 (SD 2.64) kg in the MINE group and –1.59 (SD 2.79) kg in the MINE Plus group, which was a significant loss compared with the weight difference observed in previous studies.

In our study, weight loss and lifestyle changes were documented through app use records, feedback, and satisfaction surveys; however, objective indicators could not be confirmed. A lack of power, insufficient time to produce results, and insufficient sensitivity of measurement tools to detect minor differences could be reasons for no differences in physical activity or cardiovascular outcomes [21]. To increase physical activity, it is considered essential to identify individual vulnerabilities through “just-in-time” feedback and to set goals suitable for participants, taking into consideration the available time and circumstances [41]. It also requires specific guidance and clarification on when, where, and how to act [42]. Considering this situation, interventions and elements that can increase physical activity and make it habitual should be further developed.

There was no significant difference in weight reduction in the MINE Plus group in the absence of the intervention. The group who received feedback showed a higher rate of weight loss until the intervention period, but it is likely that independence decreased after the intervention ended due to the absence of coaching. Participants may experience various problems such as anxiety and decreased self-confidence if they receive feedback for a certain period and then abruptly discontinue it for a short period [43,44]. In contrast, it seemed that the MINE group showed a continuous form of weight loss by managing goal setting based on the educational content. Therefore, it is necessary to establish a more effective feedback methodology when mediating feedback and proceed to provide feedback until the participants are independent and weight management is achieved through long-term feedback. However, considering that the waist circumference of the MINE Plus group decreased more than that of the MINE group over the entire period, it is inferred that more effective health management was conducted.

A previous study confirmed the positive effect of body shape satisfaction using Internet-based mindfulness interventions [45]. In this study also, there was a significant improvement in body shape satisfaction as the education program provided strategies to the participants on how to cope with social stigma or stress, similar to mindfulness strategies. Finally, it seems that continuous motivation and encouragement were helpful through tailored feedback.

In a study confirming the relationship between weight loss and health self-efficacy in young adults, self-efficacy increased through weight management education and showed effective results in promoting weight loss [46]. In this study, participants managed their weight with methods that could set and achieve goals through education. It showed that providing goals through feedback, complimenting them, and encouraging them were helpful. However, no other positive results could be confirmed after week 6. Previous research has indicated that the effects of tailored feedback are controversial, with effectiveness diminishing over extended periods of observation, showing no significant difference from groups who did not receive...
intervention [47,48]. The provision of goals is significantly correlated with self-efficacy, which leads to the creation of sustainable self-set goals [49]. However, it appears that, after the intervention and education period, the participants' self-efficacy and self-set goal development did not expand without being given goals. Therefore, there is a need for interventions in which participants can continue to be motivated and achieve goals.

Psychological factors for weight loss identified for young women in this study were to treat obesity when young and relieve psychological pressure through healthy weight loss. Obesity treatment should proceed in a healthy way that prevents access to compulsive and distorted knowledge and can be self-applied [50]. Therefore, the program was organized in a way to empower the participants to improve their habits and perceptions through education rather than by forced intervention. This study progressed with education and feedback based on various theories, including the social cognitive theory. Although it is difficult to determine which theories and methods worked best in the program, the approach of integrated theory will be more critical in health education [21]. Furthermore, future research should investigate and compare the effectiveness of various delivery methods in online programs to identify which theories and strategies produce the most substantial outcomes for participants or patients [51]. Furthermore, collective and institutional efforts should be accompanied at the national level to improve long-term weight management and dietary and activity environments [52].

Strengths and Limitations

This study has several strengths. First, the program was constructed by approaching the treatment of obesity in a multifactorial manner rather than by considering just one factor. Tools such as nutrition, physical activity, psychological and medical knowledge education, and tailored feedback were used to improve lifestyle, and the program was designed so that participants could improve themselves. Second, this approach can reduce time, expenses, and human resources. Since this program is only conducted online, participants can proceed with web-based education and feedback according to their preferred place and time. Furthermore, educational videos can be reused later. Feedback also allows participants and moderators to participate at any time and place of their choice. As they turned on the camera and communicated in real time, the participants could see each other’s facial expressions, understand emotions, and build bonds. Third, existing behavioral change programs were used to supplement and construct obesity treatment strategy elements in the program. Various behavioral change factors, such as goal setting, self-monitoring, and self-control, which are essential and proven effective, were continuously added to the educational content and feedback to maximize effectiveness. However, there are several limitations to this study. First, there was no long-term follow-up of the participants. Obesity is an area that requires continuous management, and it is necessary to set a period for long-term follow-up. According to the meta-analysis by Beleigoli et al [17], web-based digital interventions have shown effectiveness in the short term but not in the long term. Therefore, for long-term management, it seems necessary to combine offline management with digital interventions. Second, the use of various objective indicators was insufficient. The indicators for physical activity and psychological factors in this study were in the form of questionnaires. Therefore, more objective data should be collected through the observation of physical activity using accelerometers or various blood and biomarker data. Third, the nutritional information collected through self-monitoring was not evaluated due to measurement bias. It appears that future research will require accurate collection and analysis of nutritional information. Fourth, only university undergraduates, graduate students, and faculty members participated in this study. From a demographic perspective, most of them were highly educated participants. Therefore, the data from this program cannot be generalized to all other young adult women in the real world. Last, there was no significant change in physical activity because of the spread of COVID-19 in South Korea during the experimental period.

Conclusions

This study demonstrated the efficacy of a web-based education program, with and without tailored feedback, in promoting weight loss and enhancing psychological well-being through self-managed diet and exercise modifications. The 2 groups who received the intervention experienced significant weight loss over time, yet the magnitude of weight reduction varied across periods. Although improvements were observed in various psychological factors, these psychological improvements did not persist in the absence of the intervention. This indicates a need to integrate social support, incentives, or motivation in future digital health interventions and underscores the importance of interdisciplinary research in this field.

Acknowledgments

We extend our gratitude to all participants who took part in the experiment. The authors attest that there was no use of generative artificial intelligence (AI) technology in the generation of text, figures, or other informational content of this manuscript.

Authors’ Contributions

YH designed the research, managed the investigation process, developed the methodology, and contributed to writing the manuscript. HS was responsible for analyzing the data. JY and GK were involved in data collection and participated in editing the manuscript. YR contributed to editing the manuscript. YSK provided supervision throughout the research process and contributed to reviewing the manuscript. All authors reviewed and approved the final version of the manuscript.
Conflicts of Interest
None declared.

Multimedia Appendix 1
Web-based education program and tailored feedback satisfaction.
[DOCX File, 29 KB - cardio_v8i1e42402_app1.docx ]

Multimedia Appendix 2
Supplementary table (Effects of interaction between time and groups).
[DOCX File, 44 KB - cardio_v8i1e42402_app2.docx ]

Multimedia Appendix 3
Quiz submission rate.
[DOC File, 33 KB - cardio_v8i1e42402_app3.doc ]

Multimedia Appendix 4
CONSORT-EHEALTH checklist.
[PDF File (Adobe PDF File), 1376 KB - cardio_v8i1e42402_app4.pdf ]

References

https://cardio.jmir.org/2024/1/e42402 JMIR Cardio 2024 | vol. 8 | e42402 | p.14 (page number not for citation purposes)


Abbreviations

BP: blood pressure
BSQ: Body Shape Questionnaire
EAT: Eating Attitudes Test
GPAQ: Global Physical Activity Questionnaire
MET: metabolic equivalent
SRAHP: Self-rated Abilities for Health Practices scale
Effects of a Web-based Weight Management Education Program on Various Factors for Overweight and Obese Women: Randomized Controlled Trial

Han Y, Sung H, Kim G, Ryu Y, Yoon J, Kim YS

JMIR Cardio 2024;8:e42402
URL: https://cardio.jmir.org/2024/1/e42402
doi:10.2196/42402
PMID:38635975
Cloud-Based Machine Learning Platform to Predict Clinical Outcomes at Home for Patients With Cardiovascular Conditions Discharged From Hospital: Clinical Trial

Phillip C Yang¹, MD; Alokkumar Jha¹, PhD; William Xu², BSc; Zitao Song³, MSc; Patrick Jamp⁴, BSc; Jeffrey J Teuteberg¹, MD

¹Stanford University School of Medicine, Palo Alto, CA, United States
²Emory University, Atlanta, GA, United States
³North Carolina State University, Raleigh, NC, United States
⁴Electrical Engineering, University of California, Los Angeles, Mountain View, CA, United States

Corresponding Author:
Phillip C Yang, MD
Stanford University School of Medicine
300 Pasteur Dr # H2157 Stanford
Palo Alto, CA, 94305-2200
United States
Phone: 1 6508048828
Email: phillip@stanford.edu

Abstract

Background: Hospitalizations account for almost one-third of the US $4.1 trillion health care cost in the United States. A substantial portion of these hospitalizations are attributed to readmissions, which led to the establishment of the Hospital Readmissions Reduction Program (HRRP) in 2012. The HRRP reduces payments to hospitals with excess readmissions. In 2018, >US $700 million was withheld; this is expected to exceed US $1 billion by 2022. More importantly, there is nothing more physically and emotionally taxing for readmitted patients and demoralizing for hospital physicians, nurses, and administrators. Given this high uncertainty of proper home recovery, intelligent monitoring is needed to predict the outcome of discharged patients to reduce readmissions. Physical activity (PA) is one of the major determinants for overall clinical outcomes in diabetes, hypertension, hyperlipidemia, heart failure, cancer, and mental health issues. These are the exact comorbidities that increase readmission rates, underlining the importance of PA in assessing the recovery of patients by quantitative measurement beyond the questionnaire and survey methods.

Objective: This study aims to develop a remote, low-cost, and cloud-based machine learning (ML) platform to enable the precision health monitoring of PA, which may fundamentally alter the delivery of home health care. To validate this technology, we conducted a clinical trial to test the ability of our platform to predict clinical outcomes in discharged patients.

Methods: Our platform consists of a wearable device, which includes an accelerometer and a Bluetooth sensor, and an iPhone connected to our cloud-based ML interface to analyze PA remotely and predict clinical outcomes. This system was deployed at a skilled nursing facility where we collected >17,000 person-day data points over 2 years, generating a solid training database. We used these data to train our extreme gradient boosting (XGBoost)--based ML environment to conduct a clinical trial, Activity Assessment of Patients Discharged from Hospital-I, to test the hypothesis that a comprehensive profile of PA would predict clinical outcome. We developed an advanced data-driven analytic platform that predicts the clinical outcome based on accurate measurements of PA. Artificial intelligence or an ML algorithm was used to analyze the data to predict short-term health outcome.

Results: We enrolled 52 patients discharged from Stanford Hospital. Our data demonstrated a robust predictive system to forecast health outcome in the enrolled patients based on their PA data. We achieved precise prediction of the patients’ clinical outcomes with a sensitivity of 87%, a specificity of 79%, and an accuracy of 85%.

Conclusions: To date, there are no reliable clinical data, using a wearable device, regarding monitoring discharged patients to predict their recovery. We conducted a clinical trial to assess outcome data rigorously to be used reliably for remote home care by patients, health care professionals, and caretakers.

doi:10.2196/45130

https://cardio.jmir.org/2024/8/e45130

JMIR Cardio 2024 | vol. 8 | e45130 | p.18
Introduction

Background

Why are some discharged patients readmitted whereas others are not? Although often routine and uncomplicated, this transition of care is complex and, if not arranged properly, can lead to life-threatening consequences. Clearly, factors such as disease severity and the intensity of postdischarge care affect the risk of readmission; however, many other issues may also have substantial contributions [1]. The top contributory factors are (1) admission diagnosis: heart failure is the top cause of readmission, whereas other conditions, including sepsis, pneumonia, chronic obstructive pulmonary disease, and cardiac arrhythmia, are considered high risk; (2) insurance: Medicare and Medicaid patients have the highest rates of readmission; (3) patient demographics: race, sex, age, and income play a key role (eg, women who experience heart attacks and populations with lower-income status); and (4) patient engagement: patients who lack knowledge, skills, and confidence to manage their care have nearly double the average readmission rate [2,3].

The hospital readmission rate is approximately 20% in the United States, and the rates increase proportionately among those who are aged ≥50 years [4]. Our health care infrastructure is overburdened. Therefore, it is incumbent upon health care providers to develop risk stratification algorithms expeditiously to help predict which patients are at the highest risk for readmission. However, this determination is extremely difficult to make, particularly because the majority of the discharged patients will not become critically ill, require readmission, or die. Therefore, as we try to mitigate the risks of readmission, we need to do more than just predict the risk of readmission; we need to also tailor our home monitoring strategies to this risk [1]. Furthermore, this monitoring must not overwhelm health care providers or patients; rather, the aim should be to deliver smart, robust, and intelligent monitoring of patients convalescing at home.

Physical activity (PA) is one of the major determinants for overall clinical outcomes in chronic diseases, including diabetes, hypertension, hyperlipidemia, heart failure, and cancer, as well as mental health issues [5-8]. Moreover, these same comorbidities increase the risk of readmission. In 2017, the Centers for Disease Control and Prevention advocated adding PA as the fourth vital sign after heart rate (HR), blood pressure, and body temperature [9]. These developments underline the critical importance of PA in assessing the recovery of patients and, more importantly, indicate a clear need to measure PA quantitatively beyond the current questionnaire and survey methods [4,9,10]. PA is defined simply as any bodily movement produced by the skeletal muscles that result in energy expenditure [11]. However, it has been difficult historically to directly measure PA. It requires a dedicated laboratory to measure and perform a kinematic analysis. In addition, the measurement period is short and hard to monitor over time. Wearable technology and wireless data transmission have overcome these limitations and facilitate an accessible and long-term assessment of PA. A triaxial movement sensor was found to be a reliable, valid, and stable measurement of walking and daily PA in patients with chronic obstructive pulmonary disease [7]. Furthermore, a portable system for PA assessment in a home environment has been proposed [5]. These innovative systems provide novel and comprehensive real-time data for the evaluation of the health and quality of life of participants with limited mobility and chronic diseases. Finally, an estimate of step counts and energy expenditure strongly correlated with observed step counts and measured energy expenditure, using hip- and wrist-based Fitbit devices [6].

Development of an Advanced Data-Driven Analytic Platform

We developed an advanced data-driven analytic platform that predicts clinical outcomes based on accurate measurements of PA [10]. Artificial intelligence (AI) or machine learning (ML) analyzes the data to predict short- and long-term health outcomes. Although there is an overabundance of wearable devices (WDs) in the market, there are no known clinical outcome data that could be used reliably for home care by patients, health care professionals, or caretakers. In conjunction with AiCare Corp in San Jose, California, United States, we developed a platform consisting of the following key components: (1) a WD synced to an iPhone or app, (2) a web-based open application programming interface (API), (3) an AI and ML interface, and (4) a Health Insurance Portability and Accountability Act (HIPAA)–compliant Amazon Web Services (AWS) server environment. This platform was deployed at a skilled nursing facility where we collected >17,000 person-day data points (408,000 person-hour data points). These data provided the training set for our extreme gradient boosting (XGBoost) AI algorithm to correlate PA data to health outcomes in the Activity Assessment of Patients Discharged from Hospital-I (ACT-I) clinical trial. In this ACT-I trial, we enrolled 52 patients discharged from Stanford Hospital. Our data demonstrated a robust predictive system to forecast health outcomes in the enrolled patients based on their PA data. The clinical study generated a receiver operating characteristic (ROC) analysis with a sensitivity of 87% and a specificity of 79% in predicting the clinically significant events that were reported by the patients. Our comprehensive AI profiling of the PA of the discharged patients predicted their recovery or clinical deterioration to enable the precision guidance of appropriate and timely intervention during the 4-week follow-up period.

After considering various functionalities and requirements, the WD offered the most practical and compliant design solution to monitor discharged patients intelligently. However, the wearable technology for discharged patients should embody different applications and designs specific to their needs. In this paper, we will demonstrate these specifications in more detail. We will present AiCare’s comprehensive technology solution consisting of a WD, Bluetooth low energy (BLE)–enabled iOS infrastructure, an ML algorithm to implement AI in patient care,
and API-enabled web technology to measure the daily activities of patients. In this study, remote data collection, robust XGBoost AI analysis, and the reliable prediction of clinical outcomes are reported.

**Methods**

**Patient Recruitment**

We screened patients discharged from Stanford Hospital general cardiology and advanced heart failure program.

**Ethical Considerations**

We obtained approval from the Stanford University Institutional Review Board (53805) and recruited patients discharged from Stanford Hospital. They were invited to participate in a research study to demonstrate the safety and feasibility of the AiCare platform. Informed consent was obtained from each participant who consented to primary data collection and secondary data analysis without additional consent. The privacy and confidentiality of participants are protected by a deidentified code that is assigned to each patient. No compensation was offered to participants.

**ML Predictive Platform**

Our comprehensive ML profile of the discharged patients was designed to predict their proper recovery to enable the precision guidance of timely intervention during the 4-week follow-up period. We developed an advanced data-driven XGBoost analytics platform to predict clinical outcomes based on accurate measurements of PA [10].

We compared several techniques to analyze our training data set, including logistic regression, naïve Bayes, support vector machine, and XGBoost. We measured precision, recall, $F_1$-score, area under the ROC curve (AUC-ROC), and average critical activity level, using different data sets. Throughout the analyses, XGBoost provided the highest area under the curve (AUC) values and other measurements.

We chose XGBoost because of its interpretability through the model training process, resistance to trivial features, and the reduced risk of overfitting. For our health care use case, model transparency was an important evaluation criterion. XGBoost visualized the feature prioritization and automatic weight assignments, which allowed us to explain the model insights to the stakeholders for solution adoption. Occasionally, there are noises in sensor data. To reduce the risk of overfitting, we experimented with max_depth of 2, 3, 4, and 5 and min_child_weight of 1, 2, 3, 4, and 5. On the basis of our list of PA-related input feature set and data volume (>17,000 person-day data points), the hyperparameters we used were max_depth of 3, learning_rate of 0.01, min_child_weight of 4, and n_estimators of 100. This achieved the balance of model accuracy, reducing the risk of overfitting and reaching a tolerable learning speed. We experimented with both XGBoost 1.4.1 and XGBoost 1.7.5. A mean absolute error of 1.7.x was introduced, which boosted the training algorithm convergence process. Some assumptions we made regarding the XGBoost model that should be considered include that the encoded integer values for each input variable have an ordinal relationship; it should not be assumed that all values are present. Our algorithm could handle missing values by default. In our tree-based algorithm, missing values were learned during the training phase.

Our AI platform predicted clinical outcome risk during the 4-week follow-up period using the continuous PA data stream. The PA features were measured by the number of occurrences of the multiples of g-force (1 g, 2 g, and 3 g) in each 1-hour time window. One hour was further divided into 7200 time intervals of 500 milliseconds each. Within each 500-millisecond period, the AiCare platform detected whether the minimum level of acceleration (1 g) had occurred. If yes, it increased the 1-g value by 1 count. Therefore, on an hourly basis, a restless user could potentially accumulate up to 7200 values of 1 g. The same detection and computational logic applied to 2-g and 3-g values. The directionless g-force was an aggregation of the g-forces in 3 axes (directionless g-force $= \sqrt{(g-force_x^2 + g-force_y^2 + g-force_z^2)}$). This trial used the initial 72-hour period to build nonrisk baseline data and generated an alert when any deviation occurred, which indicated worsening health condition. The platform was able to detect the precursors of rehospitalization.

A decision tree ensemble–based multiclass classification approach was used to predict no risk, mild risk, and risk. A maximum tree depth of 3 levels was deployed. The intrinsic graph of the decision tree facilitated the explainability of the model. **Figure 1** presents a sample decision tree from our model.

This decision tree visualization provides insight into the gradient boosting process. **Figure 1** illustrates the importance and data coverage of each input feature (1 g, 2 g, and 3 g) and the decision-making process. We chose cross-entropy–based softprob objective (the loss function in the first term of the training objective equation presented after this paragraph) to predict the probabilities of 3 categories in the risk profile. Because of the tendency of the decision tree to bisect the data space and to overfit the training data when classes are not well separated, we introduced a regularization term to balance the bias-variance trade-off (the second term of the training objective equation presented after this paragraph).

$$f(x) = \sum_{i=1}^{n} \alpha_{i} g_{i}(x)$$

(1)

To reduce false-positive results, we further enhanced the platform with the clinician’s cognitive decision-based alerts. The AI model was trained continuously with the patients’ up-to-date PA data. Besides the AI model (**Figure 1**), the AiCare prediction platform was designed for higher scalability. The inbound data pipeline supports open APIs that are hardware agnostic and integrate with the PA features collected from different hardware devices. The outbound patients’ predictive risk profiles were streamed to various clinical applications to support broad clinical use cases. The ACT-I trial showed early signs of clinical efficacy with this low-cost noninvasive approach, enabling further scalability.
Wireless Protocol
Considerations regarding the requirements of data collection, long-term use, power consumption, wireless transmission distance, legal radio frequency, home use, popularity, and cost led to choosing BLE as the optimal protocol for home care indoor use. The iPhone was connected to the cloud server via the standard wireless or cellular protocol.

ID System and Data Collection
The personalized data were anonymized using an internally specified ID system for data collection. A BLE media access control address for each band enabled this functionality. The patients wore the WD (a battery-powered smart band [Rockband; AiCare Corp]) at all times to enable continuous data collection (the Rockband has a battery life of 45 days for continuous use).

AiCare Technology
The AiCare platform enabled data collection and real-time analysis as described herein. The technology consisted of the following: (1) the low-cost and water-resistant Rockband with a battery life of 45 days for continuous use, (2) iPhone connectivity, (3) a cloud-enabled HIPAA-compliant AWS server, (4) open API architecture, (5) an ML and XGBoost interface, (6) an iPhone app, and (7) an AI-enabled COVID-19–specific questionnaire. This comprehensive platform was deployed in an iOS environment to analyze the patients’ PA data. We assessed PA by a triaxial accelerometer, which provides the optimal solution between technological complexity and reliable measurement of PA. This service was designed to ensure a smart, safe, and secure environment enabled with real-time, intelligent, and timely tracking, detection, and analysis to promote a healthy and independent lifestyle for discharged patients.

Data Collection and Analysis
We used the Rockband for data collection. First, we defined the moving average (MA) of PA. The visualization of time series data obtained from AiCare’s platform allowed us to (1) identify changes in energy level (EL) and movement percentage, (2) establish a personalized baseline for each discharged patient, and (3) understand the data trend to predict any deviation in daily activity pattern.

The MA of PA
The MA method is widely used to smooth out time series data by calculating the average values for a chosen period [4,12]. In this study, we used simple MA (SMA) to avoid the noisy measurements of the EL and movement percentage feature. Each data point was calculated using SMA in time series data and weighted equally. There was no need to set any weighting parameters such as the weighted or exponential MA method to generate SMA EL or movement percentages parameter. The SMA formula was defined as follows:

$$\text{(2)}$$

where $P_k$ represented the data point at time $k$, and $n$ was the chosen number of data points. A longer-term SMA was less sensitive in reflecting the change in data movement compared with a shorter-term SMA, which was used to highlight the major trends in time series data. A shorter-term MA was relatively faster to react to changes in trend, which was beneficial to applications that required a QR code. The adjustment of the value $n$ in the equation measured the different effects of trend analysis. The specific features and the definitions of PA are outlined in Textbox 1.
Studied features and definitions for physical activity patterns.

- Daytime energy level (EL): the EL obtained during the daytime period
- Nighttime EL: the EL obtained during the nighttime period
- Daily EL difference (ELD): the difference between daytime EL and nighttime EL
- Normalized ELD: the daily ELD in percentage values
- Daytime active percentage (AP): 100% minus daytime resting percentage (RP)
- Daytime RP: the percentage of zero movements during the daytime period
- Nighttime AP: 100% minus nighttime RP
- Nighttime RP: the percentage of zero movements during the nighttime period
- Daily active percentage difference: the difference between daytime AP and nighttime AP

Kinetic EL

In this study, the estimation of kinetic energy was used to describe the EL of PA. The original formula of kinetic energy is as follows:

\[
\text{Kinetic energy} = \frac{1}{2} \times \text{mass} \times \text{velocity}^2 = \frac{1}{2} \times \text{mass} \times (\text{acceleration} \times \Delta t)^2
\]

(3)

The unit of kinetic energy is the joule (1 joule=1 kg m²/s²). To obtain a directionless measurement of acceleration from the accelerometer embedded in the Rockband, signal vector magnitude (SVM) was applied to calculate the overall magnitude of acceleration [13]:

\[
\text{SVM} = \sqrt{a_x^2 + a_y^2 + a_z^2}
\]

(4)

where \(a_x\), \(a_y\), and \(a_z\) are the acceleration values from the triaxial accelerometer. In this system, the sampling rate of the accelerometer (\(\Delta t\)) is fixed and is equal to 50 Hz. The formula of kinetic energy can be rewritten as follows:

\[
\text{Kinetic energy} = \left(\frac{1}{2} \times \text{mass} \times \Delta t^2\right) \times \text{acceleration}^2 = \text{Constant} \times \text{SVM}^2
\]

(5)

For each individual, the constant portion of this equation would be the same at any given time. Therefore, kinetic energy could be defined as SVM² (m²/s²/kg). As a result, the estimation of total EL from time 0 to time \(n\) is defined as follows:

\[
\text{Total energy level} = \text{SVM}^2(t_1) + \text{SVM}^2(t_2) + \ldots + \text{SVM}^2(t_n)
\]

(6)

After obtaining the estimated wake-up time and resting time from the cloud platform, we can calculate the total energy expenditure during the daytime period and nighttime period, respectively.

The daytime period is equal to the time between wake-up and resting times on the same day, and the nighttime period is equal to the time between resting time and subsequent wake-up time on the following day. We used daytime EL to estimate the total intensity of all PAs that happened during the daytime period and nighttime EL to represent the total intensity of all PAs that happened during the resting period. In addition, the daily EL difference (ELD) has been used to evaluate the daily PA changes:

\[
\text{Daily energy level difference} = \text{ELDaytime} – \text{ELNighttime}
\]

(7)

A positive value of daily ELD indicates that daytime EL is greater than nighttime EL. It may represent that an individual is active during the day or inactive (sleeps well) during the night, which is a healthy PA pattern. A negative value of daily ELD can be obtained when nighttime EL is greater than daytime EL. High nighttime EL may represent disrupted sleep patterns, and thus movements can be detected by the Rockband at night. A negative EL difference also means that the observed individual is inactive during the day. To compare the change in individual ELD, normalization has to be performed to convert the absolute values of ELD into the percentage of ELD, which is defined by the following equations:

\[
\text{Active percentage} (%) = 100\% – \text{resting percentage} (%)\]

(8)

\[
\text{Daily active percentage difference} (%) = \text{Active percentageDaytime} – \text{Active percentageNighttime}
\]

(10)

ML Algorithm for PA Analysis

Three key features—daily ELD, normalized ELD, and daily active percentage difference—were used to create the algorithm to predict the possible clinical worsening of discharged patients who demonstrate specific PA patterns. A risk alert was generated when the values of the features that were lower than a specific threshold were detected. The collected data correlated with the detailed measurement of the patients’ PA. We assessed the patients’ quality of recovery through accurate measurements of their activities while they were awake, while performing various activities of daily living (ADL) or participating in PA, and while
resting. Multiple layers of big data analytics, data mining algorithms, and ML methods were tested. Specifically, we applied the XGBoost ML algorithm. Our solution refined the predictive capability by using the individual PA differences during the active phase (walking, standing, or sitting) versus the resting phase (lying down). XGBoost enhanced the predictive accuracy of healthy recovery versus deterioration at home and determined the need to contact health care professionals. XGBoost distinguished itself from other gradient boost learning methods by using clever penalization of trees, proportional shrinking of leaf nodes, Newton boosting, extra randomization parameter, and the implementation of single distributed systems. These features enabled efficient ML classification of the real-time monitoring of PA to refine the patients’ risk assessment. XGBoost distributed the feed-forward module of PA. The integration started with the PA module of 3 physical acceleration features (1 g, 2 g, and 3 g). The penalty-based system determined the initial risk profiling by PA weight and retrained in a stage-agnostic way to determine the features and penalties to enhance the weight from PA. The final stage repeats the same cycle as stage 2 and provides each patient’s final weight and risk score. As the individual stage is algorithm agnostic, this method provides randomized unbiased Newtonian analysis. The training data set was achieved by our solution by predicting the clinical outcome based on the individual PA differences during the active phase (walking, standing, or sitting) versus the resting phase (lying down). On the basis of >17,000 person-day data points of 36 participants (unpublished data), we predicted healthy recovery versus death in skilled nursing facility residents based on the PA data and analysis (Figure 2). Using this training data set, our XGBoost algorithm was designed to detect deterioration in the health condition of the discharged patients to generate a risk alert, which suggested the need for early medical intervention by contacting health care professionals, and prevent hospital readmission.

Figure 2. Data for clinical prediction. (A) Healthy outcome (physical activity [PA] ratio of active and resting phase: >60/40 ratio). (B) Deteriorating (deceased) outcome (PA ratio of active and resting phase: <60/40 ratio). ALA and BPE are the anonymized names of the patients.

Statistics and the AUC-ROC Curve
The ACT-I trial was an observational study, and we performed a correlational analysis between PA and clinical outcomes by using the AI model. The population consisted of 249 patients discharged from Stanford Hospital general cardiology and heart failure services. The measurement units relate to 36 (14.5%) of the 249 patients who completed a 28-day analysis. The response is the clinical outcome, and the factor is a comprehensive profile of PA from the patients. The choice of model is XGBoost. XGBoost-generated graph is a commonly used graph that summarizes the performance of a classifier over all possible thresholds. It is generated by plotting the true-positive rate (y-axis) against the false-positive rate (x-axis) as the threshold for assigning observations to a given class. AUC measures the entire 2D area under the ROC curve. The maximum value it can reach is 1; generally, the greater the value, the better the performance of the model.

ROC analysis was used to evaluate a classifier’s prediction performance in biological and medical applications. Each data point in the ROC curve comprises a pair: true-positive rate (sensitivity) and false-positive rate (1−specificity), generated by a discrete classifier with a specific threshold [14]. This study used several periods of MA from 3 days to produce all ROC points in the ROC space. Considering the effect of the imbalanced data set, meaning that the number of healthy discharged patients is greater than the number of discharged
patients classified as deteriorating, we also used the recall-precision curve to evaluate the performance of the proposed algorithms. In the recall-precision curve space, the x-axis and y-axis represent the recall values and precision values, respectively, calculated from the different thresholds.

**User Interface**

On the weekly report, we displayed the line chart, which kept track of the patient’s activity level, and at the bottom, we generated a user-friendly emoji to report the health condition measured by our algorithm every 12 hours. The descriptor “Excellent” and a smiley face emoji indicate a healthy and normal pattern. The descriptor “Concern” and a pensive face emoji mean that there was an unusual pattern, indicating that the patients should be aware of the possible worsening of their clinical condition. Finally, the descriptor “Urgent” and a sad face emoji signify an unhealthy signal from the patient’s PA pattern. This prediction suggests that the patients should contact their health care professionals (Figure 3).

**Figure 3.** Graphic user interface for alert notifications in 3 representative patients. MAYL, AVIC, and LOPA are also anonymized names of patients. The descriptor and smiley face emoji indicate (A) “Excellent” health followed by the descriptor “Concern” and pensive face emoji for mild risk, (B) “Excellent” health followed by the descriptor “Concern” and pensive face emoji for mild risk, and (C) “Excellent” health followed by the descriptor “Urgent” and sad face emoji for indication of risk. ast: assistance.

**Results**

**Patient Enrollment**

We screened 249 patients discharged from Stanford Hospital general cardiology and heart failure services. Of these 249 patients, 52 (20.9%) were enrolled, and 36 (14.5%) completed a 28-day analysis. The reasons for noncompletion were as follows: (1) withdrawal from study (10/16, 63%), (2) battery failure (4/16, 25%), and (3) early readmission (2/16, 13%). Of the 36 patients, 30 (83%) responded to the ADL questionnaire and 30 (83%) responded to the satisfaction questionnaire.

**Prediction**

Our data demonstrated a robust prediction system to forecast the worsening clinical outcomes of these patients based on their PA data, achieving a sensitivity of 87% and a specificity of 79%. On the basis of real-time assessment of PA, our technology offered clinically reliable predictions regarding the discharged patients who would need to contact their health care professionals or caretakers to report their worsening clinical condition. This capability allowed early intervention to prevent further deterioration of these patients (Figure 4) [10].

After the patient’s discharge to home, the AiCare platform is deployed to the patient via the Rockband and iPhone. PA data and trend are displayed on the iPhone app. If there is any negative change in PA, the patient is contacted for a clinical evaluation. The ADL questionnaire is administered to the patient to see whether there is any correlation.
Our solution provided a robust low-cost technology to measure PA and predict clinical outcomes. Our platform also included the nudge technology for an AI-enabled questionnaire. This platform was designed to deliver a seamless, low-cost, and user-friendly environment for the remote monitoring of discharged patients at home to empower the patients and family members. This study analyzed the predictive capability of our platform as described in Textboxes 2-4.

The clinical diagnoses were categorized into true positive, true negative, false positive, and false negative as shown in Textbox 5.

The technical parameters were achieved and categorized into true positive (TP), true negative (TN), false positive (FP), and false negative (FN) as shown in Textbox 6.

Figure 4. Patient flow. ADL: activities of daily living; ML: machine learning.

Textbox 2. Duration to risk prediction and intervention categorized into true positive (TP), true negative (TN), false positive (FP), and false negative (FN).

- Mean number of days from discharge to risk prediction: TP=9 (SD 4); TN=none; FP=7 (SD 3); and FN=none
- Mean number of days from risk prediction to patient-initiated contact of health care professional: TP=5 (SD 2); TN=none; FP=2 (SD 2); and FN=none
- Total activity (1 g, 2 g, and 3 g per patient): TP=33,351 (SD 15,774); TN=38,998 (SD 19,062); FP=43,430 (SD 16,638); and FN=30,714 (SD 16,998)

Questionnaires were also administered at the time of risk alert as well as at the completion of the study (Textbox 7). The ADL questionnaire was administered to augment the PA data. The findings demonstrated modest correlation with the predictive capability. The patients whose condition deteriorated (true-positive group) showed the lowest function in terms of ADL, whereas those who remained stable showed higher response scores (true-negative group). However, there were low ADL scores in the false-positive group and high ADL scores in the false-negative group. The responses to the satisfaction questionnaire demonstrated that this platform was well received. The majority of the users stated that they would recommend the technology to others.
Textbox 3. Formulas of area under the receiver operating characteristic curve metrics (TP=true positive, TN=true negative, FP=false positive, and FN=false negative).

<table>
<thead>
<tr>
<th>Formula</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accuracy</td>
<td>Precision and positive predictive values</td>
</tr>
<tr>
<td>Precision and positive predictive values</td>
<td>Sensitivity, recall, or true-positive rate (TPR)</td>
</tr>
<tr>
<td>Sensitivity, recall, or true-positive rate (TPR)</td>
<td>Specificity or true-negative rate</td>
</tr>
<tr>
<td>Specificity or true-negative rate</td>
<td>Negative predictive values (NPV)</td>
</tr>
<tr>
<td>False-positive rate (FPR)</td>
<td></td>
</tr>
</tbody>
</table>

False-positive rate (FPR) = 1 – specificity

Textbox 4. Calculated values for the area under the receiver operating characteristic curve.

- Sensitivity: 90.01%
- Specificity: 81.55%
- Positive predictive value: 77.1%
- Negative predictive value: 92.3%
- Accuracy: 85%
- False-positive rate: 18.45%
Textbox 5. Clinical diagnosis and prediction data.

<table>
<thead>
<tr>
<th>True positive (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure (n=9)</td>
</tr>
<tr>
<td>Arrhythmia (n=6)</td>
</tr>
<tr>
<td>Atrial (n=5)</td>
</tr>
<tr>
<td>Ventricular (n=1)</td>
</tr>
<tr>
<td>Device (n=1)</td>
</tr>
<tr>
<td>Ischemia (n=1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>True negative (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia (n=6)</td>
</tr>
<tr>
<td>Atrial (n=4)</td>
</tr>
<tr>
<td>Ventricular (n=2)</td>
</tr>
<tr>
<td>Ischemia (n=2)</td>
</tr>
<tr>
<td>Heart failure (n=1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>False positive (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia (n=5)</td>
</tr>
<tr>
<td>Atrial (n=3)</td>
</tr>
<tr>
<td>Ventricular (n=2)</td>
</tr>
<tr>
<td>Heart failure (n=2)</td>
</tr>
<tr>
<td>Ischemia (n=2)</td>
</tr>
<tr>
<td>Pulmonary hypertension (n=2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>False negative (n=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia, ventricular (n=1)</td>
</tr>
<tr>
<td>Pericarditis (n=1)</td>
</tr>
</tbody>
</table>

Textbox 6. Technical findings.

- Signal loss hours per patient: TP=79; TN=74; FP=71; and FN=60
- Battery life per patient (d): TP=34; TN=29; FP=32; and FN=19
- Early replacement of the Rockband (number of patients): TP=1; TN=4; FP=0; and FN=1

Textbox 7. Response to the 7-question activities of daily living (ADL) questionnaire (7/7, 100%: highest function; n=30).

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>True positive: 5.5 (positive ADL engagement)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>True negative: 6.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>False positive: 4.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>False negative: 7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion

Principal Findings

We screened 249 patients discharged from Stanford Hospital general cardiology and heart failure services. Of these 249 patients, 52 (20.9%) were enrolled, and 36 (14.5%) completed a 28-day analysis looking into the correlation between PA and clinical outcome. Using our XGBoost model, we plotted the true-positive rates against false-positive rates, which helped us to generate the AUC-ROC curve and calculate the 2D AUC value to determine the performance of the model. Our data demonstrated a robust prediction system to forecast the worsening clinical outcomes of these patients based on their PA data, achieving a sensitivity of 87% and a specificity of 79%.
This innovative platform enables low-cost, robust, and precise PA tracking of patients discharged from hospital to predict stable versus unstable clinical recovery, using a WD and an iPhone. This technology is powered by our algorithms, individualized big data, personalized behavior- and function-specific web-based software, and intelligent ML analytics. This comprehensive platform offers an effective convergence of eHealth, AI, and telemedicine technology over internet-enabled mobile devices to leverage the economical, low-cost, and pervasive internet technology and, potentially, may address the socioeconomic divide seen today. Patient care at home by family members or by the individual patient is personalized by AI for maximum safety. This technology will fill an important gap in telemedicine through the use of user-friendly, real-time, and 24/7 remote monitoring for clinical outcome prediction. Patients in transition who are discharged from the hospital, emergency department, or urgent care clinic will benefit from this technology, which can monitor their progress and predict clinical deterioration to enable early intervention for successful recovery at home.

This ACT-I trial used monitoring technology to measure in-home activity and predict clinical outcomes. Although many innovative technologies claim accurate measurements of vital signs, there is no platform with proper validation of clinical outcome prediction data. A wide range of longitudinal studies to demonstrate the effectiveness of remote monitoring technology have been performed [10,15]. Most research was conducted within the area of passive infrared motion sensor technology, followed by research on body-worn sensors. Although the research into the use of monitoring technologies has been extensive, most studies only focused on demonstrating the functionality of the proposed monitoring technology by simulating activities in a laboratory setting or on an existing data set. As a result, the functionality of most systems has only been demonstrated in general terms or mechanical accuracy, sensitivity, and specificity. The long-term clinical effects of using monitoring technology are less well studied; for instance, in a meta-analysis on ambient sensors for older adult care, 25 of the 141 studies were pilot studies, with 11 focusing on the use of passive infrared motion sensor technology and 10 on the use of multicomponent monitoring technology. Study durations ranged from 3 weeks to 3 years [16]; only 4 studies were longitudinal, including 1 randomized controlled trial and 1 implementation study [17]; and all focused on the use of motion sensor technology. WDs have evolved from merely telling time to encompassing ubiquitous computing applications, miniaturized sensors, and wearable computer technology. Fitbit released its first wearable watch in 2009 and focused on activity tracking. During the ensuing years, smartwatches became common technology products manufactured by electronics companies. These developments led to a set of design guidelines for wearability and WDs that make tracking PA a much more attractive target for discharged patients [9].

PA is one of the major determinants for overall clinical outcomes in chronic diseases, including diabetes, hypertension, and heart disease, as well as mental health issues [17]. Reaching a sufficient level of PA could reduce the risk of cardiovascular disease (CVD), type 2 diabetes, obesity, depression, and anxiety [18-20]. PA even plays an important role in cancer prevention at specific sites, including breast and colon cancers [16]. In 2017, the Centers for Disease Control and Prevention advocated adding PA as 1 of the 4 vital signs [20]. Despite these efforts, automated clinical outcome prediction systems do not exist. There is a need for the accurate prediction of morbidity and mortality, particularly among older adults who are most frequently readmitted to the hospital. Patients with chronic diseases, cardiometabolic syndrome, and dementia are often underserved, growing in numbers, incurring higher costs to our society, and becoming increasingly vulnerable. Our large data set obtained from a skilled nursing facility and consisting of >17,000 person-day data points (408,000 person-hour data points of 36 patients captured over 2 years), demonstrated a high correlation of PA analysis among the residents who survived versus those who died. Using this as our training data set, we were able to identify with high accuracy patients who experienced stable recovery versus those who experienced unstable recovery during the most vulnerable 1-month posthospital discharge period.

The evidence-based management of CVDs requires substantial amounts of resources, including advanced therapeutics, complex diagnostics, and sophisticated clinical trials. However, the reliable prediction of clinical outcomes after hospital discharge has presented some challenges [11]. In response, various approaches using ML models such as artificial neural network, decision tree, support vector machine, and naïve Bayes have been attempted to predict clinical outcomes, taking into account steps, vital signs, medical conditions, and demographic information [11]. In one of the studies conducted on arrhythmic sudden cardiac death, a deep learning technology approach termed Survival Study of Cardiac Arrhythmia Risk was developed to predict risk for 156 patients with ischemic heart disease. In this model, cardiac magnetic resonance images and covariate data such as demographics, risk factors, electrocardiogram (ECG) measurements, medication use, and outcomes were used as inputs for the 2 branches, where 1 branch is used to visualize the heart’s 3D ventricular geometry, and the other is used to extract arrhythmic sudden cardiac death risk–related imaging features from the cardiac magnetic resonance images. All these data were then used to create a survival curve individualized for each patient with accurate predictions for up to 10 years. However, the limitations of this study include an inability to account for competing risks for the same symptoms and covariates that were not exhaustive or fully inclusive [17]. In another instance, regression and convolutional neural network models were used to predict CVD risk for women. As CVDs are the primary cause of death in women, with evidence of sex bias in the diagnosis of CVDs, the exploration of screening factors for risk detection has never been more urgent. This study assessed the critical risk–screening opportunities offered to women and how the integration of AI can greatly benefit health care providers in interpreting data on women [17,21]. AI may propel the analysis of patient data into meaningful interpretations of patient health, providing health care providers with an additional layer of guidance for patient management plans. After patient discharge, ML is still viable in assisting with remote health monitoring through systems such as Wanda-CVD, which uses patients’ blood pressure and BMI...
measurements as well as their low-density lipoprotein and high-density lipoprotein cholesterol levels to coach them and improve their risk factors for CVD. However, using limited inputs such as blood pressure readings and cholesterol levels may not be entirely meaningful. In a previous study, only less than half of the predictions based solely on cholesterol levels and BMI measurements were correct [8,22].

In contrast, our XGBoost ML model enhanced the accuracy of predicting stable recovery versus clinical deterioration after discharge from the hospital. Specifically, XGBoost performs self-adaptive feature selection and prioritization among our data dimensions, mitigates the risk of overfitting by controlling the complexity of the trees with penalization on leaf nodes to cope with the high-frequency nature of our temporal data set, uses a Newton boosting algorithm to better learn the tree structures, and decorrelates the individual trees with a randomization parameter to reduce the bias and variance of the model. Compared with the existing approach, our AI-enabled solution is unique in the following ways. First, our real-time PA-based algorithm enables risk prediction during the critical 1-month posthospital discharge period, whereas most of the other research on risk prediction focused on a much longer time frame of 5 to 10 years. Our approach allows a shift to early intervention and the prevention of clinical deterioration during the postdischarge period. Second, our training data set for the ACT-I clinical trial consisted of a large number of data sets obtained during a long follow-up period. Our data covered a 2-year duration, which enabled a longitudinal follow-up for a personalized benchmark to conduct individualized analysis and risk prediction. Third and last, our low-cost at-home patient onboarding process did not rely on complex hardware such as imaging or remote ECG equipment. The Rockband WD was low cost, maintenance free, and disposable. Our hardware-agnostic AI framework demonstrated highly and easily adaptable features using our simple WD.

Limitations

Although the majority of the patients were satisfied with our platform, there were some compliance issues related to the use of the WD. Furthermore, the measurement of PA only may not provide a comprehensive assessment and prediction of an individual patient’s clinical condition. Our future trial, ACT-II, will expand on the ACT-I trial’s limitations by improving the specificity (false positive) rate of the ACT-I trial by evaluating the efficacy of an augmented XGBoost algorithm. We will use an Apple Watch to complement PA measurements by also monitoring HR, HR variability, ECG, oxygen saturation, blood pressure (separate blood pressure measurement device), clinical data, and genomics to better identify stable versus unstable recovery. Our novel platform in an iOS environment will enable the capture of multidimensional real-time data to enhance patients’ awareness of their clinical condition and health care professionals’ guidance of patient management. We will investigate the feasibility of this platform, consisting of an Apple Watch, an iPhone, an XGBoost interface, and a HIPAA-compliant AWS environment, to monitor the dynamic biometric data, predict patients’ clinical outcome, and improve patient compliance.

Conclusions

The ACT-I trial demonstrated a critical proof of concept of the Rockband WD to enable real-time analysis of patients’ PA data remotely. We developed a cloud-enabled XGBoost algorithm and intelligent sensor technology to enable precision home health care. The XGBoost algorithm quantified, integrated, and predicted the pattern of each patient’s outcome seamlessly with high accuracy, precision, and recall. The Rockband cloud backend personalized the big data for behavior- and function-specific interactive software, and ML analytics allowed a comprehensive platform to converge eHealth, AI, and telemedicine technology. Our internet-enabled mobile devices leveraged the economical, low-cost, and pervasive technology to personalize health care by enabling prevention and early intervention through the real-life clinical implementation of mobile device technology and AI. Our approach developed, tested, and disseminated the next generation of health care strategy by focusing on precision health, using diagnostic information collected in real time from patients’ PA data while they were recovering at home. Our XGBoost algorithm enabled this scalable, portable, and distributed processing framework. This novel technology will introduce a nascent approach to patient care to redefine clinical practice by predicting patient outcome based on a comprehensive analysis of behavioral phenotype. This real-time risk monitoring and clinical outcome prediction platform will advance the future of remote patient care.

Acknowledgments

The authors appreciate and acknowledge the assistance of Fouzia Khan and Banu Priya Rathinam Radha Rajasekaran in patient enrollment and trial organization.

Data Availability

We hope to submit our data to JMIR Data. However, we obtained the informed consent to release their data in our repository; therefore, this may not be possible.

Conflicts of Interest

The manuscript presents a potential conflict of interest due to the financial involvement of its authors, WX’s family member, PCY, ZS, AJ, and PJ in AiCare, the company responsible for sponsoring the clinical trials discussed in the manuscript. The conflict arises from the authors holding shares in AiCare, indicating a direct financial interest in the success and promotion of
the company’s products. Full disclosure and transparency regarding these financial relationships are essential for maintaining the integrity of the scientific work and ensuring the reader’s ability to assess potential biases.

References


Abbreviations

ACT-I: Activity Assessment of Patients Discharged from Hospital-I
ADL: activities of daily living
AI: artificial intelligence
API: application programming interface
AUC: area under the curve
AUC-ROC: area under the receiver operating characteristic curve
AWS: Amazon Web Services
BLE: Bluetooth low energy
CVD: cardiovascular disease
ECG: electrocardiogram
EL: energy level
ELD: energy level difference
HIPAA: Health Insurance Portability and Accountability Act
HR: heart rate
HRRP: Hospital Readmissions Reduction Program
MA: moving average
ML: machine learning
PA: physical activity
ROC: receiver operating characteristic
SMA: simple moving average
SVM: signal vector magnitude
WD: wearable device
XGBoost: extreme gradient boosting

Edited by A Mavragani; submitted 16.12.22; peer-reviewed by S Sarejloo, K Gupta, T Bonten, X Cheng; comments to author 09.05.23; revised version received 31.08.23; accepted 19.09.23; published 01.03.24.

Please cite as:
Yang PC, Jha A, Xu W, Song Z, Jamp P, Teuteberg JJ
Cloud-Based Machine Learning Platform to Predict Clinical Outcomes at Home for Patients With Cardiovascular Conditions Discharged From Hospital: Clinical Trial
JMIR Cardio 2024;8:e45130
URL: https://cardio.jmir.org/2024/1/e45130
doi:10.2196/45130
PMID:38427393

©Phillip C Yang, Alokkumar Jha, William Xu, Zitao Song, Patrick Jamp, Jeffrey J Teuteberg. Originally published in JMIR Cardio (https://cardio.jmir.org), 01.03.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
Formative Perceptions of a Digital Pill System to Measure Adherence to Heart Failure Pharmacotherapy: Mixed Methods Study

Peter R Chai1,2,3,4, MD, MS; Jenson J Kaithamattam1, BS; Michelle Chung1, BA; Jeremiah J Tom1, MBBS; Georgia R Goodman1,4, BS; Mohammad Adrian Hasdianad1, MD, MSc, MMSc; Tony Christopher Carnes5, PhD; Muthiah Vaduganathan6, MD, MPH; Benjamin M Scirica6, MD, MPH; Jeffrey L Schnipper7, MD

1Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States
2Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, MA, United States
3The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States
4The Fenway Institute, Boston, MA, United States
5eTectRx, Gainesville, FL, United States
6Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States
7Division of Hospital Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States

Corresponding Author:
Peter R Chai, MD, MS
Department of Emergency Medicine
Brigham and Women’s Hospital
75 Francis Street
Boston, MA, 02115
United States
Phone: 1 617 732 5640
Email: pchai@bwh.harvard.edu

Abstract

Background: Heart failure (HF) affects 6.2 million Americans and is a leading cause of hospitalization. The mainstay of the management of HF is adherence to pharmacotherapy. Despite the effectiveness of HF pharmacotherapy, effectiveness is closely linked to adherence. Measuring adherence to HF pharmacotherapy is difficult; most clinical measures use indirect strategies such as calculating pharmacy refill data or using self-report. While helpful in guiding treatment adjustments, indirect measures of adherence may miss the detection of suboptimal adherence and co-occurring structural barriers associated with nonadherence. Digital pill systems (DPSs), which use an ingestible radiofrequency emitter to directly measure medication ingestions in real-time, represent a strategy for measuring and responding to nonadherence in the context of HF pharmacotherapy. Previous work has demonstrated the feasibility of using DPSs to measure adherence in other chronic diseases, but this strategy has yet to be leveraged for individuals with HF.

Objective: We aim to explore through qualitative interviews the facilitators and barriers to using DPS technology to monitor pharmacotherapy adherence among patients with HF.

Methods: We conducted individual, semistructured qualitative interviews and quantitative assessments between April and August 2022. A total of 20 patients with HF who were admitted to the general medical or cardiology service at an urban quaternary care hospital participated in this study. Participants completed a qualitative interview exploring the overall acceptability of and willingness to use DPS technology for adherence monitoring and perceived barriers to DPS use. Quantitative assessments evaluated HF history, existing medication adherence strategies, and attitudes toward technology. We analyzed qualitative data using applied thematic analysis and NVivo software (QSR International).

Results: Most participants (12/20, 60%) in qualitative interviews reported a willingness to use the DPS to measure HF medication adherence. Overall, the DPS was viewed as useful for increasing accountability and reinforcing adherence behaviors. Perceived barriers included technological issues, a lack of need, additional costs, and privacy concerns. Most were open to sharing adherence data with providers to bolster clinical care and decision-making. Reminder messages following detected nonadherence were
perceived as a key feature, and customization was desired. Suggested improvements are primarily related to the design and usability of the Reader (a wearable device).

**Conclusions:** Overall, individuals with HF perceived the DPS to be an acceptable and useful tool for measuring medication adherence. Accurate, real-time ingestion data can guide adherence counseling to optimize adherence management and inform tailored behavioral interventions to support adherence among patients with HF.

*(JMIR Cardio 2024;8:e48971)*  doi:10.2196/48971

**KEYWORDS**

behavioral interventions; cardiac treatment; digital pill system; heart failure medication; heart failure; ingestible sensors; medication adherence

**Introduction**

Heart failure (HF) is one of the leading causes of morbidity and mortality in the United States, affecting approximately 6.2 million Americans [1,2]. In 2018, a total of 13.4% of deaths in the United States were attributed to HF [2]. HF is also one of the most common causes of hospitalization in individuals aged 65 years or older [3]. Among those admitted to the hospital, nearly one-fifth will be readmitted to the hospital for complications related to HF or other comorbidities within 30 days [4-6]. Pharmacologic management of HF focuses on increasing uptake and adherence to goal-directed quadruple medical therapy: angiotensin receptor-neprilysin inhibitor, β-blocker, mineralocorticoid receptor antagonist, and sodium-glucose co-transporter 2 inhibitors [7]. This strategy has demonstrated high efficacy for reducing hospital readmission and progression of HF and its associated cardiometabolic outcomes [8,9].

Medication nonadherence is a leading driver of worsening clinical outcomes in HF. Large longitudinal cohort studies have demonstrated that nonadherence to any pillar of HF pharmacotherapy is associated with increased all-cause mortality and an increased risk of 30-day hospital readmissions [10,11]. In a large, single-center, cross-sectional study, up to 15% of hospital readmissions in individuals with HF were associated with medication nonadherence [12]. Additionally, in individuals admitted to the hospital, 28% experience primary nonadherence to a component of HF pharmacotherapy as short as 1 week after discharge, with 24% experiencing persistent nonadherence at 30 days [13]. Given the close relationship between nonadherence and hospital readmission among individuals with HF, it is critical to continue to develop techniques that allow for the assessment of medication adherence in this population [14-20].

Current strategies for measuring adherence to HF pharmacotherapy include pharmacy refills, as measured by the medication possession ratio, and the number of subsequent days the patient has access to medications, as measured by the proportion of days covered [21,22]. This approach assesses overall adherence over periods of time, yet it is suboptimal in its capacity to capture daily challenges to adherence that may ultimately affect overall adherence and HF outcomes [23]. In contrast, one strategy for directly measuring daily adherence is a digital pill system (DPS; Figure 1). DPS technology is comprised of a gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication. Following ingestion of the digital pill, the radiofrequency emitter is activated by gastric chloride ions, which then projects a unique radio signal off the body that is acquired by a wearable device (Reader) [24,25]. The Reader stores and forwards ingestion data through low-energy Bluetooth to the user’s smartphone and a clinician dashboard, enabling both patients and care teams to assess adherence patterns in real-time [26]. This strategy has been previously leveraged to measure oral pharmacotherapy adherence to antidiabetic and antihypertensive medications [27-30].

https://cardio.jmir.org/2024/1/e48971

JMIR Cardio 2024 | vol. 8 | e48971 | p.33

*(page number not for citation purposes)*
To understand potential user responses to the DPS and inform future research involving this technology among individuals with HF, we conducted brief quantitative assessments and semistructured qualitative interviews to explore perceived facilitators of and barriers to the use of a DPS that measures adherence to HF pharmacotherapy.

Methods

Participants

All participants met the following inclusion criteria: (1) aged 18 years or older, (2) admitted to inpatient general medical or cardiology services with a diagnosis of HF, and (3) currently on oral HF pharmacotherapy. Individuals were excluded if they (1) had a history of heart transplant, (2) had an implanted left ventricular assist device, (3) were non-English speaking, or (4) were admitted to an intensive care unit.

Procedures

Participants were recruited in-person at a large, urban academic quaternary care hospital in Boston, Massachusetts, where patients with HF are admitted to either the general medical service or cardiology services; both inpatient teams independently manage patients with standardized treatment algorithms. Participants were not previously known to or in direct clinical care with any members of the study team. All study procedures were conducted in-person in a private area at the hospital while participants were inpatient.

Following verbal consent, participants completed a digitally recorded, semistructured qualitative interview with a bachelor’s-level research assistant (either male or female) trained in qualitative interviewing techniques (JKJ and MC). Interviews ranged from 23 minutes to 64 minutes in length (mean duration of 39 minutes). We adhered closely to the Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines (Multimedia Appendix 1) [31]. Study staff explained the components and functionality of the DPS (ID-Cap System; etectRx) in detail. Debrief documents were written after each interview and shared with the study team, who assessed for thematic saturation. Participants also completed a brief quantitative assessment. Following the completion of all study visit procedures, remuneration was provided. Study procedures were completed from April to August 2022.

Measures

Qualitative Interview

A qualitative interview guide (Multimedia Appendix 2) was developed by the study team members with expertise in the DPS, goal-directed medical therapy for HF, medication adherence, and technology development (PRC, JLS, MV, and BMS). Questions explored baseline adherence to HF medications and current adherence strategies, initial responses to DPS technology and messaging infrastructure through the DPS app or SMS text messaging, perceived facilitators of and barriers to DPS use, and perceptions of data privacy in the DPS context. Following an overview of the DPS technology and component parts, participants were asked whether they would be willing to use the DPS for HF adherence monitoring; this question was used to evaluate overall acceptance of the technology. The interview guide was piloted for completeness among members of the study team before implementation. Sample interview questions are provided in Table 1.
Table 1. Sample qualitative interview content areas, questions, and probes used during the study.

<table>
<thead>
<tr>
<th>Content area</th>
<th>Sample probes</th>
</tr>
</thead>
</table>
| Current adherence strategies        | • How long have you been prescribed a diuretic or SGLT2 inhibitor?  
• How have you tried to remember to take your medications?  
• What kind of barriers do you face to taking your medications on time? |
| DPS technology                      | • What are your initial reactions to the digital pill?  
• Are there design factors to the digital pill and Reader that prevent you from wanting to use it?  
• Why would these factors prevent your use of digital pills? |
| DPS messaging components            | • Tell me about situations you would like to receive notifications about your adherence.  
• What kind of messages would you want to receive in relation to the digital pill? |
| Data privacy and sharing            | • The digital pill allows your provider or study team to view your adherence. What do you think of this?  
• What concerns do you have regarding the privacy of your adherence data?  
• Who do you think should have access to your adherence data? Why? |
| Acceptance of and willingness to use the DPS | • Given what you know, would you be willing to use the digital pill? Why or why not? |

aSGLT2: sodium-glucose co-transporter 2 inhibitors.  
bDPS: digital pill system.

Quantitative Assessment

Quantitative assessments collected data surrounding sociodemographics and HF history. Participants were asked to estimate their adherence to HF medications over the past 3 months on a 0% to 100% sliding scale. We also provided a list of common medication adherence systems (eg, pill boxes, automated phone reminders, and smartphone apps) to assess previous use of such adherence strategies. These questionnaires were developed by the study team, which also supervised participants in completing the baseline assessment.

We used 3 subscales of the previously validated Media Technology Usage and Attitudes Scale (MTUAS) to measure attitudes toward technology: the positive attitudes subscale (6 items, eg, “With technology anything is possible”), the negative attitudes subscale (3 items, eg, “New technology makes life more complicated”), and the anxiety or dependence on technology subscale (3 items, eg, “I get anxious when I don’t have my cell phone”) [32]. Items were rated on a 5-point Likert scale (1=strongly disagree and 5=strongly agree). Score ranges were 1-5 for each subscale, with higher scores indicating more positive attitudes, more negative attitudes, and more technological anxiety and dependence [32]. The final quantitative assessment was cognitively tested among the study team to ensure clarity of questions before deployment with participants.

Analyses

Descriptive statistics were calculated to characterize the sample. Qualitative interviews were professionally transcribed and scrubbed of identifiers. Applied thematic analysis was used to code and analyze the interviews [33]. As part of the applied thematic analysis approach, 3 study team members (JJK, JJT, and GRG) reviewed all interview transcripts in order to iteratively generate a coding framework using a combination of the interview guide questions and data from the interviews themselves. Parent codes and subcodes were iteratively added to the coding framework throughout the transcript review process, and the final coding framework was then reviewed and revised by the study team before the formal coding of transcripts for the purpose of identifying qualitative domains and themes. Our 2 independent coders (JJK and JJT) double-coded 25% of the transcripts to establish interrater reliability; a κ score of >0.8 was used to establish adequate reliability between the coders, and this threshold was met. Study team members (JJK, JJT, and GRG) reviewed and compared coding throughout this process to discuss and resolve discrepancies, with oversight from the study’s principal investigator (PRC). Following the resolution of all coding discrepancies in double-coded transcripts, the coders (JJK and JJT) then independently coded the remaining 75% of transcripts. An audit trail of computerized coding was maintained. Salient quotes from the interviews were extracted, discussed with a subset of the study team (JJK, JJT, PRC, and GRG) to identify major domains and themes, and then disseminated to the entire study team for review. Coding was facilitated by NVivo software (QSR International).

Ethical Considerations

All study procedures were approved by the Mass General Brigham Institutional Review Board (2022P000545). We obtained written informed consent from all study participants. Study data were anonymized, and all study participants were only identified by a unique study identification number. Transcripts of interviews were scrubbed of any identifiers before analysis. Participants were compensated US $40 at the completion of interviews.

Results

Participant Characteristics

Over the study period, 96 individuals met the inclusion criteria. Of these, 43 (45%) were discharged before they could be...
approached by the study team. Of the remaining 53 individuals, 12 (23%) were unavailable for consent, and 21 (40%) declined to participate. The reasons provided for declining participation included the time commitment for study procedures (n=2), general lack of interest (n=10), lack of knowledge of current medications (n=1), perception that they did not match the target study population (n=1), dissatisfaction with current clinical care (n=1), and reason unknown (n=6). A total of 20 participants consented and completed all study procedures (mean age 68, SD 14.3 years). The sample was predominantly female (n=11, 55%), White (n=13, 65%), and non-Hispanic (n=18, 90%). Full sociodemographic information is provided in Table 2.

### Table 2. Sociodemographic characteristics of study participants (n=20).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>68 (14.3)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 (45)</td>
</tr>
<tr>
<td>Female</td>
<td>11 (55)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
</tr>
<tr>
<td>Black or African American</td>
<td>6 (30)</td>
</tr>
<tr>
<td>White</td>
<td>13 (65)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>18 (90)</td>
</tr>
<tr>
<td>Education, n (%)</td>
<td></td>
</tr>
<tr>
<td>High school graduate or GEDa</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Some college</td>
<td>6 (30)</td>
</tr>
<tr>
<td>College degree</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Some graduate school</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Graduate or professional</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Annual income (US $), n (%)</td>
<td></td>
</tr>
<tr>
<td>6000-11,999</td>
<td>4 (20)</td>
</tr>
<tr>
<td>12,000-23,999</td>
<td>3 (15)</td>
</tr>
<tr>
<td>24,000-29,999</td>
<td>2 (10)</td>
</tr>
<tr>
<td>30,000-59,999</td>
<td>3 (15)</td>
</tr>
<tr>
<td>≥60,000</td>
<td>8 (40)</td>
</tr>
</tbody>
</table>

aGED: general educational development.

### Quantitative Results

Half (10/20, 50%) of the sample had HF with preserved ejection fraction, and the other half (10/20, 50%) had HF with reduced ejection fraction. Most (11/20, 55%) were diagnosed with HF over 5 years ago, and half (10/20, 50%) had been admitted to the hospital multiple times due to HF in the past year. All (20/20, 100%) expressed at least some degree of concern regarding worsening HF. Self-reported adherence during the previous 3 months was high (mean 90.1%, SD 17.1%), and most (12/20, 60%) reported using a system to maintain adherence, with a standard pill box as the most common strategy (10/20, 50%). Finally, most participants (11/20, 55%) reported that visualizing their individual adherence patterns would motivate them to maintain adherence. Full HF status and pharmacotherapy adherence data are presented in Table 3.
Table 3. Heart failure (HF) status and pharmacotherapy adherence among study participants (n=20).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HF status</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Duration of HF (years), n (%)</strong></td>
<td>1 (5)</td>
</tr>
<tr>
<td>&lt;1</td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>2 (10)</td>
</tr>
<tr>
<td>2-5</td>
<td>6 (30)</td>
</tr>
<tr>
<td>&gt;5</td>
<td>11 (55)</td>
</tr>
<tr>
<td><strong>Primary physician managing HF treatment, n (%)</strong></td>
<td>13 (65)</td>
</tr>
<tr>
<td>Cardiologist</td>
<td></td>
</tr>
<tr>
<td>Primary care physician</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Does not know</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (5)</td>
</tr>
<tr>
<td><strong>Number of prescribed HF medications, n (%)</strong></td>
<td>1 (5)</td>
</tr>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2-5</td>
<td>10 (50)</td>
</tr>
<tr>
<td>&gt;5</td>
<td>9 (45)</td>
</tr>
<tr>
<td><strong>Type of HF, n (%)</strong></td>
<td>10 (50)</td>
</tr>
<tr>
<td>HFP EF&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>HFr EF&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Number of hospital admissions for HF over the last 12 months, n (%)</strong></td>
<td>2 (10)</td>
</tr>
<tr>
<td>0</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>7 (35)</td>
</tr>
<tr>
<td>2-5</td>
<td>10 (50)</td>
</tr>
<tr>
<td>&gt;5</td>
<td>1 (5)</td>
</tr>
<tr>
<td><strong>Number of physician encounters due to concerns surrounding worsening HF over last 12 months, n (%)</strong></td>
<td>7 (35)</td>
</tr>
<tr>
<td>0</td>
<td></td>
</tr>
<tr>
<td>1-5</td>
<td>10 (50)</td>
</tr>
<tr>
<td>6-10</td>
<td>1 (5)</td>
</tr>
<tr>
<td>11-20</td>
<td>2 (10)</td>
</tr>
<tr>
<td><strong>Degree of concern about HF, n (%)</strong></td>
<td>2 (10)</td>
</tr>
<tr>
<td>Slightly concerned</td>
<td></td>
</tr>
<tr>
<td>Moderately concerned</td>
<td>5 (25)</td>
</tr>
<tr>
<td>Very concerned</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Extremely concerned</td>
<td>9 (45)</td>
</tr>
<tr>
<td><strong>Pharmacotherapy adherence</strong></td>
<td></td>
</tr>
<tr>
<td>Percentage of self-reported HF medication adherence over last 3 months, mean (SD)</td>
<td>90.1 (17.1)</td>
</tr>
<tr>
<td><strong>Uses a system to maintain medication adherence, n (%)</strong></td>
<td>12 (60)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>8 (40)</td>
</tr>
<tr>
<td><strong>Medication adherence systems used, n (%)</strong></td>
<td>1 (8)</td>
</tr>
<tr>
<td>Smart pill box</td>
<td></td>
</tr>
<tr>
<td>Pill organizer</td>
<td>10 (83)</td>
</tr>
</tbody>
</table>
In terms of technology usage, three-quarters (15/20, 75%) of the sample owned a smartphone. MTUAS scores indicated positive attitudes toward technology (mean 4.2, SD 1.1) and a moderate degree of anxiety around being without technology and dependence on technology (mean 3.3, SD 1.4). Technology usage and MTUAS scores are provided in Table 4.

### Table 4. Technology usage and the Media Technology Usage and Attitudes Scale (MTUAS) scores among study participants (n=20).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Technology usage, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Owns a smartphone</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>15 (75)</td>
</tr>
<tr>
<td>No</td>
<td>5 (25)</td>
</tr>
<tr>
<td><strong>Ever used a smartphone to communicate with medical care team</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13 (65)</td>
</tr>
<tr>
<td>No</td>
<td>7 (35)</td>
</tr>
<tr>
<td><strong>Methods used to communicate with medical care team using a smartphone</strong></td>
<td></td>
</tr>
<tr>
<td>Phone call</td>
<td>12 (92)</td>
</tr>
<tr>
<td>Through hospital portal (Patient Gateway)</td>
<td>10 (77)</td>
</tr>
<tr>
<td>Email</td>
<td>8 (62)</td>
</tr>
<tr>
<td>SMS text message</td>
<td>6 (46)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (15)</td>
</tr>
<tr>
<td><strong>MTUAS, mean (SD)</strong></td>
<td></td>
</tr>
<tr>
<td>Positive attitude toward technology subscale score</td>
<td>4.2 (1)</td>
</tr>
<tr>
<td>Negative attitude toward technology subscale score</td>
<td>3.0 (1)</td>
</tr>
<tr>
<td>Anxiety or dependence on technology subscale score</td>
<td>3.3 (1)</td>
</tr>
</tbody>
</table>

*Participants were provided with the opportunity to select multiple options.*

## Qualitative Results

Key findings surrounding the use of DPS technology for HF pharmacotherapy adherence emerged across the following major domains: (1) initial responses to the DPS, perceived barriers to use, and overall willingness to use the technology; (2) perceptions around privacy and sharing of DPS data; (3) responses to DPS messaging components; and (4) suggested improvements for future iterations. Multiple themes emerged within each domain; these are discussed in detail below.

### Initial Responses, Perceived Barriers, and Overall Willingness to Use the DPS

Most participants perceived the DPS to be a novel, reliable tool for adherence measurement. They described the real-time data it generates as potentially useful for reinforcing adherence
behavior and noted that it would increase their sense of personal accountability for their HF regimen. Importantly, many participants described instances in which they were unsure whether they had taken their medications for the day and viewed the DPS as a valuable means for confirming past medication ingestions to avoid double dosing; this was interpreted as an indication of participants' perceived usefulness. After learning about the DPS, 60% (12/20) participants indicated a willingness to use the DPS to measure their HF pharmacotherapy adherence.

Absolutely I would use it. Because it’s easier...It would help a whole lot. Because it would show [my physician] when or if I was adhering to the protocol. He’d know I’m taking my medicine or if I’m not. [Aged 59 years, male]

I think it would be great—like a 30-day regime, make sure we’re all on the same book kinda thing...If I was older, or I was gettin’ blinky, or I didn’t have caretakers or people looking out for me, it wouldn’t be a bad idea. [Aged 67 years, female]

I think it could be very useful for some people, and I doubt that I would use it right now in my present level of decline. But if I start having memory problems or if I ever start having problems taking medication, I’d be very interested in it. [Aged 80 years, male]

Participants also identified a number of key barriers to DPS use. These included the perceived complexity of operating the technology, which was particularly salient among individuals who did not own smartphones. Some participants also described the Reader as large and potentially stigmatizing in the event that they needed to use the DPS in public. For some participants, the presence of electronics within the digital pill itself (ie, the radiofrequency emitter) raised questions around safety; however, the presence of a motherboard inside and it’s gonna randomly broadcast to an outside device, and tell people what medications you’re on, what you’re taking, when you’re taking it—and potentially additional information about it.” [Aged 58 years, female]

Despite expressing some concerns around data transmission and privacy, overall, participants expressed a desire for their DPS adherence data to be shared with their clinical care teams, given its importance for preventing the progression of HF. They reported that sharing DPS data with providers would be more reliable than self-reporting adherence and that it could be used to guide conversations around medication side effects, additional adherence or behavioral support that may be needed, and adjustments to medication regimens, including in the setting of worsening disease. Other participants shared more mixed opinions; while these individuals were willing to share adherence data with providers, they were unsure if doing so would meaningfully impact their ongoing HF treatment.

If a doctor looks at it and sees that you’re not taking your medication, well, of course, something’s gonna have to be done...There’s nothing bad about the data going to the doctor...it’s all positive. It certainly can’t hurt. [Aged 71 years, male]

It’s so important to let your physician know you’re actually taking that medication as prescribed. So if something is not working, then they know there’s no question that this person was adhering to the prescribed treatment. And maybe this medication is not working for them. Maybe they need to increase it or get another one. [Aged 62 years, female]

Responses to DPS Messaging Components

Participants were presented with an overview of three types of messages that can be programmed within the DPS: (1) confirmatory messages, sent after each ingestion to indicate successful detection; (2) reminder messages, sent before a prespecified dosing window; and (3) nonadherence reminder messages, sent after a dosing window if no ingestion had been detected.

Most participants accepted confirmatory messages following ingestions and viewed them as a useful feature for instances in which they were unsure if they had correctly operated the DPS. Importantly, because HF pharmacotherapy consists of multiple medication regimens, participants emphasized the need for confirmatory messages to specify the name of the medication ingested. They also expressed a desire to customize the timing of confirmatory messages; while some preferred a confirmation after each ingestion, others preferred less frequent messages, such as only at the end of the day or the week, as part of an adherence summary. Relatedly, participants suggested that the

Perceptions Around Privacy and Sharing of DPS Data

Some participants reported privacy-related concerns, including a fear of unwarranted tracking or interdiction of their adherence data and the potential for tampering with data, as additional barriers to DPS use. In particular, these participants expressed worries about whether swallowing a pill containing a radiofrequency emitter could transmit unwanted personal information to others related to their medications, adherence behavior, location tracking, and other physiological data.

You’re gonna have to sit in front of me and explain to me how it’s secure. What is making that radio frequency secure? Because I’m not just gonna randomly believe somebody that says. “Oh, well, you’re gonna swallow this magic pill. It’s gonna have a motherboard inside and it’s gonna randomly broadcast to an outside device, and tell people what medications you’re on, what you’re taking, when you’re taking it—and potentially additional information about it.” [Aged 58 years, female]
frequency of messages could increase or decrease over time, based on DPS-detected patterns of adherence and nonadherence.

I found the [confirmatory messages] a little annoying. I get too many text messages, so where it would be helpful is if I’d forgotten to take the medicine, then if I got a reminder in a text message to take my medicine, that would be great. Once I’ve done it, I don’t need the confirmation. [Aged 80 years, male]

Overall, the majority of participants viewed reminder messages—and in particular, reminder messages that follow nonadherence detected by the DPS—as one of the most important features of the technology. Most reported that changes in routine and forgetfulness were common reasons for missed doses and noted that just-in-time reminders would be helpful for maximizing the potential for adherence in the moment, as well as for positive reinforcement around adherence behavior more generally. Some participants also noted that it would be useful to integrate their existing reminder systems, such as smartphone alarms, into DPS-based reminder messages in order to further reinforce adherence.

Usually what happens is, I don’t know until the next day that I forgot to take [my medications], whereas, if I got a reminder at 9:00 p.m. saying, “Hey, you didn’t take your nightly pills,” that would be better, because then I could go take them. [Aged 82 years, male]

So you don’t need to beat somebody over the head, but they need to be told, “You missed your Lasix. This is a problem. You know, if you keep missing your Lasix, you could end up in the hospital.” Like it needs to be made clear. [Aged 58 years, female]

Participants also expressed an interest in customizing both the timing and content of reminder messages. In terms of timing, participants largely preferred a maximum of 2 messages proximal to each dosing window—for example, a reminder 30 minutes before the window and a follow-up reminder 15 minutes after the window if no ingestion was detected. Regarding the content of nonadherence reminders, participants reported an interest in simple messages indicating that they had forgotten to take their medication. Some also suggested that reminder messages could represent an opportunity to deliver HF-related educational information, especially related to the consequences of medication nonadherence.

You could do a snooze. You can pick, “Okay. Remind me five minutes before or five minutes after and during.” I don’t know. But let the person be able to choose how many reminders that they get. [Aged 40 years, female]

If on the app, there’s a little alarm that goes, “Hey, dummy, it’s time to take your pill,” and then I take a pill, and it monitors me taking the pill, then that’s pretty much all you could ask. [Aged 63 years, male]

Suggested Improvements for Future Iterations

Most recommendations focused on technological and design-based improvements to the Reader that would improve the user experience. Suggested enhancements included a new form factor that could integrate into typical clothing (eg, a pocket clip, wristband, smartphone case, or necklace). Participants also suggested that integrating additional features into the Reader, such as a voice assistant and colored lights to indicate adherence and reminders, would be helpful for individuals who do not carry a smartphone. Customization of the exterior casing of a Reader was also proposed, as was a stand-alone device that could provide adherence feedback independent of a smartphone. Finally, participants emphasized that future iterations of the system should come with detailed information around security protections and clear instructions for use.

I’d rather put it in my pocket or hold it in my hand. The best is just being able to plug it in and forget it...just because it’s something you don’t have to worry about anymore. I mean I have things plugged in around my house...I don’t think anything about ’em—they’re doing their job and that’s all I have to do. [Aged 82 years, male]

In the directions, I would want to be told that it’s not harmful and why it’s not harmful...I would like to know how long this is for. Like, the directions say, if you take this gelatin pill...it will stay inside you for three months and it’ll help us to track this for three months. I would like very clear instructions on how to use it. [Aged 58 years, female]

Discussion

Overview

HF is one of the leading causes of hospital readmissions and mortality in the world [1,2]. One key pillar in efforts to optimize medical management of HF includes maximizing adherence to pharmacotherapy. While DPS technology has previously been shown to accurately measure medication adherence across a wide spectrum of diseases, its efficacy has yet to be described in the context of HF treatment [27-30]. This qualitative investigation provides formative data surrounding the acceptance and design of a DPS that directly measures HF pharmacotherapy adherence. Findings indicate that participants were accepting of the DPS overall and perceived the system as a tool for enhancing accountability and providing data to inform the ongoing medical management of HF. Personalized adherence reminders were identified as a key component of the system. These data demonstrate the potential for DPS deployment to measure adherence among individuals with HF.

Principal Findings

After learning about the DPS, 60% (12/20) of participants perceived the system as an “acceptable” strategy to measure HF pharmacotherapy adherence. Participants also expressed the “usefulness” of the DPS based on its perceived ability to motivate adherence, provide accountability, and avoid double-dosing. For most individuals, having incontrovertible evidence of their adherence (or nonadherence)—especially in the context of clinical care, where their DPS adherence data could aid discussions with their HF physicians and guide future medication decisions—was perceived as the most valuable benefit. These qualitative findings reinforce other proposed
benefits in the literature of leveraging real-time adherence data to not only address medication adherence in chronic disease but potentially enhance the patient-physician relationship by providing key data to ground conversations surrounding disease progression [34]. This concept was reflected in the quantitative portion of the study, where 55% (11/20) of individuals considered having a visual record of ingestion patterns over time as a motivating factor to continue to maintain medication adherence. These perceptions are consistent with other investigations that suggest individuals with other chronic diseases find value in DPS-based adherence data as a technique to guide pharmacotherapy [35-37]. Together, our data suggests that future research investigations should seek to understand the feasibility of real-world DPS operation among individuals with HF, as well as evaluate the impact of adherence metrics on disease progression and treatment regimens in both research and clinical deployment contexts.

Efforts to optimize the design of DPS technology to measure adherence to HF medication should also include a customizable messaging architecture that responds to detected patterns of adherence. Based on our data, messaging components should include confirmation messages to help individuals recognize that they correctly operated the DPS and recorded their medication ingestion. Most importantly, messaging modules should include nonadherence reminder messages that respond to adherence patterns from the DPS, which participants identified as a critical and valuable component of the system. A major theme that emerged from our interviews was participants’ desire for control over both the timing and content of reminder messages related to their adherence patterns. While some wanted daily or even more frequent messaging that would coach them through adherence lapses, others preferred only on-demand access to their adherence data and less frequent feedback from the system. Importantly, some participants also reported that reminder messages could represent a potential method for providing educational information about HF and reinforcing DPS users’ understanding of the consequences of medication nonadherence. These emerging themes demonstrate the importance of involving patients in the design and delivery of adherence interventions linked to digital health systems such as the DPS [29,38]. Barriers to the use of the DPS included discomfort with technology among some users and concerns about the privacy and security of their data.

Ultimately, participants viewed the DPS in its current iteration as usable, but they suggested several key improvements that would enable better integration into daily life. Some of these suggestions, including miniaturizing the Reader and providing alternative off-body systems that can collect adherence data, are currently under investigation in other ingestible sensor trials [39]. Additionally, participants expressed that DPS deployment should only occur alongside a detailed discussion with users about the safety and security of the system. While the DPS is FDA 510k cleared, participants emphasized the importance of providing users with data from past users of the system, particularly surrounding any DPS-related adverse events [25].

Limitations and Future Studies

This study had several limitations. First, the sample consisted of a small number of inpatients recruited as part of a convenience sample at a single hospital site. Qualitative data around patient experiences with HF and responses to DPS technology may vary across other health care institutions and patient populations. Second, perspectives from non–English-speaking individuals are missing, as this study only enrolled English-speaking participants; future investigations should explore responses to DPS technology in non-English speakers. Third, qualitative interviews explored perceptions of the technology among participants who did not ingest any digital pills or use the DPS themselves. The lived experiences of participants who use and operate the DPS in a clinical trial setting may differ.

Conclusions

In conclusion, this study demonstrates that individuals with HF perceived DPS technology to be an acceptable and useful tool for measuring medication adherence, informing our understanding of how this technology can be operationalized with this patient population in the real world. Importantly, this investigation also defined key boundary conditions for the physical design of the DPS as well as the structure of reminder messages that both support adherence and confirm the correct operation of the DPS. Finally, these formative data will help to inform best practices for future studies that develop interventions to support HF pharmacotherapy adherence and assess the efficacy of the DPS in this context.

Acknowledgments

The work on this study was funded by discretionary funds to PRC from the Department of Emergency Medicine, Brigham and Women’s Hospital.

Data Availability

The data sets generated during and/or analyzed during this study are available from the corresponding author on reasonable request.

Authors’ Contributions

PRC, JLS, MV, and BMS designed the study and developed the qualitative interview guide. JJK and MC conducted participant screening and approach, enrolment, and qualitative interviews. JJK, JJT, and GRG generated the codebook for evaluation of
results and facilitated the coding using NVivo. JJK, JJT, PRC, and GRG evaluated and identified major themes in the qualitative results. All authors read and approved the final manuscript.

Conflicts of Interest

PRC is funded by National Institutes of Health (NIH) K23DA044874 and DP2DA056107. PRC reports equity in Biobot Analytics and consulting fees from Syntis Bio. BMS reports institutional research grants to Brigham and Women’s Hospital from Better Therapeutics, Boehringer Ingelheim, Merck, NovoNordisk, and Pfizer. Consulting fees from Abbvie (DSMB), AstraZeneca (DSMB), Boehringer Ingelheim, Better Therapeutics, Bristol Myers-Squibb, Elsevier Practice Update Cardiology, Esperion, Hanmi (DSMB), Lexeo (DSMB), Lexicon, NovoNordisk, and equity in Health at Scale and Dooxim. MV reports grants from American Regent, Amgen, AstraZeneca, Roche Diagnostics, Galmed, Novartis, Bayer AG, Oclutech, and Impulse Dynamics. Consulting fees from American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Merck, NovoNordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health. Payment for lectures, presentations, speakers, and manuscript writing comes from AstraZeneca, Boehringer Ingelheim, Cytokinetics, Novartis, and Roche Diagnostics. JLS received funding from Synapse Medicine to conduct an investigator-initiated study of their medication decision support software and a stipend from the American Society of Health-System Pharmacists to develop a web-based course on medication history taking.

Multimedia Appendix 1
COREQ (Consolidated Criteria for Reporting Qualitative Research) checklist.

Multimedia Appendix 2
Qualitative interview guide.

References


Richey AG, Kovacs I, Browne S. Use of an ingestible, sensor-based digital adherence system to strengthen the therapeutic relationship in serious mental illness. JMIR Ment Health 2022;9(12):e39047 [FREE Full text] [doi: 10.2196/39047] [Medline: 36459392]


Abbreviations
- COREQ: Consolidated Criteria for Reporting Qualitative Research
- DPS: digital pill system
- FDA: Food and Drug Administration
- HF: heart failure
- MTUAS: Media Technology Usage and Attitudes Scale

©Peter R Chai, Jenson J Kaithamattam, Michelle Chung, Jeremiah J Tom, Georgia R Goodman, Mohammad Adrian Hasdianda, Tony Christopher Carnes, Muthiah Vaduganathan, Benjamin M Scirica, Jeffrey L Schnipper. Originally published in JMIR Cardio (https://cardio.jmir.org), 15.02.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
Association of Arterial Stiffness With Mid- to Long-Term Home Blood Pressure Variability in the Electronic Framingham Heart Study: Cohort Study

Xuzhi Wang¹, MS; Yuankai Zhang¹, MA; Chathurangi H Pathiravasan¹, PhD; Nene C Ukonu¹, MA; Jian Rong², PhD; Emelia J Benjamin³,³,⁴, MD, ScM; David D McManus⁵,⁶, MD, ScM; Martin G Larson¹,², SD; Ramachandran S Vasan²,⁷, MD; Naomi M Hamburg⁸, MD; Joanne M Murabito⁹, MD; Chunyu Liu*, PhD; Gary F Mitchell¹⁰*, MD

¹Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States
²Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Boston, MA, United States
³Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States
⁴Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States
⁵Cardiology Division, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States
⁶Department of Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States
⁷Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States
⁸Section of Vascular Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States
⁹Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States
¹⁰Cardiovascular Engineering, Boston, MA, United States
*these authors contributed equally

Corresponding Author:
Chunyu Liu, PhD
Department of Biostatistics
Boston University School of Public Health
715 Albany Street
Boston, MA, 02118
United States
Phone: 1 6176385104
Email: liuc@bu.edu

Abstract

Background: Short-term blood pressure variability (BPV) is associated with arterial stiffness in patients with hypertension. Few studies have examined associations between arterial stiffness and digital home BPV over a mid- to long-term time span, irrespective of underlying hypertension.

Objective: This study aims to investigate if arterial stiffness traits were associated with subsequent mid- to long-term home BPV in the electronic Framingham Heart Study (eFHS). We hypothesized that higher arterial stiffness was associated with higher home BPV over up to 1-year follow-up.

Methods: At a Framingham Heart Study research examination (2016-2019), participants underwent arterial tonometry to acquire measures of arterial stiffness (carotid-femoral pulse wave velocity [CFPWV]; forward pressure wave amplitude [FWA]) and wave reflection (reflection coefficient [RC]). Participants who agreed to enroll in eFHS were provided with a digital blood pressure (BP) cuff to measure home BP weekly over up to 1-year follow-up. Participants with less than 3 weeks of BP readings were excluded. Linear regression models were used to examine associations of arterial measures with average real variability (ARV) of week-to-week home systolic (SBP) and diastolic (DBP) BP adjusting for important covariates. We obtained ARV as an average of the absolute differences of consecutive home BP measurements. ARV considers not only the dispersion of the BP readings around the mean but also the order of BP readings. In addition, ARV is more sensitive to measurement-to-measurement BPV compared with traditional BPV measures.
Introduction

Nearly half of US adults have hypertension [1]. The 2017 American College of Cardiology/American Heart Association blood pressure (BP) guidelines recommended out-of-office self-monitoring with home BP measurements to assist with hypertension diagnosis and management. Moreover, home-based BP measurements are stronger predictors of cardiovascular risk than office-based measurements [2]. BP fluctuates in response to everyday activities including exercise, mental stress, sleep, and other environmental stimuli. Parati et al [3] defined several types of blood pressure variability (BPV), including short-term BPV (eg, ambulatory BP monitoring within 24 hours), midterm BPV (eg, day-to-day BP monitoring in at least 3 days), and long-term BPV (eg, visit-to-visit BP monitoring over weeks to years). Elevated short-term BPV from ambulatory BP monitoring is associated with a higher risk of cardiovascular outcomes and all-cause mortality [4]. Day-to-day home BPV over 1 [5,6] to 4 weeks [7,8] is associated with cardiovascular risk and may identify persons at risk for cognitive decline [9]. Long-term BPV is associated with adverse cardiovascular events and mortality even after accounting for mean BP [10,11] in persons with and without hypertension [12]. However, week-to-week home BPV that is measured over the course of up to 1 year has not been well defined in the literature. In our study, we define mid- to long-term home BPV as the week-to-week home BPV collected during up to 1-year follow-up. Limited data are available on mid- to long-term home BPV in association with cardiovascular risk.

Arterial stiffness may be 1 biological mechanism linking BPV to cardiovascular disease risk [13]. Higher arterial stiffness is associated with a higher risk for incident hypertension [14] and is associated with both short-term and long-term adverse health outcomes including coronary disease events and heart failure [15,16]. Increased long-term visit-to-visit systolic BPV may contribute to the progression of arterial stiffness, regardless of mean BP levels [17]. Short-term (24-hour) BPV is associated with arterial stiffness [18]. Studies of mid- to long-term home BPV and arterial stiffness are limited; in one study, home BPV was correlated with a measure of arterial wave reflection in persons with high normal BP or hypertension [19]. Evaluation of the association of direct measures of arterial stiffness and wave reflection with home BPV over a mid- to long-term span is needed [3].

BPV indices have been proposed to calculate the overall variability as well as specific BP patterns [3], including SD, coefficient of variation (CV), average real variability (ARV), and variability independent of the mean. In our study, we obtained the ARV of week-to-week home BP from participants in the electronic Framingham Heart Study (eFHS) who returned digital BP data over up to 1-year follow-up. We investigated the association between arterial stiffness traits and the mid- to long-term home BPV, that is, the ARV of week-to-week home systolic blood pressure (SBP) and diastolic blood pressure (DBP) over up to 1-year follow-up from the eFHS participants. We hypothesize that higher arterial stiffness is associated with higher mid- to long-term home BPV over up to 1-year follow-up.

Methods

Study Participants

The Framingham Heart Study (FHS) is a multigenerational cohort study that began in 1948 with the original cohort enrolling 5209 residents from Framingham, Massachusetts. In 1971, the offspring cohort enrolled 5214 participants who were offspring of the original cohort and the spouses of these offspring. The FHS enrolled the Third Generation (Gen 3) cohort (N=4095), which included the grandchildren of original cohort from 2002 to 2005. During the same time, the FHS recruited and enrolled the Omni 2 cohort comprised of 410 multiethnic participants, and the New Offspring Spouse cohort (n=103) comprised of previously unenrolled parents of the Gen 3 participants. The participants in the Gen 3, Omni 2, and New Offspring Spouse cohorts underwent research exams approximately every 6 to 8 years. At examination 3 (2016 to 2019) participants underwent arterial tonometry testing and participants who owned a smartphone (including iPhone 4S or higher with iOS version 8.2 or higher or an Android phone beginning October 30, 2017) were invited to enroll in the eFHS. The eFHS participants downloaded a smartphone app and for participants using an iPhone, a Nokia Withings digital BP cuff was provided for home BP monitoring (Multimedia Appendix 1). The Nokia Withings digital cuff has been cleared for marketing by the Food and Drug Administration and it has been validated [20,21]. The eFHS participants downloaded the eFHS...
smartphone app from the Apple Store with in-person help from the eFHS–trained staff or with written instructions provided by eFHS staff.

Participants with arterial tonometry measures who returned valid digital home BP readings as part of eFHS were eligible for inclusion in the study sample. A total of 3451 participants underwent arterial tonometry at examination 3. Of the 3451 participants, 2125 participated in the eFHS study. Among the eFHS participants, 1156 participants provided BP data using the digital BP cuff and the study smartphone app. We further excluded 299 participants for the following reasons: participants did not return BP measurements within the first 12 months of attending examination 3 (n=126), participants returned BP readings for <3 weeks (n=153), or participants had missing values in tonometry measures or covariates (n=20). After exclusion, 857 participants remained for subsequent statistical analysis (Multimedia Appendix 2). We further compared our final study sample with those who did not enroll in eFHS and those ineligible for inclusion in our final sample.

**Assessment of Arterial Tonometry Measures**

We examined 3 measures of arterial stiffness and wave reflection obtained from arterial tonometry including carotid-femoral pulse wave velocity (CFPWV), central forward pressure wave amplitude (FWA), and reflection coefficient (RC). Trained sonographers obtained the tonometry measurements using a standard protocol previously reported [22,23]. We chose to investigate CFPWV as this measure is the standard noninvasive measure of arterial stiffness recommended for vascular research [24]. CFPWV was calculated from carotid-femoral transit time delay and carotid-femoral transit distance adjusted for parallel transmission in the brachiocephalic and carotid arteries and aortic arch [23]. Wave separation was performed in the time domain [23]. FWA was defined as the amplitude of the forward pressure wave. RC was defined as the ratio of backward and forward wave amplitudes. As compared with CFPWV, FWA is comparably sensitive to aortic wall stiffness but is more sensitive to aortic diameter [14]. RC was assessed as a measure of relative wave reflection as described previously [25]. The magnitude of the RC relies on the degree of impedance mismatch between proximal and distal vessels. Impedance matching reduces RC and hence the amount of wave reflection at the interface between the aorta and branch vessels, which may result in the transmission of excessive pulsatile energy into the microcirculation where it can cause damage [25].

**Assessment of Week-to-Week Home BP Measurement and BP Variability**

eFHS participants were asked to measure and transmit home BP readings once each week using the Withings-Nokia digital BP cuff for up to 1 year following enrollment. Multimedia Appendix 1 displays the timeline of data collection for arterial tonometry measures, as well as for weekly home BP readings. eFHS staff demonstrated proper use of the digital BP cuff while the participant was in the Research Center. Written instructions were also provided as some participants chose to set up the digital cuff at home. Participants were asked to take a BP reading at about the same time of day and the same day of the week each week. Participants were advised to sit in a comfortable position and rest for 5 minutes before each BP reading was measured. Participants were instructed to avoid taking BP readings after doing exercise or consuming caffeinated beverages. All BP recordings were date- and time-stamped. We conducted quality control procedures in the following way: BP readings taken at the research center during training by eFHS staff, duplicate observations with identical BP readings, observations with values that likely represented spurious results including observations with DBP>SBP, SBP>250, DBP>140, SBP>70, or DBP<40 were excluded. To reduce the bias of week-to-week home BPV, we included eFHS participants who had BP readings for at least 3 weeks [26]. Because we aimed to investigate the association of antecedent arterial stiffness with week-to-week home BPV over a mid- to long-term time span, we excluded BP measurements assessed more than 1 year after enrollment.

Several common variability measures have been used to assess BPV, including SD and CV. Compared with these BPV indices, ARV not only considers the dispersion of the BP time series around the mean but also accounts for the order of BP readings [27,28]. Furthermore, SD and CV are sensitive to long-range variation, such as a progressive increase or decrease in BP, while being less sensitive to measurement-to-measurement variability. ARV was first proposed to calculate the 24-hour ambulatory BPV. In our study, we proposed to apply the ARV to week-to-week home SBP and DBP measurements over a mid- to long-term time span defined as up to 1 year. ARV was calculated as the average of absolute differences between the adjacent BP readings using the following formula:

\[
ARV = \frac{1}{N(K-1)} \sum_{k=1}^{K} |X_{k} - X_{k+1}|
\]

where \( N \) is the number of weekly BP measurements and \( K \) is the order of weekly BP measurements.

**Covariates**

Clinical and laboratory variables were collected during examination 3 at the research center. BMI was calculated by dividing body weight (kg) by height (meters) squared. The current smoking variable was defined as self-reported smoking 1 or more cigarettes per day on average in the year before the examination. Lipid-lowering treatment variable was defined as a self-report of receiving lipid treatment in the past month before the examination. Antihypertensive medication variable was defined as a self-report of taking antihypertensive medication in the past month before the examination. Diabetes was defined as fasting plasma glucose ≥126 mg/dL or self-reported use of medications for diabetes. SBP and DBP were measured by averaging 2 readings while the participant was seated in a chair following a minimum of 5 minutes of rest at the research center. Hypertension was defined as SBP ≥130 mm Hg, DBP ≥80 mm Hg, or self-reported use of antihypertensive medications. Pulse pressure (PP) was calculated by taking the difference between SBP and DBP (SBP-DBP). Mean arterial pressure (MAP) was calculated as the integrated mean of the calibrated brachial pressure waveform at the time of the arterial tonometry test at examination 3. Fasting total cholesterol, high-density lipoprotein cholesterol, triglycerides, and blood glucose were also obtained during examination 3 at the research center.
Statistical Analyses
We reported mean and SD for continuous variables with approximately normal distributions, median and IQR for continuous variables with skewed distributions, and frequency and proportion for categorical variables. We conducted linear regressions to investigate the relations between arterial stiffness traits (predictors) and home BPV as estimated by ARV (outcomes). Prior to regression analysis, CFPWV was inverse-transformed to reduce heteroscedasticity and skewness and was then multiplied by –1000 to convert the units to milliseconds per meter and restore directionality. Therefore, the transformed CFPWV was expressed as –1000/CFPWV. To facilitate comparison and interpretation, all predictors and outcomes were scaled to unit SD in the regression analysis.

For each of the arterial stiffness traits (CFPWV, FWA, and RC), the association with home BPV was evaluated using separate linear models for ARV indices derived from home SBP and home DBP. In the base models, we performed linear regressions adjusting for age, age-squared, and sex. We adjusted for age-squared because previous studies observed that many stiffness measures and BP measures showed nonlinear age relations [22]. In the multivariable models, all base models were further adjusted for the following covariates: BMI, height, heart rate, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipid-lowering treatment, fasting glucose, diabetes, current smoking, and antihypertensive medication. The multivariable model helps us determine if there is a residual association of stiffness after adjusting for the other partially downstream and partially independent or upstream effects. In addition, in secondary analysis, to account for any pressure dependence of stiffness variables, we investigated how MAP influenced the associations between arterial stiffness traits and ARV of home BP by further adjusting for MAP in the multivariable model.

All statistical analyses were conducted using R (version 4.0; R Foundation for Statistical Computing). We used 2-tailed \( P < .05 \) for significance.

Ethical Considerations
All study participants provided informed consent. The eFHS and FHS protocols were approved by the institutional review board at the Boston University Medical Center (H-36586 and H-32132). We confirm that we have the permission to use the data.

Results
Participant Characteristics
Characteristics of the study sample are summarized in Table 1. Our study sample consisted of 857 participants who were middle-aged on average, with a moderate prevalence of hypertension. Average SBP and DBP were within the normal range, whereas approximately 1 in 5 participants reported taking antihypertensive medications. Participants were overweight on average, whereas the prevalence of smoking and diabetes was low. Compared with the BP readings at examination 3, the average home SBP during eFHS over 1-year of follow-up was slightly higher, and the average home DBP was similar. Compared with the FHS attendees who did not enroll in eFHS and the eFHS participants ineligible for our final analysis, the eFHS participants in our study sample were generally healthier, more likely to be female, and had a lower prevalence of risk factors. In addition, the final study sample had a lower mean CFPWV, larger mean RC, and lower mean SBP compared with the FHS participants who did not enroll in eFHS. However, compared with the ineligible eFHS participants, while our final study sample also had a larger mean RC, there were no significant differences in terms of CFPWV and SBP (Multimedia Appendix 3).
Table 1. Characteristics of the study sample (N=857).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Characteristics or covariates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>54 (9)</td>
</tr>
<tr>
<td>Sex (female), n (%)</td>
<td>508 (59)</td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>27.6 (4.79)</td>
</tr>
<tr>
<td>Race and ethnicity, n (%)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>17 (2)</td>
</tr>
<tr>
<td>Black</td>
<td>18 (2.1)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>19 (2.2)</td>
</tr>
<tr>
<td>White</td>
<td>786 (91.7)</td>
</tr>
<tr>
<td>Other</td>
<td>17 (2)</td>
</tr>
<tr>
<td>Height (inches), mean (SD)</td>
<td>66.6 (3.52)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL), mean (SD)</td>
<td>190 (35.8)</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol (mg/dL), mean (SD)</td>
<td>62.0 (19.9)</td>
</tr>
<tr>
<td>Triglycerides (mg/dL), median (IQR)</td>
<td>87 (65-104)</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL), mean (SD)</td>
<td>97.9 (17.9)</td>
</tr>
<tr>
<td>Heart rate (bpm), mean (SD)</td>
<td>58 (9.08)</td>
</tr>
<tr>
<td>Antihypertensive use, n (%)</td>
<td>189 (22.1)</td>
</tr>
<tr>
<td>Lipid lowering treatment, n (%)</td>
<td>194 (22.6)</td>
</tr>
<tr>
<td>Current smoking, n (%)</td>
<td>36 (4.2)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>49 (5.7)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>405 (47)</td>
</tr>
<tr>
<td>SBP&lt;sup&gt;a&lt;/sup&gt; (mm Hg), mean (SD)</td>
<td>119 (14.1)</td>
</tr>
<tr>
<td>DBP&lt;sup&gt;b&lt;/sup&gt; (mm Hg), mean (SD)</td>
<td>76 (8.5)</td>
</tr>
<tr>
<td>Mean arterial pressure (mm Hg), mean (SD)</td>
<td>92 (10.8)</td>
</tr>
<tr>
<td>Arterial tonometry measures</td>
<td></td>
</tr>
<tr>
<td>Carotid-femoral pulse wave velocity (m/second), mean (SD)</td>
<td>7.79 (1.79)</td>
</tr>
<tr>
<td>Forward pressure wave amplitude (mm Hg), mean (SD)</td>
<td>47.6 (12.1)</td>
</tr>
<tr>
<td>Reflection coefficient, mean (SD)</td>
<td>0.39 (0.07)</td>
</tr>
<tr>
<td>Digital home BP&lt;sup&gt;c&lt;/sup&gt; during eFHS&lt;sup&gt;d&lt;/sup&gt; follow-up</td>
<td></td>
</tr>
<tr>
<td>Follow-up weeks, median (IQR)</td>
<td>47 (21-52)</td>
</tr>
<tr>
<td>Number of BP readings, median (IQR)</td>
<td>23 (10-47)</td>
</tr>
<tr>
<td>Average SBP (mm Hg), mean (SD)</td>
<td>122 (12.3)</td>
</tr>
<tr>
<td>Average DBP (mm Hg), mean (SD)</td>
<td>76 (8.2)</td>
</tr>
<tr>
<td>ARV&lt;sup&gt;e&lt;/sup&gt; of SBP (mm Hg), mean (SD)</td>
<td>8.61 (3.34)</td>
</tr>
<tr>
<td>ARV of DBP (mm Hg), mean (SD)</td>
<td>5.50 (2.22)</td>
</tr>
</tbody>
</table>

<sup>a</sup>SBP: systolic blood pressure.
<sup>b</sup>DBP: diastolic blood pressure.
<sup>c</sup>BP: blood pressure.
<sup>d</sup>eFHS: electronic Framingham Heart Study.
<sup>e</sup>ARV: average real variability.
Association Between Arterial Stiffness Traits and Home BP Variability

We observed that higher CFPWV, FWA, and RC were associated with higher ARV of week-to-week home SBP adjusting for sex, age, and age-squared in the base models (Figure 1). For example, we observed that 1 SD increments in FWA were associated with 0.19 SD increments in the ARV of home SBP. The association of FWA with ARV of home SBP was attenuated but persisted in the multivariable model that adjusted for additional covariates, albeit with a 16% reduction in the magnitude of association. The association between RC and ARV of home SBP was strengthened after including additional covariates in the multivariable model; however, the association between CFPWV and ARV of home SBP was attenuated and became nonsignificant. After further adjusting for MAP, the associations of FWA and RC with ARV of SBP were robust (attenuation: 44% and 43%, respectively; Multimedia Appendix 4).

Next, we performed association analyses between arterial stiffness traits and ARV of week-to-week home DBP (Figure 2). Higher CFPWV and FWA were associated with higher ARV of home DBP in the base models. However, we found no evidence of an association of RC with ARV of home DBP in the base models. The association of FWA with ARV of DBP persisted after adjustment for additional covariates (attenuation: 33%). Higher RC was associated with higher ARV of home DBP with a larger effect estimate, and CFPWV was no longer associated with ARV of home DBP in the multivariable model. When further adjusting for MAP, the directionality of the association between CFPWV and ARV of home DBP was reversed, resulting in higher CFPWV associated with lower ARV of DBP. Neither FWA nor RC was associated with ARV of DBP in the model that further considered MAP (Multimedia Appendix 5).

Figure 1. Association of arterial stiffness traits with ARV of home SBP in the base model and multivariable model. Covariates in base models include sex, age, and age squared. Covariates in the multivariable models include sex, age, age squared, BMI, height, heart rate, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipid-lowering treatment, fasting glucose, diabetes, current smoking, and antihypertensive medication. ARV: average real variability; CFPWV: carotid-femoral pulse wave velocity; FWA: forward pressure wave amplitude; RC: reflection coefficient; SBP: systolic blood pressure.

<table>
<thead>
<tr>
<th>Trait</th>
<th>B</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>RC</td>
<td>0.14</td>
<td>(0.07 to 0.22)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>0.08</td>
<td>(0.01 to 0.15)</td>
<td>.02</td>
</tr>
<tr>
<td>FWA</td>
<td>0.16</td>
<td>(0.09 to 0.23)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>0.19</td>
<td>(0.12 to 0.26)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CFPWV</td>
<td>0.07</td>
<td>(−0.01 to 0.16)</td>
<td>.10</td>
</tr>
<tr>
<td></td>
<td>0.13</td>
<td>(0.05 to 0.21)</td>
<td>.001</td>
</tr>
</tbody>
</table>
Discussion

We investigated the association of arterial stiffness measures with mid- to long-term BPV defined as ARV of week-to-week home SBP and DBP collected using a digital BP cuff for up to 1-year follow-up among middle-aged to older community-dwelling adults with and without hypertension. Higher FWA and RC were associated with higher mid- to long-term ARV of home SBP after adjustment for important covariates (eg, antihypertensive use), while CFPWV was not associated with ARV of home SBP. Similarly, both FWA and RC exhibited positive associations with ARV of DBP in the multivariable models, while there was no evidence of an association of CFPWV with ARV of DBP. After further adjusting for MAP in the secondary analysis, the associations of FWA and RC with ARV of SBP were weakened but persisted compared with multivariable models without accounting for MAP, and we also observed an association between higher CFPWV and lower mid- to long-term ARV of DBP. This negative association relates to the opposing effects of MAP and CFPWV on DBP. An increase in MAP tends to increase DBP, while the MAP-related increase in CFPWV tends to increase PP and therefore decrease DBP [29]. As a result, when the aorta is compliant, changes in MAP will be directly reflected in commensurate changes in DBP. However, as the aorta stiffens, the effects of changes in MAP on DBP will be opposed by changes in PP, resulting in reduced DBP variability. Our findings suggest that measures of higher aortic stiffness and wave reflection were associated with week-to-week variation of BP in a home-based setting.

We used ARV due to its advantages over conventional indices like SD and CV. In comparison, ARV is an average of the absolute differences between consecutive BP measurements. It is more sensitive to the individual BP measurement sequence and may be a better index to represent short-term, reading-to-reading changes. For instance, a steady change (eg, 140, 130, 120, and 110) versus a more chaotic change (eg, 140, 120, 130, and 110) in BP will have the same mean, SD, and CV but a different ARV. Therefore, the ARV considers the order of the measurements and differences in consecutive BP measurements and therefore may be able to better reflect differences between steady change versus more dynamic change.

Central artery stiffness contributes to the pathogenesis of hypertension and the risk for target organ damage in the heart, kidneys, and brain. In contrast, while wave reflection can add to the load on the heart, it may be protective in the periphery by limiting the potentially harmful pulsatile energy transmitted to target organs [14,30]. Among Japanese adults with at least 1 risk factor for cardiovascular disease (CVD), day-to-day home BPV was associated with CVD events in adults with higher baseline arterial stiffness suggesting that arterial stiffness contributes to the association between home BPV and CVD risk [13] observed in a number of studies [6,8,31]. In the population-based Maastricht Study focusing on type 2 diabetes, 7-day systolic BPV was associated with aortic stiffness [32]. Similarly, a study of middle-aged Korean adults with high normal BP or hypertension, identified a significant relationship between home SBP variability and arterial stiffness. In that study, home BP measurements also occurred over 7 consecutive days. Our study extends these findings to home BP measurements taken week-to-week over a longer time horizon.
of up to 1 year and observed an association of arterial stiffness measures with mid- to long-term ARV of home BP.

The underlying pathophysiology of systolic versus diastolic BPV has been posited to be different [33]. The main distinction between SBP and DBP variability lies in the differing effects of PP variability and MAP variability. PP variability and MAP variability have additive effects on SBP and offsetting effects on DBP. The ARV of SBP correlates with arterial stiffness as observed in our study while ARV of DBP may be more related to endothelial dysfunction and impaired autonomic function [34].

Out-of-office home BP self-monitoring is a strategy that can be achieved in the community and in low-resource areas to improve hypertension awareness, treatment, and control and is supported by data from the International Databases on Ambulatory and Home Blood Pressure in Relation to Cardiovascular Outcomes [35] and endorsed by the American Heart Association and American College of Cardiology [1]. In addition, the ability to measure BP at home offers the patient the convenience of avoiding some office-based visits, empowers the patient to take multiple measurements over a longer period of time, and can improve engagement with BP management resulting in lower BP [36,37]. Using data from the National Health and Nutrition Examination Survey, less than 50% of people with known hypertension engaged in home BP monitoring at least monthly, leaving more work to be done [38]. With the rising use of mobile phones in the United States across diverse populations (White, Black, Hispanic, urban, and rural) [39], the extension of home BP measurements to digital measurements as in our study may permit the transmission of BP measurements to the health care team, development of educational visualization tools to enhance understanding of the BP measurement, and the use of nudges to encourage an individual to take BP measurements [40].

Our study had several strengths including the well-characterized community-based sample, the arterial stiffness measures obtained with a standardized protocol, and the tracking of BPs in the home setting using a digital device over up to 1 year. Higher SBP variability (visit-to-visit) is associated with adverse CVD outcomes in adults with optimal BP levels irrespective of underlying hypertension [12]. Therefore, it is critical to include individuals across the BP spectrum in studies that investigate BPV and other risk factors for CVD. Our study included individuals across a broad spectrum of BP levels, including those with and without underlying hypertension. This comprehensive inclusion enabled us to contribute valuable insights into understanding the potential biological mechanism that leads to increased risk of CVD with elevated BPV.

Our study also had some limitations that merit comment. First, more than half of the eFHS participants were excluded from our final sample, which led to differences in participant demographics between the study sample and the eFHS participants ineligible for our final analysis. The exclusion process potentially introduced a selection bias and limited the generalization of our findings to individuals of more diverse backgrounds. However, it is important to note that these 2 groups did not show significant differences in the prevalence of hypertension, reported use of antihypertensive medications, or measures of arterial stiffness, except for RC. This similarity may help mitigate the impact of selection bias to some extent. Second, the study is observational and cannot infer a causal relationship. Third, home BP measurements were taken by participants once per week at about the same time of the day each week. This schedule limited our ability to collect more frequent BP data, consequently restricting our ability to investigate BPV within a day or across different days within the same week. Advances in technology include wearables that measure BP at the wrist, which can provide more frequent data and a more convenient approach to collecting BP measurements than our method. However, more data are needed to determine the accuracy and usefulness of these devices. In addition, we did not correct for multiple statistical tests, which may lead to an inflated type I error. However, traditional correction techniques such as the Bonferroni correction would be overly conservative in our case due to correlated traits. Notably, upon applying multiple testing corrections, the results in our primary analysis remained largely unaffected, except for the association between ARV of home DBP and FWA, which subsequently lost its statistical significance.

In conclusion, in our middle-aged to older adult community-based sample, higher FWA and RC were associated with higher mid- to long-term ARV of home SBP and ARV of home DBP. Our findings suggest that higher aortic stiffness, as assessed by FWA, and greater relative wave reflection, as assessed by the global RC, may increase the week-to-week variation of home-based BP. The association of arterial stiffness with ARV of home BP may be a biological mechanism contributing to the increased risk of CVD associated with home BPV. Future work is needed to determine the potential beneficial effects on CVD outcomes of targeted attempts to reduce home BPV. The importance of defining the contribution to cardiovascular risk and outcomes of not only magnitude and duration but also variability of risk factors, including BP, is being recognized and requires additional work.

Acknowledgments

This study was supported by a grant (R01HL141434); the Framingham Heart Study (contract 75N92019D00031 and RWJ 74624); and the National Heart, Lung, and Blood Institute (contracts N01-HC-25195, HHSN268201500001l, and 75N92019D00031; [RSV]; R01-DK-080739 [RSV]; R01-HL-107385, 1R01HL126136-01A1, HL93328, HL142983, HL143227, and HL131532 [RSV and GFM]; and 1RO1-HL-70100, R01HL092577, 2U54HL120163, and 1R01AG066010 [EJB]).
**Data Availability**

The data sets generated and analyzed during this study are available from the corresponding author on reasonable request and will be available at public repositories (DbGAP and BioLINCC).

**Conflicts of Interest**

GFM is the owner of Cardiovascular Engineering, Inc, a company that designs and manufactures devices that measure vascular stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. GFM also serves as a consultant to and receives grants and honoraria from Novartis, Merck, Bayer, Servier, Philips, and deCODE genetics. DDM has received research support from Apple Inc, Bristol-Myers Squibb, Boehringer-Ingelheim, Pfizer, Flexcon, Samsung, Philips Health care, and Biotronik, and has received consultancy fees from Heart Rhythm Society, Bristol-Myers Squibb, Pfizer, Flexcon, Boston Biomedical Associates, and Rose Consulting. DDM also declares financial support for serving on the Steering Committee for the GUARD-AF study (NCT04126486) and the Advisory Committee for the Fitbit Heart Study (NCT04176926). NMH has received funding from the American Heart Association and the National Institutes of Health.

---

**Multimedia Appendix 1**

The timeline of data collection for arterial tonometry measures, as well as weekly home BP readings.

[ PNG File, 59 KB - cardio_v8i1e54801_app1.png ]

**Multimedia Appendix 2**

Flowchart of sample selection.

[ PNG File, 219 KB - cardio_v8i1e54801_app2.png ]

**Multimedia Appendix 3**

Comparison between three groups of samples.

[ DOCX File, 19 KB - cardio_v8i1e54801_app3.docx ]

**Multimedia Appendix 4**

Association of arterial stiffness traits with ARV of home SBP in the base model, multivariable model, and multivariable model that adjusted for MAP. Covariates in base models include sex, age and age squared. Covariates in the multivariable models include sex, age, age squared, BMI, height, heart rate, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipid-lowering treatment, fasting glucose, diabetes, current smoking, and anti-hypertensive medication. The multivariable model with MAP was further adjusted for MAP in addition to the variables in the multivariable model. ARV: average real variability; MAP: mean arterial pressure; RC: reflection coefficient; CFPWV: carotid femoral pulse wave velocity; FWA: forward pressure wave amplitude; SBP: systolic blood pressure.

[ PNG File, 149 KB - cardio_v8i1e54801_app4.png ]

**Multimedia Appendix 5**

Association of arterial stiffness traits with ARV of home DBP in the base model, multivariable model, and multivariable model that adjusted for MAP. Covariates in base models include sex, age and age squared. Covariates in the multivariable models include sex, age, age squared, BMI, height, heart rate, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipid-lowering treatment, fasting glucose, diabetes, current smoking, and anti-hypertensive medication. The multivariable model with MAP was further adjusted for MAP in addition to the variables in the multivariable model. ARV: average real variability; MAP: mean arterial pressure; RC: reflection coefficient; CFPWV: carotid femoral pulse wave velocity; FWA: forward pressure wave amplitude; DBP: diastolic blood pressure.

[ PNG File, 146 KB - cardio_v8i1e54801_app5.png ]

**References**


https://cardio.jmir.org/2024/1/e54801


**Abbreviations**

- **ARV:** average real variability
- **BP:** blood pressure
- **BPV:** blood pressure variability
- **CFPWV:** carotid-femoral pulse wave velocity
- **CV:** coefficient of variation
- **CVD:** cardiovascular disease
- **DBP:** diastolic blood pressure
- **eFHS:** electronic Framingham Heart Study
Accurate Modeling of Ejection Fraction and Stroke Volume With Mobile Phone Auscultation: Prospective Case-Control Study

Martin Huecker1, MD; Craig Schutzman1, MD; Joshua French1, MD; Karim El-Kersh2, MD; Shahab Ghafghazi1, MD; Ravi Desai3, MD; Daniel Frick1, MD; Jarred Jeremy Thomas1, MD

1Department of Emergency Medicine, University of Louisville, Louisville, KY, United States
2Department of Pulmonary and Critical Care Medicine, The University of Arizona, Phoenix, AZ, United States
3Lehigh Valley Health Network Cardiology and Critical Care, Allentown, PA, United States

Corresponding Author:
Martin Huecker, MD
Department of Emergency Medicine
University of Louisville
530 South Jackson St.
Louisville, KY, 40202
United States
Phone: 1 5028525689
Email: martin.huecker@louisville.edu

Abstract

Background: Heart failure (HF) contributes greatly to morbidity, mortality, and health care costs worldwide. Hospital readmission rates are tracked closely and determine federal reimbursement dollars. No current modality or technology allows for accurate measurement of relevant HF parameters in ambulatory, rural, or underserved settings. This limits the use of telehealth to diagnose or monitor HF in ambulatory patients.

Objective: This study describes a novel HF diagnostic technology using audio recordings from a standard mobile phone.

Methods: This prospective study of acoustic microphone recordings enrolled convenience samples of patients from 2 different clinical sites in 2 separate areas of the United States. Recordings were obtained at the aortic (second intercostal) site with the patient sitting upright. The team used recordings to create predictive algorithms using physics-based (not neural networks) models. The analysis matched mobile phone acoustic data to ejection fraction (EF) and stroke volume (SV) as evaluated by echocardiograms. Using the physics-based approach to determine features eliminates the need for neural networks and overfitting strategies entirely, potentially offering advantages in data efficiency, model stability, regulatory visibility, and physical insightfulness.

Results: Recordings were obtained from 113 participants. No recordings were excluded due to background noise or for any other reason. Participants had diverse racial backgrounds and body surface areas. Reliable echocardiogram data were available for EF from 113 patients and for SV from 65 patients. The mean age of the EF cohort was 66.3 (SD 13.3) years, with female patients comprising 38.3% (43/113) of the group. Using an EF cutoff of ≤40% versus >40%, the model (using 4 features) had an area under the receiver operating curve (AUROC) of 0.955, sensitivity of 0.952, specificity of 0.958, and accuracy of 0.956. The mean age of the SV cohort was 65.5 (SD 12.7) years, with female patients comprising 34% (38/65) of the group. Using a clinically relevant SV cutoff of <50 mL versus >50 mL, the model (using 3 features) had an AUROC of 0.922, sensitivity of 1.000, specificity of 0.844, and accuracy of 0.923. Acoustics frequencies associated with SV were observed to be higher than those associated with EF and, therefore, were less likely to pass through the tissue without distortion.

Conclusions: This work describes the use of mobile phone auscultation recordings obtained with unaltered cellular microphones. The analysis reproduced the estimates of EF and SV with impressive accuracy. This technology will be further developed into a mobile app that could bring screening and monitoring of HF to several clinical settings, such as home or telehealth, rural, remote, and underserved areas across the globe. This would bring high-quality diagnostic methods to patients with HF using equipment they already own and in situations where no other diagnostic and monitoring options exist.

(JMIR Cardio 2024;8:e57111) doi:10.2196/57111
KEYWORDS
ejection fraction; stroke volume; auscultation; digital health; telehealth; acoustic recording; acoustic recordings; acoustic; mHealth; mobile health; mobile phone; mobile phones; heart failure; heart; cardiology; health care costs; audio; echocardiographic; echocardiogram; ultrasonography; echocardiography; accuracy; monitoring; telemonitoring; recording; recordings; ejection; machine learning; algorithm; algorithms

Introduction

Cardiovascular disorders contribute immensely to morbidity and mortality in the United States and worldwide. Heart failure (HF) is defined as “a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion” [1]. At least 64.3 million people around the world have HF, with that number expected to increase due to improved health care [2]. HF accounts for 1% to 2% of all hospitalizations in high-income countries and is the top cause of admission for patients older than 65 years of age [2]. The United States spent more than US $30 billion on HF in 2012, with a projected increase to US $69.8 billion by 2030 [2]. The mortality of HF ranges from as low as 2% to 4% per year in those with chronic HF and up to 36.5% in those with acute HF [2]. In the United States, the mandatory federal pay-for-performance Hospital Readmissions Reduction Program targets patients with HF and ties reimbursement to 30-day, all-cause, Medicare, fee-for-service readmissions after initial hospitalization for HF; rates reach as high as 23% in some studies [3].

HF is divided into three categories based on the left ventricular ejection fraction (LVEF): (1) HF with reduced ejection fraction (EF), (2) mildly reduced EF, and (3) preserved EF, with EF ranges of ≤40%, 41% to 49%, and ≥50%, respectively [1,2]. LVEF, the percentage of blood in the left ventricle that exits into the aorta during a cardiac cycle, is determined using various imaging techniques, such as echocardiography, cardiac magnetic resonance imaging, nuclear cardiology, or cardiac catheterization [1,4,5]. Thus, the classification of HF depends on the accurate determination of LVEF using expensive diagnostic methods obtained in outpatient or inpatient settings [6,7]. A study from the United Kingdom found that most new HF cases were diagnosed in inpatient settings despite the presence of symptoms that should have triggered an earlier outpatient evaluation [8]. This is at least partly due to barriers such as the availability of transportation, cost concerns, and access to medical facilities. Millions of potential patients with HF worldwide lack access to even basic medical care and are, therefore, unable to undergo risk assessment for heart disease.

The management of patients diagnosed with HF involves serial testing to detect changes in heart function. The techniques used to measure LVEF and other cardiac parameters (cardiac output, indexed stroke volume, etc) can have significant variability, limiting prognostication and treatment efficacy [5]. Diagnostic tests to determine EF also experience great variability, limiting prognostication and treatment efficacy [5]. Due to the somewhat limiting paradigm of EF categories, more regular use of vital measures such as stroke volume (SV) could delineate patients with HF with more granularity, even having implications for treatment [9]. Telehealth represents a potential mechanism to reduce the rates of 30-day readmission in patients with HF [10]. Patients without access to large hospital systems and diagnostic testing would benefit immensely from a low-cost yet accurate method of determining these parameters. The technology harnessing more than 8 billion global mobile phones could vastly improve health care disparities [11].

This pilot study describes a novel diagnostic technology using audio recordings from a standard mobile phone. Prior publications have sought both invasive and noninvasive means of describing cardiac function, but very few have moved out of research phases to clinical or practical use [12-16]. This study aims to establish a set of markers using complex but reproducible mathematics from mobile phone auscultation data that would enable the determination of EF and SV for HF detection, classification, and monitoring. The goal of this study was to demonstrate the feasibility of creating mobile phone models for the classification of LVEF and SV by matching echocardiographic results to phone recordings.

Methods

Settings and Participants

This is a pilot prospective study of convenience samples of patients presenting to 2 hospital systems for cardiac workups. At site 1, an urban academic center in the Southern United States, study personnel obtained recordings from patients who received inpatient clinical evaluation for cardiac disease. All participants had a transthoracic echocardiogram within 30 days. At site 2, a large community clinical site in the Northeastern United States, patients already scheduled for outpatient transthoracic echocardiogram were enrolled at the time of the study, and recordings were obtained at the same time as the echo. To minimize audible confounding, the team excluded patients with mechanical heart valves. Patients were also excluded if they had a positive SARS-CoV-2 test, were younger than 18 years of age, or were pregnant.

Ethical Considerations

This study was approved by the human participants’ research institutional review boards of the University of Louisville (number 20.0605) at both clinical sites. Written informed consent was obtained from all participants, with the specification that data obtained would be used for research. Patients had the freedom to withdraw at any time, including after data collection and analysis. Privacy and confidentiality were protected by storing all data in secure, encrypted locations. At all times, only IRB-approved personnel had access to the stored data. The participants did not receive any compensation for participation. Patients were consented after the completion of any urgent or emergent diagnostic testing or treatment and after evaluation by inpatient physician teams, to ensure that the study would not
delay necessary evaluation or treatment. The study team did not recommend, order, or perform any testing.

**Data Collection**

The research team obtained demographics and clinical information from the electronic medical record at each site. Echocardiography was obtained by a single laboratory at each clinical site. The coders used the EF from the final interpretation of the echocardiogram report. Data from site 1 were uploaded into CardBox (Box Inc), a web-based, encrypted research cloud space. Data from site 2 were uploaded to password-protected Google Drive. Data included demographics and formal echo results, as well as other data such as cardiac catheterization reports, vascular imaging, and primary admission diagnoses. Clinical data were matched to respective (deidentified) sound recording files using unique identification codes. SV estimates were based on the Teichholz method—not because it was preferred, but because it was available on most echocardiogram reports.

**Technology and Analytic Method**

In addition to open-source Python (Python Software Foundation)-based software, 2 proprietary software were used in the study. The first is Another Sound Recorder (ASR), a recording app developed by NLL APPS. It allowed all recordings to be made in a standardized format across the various phone brands used in the study. The second is Time Series Dynamics (TSD) software developed by Fleming Scientific. It maps time series observation of systems, such as auscultation and waveform data, into a set of descriptive “features.” The mapping relies entirely on models from “dynamics” which, in physics, is the study of motion resulting from force. These “physics-based” features can then be reduced and used as dependent variables in rigorous statistical modeling. The TSD approach, which intends to preserve physical and mathematical rigor throughout the modeling process, eliminates the need for neural networks and makes it possible to work effectively with smaller data sets [17]. The research team has extensive experience with the TSD approach and is currently using it in analogous respiratory mobile phone auscultation studies funded by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

Cardiac auscultation acoustics represent primarily the sounds of hemodynamics, which is the movement of blood resulting from forces applied by the heart and vascular system. In traditional auscultation, providers use these acoustics to make inferences about organ and system functionality. The approach in this paper is analogous, except that the acoustics are mapped by dynamics-based models. The approach also differs from more common machine learning approaches to auscultation data processing that typically rely on some combination of frequency domain, linear stochastics, and neural networks.

The research team hypothesizes that, in the classification of hemodynamics, the use of dynamics-based mapping is domain relevant. It is also consistent with published chaos-based and enthalplic-based views of cardiac function [18,19]. In the approach, thousands of dynamics-based features were extracted from the acoustic recordings by TSD software. Selected features were then matched to echocardiogram findings by simple logistic regression [20]. To maintain statistical rigor by avoiding overfitting, the number of features used in the regression was limited to 4, which represents the minimum number of positive or negative testing cases divided by 10. The 4 features were selected by the maximum entropy method that produced 35 similar combinations that were evaluated separately for best performance. Dimensionality reduction was sufficient to eliminate the need for a validation step.

Developed by Fleming Scientific, this proprietary unpublished technology extracts features found in sound recordings from microphones of unmodified mobile phones. By using models from actual physical acoustics, we created algorithms to match echocardiogram findings. The physics models are designed to describe hemodynamics from the acoustic data, thereby making it possible to classify organ functionality directly. The method produces thousands of candidate features for modeling but uses only a few to avoid overfitting. The features were matched to echocardiogram findings by using logistic regression [20]. The approach eliminates the need for neural networks entirely and offers a more rigorous approach to developing artificial intelligence (AI) software.

The research team obtained audio recordings with an assortment of unmodified, nonencased Android mobile phones including LG and Motorola Trac phones and 2 Samsung Galaxy models. The voice recorder was standardized by using ASR, a free open-source app easily installed on any Android product. Both sites used the following ASR settings: WAV format, similar frame speed, mono recording, and no filters or other settings activated. Recordings took place in settings with moderate background noise, such as emergency department rooms, inpatient rooms, and echocardiography labs.

Study personnel obtained the recordings by pressing the microphone lightly into the patient’s skin to minimize surface noise. The participants underwent a 20-second recording at the aortic valve area (second intercostal space just to the right of the sternum). The participants were not required to hold their breath. Patients could be in any position for recording, but most were sitting or semirecumbent. The phones were capable of capturing frequencies as low as 10 Hz, which are well below the range of human auscultation perception. The phones were kept in a secure location at each site, for use only by study personnel.

Recordings from patients underwent physics-based analysis to create the features for use in modeling. The features would serve as independent variables while the dependent variables were parameters such as LVEF, determined by diagnostic testing during hospitalization. By matching selected features to the gold-standard parameters from established diagnostic procedures, algorithms were created that enable common phones to reproduce the gold-standard parameters.

The goal of the analysis was to demonstrate the feasibility of creating mobile phone algorithms for the classification of LVEF and SV by matching echocardiographic results to the phone recordings.
TSD differs from machine learning–based AI in that its overarching goal is to deduce the best physics-based models for making algorithms, thereby maintaining rigor as much as possible. The hemodynamics deduced in this study are consistent with published chaos-based and enthalpic-based views of cardiac function [18,19]. However, this study was not designed to provide physiological verification of the deduced physics.

TSD’s physics-based approach eliminates the need for neural networks and overfitting strategies entirely, potentially offering advantages in data efficiency, model stability, regulatory visibility, and physical insightfulness [17]. TSD’s use of passive signals rather than active signals differs from echocardiogram and most other gold-standard imaging technologies; it uses an analytical foundation designed to describe dynamics directly.

Although the algorithms are based on physics, evaluating them relies on statistical methods consistent with logistic regression analysis. The algorithms were evaluated for the area under the receiver operating curve (AUROC) using the trapezoidal method. Values >0.9 can be interpreted as “excellent,” whereas values in the range of 0.8-0.9 can be interpreted as “good” [21]. Sensitivity, specificity, and accuracy were also calculated and presented with confusion matrix values per common practice. The validity of features was also verified by $Z$ test>2 criteria in addition to the heuristic argument.

**Results**

**Study Population**

In total, 113 patients were enrolled across 2 sites. No recording had to be excluded from the analysis. However, some echocardiogram reports were excluded because of incomplete or inconsistent reporting of EF (n=2) or SV (n=50). From the recent echocardiogram reports, it was possible to match EF findings in 113 patients and estimated SV in 65 patients. For the 113 patients in the EF cohort, the mean age was 66.3 (SD 13.3) years. The cohort consisted of 61.7% (n=70) male patients and 38.3% (n=43) female patients. Regarding race and ethnicity, 77% (n=87) were White, 20.4% (n=23) were Black, and 2.6% (n=3) were Hispanic or Latino. For the 65 patients in the SV cohort, the mean age was 65.5 (SD 12.7) years. The cohort consisted of 66% (n=43) male patients and 34% (n=22) female patients. Regarding race and ethnicity, 74% (n=48) were White and 26% (n=17) were Black. The EF cohort had a mean BMI of 28.3 (SD 6.323) and a mean body surface area (BSA) of 2.03 (SD 0.273). The SV cohort had a mean BMI of 29.3 (SD 6.561) and a mean BSA of 2.05 (SD 0.272).

**LVEF Results**

The 113-participant EF cohort consisted of 81 participants from site 1 and 32 from site 2. Of note, 57 participants had EF <55% and 56 had an EF>55%. For analysis, the cases were separated into a binary “positive” versus “negative” classification based on the HF disease EF cutoff of 40%. A total of 42 participants with EF ≤40% were designated “positive” in binary classification and they represented 37.2% (n=42) of the cohort; the other 71 (62.8%) participants had EF >40%. The number of features was limited to 4 to avoid overfitting the algorithm. The AUROC was 0.955 (“excellent”), as shown in Table 1. Case separation was also excellent as shown in Figure 1. The EF algorithm accuracy performed similarly across demographics, BSA, and clinical sites (Table 2).

<table>
<thead>
<tr>
<th>Cases (N=113)</th>
<th>Model evaluation</th>
<th>Features</th>
<th>$Z$ test</th>
</tr>
</thead>
<tbody>
<tr>
<td>True negative (n=68)</td>
<td>AUROC$^a$ 0.955</td>
<td>1</td>
<td>2.3</td>
</tr>
<tr>
<td>False negative (n=2)</td>
<td>Sensitivity 0.952</td>
<td>2</td>
<td>7.2</td>
</tr>
<tr>
<td>True positive (n=40)</td>
<td>Specificity 0.958</td>
<td>3</td>
<td>3.9</td>
</tr>
<tr>
<td>False positive (n=3)</td>
<td>Accuracy 0.956</td>
<td>4</td>
<td>9.4</td>
</tr>
</tbody>
</table>

$^a$AUROC: area under the receiver operating curve.
Figure 1. Actual versus predicted ejection fraction (EF). FN: false negative; FP: false positive; TN: true negative; TP: true positive.

Table 2. EF\textsuperscript{a} model had high accuracy across sex, race, BSA\textsuperscript{b}, and age.

<table>
<thead>
<tr>
<th>Profile</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.94</td>
</tr>
<tr>
<td>Female</td>
<td>0.98</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>0.97</td>
</tr>
<tr>
<td>Black or African American</td>
<td>0.95</td>
</tr>
<tr>
<td>BSA</td>
<td></td>
</tr>
<tr>
<td>BSA&lt;2.04\textsuperscript{c}</td>
<td>0.97</td>
</tr>
<tr>
<td>BSA&gt;2.04\textsuperscript{c}</td>
<td>0.95</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>Younger than 66.3\textsuperscript{c}</td>
<td>0.98</td>
</tr>
<tr>
<td>Older than 66.3\textsuperscript{c}</td>
<td>0.93</td>
</tr>
<tr>
<td>Site</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.98</td>
</tr>
<tr>
<td>2</td>
<td>0.97</td>
</tr>
</tbody>
</table>

\textsuperscript{a}EF: ejection fraction.
\textsuperscript{b}BSA: body surface area.
\textsuperscript{c}EF sample mean.

SV Results

In all, 65 participants with SV data were all enrolled at site 1. Using a clinically relevant cutoff of <50 mL, 33 (51%) were categorized as positive and 32 (49%) were categorized as negative. For analysis, the number of features was limited to 3 to avoid overfitting the algorithm. Results showed a sensitivity of 100% for the model, with an AUROC of 0.922 (Table 3). Figure 2 illustrates case separation. The SV algorithm accuracy performed similarly across demographics but had a slight drop off in accuracy among patients with higher BSA (Table 4). Acoustics frequencies associated with SV were observed to be higher than those associated with EF and, therefore, were less likely to pass through tissue without distortion.
Table 3. SV<sup>a</sup> algorithm performance and features.

<table>
<thead>
<tr>
<th>Cases (N=65)</th>
<th>Model evaluation</th>
<th>Features</th>
<th>Z test</th>
</tr>
</thead>
<tbody>
<tr>
<td>True negative (n=27)</td>
<td>AUROC&lt;sup&gt;b&lt;/sup&gt; 0.922</td>
<td>1</td>
<td>4.0</td>
</tr>
<tr>
<td>False negative (n=0)</td>
<td>Sensitivity 1.000</td>
<td>2</td>
<td>2.5</td>
</tr>
<tr>
<td>True positive (n=33)</td>
<td>Specificity 0.844</td>
<td>3</td>
<td>3.1</td>
</tr>
<tr>
<td>False positive (n=5)</td>
<td>Accuracy 0.923</td>
<td>N/A&lt;sup&gt;c&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<sup>a</sup>SV: stroke volume.
<sup>b</sup>AUROC: area under the receiver operating curve.
<sup>c</sup>N/A: not applicable.

Figure 2. Actual versus predicted SV. FP: false positive; SV: stroke volume; Teich: Teichholz; TN: true negative; TP: true positive.

Table 4. SV<sup>a</sup> model had high accuracy across sex, race, BSA<sup>b</sup>, and age.

<table>
<thead>
<tr>
<th>Profile</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.93</td>
</tr>
<tr>
<td>Female</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>0.92</td>
</tr>
<tr>
<td>Black or African American</td>
<td>0.94</td>
</tr>
<tr>
<td><strong>BSA</strong></td>
<td></td>
</tr>
<tr>
<td>BSA&lt;2.05&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.97</td>
</tr>
<tr>
<td>BSA&gt;2.05&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
</tr>
<tr>
<td>Younger than 65.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.94</td>
</tr>
<tr>
<td>Older than 65.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Site</strong></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.92</td>
</tr>
</tbody>
</table>

<sup>a</sup>SV: stroke volume.
<sup>b</sup>BSA: body surface area.
<sup>c</sup>SV sample mean.
Discussion

Principal Findings

In this cohort from 2 clinical sites, mobile phone auscultation and dynamics-based modeling allowed accurate detection of low LVEF and SV. These results were obtained using ordinary mobile phones to record from 1 anatomic site with no additional hardware or materials. Prior research suggests that both mobile phones and acoustic recording can assist in HF diagnosis or monitoring; however, no current technologies use basic cellular microphone capability to obtain the acoustic data that can estimate EF or SV. This novel, proprietary unpublished technology has far-reaching potential for screening and management of patients with HF, including the undiagnosed. Perhaps the most obvious use for the technology is telehealth and application to remote and underserved global settings, where even a physical exam by the clinician may not be possible.

Prior work has described technologies that can aid in the monitoring of patients with HF [22-26]. Most technologies use telehealth communications and patient data entry, such as weight, blood pressure, and pulse rate, to risk stratify and monitor disease progress [22,24]. A 2011 Cochrane review established the mortality benefit of telemonitoring in patients with HF [27]. A review by Conway et al [22] identified 4 categories: (1) structured telephone calls; (2) videophone; (3) voice response, which involved the manual input of data using a telephone keypad in response to questions from a computerized voice response system; and (4) telemonitoring. Structured phone calls and telemonitoring showed efficacy in reducing all-cause mortality [22]. Technologies that use true physiologic monitoring require invasive intrathoracic device implantation [28,29], specialized electrocardiography [30], stethoscopes, patches [31,32], or other expensive equipment. Protocols that integrate mobile phones typically use Bluetooth to pair proprietary equipment to a phone in order to transmit data to the care providers [22,25].

Very few described innovations address population screening for HF. A review by Brons et al [33] summarized 99 studies, finding that 100% of algorithms used body weight, 85% used blood pressure, and 61% used heart rate. Bachtiger et al [8] compared 105 patients with low EF to 945 with EF >40% using AI-electrocardiogram (ECG) retrained to interpret a single-lead ECG input. Using a weighted logistic regression from pulmonary and handheld positions, they found an AUCROC of 0.91 (95% CI 0.88-0.95), sensitivity of 91.9%, and specificity of 80.2% [8]. One study proposed a method to detect low EF using machine learning or artificial intelligence [34]. Attia et al [35] report on a method using AI-augmented ECG (EKO) to determine the presence of low EF in more than 50,000 patients. The protocol found AUROC, sensitivity, specificity, and accuracy of 0.93%, 86.3%, 85.7%, and 85.7%, respectively. They also found some degree of prediction of future dysfunction: those with a positive AI screen were 4 times more likely to develop ventricular dysfunction in the near future [35].

Shandhri et al [31] compared seismocardiographic data obtained with a wearable sensing patch to objective measurements of pulmonary artery mean pressure and pulmonary capillary wedge pressure following vasodilator infusion during a right heart catheterization, finding reasonable $R^2$ accuracy (using the Cardiosense technology). These devices use seismocardiological signals in conjunction with ECG signals, thus requiring a hardware device approved by the US Food and Drug Administration (FDA) that must be purchased and maintained. By relying on physics instead of traditional machine learning, a tele-stethoscope does not require the ECG component, making it possible to perform similarly to these more expensive technologies with only an ordinary mobile phone.

One group used computerized acoustic cardiography to detect the third and fourth heart sounds along with systolic time intervals to develop a left ventricular dysfunction index to predict ventricular dysfunction [12]. Their equipment also consisted of an accessory device for a normal ECG machine. Kang et al [36] studied 46 participants to determine the feasibility of phone recordings for detecting heart sounds. Constrained by the presence of 35% of recordings being uninterpretable, the authors found acceptable sensitivity (81%-94%), specificity (79%-100%), positive predictive value (83%-100%), and negative predictive value (82%-92%), with variance depending on which phone was used [36].

Another group tested EF estimation with a novel acoustic-based device (vibration response imaging) that detects low-frequency acoustic signals (10 Hz-70 Hz). The device found sensitivity and specificity around 80%, but the protocol examined requires 36 microphones and a simultaneous ECG [14]. A study using acoustic cardiography in cohorts with and without atrial fibrillation found systolic dysfunction with moderate sensitivity and high specificity (Audicor; Inovise Medical, Inc) [37]. Researchers added sensors to a standard ECG machine to determine 2 systolic parameters: electromechanical activation time and systolic dysfunction index. Another study of the same Audicor device found sensitivity around 80% and specificity in the high 50% range depending on the parameter used [16].

None of these novel approaches show promise for monitoring or diagnosing HF using only mobile phone hardware. Most of the technologies implement proprietary devices and integrate with phones only to transmit data to providers. Tele-stethoscope allows real-time detection of data and rapid transmission of findings directly to clinicians to assist in decision-making. We estimated SV due to its use in approximating cardiac output (SV × heart rate). Noninvasive detection of cardiac output could enhance care for ambulatory and admitted patients. Additionally, SV may represent a parameter that could help distinguish different categories of HF [38].

While this study used research volunteers to obtain the sound recordings, the facile approach allows patients and family members to obtain recordings that can be transmitted with ease using Wi-Fi or cellular signals. This would bring HF diagnosis and monitoring to remote and underserved areas all over the world, to more than 8 billion mobile phones worldwide [11]. Future work will involve matching to other HF diagnostic parameters, such as measures of preserved ejection fraction (early to late diastolic transmural flow velocity [E/A] to assess diastolic function, and E to early diastolic mitral annular tissue velocity [E/e’] to estimate left ventricular filling pressures) and
pulmonary disease markers (spirometry, chronic obstructive pulmonary disease severity scores, and emphysematous changes on computed tomography imaging). In 1 earlier large-scale human study, this technology was used to match phone acoustics to COVID-19 polymerase chain reaction test results to produce a reliable device for disease detection [39].

Limitations
This work has important limitations. Although relatively small, the sample size was sufficient to demonstrate the feasibility of reproducing echocardiogram EF and SV findings. Additionally, the sample included patients in 2 different cities at 2 different medical centers, 1 inpatient and 1 outpatient. Further studies could center on larger sample sizes and more representative (race, sex, and living areas) recruiting. In a true patient diagnostic model, the best available gold-standard test results, confirmed by diagnosis, would be used rather than echocardiogram reports alone. The enrollment was based on a convenience sample, creating potential selection bias. In the phase 2 study, larger sample sizes will make possible the test or train analysis to demonstrate reproducibility. Larger sample sizes would also make it possible to add more features, if necessary, and reduce the population margin of error.

According to the FDA, a mobile medical app is “a mobile app that incorporates device software functionality that meets the definition of device in section 201(h) of the FD&C Act 11; and either is intended to be used as an accessory to a regulated medical device; or to transform a mobile platform into a regulated medical device” [40]. According to this language, mobile phones and stethoscopes can be considered equivalent. Regarding applicability, the research team views this as a strength rather than a limitation, opening the technology to resource-poor settings all around the world. This would allow fully impromptu data collection in situations where advanced diagnostic equipment is not available and even a physical exam is not possible (telehealth). Phones must be placed directly on the skin and have no motion across the skin, a consideration of importance in future studies where patients will take their measurements. Of note, the fidelity of recordings from this study was not disrupted by background noise; future use in other settings such as ambulance or combat will likely not be limited by ambient noise. Additionally, multiple phone brands were used in the study without any discernible impact on the algorithms.

The comparison of recordings to echocardiogram opens the potential for inaccuracy as transthoracic echocardiogram can have somewhat large margins of error, especially related to EF. The 40% threshold for EF is intended to reduce the rate of false positives. Future work in larger cohorts will allow for a more granular separation of participants. Ongoing work includes recruitment in right heart catheterization and cardiac magnetic resonance imaging patients. Additionally, not all participants at site 1 had the index echocardiogram on the same admission during which acoustic recordings were obtained, but all had the echocardiogram within a 30-day window. Results found no difference in accuracy based on the clinical site or the time of echocardiogram. We did not collect data on the volume status of the participants in the study; acoustic data could potentially vary based on volume status.

It should be noted that no viable features were produced through spectral analysis. One possible explanation is that spectral analysis was unable to manage the nonlinearity of the acoustic signals. Another possible explanation is that it inadvertently created false neighbors among different physical phenomena that happen to share common spectral bands such as low-frequency blood and muscle sounds. Purely from a physics point of view, the features can be interpreted as representing descriptions of fluid and thermodynamics. Although the features used in the modeling are “dynamics-based,” and apparently useful in the modeling, their exact physiological interpretation is unknown. At this stage, all that can be said about these features is that they represent some novel interpretation of hemodynamics as “dynamics.”

Conclusions
Cardiovascular disease and in particular HF continues to have high morbidity, mortality, and cost worldwide. In this pilot cohort of patients from 2 clinical sites in 2 different cities, passive acoustic recording with mobile phones allowed accurate estimation of EF and SV. No previous study or available technology combines mobile phones and acoustic recording in HF diagnosis or monitoring that could be deployed to low-resource settings. The technology represents a novel and potentially far-reaching tool for the screening and management of patients with known and undiagnosed HF.

Acknowledgments
The research team would like to acknowledge research coordinator Alyssa Thomas for working with medical students and residents who enrolled and consented participants for this study. This study was not funded by any agency. As stated in the institutional review board approval, Fleming Scientific served as the sponsor of this research, providing phones and assisting in quality control and analysis of the acoustic data. No funds were transferred among any of the parties in this team research effort. No financial relationships exist among any of the entities involved in this research and study.

Data Availability
The data sets generated and analyzed during this study are not publicly available due to proprietary analytical techniques. Clinical data are available from the corresponding author on reasonable request.

https://cardio.jmir.org/2024/1/e57111

JMIR Cardio 2024 | vol. 8 | e57111 | p.64
(page number not for citation purposes)
References


27. Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JGF. Which components of heart failure programmes are effective? a systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. Eur J Heart Fail 2011;13(9):1028-1040 [FREE Full text] [doi: 10.1093/eurhj/hfr039] [Medline: 21733899]


30. Winkler S, Schieber M, L...
ECG: electrocardiogram
EF: ejection fraction
FDA: US Food and Drug Administration
HF: heart failure
IRB: institutional review board
LVEF: left ventricular ejection fraction
NIH: National Institutes of Health
SV: stroke volume
TSD: Time Series Dynamics

Edited by A Mavragani; submitted 05.02.24; peer-reviewed by T Aslanidis, S Chatterjee, T Dr. Edoh, C Baxter; comments to author 12.03.24; revised version received 19.03.24; accepted 10.04.24; published 26.06.24.

Please cite as:
Accurate Modeling of Ejection Fraction and Stroke Volume With Mobile Phone Auscultation: Prospective Case-Control Study
JMIR Cardio 2024;8:e57111
URL: https://cardio.jmir.org/2024/1/e57111
doi:10.2196/57111
PMID:

©Martin Huecker, Craig Schutzman, Joshua French, Karim El-Kersh, Shahab Ghafghazi, Ravi Desai, Daniel Frick, Jarred Jeremy Thomas. Originally published in JMIR Cardio (https://cardio.jmir.org), 26.06.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
Cardiac Rehabilitation During the COVID-19 Pandemic and the Potential for Digital Technology to Support Physical Activity Maintenance: Qualitative Study

Linda G Park¹,², PhD, FNP-BC; Serena Chi³, BA; Susan Pitsenbarger⁴, BA; Julene K Johnson⁵, PhD; Amit J Shah⁶, MSCR, MD; Abdelaziz Elhaggar¹,², MPH, MBBS; Julia von Oppenfeld⁷, BA; Evan Cho⁷, BS; Arash Harzand⁸, MBA, MD; Mary A Whooley²,⁹,¹⁰, MD

¹Department of Community Health Systems, University of California San Francisco, San Francisco, CA, United States
²Veterans Affairs Medical Center, San Francisco, CA, United States
³Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, United States
⁴Bennett ReGen, Dearborn, MI, United States
⁵Institute for Health & Aging, School of Nursing, University of California San Francisco, San Francisco, CA, United States
⁶Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States
⁷College of Medicine, California Northstate University, Elk Grove, CA, United States
⁸Division of Cardiology, School of Medicine, Emory University, Atlanta, GA, United States
⁹Department of Medicine, University of California San Francisco, San Francisco, CA, United States
¹⁰Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, United States

Corresponding Author:
Linda G Park, PhD, FNP-BC
Department of Community Health Systems
University of California San Francisco
2 Koret Way
Room 531A
San Francisco, CA, 94143-0610
United States
Phone: 1 415 502 6616
Email: linda.park@ucsf.edu

Abstract

Background: Social distancing from the COVID-19 pandemic may have decreased engagement in cardiac rehabilitation (CR) and may have had possible consequences on post-CR exercise maintenance. The increased use of technology as an adaptation may benefit post-CR participants via wearables and social media. Thus, we sought to explore the possible relationships of both the pandemic and technology on post-CR exercise maintenance.

Objective: This study aimed to (1) understand CR participation during the COVID-19 pandemic, (2) identify perceived barriers and facilitators to physical activity after CR completion, and (3) assess willingness to use technology and social media to support physical activity needs among older adults with cardiovascular disease.

Methods: We recruited participants aged 55 years and older in 3 different CR programs offered at both public and private hospitals in Northern California. We conducted individual interviews on CR experiences, physical activity, and potential for using technology. We used thematic analysis to synthesize the data.

Results: In total, 22 participants (n=9, 41% female participants; mean age 73, SD 8 years) completed in-depth interviews. Themes from participants’ feedback included the following: (1) anxiety and frustration about the wait for CR caused by COVID-19 conditions, (2) positive and safe participant experience once in CR during the pandemic, (3) greater attention needed to patients after completion of CR, (4) notable demand for technology during the pandemic and after completion of CR, and (5) social media networking during the CR program considered valuable if training is provided.

Conclusions: Individuals who completed CR identified shared concerns about continuing physical activity despite having positive experiences during the CR program. There were significant challenges during the pandemic and heightened concerns for safety and health. The idea of providing support by leveraging digital technology (wearable devices and social media for...
social support) resonated as a potential solution to help bridge the gap from CR to more independent physical activity. More attention is needed to help individuals experience a tailored and safe transition to home to maintain physical activity among those who complete CR.

(JMIR Cardio 2024;8:e54823) doi:10.2196/54823

KEYWORDS
cardiac rehabilitation; cardiac rehab; COVID-19; digital health; digital technology; physical activity; physical activity maintenance; social media; older adults; pandemic; social distancing; technology; wearables; CR; exercise; cardiovascular disease; gerontology; geriatric; geriatrics; hospital; medical facility; California; interview; thematic analysis; anxiety

Introduction
Cardiac rehabilitation (CR) is a critical aspect of recovery that is offered to adults who experience cardiac events, such as a myocardial infarction, coronary revascularization, and valve replacement, but is significantly underused. CR involves a comprehensive 12-week group program consisting of supervised physical activity training, patient education, and risk modification and is considered an American Heart Association/American College of Cardiology Class IA level recommendation for its health benefits [1]. CR is associated with reduced morbidity and mortality as well as improved quality of life, functional capacity, independence, and symptoms of dyspnea and fatigue [2-6]. Maintaining regular physical activity after CR improves physical function [7,8] and health-related quality of life [4] and is associated with a reduction in the risk of secondary cardiac events, depression, and all-cause mortality [9].

Despite the myriad benefits, many CR participants eventually return to a sedentary lifestyle [10-12] despite the expectation to maintain physical activity independently upon completion. Only 15%-50% report any exercise 6 months after CR completion [10-12], negating the long-term health benefits of CR [13]. Reported barriers to maintaining physical activity after CR include diminished physical condition, competing demands (eg, family health issues), lack of motivation, lack of interest, lack of social support, environmental factors (eg, lack of transportation), and financial costs [14,15]. In addition, participants of CR often receive little to no support during the transition from CR to community- or home-based exercise and desire support mechanisms to ease their transition [16]. The potential enablers to maintaining physical activity after CR include continued contact with CR staff after finishing a CR program, extending the weeks of the CR program, returning for check-ins after CR discharge, having an exercise plan after CR completion, and receiving social support from family and friends [13]. Prior research shows that personal contact is essential to support a successful transition to community-based exercise after CR [16].

In addition to personal contact, the use of personal technology has emerged as a key ally in maintaining an active lifestyle for CR patients. Using technological solutions post phase II CR offers a multitude of benefits for patients. Advanced wearables, such as heart rate monitors and fitness trackers, enable individuals to self-monitor their exercise performance and vital signs, promoting self-awareness and motivation [17]. Mobile apps and telehealth platforms also facilitate access to personalized tracking and provide a digital connection to health care providers [18]. This accessibility enhances patient engagement and adherence to prescribed exercise routines, reducing the risk of relapse and promoting long-term cardiovascular health [19].

The COVID-19 pandemic posed additional challenges related to participation in CR and health-promoting behaviors. A survey study in the United Kingdom reported that COVID-19 lockdown restrictions were associated with significantly decreased participation in CR; changes in CR location, goals, supervision, duration, and enjoyment; and increased perceived effort [20]. A confluence of factors contributed to challenges of participating in CR during the pandemic including programs being forced to suspend or terminate in-person, facility-based services. Declines in CR participation were most marked among dual Medicare and Medicaid enrollees as well as those living in rural areas or socially vulnerable communities based on the Social Vulnerability Index [21]. Compared with CR programs that remained open since the pandemic, the 220 CR centers that closed were more likely to be affiliated with public hospitals located in rural areas and served the most socially vulnerable communities [21].

While mobile phone and social media use has increased among older adults over the past several decades [22], the pandemic showed that older adults rely on and can engage with digital technologies for health care access. Beyond the pandemic, understanding the barriers and experiences of CR participants may lead to more patient-centered CR for those who are unable to or do not wish to participate in facility-based CR and may also be useful for the rapid and effective implementation of CR. This study aimed to (1) describe perceived barriers and facilitators to physical activity after CR completion and (2) understand CR participation during the COVID-19 pandemic among older adults who participated in the ACTION (Americans & Cardiac Rehabilitation Training In Older Adults Needs) study.

Methods
Ethical Considerations
The ACTION study was approved by the institutional review boards from all 3 participating sites (John Muir Medical Center IRC-ID 20-08-02; NorthBay Healthcare NBH 21-05; and University of California, San Francisco IRB 20-31215). Participants provided written informed consent by reading the participant information sheet and signing the participant consent form. All participants were given the opportunity to ask questions. All subject data were deidentified (eg, questionnaires,
recordings, and transcripts were coded with specific ID numbers). Data were encrypted and stored on a password-secured database. We collected both quantitative and qualitative experiences after completing CR and compensated interview participants US $50 and survey participants US $30. The former will be reported in subsequent publications.

**Design, Recruitment, and Study Sample**

This paper describes a qualitative research study that sought to understand beliefs and experiences related to CR among participants with a history of CR participation. Our approach involved conducting in-depth interviews to obtain open-ended responses that were then organized into themes after generating initial codes (ie, thematic analysis). We also collected quantitative data from numerical ratings on comfort levels with various technologies. Two of the coauthors (SP and SC) conducted interviews and data analysis, with a final agreement on the themes by the principal investigator (LGP).

The recruitment sites included 2 community CR centers and 1 university-affiliated center in Northern California. Recruitment occurred between March and September 2022, a time period when public health directives on mask mandates, strict infection control measures, and social distancing practices were evolving from the COVID-19 pandemic. Inclusion criteria were being 55 years of age or older, between 3 and 24 months post-CR participation (of at least 1 session), having English fluency of moderately well to proficient, and being able to provide informed consent. The exclusion criterion was participation in phase III CR (optional extended CR after outpatient CR for those who pay out-of-pocket; reasons for nonparticipation could be the inability to afford phase III CR or other personal reasons). We used multiple methods to identify possible participants. Initial screening for eligibility and recruitment was done by CR staff who also contacted participants to verify eligibility for study participation. We also screened and recruited participants from a pool of respondents who completed a web-based Qualtrics survey that collected quantitative data related to CR experiences, which will be described in future manuscripts. At the end of the survey, respondents indicated if they were interested in participating in an individual 30-minute phone or video interview. Recruitment continued until data saturation was reached when no new codes arose in the analysis of iterative and open-ended questions.

**Data Collection**

We collected sociodemographic information such as age, self-identified gender, race, partner status, employment, education, income, and diagnoses for CR. Participants were also asked about their experience with technology. Specifically, they were asked to rate their comfort level with smartphone technology, wearable devices, and social media on a scale of 0-10, with 0 being extremely uncomfortable to 10 being extremely comfortable. The interview guide consisted of 23 questions that were categorized into four major areas: (1) perspectives on their CR experience as a whole, (2) physical activity since completing the CR program, (3) impact of the COVID-19 pandemic on physical activity, and (4) thoughts on various technologies that may aid CR (Multimedia Appendix 1).

Individuals had the choice of interviewing over the phone or video conferencing (ie, Zoom [Zoom Technologies] and Facetime [Apple]); however, all participants elected to be interviewed via phone. All interviews were conducted between June and August 2022 and led by either or both interviewers (SP and SC). All interviews were audio-recorded and transcribed verbatim by a third party. The interviewers also took notes to capture key points and latent data.

**Data Analysis**

We analyzed interview transcripts using thematic counts [23] to accurately complete an inductive thematic analysis [24]. Each interview transcript underwent a close reading and coding by 2 raters (SP and SC). The data were organized using Microsoft Excel (Microsoft Corp) and then analyzed [25,26]. Upon reviewing the transcript, 2 raters (SP and SC) independently identified key quotes and developed or assigned them to inductive codes. Such independent analysis ensured intercoder reliability and maintained the credibility and dependability of findings [27,28]. After the initial thematic analysis, raters discussed any coding discrepancies until consensus on the final coding scheme and analysis was achieved or settled by the principal investigator. A running count of responses for each code allowed qualitative data to be transformed for a quantitative understanding of patient responses [29]. Sociodemographic and self-reported technology use were summarized using descriptive statistics.

**Results**

**Patient Characteristics and Technology Use**

We completed 22 interviews until we achieved data saturation. Table 1 displays the sociodemographic characteristics of the 22 participants, who had a mean age of 73 (SD 8) years, with 41% (n=9) female participants with the majority identifying as White. More than half of the participants were considered low income for living in Northern California. Table 2 outlines the number of participants who were able to complete CR compared to those who had interruptions to CR related to the COVID-19 pandemic.
Table 1. Patient characteristics (N=22).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Values, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>73 (8)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>9 (41)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1 (5)</td>
</tr>
<tr>
<td>White</td>
<td>19 (86)</td>
</tr>
<tr>
<td>With partner</td>
<td>14 (64)</td>
</tr>
<tr>
<td>Employed</td>
<td>6 (27)</td>
</tr>
<tr>
<td>College graduate</td>
<td>19 (86)</td>
</tr>
<tr>
<td>Income ≥ US $75,000 per year</td>
<td>10 (71)a</td>
</tr>
<tr>
<td><strong>Diagnoses for CRb</strong></td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>17 (77)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>3 (14)</td>
</tr>
</tbody>
</table>

a A total of 8 participants declined to answer (n=14).
bCR: cardiac rehabilitation.

Table 2. Participants enrolled in the CRa program between 2020 and 2021.

<table>
<thead>
<tr>
<th>Timeline (weeks)</th>
<th>Completed CR program (n=16)</th>
<th>CR stopped due to COVID-19 (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>4-8</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>9-12</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>≥13</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>N/Ab</td>
<td>2</td>
</tr>
</tbody>
</table>

aCR: cardiac rehabilitation.
bN/A: not available.

The comfort level with technology (smartphone, wearable devices, and social media) was relatively high. Table 2 outlines the number of participants who were able to complete CR compared to those who had interruptions to CR related to the COVID-19 pandemic. Of the 22 participants, 18 owned smartphones, 14 owned a wearable device, and 10 used social media. On a self-reported scale of 0-10 representing the level of comfort using technology, participants reported a mean comfort level of 8.2 with smartphones (n=18), 7.9 with wearable devices (n=14), and 6.8 with social media (n=10).

Textbox 1. Summary of themes from qualitative interviews.

**Themes**

- Anxiety and frustration about the wait for cardiac rehabilitation caused by COVID-19 conditions
- Positive and safe participant experience once in cardiac rehabilitation during the pandemic
- Greater attention is needed for patients after cardiac rehabilitation completion
- Notable demand for technology during the pandemic and after cardiac rehabilitation completion
- Social media networking during the cardiac rehabilitation program is considered valuable if training is provided

**Overview of Themes**

Five themes prevailed from CR participant responses as displayed in Textbox 1 and as detailed as follows. There was congruence in perspectives without distinct differences noted based on CR site or other patient characteristics. One site had additional challenges beyond the pandemic compared to the other sites due to the relocation of CR services from unexpected facility damage.
**Theme 1: Anxiety and Frustration About the Wait for CR Caused by COVID-19 Conditions**

Interviews revealed that participants experienced anxiety and frustration due to the long wait to get into the CR program. The majority of participants (17 of 22) experienced long entry wait periods of between 2 and 3 months to enter the program or faced program closure due to the pandemic. Furthermore, 1 primary on-site location housing the CR program was closed due to facility infrastructure issues, forcing participants to relocate to a more distant location and exacerbating preexisting stressors. In general, delays in getting into the CR program resulted in decreased exercise activity for patients who were newly discharged from the hospital, as they were unable to enter a CR program for many months. Participants expressed their desperation to get into any program, and some called the nearest city with similar programs yet yielded similar wait times. Consequently, patients used resources of personal trainers, internet videos, or were able to get into a home-based physical therapy program. One participant stated:

> Yeah, it was a long wait. But I was told, when I started the process, it might be three months before I could get in. At one point I made contact with the program in XX County that’s affiliated with XX to see if I could get in there. And they also had a long wait list.

Facing the COVID-19 barrier, patients expressed they felt an urgency to independently create a healthy environment with exercise and nutrition. It was prevalent with all 22 participants that the urgency to get started after discharge from the hospital was strong. However, without direction or exercise monitoring, patient hesitation to start exercising at home was highly noted, as reflected by 1 patient:

> The thing you always worry about when you exercise after having a surgery like that is am I going to have a heart attack.

**Theme 2: Positive and Safe Participant Experience Once in CR During the Pandemic**

Once in the CR program, all of the participants agreed that the program was well organized and professional. After the aggravation of the long wait to enroll in the program for some, patient consensus was that the staff were exceptional in their care and monitoring. One participant explained this:

> I was very impressed by both the way in which the program operated, and the people themselves in terms of their competence level and their understanding of the issues, and their concern for patients, and their flexibility.

Many patients considered the program a “safe zone,” which increased their level of confidence to exercise. In developing a fitness regime after cardiac surgery, the presence of monitoring was appreciated:

> ...knowing there was a registered nurse for every two people, they monitored you – when you’re getting back into physical therapy activity after you’ve had some kind of heart situation, is comforting.

One participant described this further:

> The ability to test all the equipment that had monitors was most effective in giving the patients the freedom to try equipment to see what worked well for them to do the work that needed to be done.

Overall, all participants had positive comments about the CR program and felt they would have stayed in the program on a long-term basis if their insurance would cover the cost for more sessions.

**Theme 3: Greater Attention Needed to Patients After CR Completion**

Once patients finished the CR program, many felt on their own and were concerned about keeping up with the regime they learned, as well as lacking the specific equipment provided in the CR program. Voicing concern that there was no follow-up after finishing the program, 1 participant expressed,

> Maybe they could have a month later call and say to you how are you doing, are you keeping up with your exercises, how many steps are you having a day?

This quote reflected the sentiment of the majority of the CR program participants. Another said,

> I would go back and say “can I use those other four appointments?” because I want to see where I am, I know where I am, and it’s not where I was when I ended the program.

Having no one to follow-up on their progress once home, a participant indicated,

> ...(her exercise) is on and off. And so, the only consistent exercise is walking. And so, the weights have dropped off pretty much. The bike work has dropped off pretty much, and I’m having trouble now with my back with being able to walk without pain in it. So, I do walk but I don’t walk anywhere near where I’m supposed to be walking as far as the amount of activity I’m supposed to be doing. So, what I planned to do is take my information and start slowly again and build up, pretend I’m at rehab, only it’s just me.

After CR completion, several participants worked and were financially able to hire a personal trainer. Those who worked and did not hire a personal trainer expressed a need to develop greater time management skills to keep up with the needed exercises recommended in the program. Retirees turned to family members and spouses for support with mobile apps, walking together, or going to the community gym.

**Theme 4: Notable Demand for Technology During the Pandemic and After CR Completion**

While on the waitlist for the CR program during COVID-19, many patients sought technological options (eg, computers, phones, and the internet) to sustain physical activity and self-care. A participant said,

> Sometimes during Covid, when like everybody was locked down, I did do that on my computer. I did (exercise) classes on my computer.

Most felt it would be a positive alternative if there was another lockdown for those in a program; additionally, 82% (n=18) of
the participants believed web-based forms to engage in physical activity would be a great option once they finished in the program.

Participants were asked their opinion about the idea of using a wearable device for self-monitoring to help with physical activity after the prescribed CR program (with a prompt related to having a personal coach). The reassertance of a monitor in tracking several health metrics along with personal progress and having a personal coach to review health data were considered most important to individuals who had experienced a life-threatening event. Having these resources would give them a sense of being in a “safe zone.” One participant’s comment reflected similar responses from the other participants:

“I’m through the program, but now I have to pay and if there was something like this, you know, with a wrist monitor and you could do your exercises and meet with, you know a personal coach from the rehab, or who’s monitoring you, that would be wonderful.”

Finding the resources on “what to do, how to use and what information can I get from this tool” was a key factor in moving forward with working with a utility device.

In total, 14 participants stated they owned a wearable device; however, not all participants actively used it. The barrier to use (brought up by 4 participants) was the lack of user friendliness or guidance in learning how to use the device. Some participant quotes were “I can see what I want to see, you probably learn more,” “It’s manageable, but I feel my abilities with it are limited,” and “I have a smartwatch, but I need help setting it up.” When considering using a wearable device for tracking health metrics and monitoring personal progress, a concern arose that “I would need training on how to set it up.” A participant considered seeking assistance from family: “my grandchildren would help my wife. They were born with those things, you know?”

**Theme 5: Social Media Networking During the CR Program Considered Valuable if Training Was Provided**

When asked about their opinion on using social media to supplement their CR experience, half of the participants actively used it. The barrier to use (brought up by 4 participants) was the lack of user friendliness or guidance in learning how to use the device. Some participant quotes were “I can see what I want to see, you probably learn more,” “It’s manageable, but I feel my abilities with it are limited,” and “I have a smartwatch, but I need help setting it up.” When considering using a wearable device for tracking health metrics and monitoring personal progress, a concern arose that “I would need training on how to set it up.” A participant considered seeking assistance from family: “my grandchildren would help my wife. They were born with those things, you know?”

Finding the resources on “what to do, how to use and what information can I get from this tool” was a key factor in moving forward with working with a utility device.

Most of the participants were open to trying technology, including Facebook, with the condition there was training or assistance. With social media, some responded they did not know how to maneuver through Facebook beyond keeping up to date with family or browsing posts. A participant shared, “I would do it probably. If I could work the Facebook system to do that, I would.” Ultimately, there was agreement on the need for technological options and guidance while in a CR program as well as after finishing the program.

**Discussion**

**Principal Findings**

This qualitative study presents the positive experiences participants have in CR, the impact of the COVID-19 pandemic on both physical activity and their CR experience, and the need for additional clinical and social support after CR completion (eg, wearable devices and social media). Along with the 5 themes that have been presented, the findings could also be summarized from the standpoint of stages of CR. More specifically, the way in which technology could be deployed as a solution to barriers at all stages. Before the CR initiation, there was heightened anxiety in getting enrolled into a program due to long pandemic-related waitlists and program closures. During this waiting period, participants expressed fear and hesitation to start exercising without supervision. Technology in the form of positive messages and education regarding safe exercise could be delivered before, during, and after CR to address these concerns. Due to the persistence of long wait times for CR initiation after the pandemic, clinicians may reconsider the role of proper discharge instructions from the hospital and include more details about exercise safety while they wait for phase II CR. During enrollment in CR, there was an increase in participant confidence and comfort with exercise. During and after CR participation, patients reported the potential benefit of wearable health devices to track exercise and to have those data reviewed by their CR team. In addition, patients were enthusiastic about using wearable devices and health apps to support their participation in phase II CR or their health behaviors after completing CR. Furthermore, wearable devices could potentially provide a practical alternative to CR in the case where in-person CR is inaccessible (ie, long enrollment waitlists or another pandemic). After CR, participants expressed concerns about maintaining exercise without equipment and not being able to ask questions to a CR provider. This older group of participants were open to participating in social media networking groups as a means to increase social support and use peers as a resource for answering questions. Some participants cited they could solicit technology support from their family members if needed. These data affirm the benefits of CR, despite pandemic-related barriers, and the positive outlook on using technology as a solution to shortcomings in exercise monitoring and social support.

Although drop-offs in exercise following CR completion are well-known, our study found several reasons that may help design future policy changes or interventions that can increase post-CR exercise. As noted above in theme 3, after program completion, patients had variable access to necessary exercise
equipment and felt a lack of guidance or follow-up from professional staff. Such findings are key for understanding the impacts on long-term physical and mental health. Exercise is critical for maintaining cardiovascular health and reducing the risk of future cardiac events [30], thus policy changes including reimbursement of long-term exercise equipment (eg, stationary bike) or periodic web-based or in-person check-ins with the CR team could be considered. With limited access to exercise equipment or continued training, patients may struggle to maintain their physical health improvements. Additionally, lack of check-ins following CR completion decreases adherence to a healthy lifestyle and increases the likelihood of patients returning to previous unhealthy behaviors such as smoking, unhealthy eating habits, or a sedentary lifestyle, thereby increasing the risk of future cardiac events and negative patient outcomes [31]. In addition to physical effects, the period following CR may have a significant psychological impact as patients may experience depression, anxiety, or fear of future cardiac events [32]. While CR may assist patients in managing these emotions, without continued support, patients may struggle to cope. Evident in our study, patients felt ill-prepared to maintain health improvements and track progress, heavily relying on guesswork with high anxiety. This only magnifies existing mental health risks. Thus, attention to post-CR health remains an area for improvement for health care providers.

Further research is needed to determine optimal check-in frequency and methods for ongoing physical and psychological support. This study specifically addressed the potential role of integrating technology to improve physical activity after CR completion. Traditionally, older adults have been considered resistant to the use of new technologies; however, our study refutes this myth and validates that older adults are eager to engage with certain technologies and have high self-reported comfort levels with using technology. Other recent studies have shown that modern technology, including wearable devices and mobile apps, can be practical tools in maintaining physical activity levels after completing CR [33,34]. In particular, older adults have demonstrated a strong potential for adopting new technologies to support their physical activity and maintain healthy lifestyles [35,36]. For example, in a previous study, we found that a home-based CR program that included wearable activity trackers and web-based support was well received by older adults who reported improved physical activity levels and overall satisfaction with the program [37]. Other studies have found that technology-based interventions can be effective in reducing anxiety and depression in post-CR patients, as well as improving adherence to healthy lifestyle behaviors [38,39]. With the increasing availability and affordability of digital health technologies, there is significant potential to integrate these tools into CR programs to provide ongoing support and improve long-term health outcomes for patients. However, it is crucial to consider older adults’ specific needs and preferences in designing and implementing technology-based interventions and provide appropriate training and support to ensure successful adoption and sustained use.

There are several clinical and research implications that can be derived from this study’s findings. CR providers should assess participant needs early on in their program to assess psychological status (anxiety or depression) and other barriers (equipment or gym access) to be successful with independent physical activity after CR completion. In addition, providers can assess other needs such as health conditions that require safety precautions for home exercise. Standardized evidence-based practice guidelines are needed to guide participants who graduate from the CR program. Patients need to be taught about long-term habit formation and motivation to continue physical activity after phase II CR is over, as well as discuss a transition plan in advance of finishing the programs with their CR clinical team. In addition, incorporating the use of a wearable device with personal monitoring could alleviate fears of having secondary events as expressed by many participants. Building in the use of digital technology during phase II CR may be helpful to have patients have a warm-up period with support for using the same technology independently after CR completion. For research implications, opportunities include collecting and analyzing data on long-term clinical outcomes (rehospitalization and mortality) from diverse populations who receive any versus no support after CR ends. There is also a need for conducting cost analyses on tools such as digital wearable devices and mobile apps to improve health outcomes.

There are also significant policy implications. This study emphasizes the interest of older adults to engage with wearable devices and social media and may be relevant to multiple stakeholders (ie, payors and health systems) in making decisions on what to pay for and how to deploy the technology. Participants’ expressed need for additional support after phase II CR to maintain physical activity is also an important policy implication. Extending insurance coverage for maintenance of remote home-based CR services beyond the traditional 12-week program will help participants transition to independent exercise. This covered extension could be in the form of phase III CR or different payment models that fuse remote patient monitoring with coaching for long-term exercise maintenance. Based on this study, the integration of wearable device data into these services may be beneficial, and financial reimbursement and secure implementation remain an area for future investigation.

**Limitations**

Our sample mostly comprised White individuals and those from higher educational backgrounds; thus, the findings may not be generalizable to other diverse racial groups and those with low educational attainment. We are also unclear whether financial resources were associated with CR attendance among our participants, including ownership of smartphones and wearable technology that may have influenced their opinions about technology use. In addition, we recruited all participants from 3 urban institutions in Northern California; therefore, our sample may not be generalizable to a broader population including rural populations. There may be heterogeneity in the participants’ experiences of older adults and their CR experiences with at least 1 completed CR session (versus up to 36 sessions in some programs) within 3–24 months after CR participation. Despite these limitations, this study provides important insights into the lived experiences and perspectives of 22 older adults representing 3 different CR programs. This study confirmed previous research that describes the perceived lack of support...
after CR termination [14]. In addition, this study supports the perceived benefits of adding digital technology as a component of providing tailored feedback to CR participants.

Conclusions

Despite the critical role physical activity plays in sustaining patient cardiovascular health improvements, maintaining adequate activity levels after CR proves to be an immense challenge for several reasons. For example, the transition from the supportive and structured environment of CR centers to daily life leaves patients without the guidance and encouragement they once had. This study highlights requests from participants for regular check-ins and support from health professionals, as well as the integration of digital technologies to improve individuals’ motivation and accountability in adhering to their exercise routines. Amplified by the COVID-19 pandemic, these challenges demand thoughtful consideration and tailored strategies to ensure sustained adherence to regular physical activity. This study’s findings support the opportunity to leverage technology through wearable devices or mobile apps to sustain engagement in healthy lifestyle behavior because they are cost-effective, tailored, and provide motivation and support for patients in the long term. Although these data were collected during a pandemic, the experiences and perspectives of the participants are generalizable in the current environment of CR with the need to support patients after CR completion and the opportunities that technology offers.

Acknowledgments

We are grateful to the health care team at John Muir Cardiac Conditioning, NorthBay Healthcare Cardiac and Pulmonary Rehabilitation, and the University of California, San Francisco Cardiac Rehabilitation and Wellness Center for facilitating this research as well as the participants who provided their valuable input. Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (award P30AG015272). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data Availability

The qualitative data generated and analyzed during this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Interview guide.

References


https://cardio.jmir.org/2024/1/e54823
from the American Heart Association. Circulation 2017;135(16):e894-e918 [FREE Full text] [doi: 10.1161/CIR.0000000000004083] [Medline: 28336790]


17. Kang HS, Exworthy M. Wearing the future-wearables to empower users to take greater responsibility for their health and care: scopeing review. JMIR Mhealth Uhealth 2022;10(7):e35684 [FREE Full text] [doi: 10.2196/35684] [Medline: 35830222]


Abbreviations

ACTION: Americans & Cardiac Rehabilitation Training In Older Adults Needs
CR: cardiac rehabilitation
Persuasive Systems Design Trends in Coronary Heart Disease Management: Scoping Review of Randomized Controlled Trials

Eunice Eno Yaa Frimponmaa Agyei¹, PhD; Akon Ekpezu¹, MSc; Harri Oinas-Kukkonen¹, PhD

Oulu Advanced Research on Service and Information Systems, Faculty of Information Technology and Electrical Engineering, University of Oulu, Oulu, Finland

Corresponding Author:
Eunice Eno Yaa Frimponmaa Agyei, PhD
Oulu Advanced Research on Service and Information Systems
Faculty of Information Technology and Electrical Engineering
University of Oulu
Pentti Kaiteran katu 1
Oulu, 90570
Finland
Phone: 358 0449511559
Email: eunice.agyei@oulu.fi

Abstract

Background: Behavior change support systems (BCSSs) have the potential to help people maintain healthy lifestyles and aid in the self-management of coronary heart disease (CHD). The Persuasive Systems Design (PSD) model is a framework for designing and evaluating systems designed to support lifestyle modifications and health behavior change using information and communication technology. However, evidence for the underlying design principles behind BCSSs for CHD has not been extensively reported in the literature.

Objective: This scoping review aims to identify existing health BCSSs for CHD, report the characteristics of these systems, and describe the persuasion context and persuasive design principles of these systems based on the PSD framework.

Methods: Using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines, 3 digital databases (Scopus, Web of Science, and MEDLINE) were searched between 2010 to 2022. The major inclusion criteria for studies were in accordance with the PICO (Population, Intervention, Comparison, and Outcome) approach.

Results: Searches conducted in the databases identified 1195 papers, among which 30 were identified as eligible for the review. The most interesting characteristics of the BCSSs were the predominant use of primary task support principles, followed by dialogue support and credibility support and the sparing use of social support principles. Theories of behavior change such as the Social Cognitive Theory and Self-Efficacy Theory were used often to underpin these systems. However, significant trends in the use of persuasive system features on par with behavior change theories could not be established from the reviewed studies. This points to the fact that there is still no theoretical consensus on how best to design interventions to promote behavior change in patients with CHD.

Conclusions: Our results highlight key software features for designing BCSSs for the prevention and management of CHD. We encourage designers of behavior change interventions to evaluate the techniques that contributed to the success of the intervention. Future research should focus on evaluating the effectiveness of the interventions, persuasive design principles, and behavior change theories using research methodologies such as meta-analysis.

(JMIR Cardio 2024;8:e49515) doi:10.2196/49515

KEYWORDS
coronary heart disease; persuasive systems design; behavior change; randomized controlled trial; RCT; controlled trials; heart; CHD; cardiovascular
Introduction

Coronary heart disease (CHD), also referred to as coronary artery disease (CAD), is the third leading cause of death worldwide and is associated with 17.8 million deaths annually [1]. Despite its significant association with a high mortality rate, it is preventable. With risk factors such as a sedentary lifestyle, physical inactivity, smoking, poor diet, hypertension, and obesity, both pharmacological and nonpharmacological interventions have been proposed to mitigate this menace [2]. Existing evidence suggests that preventing CHD requires lifestyle and health behavior changes [3]. Digital interventions, particularly behavior change support systems (BCSSs), have the potential to reduce risky health behaviors, improve the well-being of the user, and promote healthy lifestyles in patients with CHD. These are information systems that are designed to form, alter, or reinforce the attitudes, behaviors, or compliance of their users voluntarily [4]. A key element in behavior and attitude change is persuasion; the intention to change the behavior of an individual via persuasion may lead to a positive behavioral outcome [5]. Over the past decade, BCSSs and persuasive design have received elaborate attention with strategies that stem from behavior change theories. Although the development of these systems has increased at a startling rate to promote behavior change, the persuasion context (ie, the interdependencies between the user, technology, and the problem domain) and persuasive systems design principles are often ignored [6].

The existing literature reviews have predominantly focused on determining the effectiveness of different kinds of health BCSSs in changing lifestyle behavior, controlling modifiable risk factors, and improving CHD patient outcomes using mobile technologies [7,8], web-based technologies [9], and telerehabilitation [10]. However, evidence on how these systems were developed (ie, the design principles) to achieve the reported behavior change outcomes is not clear [11,12]. Moreover, these studies have focused on specific technologies; hence, the evidence cannot be generalized for all CHD BCSSs. Designing for behavior change involves identifying behavioral goals [5] and gaining an understanding of the behavior change context including the behavior change strategies, system features, and theoretical foundations [13,14] that underpin it.

This scoping review seeks to address this gap by providing an overview of persuasive context and behavior change strategies that support the management of CHD. Identifying these features will provide designers and researchers with an understanding of the persuasion context and persuasive features in systems that seek to promote behavior change in patients with CHD. More specifically, this review seeks to answer the broad review question, What persuasive systems design trends are evident in the management of CHD? To answer this question, this review aims to identify existing health BCSSs, report the characteristics of these systems, and describe the persuasion context and persuasive system design principles of the identified BCSSs for CHD using the Persuasive Systems Design (PSD) model proposed by Oinas-Kukkonen and Harjumaa [13].

The PSD model is the most-used framework for designing and evaluating persuasive systems [15]. Built on theories from psychology, information systems, and other disciplines, the PSD model guides the analysis of the persuasion context, including recognizing the intent of the persuasion, understanding the persuasion event, and defining the strategies in use [13]. Recognizing the persuasion intent involves understanding the roles of the persuader, the persuadee, the change type (ie, compliance, behavior, and attitude change), and the outcome (ie, forming, altering, or reinforcing compliance, behavior, and attitude change). Understanding the persuasion event entails features and characteristics arising from the problem domain (ie, use context), the user (ie, user context), and technology (ie, technology context). Persuasive systems have information content (ie, message) and software features. Defining the strategy involves crafting the content of the message to be delivered, deciding how to present arguments, the route to deliver the message, and the persuasiveness of the message. The model also provides a structure for designing and evaluating persuasive systems based on 7 key postulates and 4 system design principles, including primary task support (supports the user to carry out the actions that will lead to the desired behavior), dialogue support (facilitates the interaction between the user and the technology), credibility support (enhances the perception of trust and reliability of the system), and social support (aids behavior change by leveraging social influence).

Table 1 describes specific variables of the PSD model used in evaluating and analyzing the persuasion context and system design features of the reviewed studies.
### Analyzing the persuasion context

#### The intent

**Intended outcome/change**
The intended outcomes of interest in this review will be classified as clinical outcomes, behavioral outcomes, psychological outcomes, and improved quality of life.

**Designer/persuader bias**
This refers to the unintentional influence that designers, developers, or creators have on the features, content, or functionalities of an intervention due to their viewpoints, experiences, or preferences.

#### The event

**Use context**
The general application domain is health—specifically, CHD as a preventable health condition.

**User context**
The population of interest will be patients living with CHD.

**Technology context**
This will include any technological platforms including wearable devices, mobile apps, and web apps.

#### The strategy

**Message**
This will describe the content delivered to inform or educate the user to change their behavior.

**Route**
This will describe how information and content are delivered to users via the direct route, which uses the user’s cognition, or the indirect route using societal cues.

#### Persuasive principles

**Primary task support**
System features that support CHD to perform their primary task by reducing the cognitive load associated with the activity.

**Dialogue support**
System features that provide computer-human dialogue as a means of reinforcing and motivating patients with CHD to perform the primary task.

**Credibility support**
System features that make the patients with CHD believe that the intervention is reliable and credible.

**Social support**
System features that motivate patients with CHD using social influence.

---

aCHD: coronary heart disease.

Drawing upon the PSD model, this research aims to provide an overview of BCSSs for managing CHD, report the characteristics of these systems, and describe the persuasion context and persuasive design principles. The rest of the paper is organized as follows: The Methods section describe how this research was conducted. The Results section reveals the findings of the research. This is followed by the Discussion section, which includes the implications of the findings and the conclusion.

### Methods

#### Identification of Studies

This scoping review was conducted by following PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) [16]. We conducted a scoping literature search in the Scopus, Web of Science, and MEDLINE electronic databases from 2010 to 2022 using the Population, Intervention, Comparison, and Outcome (PICO) approach. The search domains included patients with CHD aged 18 years and older (population), randomized controlled trial (RCT) and BCSSs for CHD (intervention), and behavior change (outcome). The following search string related to the PICO approach was used (“coronary artery disease” OR “coronary heart disease” OR “ischemic heart disease”) AND (“mobile” OR “smart phone” OR “smartphone” OR “web” OR “internet”) AND (“prevention” OR “intervention”). The literature search was limited to studies published from 2010 because the PSD framework was proposed in 2009. Thus, including studies from 2010 would reveal evidence-based research trends. The first and second authors (EEYFA and AE, respectively) carried out the literature search and study selection independently. Divergent opinions on study inclusion were resolved through consensus among the 3 authors.

#### Data Inclusion and Exclusion Criteria

The titles and abstracts were screened for keywords by the first and second authors. These authors downloaded the full text and examined if they were suitable using the following criteria. First, the study had to be an RCT on CHD, published in a peer-reviewed academic journal or conference, and written in the English language. Additionally, the study intervention had to be technology-mediated (ie, used mobile, web, or internet-based applications). Finally, the study intervention had to have the aim of promoting behavioral change, such as physical activity, diet, or smoking cessation to manage or prevent CHD.

#### Data Extraction

Using the inclusion and exclusion criteria previously outlined, 30 papers were selected and reviewed. These articles were reviewed using the PSD framework. Data extraction and coding were conducted by the first and second authors independently. The 2 authors read the articles, identified the textual descriptions applicable to the design features, and coded them in a Microsoft Excel (Microsoft Corp) spreadsheet. The third author (HO-K) verified and validated the extracted data. Disagreements were...
resolved by revisiting the specific papers and reviewing them together until a consensus was reached.

The characteristics of the persuasion context and persuasive design features were extracted. The data extracted from each article were as follows: (1) name of the intervention; (2) objective of the study, which reveals the intention of the intervention; (3) primary and secondary outcome(s) (ie, intended outcome); (4) features/characteristics of the problem domain (ie, use context); (5) description of the study participants (ie, user context); (6) description of the technology-dependent characteristics of the intervention (ie, technology context); (7) description of the target behavior, and (8) persuasive software features of the intervention.

**Results**

**Selection of Studies**

The initial search produced 1195 articles that were distributed among the aforementioned databases. Duplicates were removed, leaving 181 papers. The articles were excluded by title if they did not contain the keywords “CHD” and “randomized controlled trial,” while articles were excluded by abstract if the technological context was not mentioned and if the intervention was not targeted at either behavior change or clinical outcome. Consequently, 151 articles were excluded by title and abstract. Finally, 30 RCT studies were analyzed in this scoping review. Figure 1 highlights the selection process using the PRISMA-ScR flow diagram.

**Characteristics of the Included Studies**

The 30 included RCTs were published in 16 different peer-reviewed journals, namely *Journal of Medical Internet Research* (n=5, 17%), *JMIR MHealth and Uhealth* (n=4, 13%), *European Journal of Preventive Cardiology* (n=3, 13%), *Journal of Cardiopulmonary Rehabilitation and Prevention* (n=3, 10%), *Hearts* (n=2, 7%), *BMJ Open* (n=2, 7%), *Circulation* (n=2, 7%), and the rest in *JAMA, Lancet Digital Health, Plos ONE, Patient Education and Counseling, Journal of Cardiovascular Translational Research, Pharmacy Education, JAMA Cardiology, Coronary Artery Disease,* and *Health and Quality of Life Outcomes*.

The study duration for all included RCTs ranged between 4 weeks to 52 weeks, and the sample size for study participants ranged between 84 and 879. Additionally, 70% (n=21) of the studies focused on patients with CHD, 10% (n=3) on patients with acute coronary syndrome, 7% (n=2) on patients with CAD, and the remaining 13% (n=4) on patients with CHD and diabetes, CHD and depression, ischemic heart disease, and clinical manifestation of atherosclerosis in the coronary, cerebral, or peripheral arteries.

**Analyzing the Persuasion Context**

**Overview**

As highlighted in Table 1, analyzing the persuasion context involves recognizing the intent of the persuader, understanding the persuasion event, and defining the strategies in use.

**The Intent**

All studies stated the objective of their study, which reveals the intention of the persuader as well as the intention behind the intervention. The intention behind the interventions was to use information and communication technology to support patients with CHD to improve their health and lifestyle. The persuaders were researchers (ie, people who participated in the design), and in some cases, clinicians (when the study was intended to be used in a clinical setting). The persuadees were study participants who received the intervention in the RCT. In the design of the interventions, decisions regarding features and content were mostly influenced by the viewpoints, experiences,
and assumptions of the design team. Only 17% (5/30) of studies involved users directly. These users were primarily involved in creating messages delivered through the intervention [17-21]. One (3%) study obtained feedback from users via a pilot test to improve the intervention [22]. Two (7%) studies disclosed the composition of their design team, yet users were not involved in the process [23,24]. Finally, 73% (n=22) of studies did not provide any information on the users/prospective users’ involvement in the design of the intervention. Given the potential effect of designer bias on the usability and effectiveness of an intervention, it is important to acknowledge this and put in measures to mitigate its effects.

We identified and classified the intended outcomes of the 30 included RCTs into 4 categories: clinical outcomes, behavioral outcomes, psychological outcomes, and improved quality of life. The distribution of identified intended outcomes in each publication year of the included studies is presented in Figure 2. Multimedia Appendix 1 contains more detailed information [17-46].

The Event

Analyzing the event provided insights into the problem domain (use context), user characteristics (user context), and technology (technology context). Although the main user group was people who had been diagnosed with CHD, some of them had multiple health conditions, such as diabetes and depression, or needed to change at least one behavior (eg, smoking, physical inactivity, and medication adherence) to prevent further health complications. The varying characteristics of the use context presented unique scenarios and opportunities for health behavior change (Multimedia Appendix 2 [17-46]). Users were mainly older than 18 years. A total of 20 (67%) studies [17-22,24,25,28,30,31,33-35,37,39,40,43,46] required the users to be able to read and understand the text, while 2 studies (7%) [18,29] required users to be computer literate.

The RCTs were conducted on various continents, including Oceania, Asia, Europe, and North America. In Oceania, studies were conducted in Australia [17,20,30,43,45,46] and New Zealand [26,33-35,38]. In Asia, there were 6 (20%) studies conducted in China [19,21,27,28,32,36,42], 3% (n=1) from Singapore [23], 3% (n=1) from the Republic of Korea [25], 3% (n=1) from Indonesia [39], and 3% (n=1) from Pakistan [31]. In Europe, 7% (n=2) of studies were conducted in the United Kingdom [18,40], 3% (n=1) in Italy [44], 3% (n=1) in the Netherlands [22], 3% (n=1) in Belgium [29], and 3% (n=1) across multiple European countries [41]. Two (7%) studies were conducted in North America, namely, the United States [37] and Canada [24].

Furthermore, it was observed that the nationality and cultural factors of users influenced the design of the intervention. For example, in Dorje et al [27], the popular Chinese social media app WeChat, together with Chinese avatars, was used to educate patients. Moreover, different types of technologies were chosen for the design and development for various reasons. The selection of the type of technology was based on some characteristics of the problem and user domain. For example, an SMS or other type of text message was used for delivering the intervention in one study because of its ease of use and cost-effectiveness [20]. In China, WeChat, which has an instant messaging component, was used in 3 (10%) studies [27,36,42].

The Strategy

Exactly 25 (83%) studies stated that they used content in their intervention. The content presented to the users in the 25 studies was mainly to educate users and support the behavior change process. This implies that the user’s cognition was required to process the information presented to them. Additionally, the RCTs conducted in Oceania and North America presented content to their users via the interventions, while 2 (7%) RCTs in both Asia and Europe did not present any content. Multimedia Appendices 3 and 4 [17-46] contain additional details.
Within the included RCTs, half (n=15, 50%) incorporated behavior change theories in their intervention designs. The most used behavior change theory was Social Cognitive Theory (n=10, 33%) [17,19-21,24,28,31,35,38,45]. This was followed by Self-Efficacy Theory, which was used in 17% (n=5) of studies [26,33,34,37,38]. Two (7%) studies [17,20], used the Behavior Skill Model, Theory of Reasoned Action, Theory of Planned Behavior, and Control Theory. The Health Belief Model was used in 2 studies [23,31] and the Commonsense Model was used in 2 studies [26,35]. Meanwhile, the Health Action Process Approach theory [28] and Cognition and Behavior theory [42] were each used once. It was observed that the number of theories used across these studies varied from 1 to 5. Interestingly, none of the RCTs conducted in Europe used behavior change theories in their interventions (Multimedia Appendix 4).

Analyzing the Persuasive Features

Overview

System features that were used in the CHD interventions were identified and coded based on the PSD model software feature categories. As shown in Table 1, they comprised primary task support, dialogue support, credibility support, and social support. Multimedia Appendix 4 highlights the distribution of identified persuasive system features. Apart from Putra et al [39], all the analyzed interventions used a minimum of 1 persuasive feature and a maximum of 6 persuasive features. Features of the primary task support principle were the most used, while that of the social support principle was the least used in the interventions for patients with CHD (Multimedia Appendix 5 [17-46]).

Primary Task Support

Primary task support features assist the user in carrying out the primary tasks that lead to behavior change; they include personalization, self-monitoring, reduction, rehearsals, tunneling, tailoring, and simulation [13]. Personalization (n=23, 77%) and self-monitoring (n=18, 60%) were found to be the most widely represented primary task support features in the articles reviewed. Tailoring was identified in 6 (20%) studies. The reduction feature was identified in 1 (3%) study to grade tasks for users [18]. Features such as rehearsal, tunneling, and simulation were not identified. Personalization and semipersonalization were implemented in different forms, such as (1) selecting and providing educational content on CHD based on user characteristics, such as age and gender [40], and baseline characteristics [17,20,43], such as smoking status and diet; (2) using the preferred name of users [19,21,26,35,37] (semipersonalization); (3) using their smoking status and diet pattern [25] (semipersonalization); (4) sending messages at the preferred time of the user [26,35]; (5) individualized exercise programs [27,29,33,38,42]; (6) individualized feedback [28,45]; (7) customizable sounds for reminders [46]; (8) a personalized website based on risk factors [22]; and (9) personalized medication SMS text messages [31].

Self-monitoring was implemented by setting and tracking goals [18,24,40], monitoring physical activities [26,27,29,30,34,44], glucose monitoring [19], heart rate monitoring [27,42], monitoring of cardiovascular risk factors [45], blood pressure monitoring [21,32], step counting with a pedometer [26], and medication adherence using electronic pill bottles [37]. Different messages were tailored for different user groups. For example, different messages were delivered to smokers and nonsmokers [17,20,35,43], dietary messages for vegetarians and nonvegetarians [25] and tailored programs for the working population [23].

Dialogue Support

This support category comprises 7 system features, namely reminders, praise, rewards, liking, similarity, suggestions, and social role. Dialogue support incorporates forms of social or interpersonal interactions into feedback to encourage the user to respond to requests made by the intervention that may lead to behavior change [47]. Reminders, praise, rewards, suggestions, and social role were identified in the studies.

Reminders were the most used software feature in this category (n=13, 43%). Some examples of how reminders were implemented include reminders about behavior change to decrease CHD risk [17,20,43], exercise reminders [23,38], reminders to check blood pressure [27], push notifications [30], medication reminders [31,32,36,37,46], and checkup reminders [26]. This was followed by praise (n=12, 40%). The implementation of praise included individualized feedback to manage outcomes [27,28], motivational messages [29,33,41], personalized feedback on progress [33,40,42,45], and performance [18,26,34].

In addition to these, suggestions (n=3, 10%), rewards (n=10, 3%), and social roles (n=10, 3%) were used, albeit rarely. Suggestions were implemented by providing tips on overcoming hindrances [40], dietary recommendations [46], and information on various physical activities [33]. The social role feature was implemented via a virtual cardiologist coach who offered advice to users [27]. Reward in the form of social rewards was identified in the intervention by Devi et al [18]. Though the liking and similarity feature may have been present in the interventions, we could not evaluate it due to its subjective nature.

System Credibility Support

Design principles in this category support the credibility of the system as a function of persuasion. Its features include expertise, surface credibility, authority, third-party endorsement, real-world feel, trustworthiness, and verifiability. Here, the visual elements of the user interface, as well as the believability of the content of messages or information delivered via the intervention, are crucial. Expertise was evident in most of the interventions (n=10, 33%), as the content was created by experts. Multidisciplinary teams consisting of researchers, physicians, clinicians, therapists, and practitioners (ie, software developers) were involved in creating content for the interventions [17,19-21,25,30,33,36,43]. This was followed by authority (n=9, 30%) and verification (n=50, 17%). Authority was identified in several interventions [17,19-21,25,30,33,36,43]. This was in the form of citing health quotes from recognized authorities such as the National Heart Foundation of Australia and the American College for Sports Medicine. Verifiability was identified in 17% (n=5) of the interventions [22,23,25,27,33]. In these interventions, links were provided for fact-checking.
purposes. A total of 5 (17%) interventions were observed to implement the “real-world feel” feature such that participants could contact researchers or clinicians for various purposes [22-24,31,42].

Social Support

Social learning was the only social support feature identified in the analyzed interventions. The intervention enabled users to watch others go through a similar behavior change process [38]. Other features, such as social comparison, cooperation, social facilitation, normative influence, competition, and recognition, were not identified in the research articles. The minimal use of social support features may be associated with the tendency of these features to trigger high intensities of negative sentiment and emotional backfire [48,49].

Discussion

Principal Findings and Implications

CHD is a severe health problem, with an increasing prevalence worldwide. Adopting a healthy lifestyle and being aware of CHD risk factors are essential for its prevention and management. This scoping review identified existing health BCSSs from RCTs, reported their characteristics, and analyzed the persuasion context and persuasive design principles of the systems identified for CHD self-management using the PSD model. We found that trends in the use of persuasive system features on par with behavior change theories were identified for only 50% (n=15) of the RCTs; this points to the fact that there is still no consensus on the need to use theories and the best approaches to design interventions to promote behavior change in patients with CHD.

The intention behind the BCSSs was to support patients with CHD to improve their health and lifestyle. The interventions analyzed sought to improve clinical outcomes, behavioral outcomes, psychological outcomes, and improved quality of life outcomes associated with CHD for their users. The analysis of the events provided insights into the problem domain, user characteristics, and technology-related factors. Although the main user group was people who had been diagnosed with CHD, some of them had multiple health conditions such as diabetes and depression or needed to change at least one behavior (eg, smoking, physical inactivity, and medication adherence) to prevent further health complications. Users of the interventions were aged at least 18 years, cognitively sound, and computer literate.

Different types of information technology platforms were chosen for BCSS design and development for various reasons. For example, SMS and other types of text messages were used for delivering the intervention in 3% (n=1) of the studies because of their ease of use and cost-effectiveness. Moreover, WeChat, an instant messaging app, was adopted because it is a widely used social networking site in China.

Furthermore, the analysis of the strategy showed that the content delivered via the BCSSs was for educational purposes and hence required users to engage their cognitive resources. Another interesting finding was the lack of educational content in 13% (n=4) of the interventions. One would expect BCSSs to have educational content because such content provides a means to educate patients and reinforce behavior change [50].

Additionally, although the RCTs conducted in Europe used at least one persuasive feature in their interventions, none of the studies mentioned the behavior change theory that underpinned the BCSS. Proponents of the use of behavior change theories argue that theories explain the mechanisms through which behavior change occurs [51]. Often, developers prioritize the use of behavior change techniques at the expense of gaining an in-depth understanding of the theories that underlie them [14]. A potential problem that may arise with the use of BCSSs without a solid theoretical foundation is the creation of conflicting mechanisms that can affect the system’s long-term effectiveness. This also points to the fact that there is still no consensus on the relevance of theories and best approaches to design interventions to promote behavior change in patients with CHD.

Another issue worth mentioning is designer or persuader bias and how it manifests itself in designing persuasive and behavior change interventions. This bias may have important ethical implications, as persuasive design decisions should be neither deceptive, manipulative, nor coercive [52]—nor cause harm to the users. Although a lot of emphasis has been placed on user-centered design in recent times, there may be a tendency for designers and developers to make design decisions affected by cognitive biases (such as the inability to evaluate all solutions to determine optimal solutions due to resource limitations) and illogical decisions (eg, intuitive reasoning, which uses low cognitive resources) [53]. In the design of BCSSs, persuader bias can manifest itself in, for example, the kind of content presented to users and the implementation of features. Designers are tasked to make design decisions based on insights generated from the context of use, user characteristics, and affordances of technology [13]. These decisions can influence the acceptability and, subsequently, the effectiveness of the system because users are sensitive to design features (eg, tailoring) [54]. From the results of the analysis, it appears that the involvement of users (eg, to create messages) may serve as a strategy to mitigate designer bias in the development of health interventions. Further research is needed to confirm this claim.

The findings from this review suggest that BCSSs have the potential to support the self-management of CHD and promote healthy lifestyles. Studies argue that the effectiveness of these systems depends on their design and implementation [55,56]. The major challenge that emerges is identifying the components of the BCSS and pertinent PSD features that are responsible for driving behavioral change [56]. This will require a deep understanding of the intricate interplay between various elements within the BCSS, such as behavior change theories, educational content, and persuasive features. Additionally, knowing the individual contribution of persuasive components and synergistic effects in this regard is desired [56]. Further research shows that the patterns of use of the intervention influence its effectiveness in achieving the desired outcome [57].

Apart from Putra et al [39], between 1 and 6 persuasive features were used in the analyzed BCSSs. In the primary task support category, personalization and self-monitoring were found to be
the most widely represented features. Within the dialogue support category, reminders and praise were the most-used features. Expertise and authority were the most-used features regarding credibility, while social learning was the only feature identified in the social support category. The frequent use of these features may imply their importance for BCSSs developed for managing or preventing CHD.

Additionally, we found that feedback is closely related to praise in the PSD model, yet distinct based on the textual descriptions. Users can receive feedback that is not necessarily of a positive tone (like praise). Feedback can be given on the user’s performance, which may be motivational, constructive, or both. Another interesting finding was the use of the term “semipersonalization,” a form of personalization. Semipersonalization describes a weak level of personalization. This brings to light the commentary by Oinas-Kukkonen [58] on a concept called “personalization myopia,” which seeks to clarify the misunderstanding surrounding the level and type of personalization offered in mobile and web apps. The level and type of personalization identified in the studies varied. In the studies analyzed, personalization of content was widely used. For instance, mobile text message–based interventions simply used the names of users to indicate personalization. With that being said, some of the studies did clarify the use of the level of personalization by using semipersonalization. A critical look at some studies revealed the use of user data to generate personalized content other than just the name. This is a step in the right direction toward true personalization. True personalization requires detailed information, such as the user’s preferences, to create individualized experiences [59] in the different stages of the user’s journey through the app. Moreover, the use of personalization accounts for differences in preferences between and within groups of participants [60].

It was reassuring that design principles that make the system credible were identified in 60% (n=18) of the BCSSs studied. System credibility support principles tend to increase user satisfaction and influence their intention to use an intervention [61]. Incorporating this principle shows the intention and commitment of the designers to deliver credible content and a trustworthy system.

Limitations
We acknowledge some limitations in our work. First, we relied on textual descriptions provided in the original papers, which were subjectively interpreted by the reviewers, creating an avenue for subjective bias. Second, our study is based on English-language publications only, thus excluding publications in other languages that could provide rich content to this analysis. Third, this review did not analyze the effectiveness of the analyzed interventions as it fell beyond the scope of this research. Instead, the focus was on identifying trends in persuasive design characteristics used in BCSSs for CHD. This encompassed key persuasive elements like behavior change theories, techniques, educational content, and persuasive features in the analyzed studies. Also, recognizing prevailing trends can contribute to the refinement and development of theories and practices for BCSSs. This valuable information can also help developers, clinicians, and developers to make informed decisions. To deepen our understanding, future research should assess the relevance and impact of persuasive elements through meta-analysis. This approach may yield much-needed evidence and insights and contribute to developing effective interventions.

Conclusion
This study sought to identify persuasive design characteristics in mobile, web, and other information system interventions for CHD. We analyzed 30 peer-reviewed RCT papers that implemented BCSSs for patients with CHD. This study highlights the key issues that should be considered when designing and developing BCSSs for CHD. From the analysis of RCTs, we found that trends in the use of persuasive system features on par with behavior change theories were identified for only 50% (n=15) of RCTs. This points to the fact that there is still no consensus on the need to use theories and the best approaches to design interventions to promote behavior change in patients with CHD. Although we were able to highlight the trends in the persuasive features, we were unable to determine if these features influenced the effectiveness of the analyzed BCSSs. Moreover, there is a need to evaluate the actual effect of the intervention on users. Thus, future research should address this using data analysis methodologies such as meta-analysis.

Acknowledgments
We would like to thank Markku Savolainen, MD and Piaaistiina Tikka, PhD, for their feedback and comments on an early draft of this paper. Additionally, we would like to express our gratitude to Sami Pohjolainen for his thorough review of the Persuasive Systems Design features. This study has received funding from the European Union’s Horizon 2020 research and innovation program (grant 848056) and from the Academy of Finland project, known as PerFeat (decision 351670). It reflects only the authors’ views and neither the Commission of Finland nor the Academy of Finland are responsible for any use that may be made of the information it contains.

Data Availability
The data used in this research is publicly available in the Multimedia Appendices.

Conflicts of Interest
None declared.
Multimedia Appendix 1
The analysis of intent describes the primary and secondary outcomes of the randomized controlled trials.
[XLSX File (Microsoft Excel File), 18 KB - cardio_v8i1e49515_app1.xlsx]

Multimedia Appendix 2
The analysis of the event describes the use, user, and technology context in the studied interventions.
[XLSX File (Microsoft Excel File), 18 KB - cardio_v8i1e49515_app2.xlsx]

Multimedia Appendix 3
The analysis of the strategy describes the message and route for presenting information in the studied intervention.
[XLSX File (Microsoft Excel File), 17 KB - cardio_v8i1e49515_app3.xlsx]

Multimedia Appendix 4
Distribution of identified persuasive systems features, contents, and theories as shown by the shaded areas. "Content" refers to the number of contents identified in each intervention. "Theories" refers to the number of theories identified in each intervention. AUT: authority; CRED: credibility support; DIAL: dialogue support; EXP: expertise; PER: personalization; PRA: praise; PRIM: primary task support; RED: reduction; REM: reminder; REW: rewards; RWF: real-world feel; SMO: self-monitoring; SOCI, SLE: social learning; SRO: social role; SUG: suggestion; TAI: tailoring; VER: verifiability.
[XLSX File (Microsoft Excel File), 12 KB - cardio_v8i1e49515_app4.xlsx]

Multimedia Appendix 5
The analysis of persuasive features used in the interventions examined.
[XLSX File (Microsoft Excel File), 21 KB - cardio_v8i1e49515_app5.xlsx]

Multimedia Appendix 6
PRISMA checklist.
[PDF File (Adobe PDF File), 120 KB - cardio_v8i1e49515_app6.pdf]

References


54. Materia FT, Smyth JM. Acceptability of intervention design factors in mHealth intervention research: experimental factorial study. JMIR Mhealth Uhealth 2021 Jul 26;9(7):e23303 [FREE Full text] [doi: 10.2196/23303] [Medline: 34309563]


Abbreviations

BCSS: behavior change support system
CAD: coronary artery disease
CHD: coronary heart disease
PICO: Population, Intervention, Comparison, and Outcome
PRISMA-ScR: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews
PSD: Persuasive Systems Design
RCT: randomized controlled trial

©Eunice Ena Yaa Frimponmaa Agyei, Akon Ekpezu, Harri Oinas-Kukkonen. Originally published in JMIR Cardio (https://cardio.jmir.org), 19.06.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any form, provided the original work is properly cited.
medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
Feasibility of Using Text Messaging to Identify and Assist Patients With Hypertension With Health-Related Social Needs: Cross-Sectional Study

Aryn Kormanis¹, DO; Selina Quinones¹, BS; Corey Obermiller¹, MAS; Nancy Denizard-Thompson¹, MD; Deepak Palakshappa¹,²,³, MS, MD

¹Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC, United States
²Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, NC, United States
³Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, NC, United States

Corresponding Author:
Deepak Palakshappa, MS, MD
Department of Internal Medicine
Wake Forest University School of Medicine
Medical Center Blvd
Winston Salem, NC, 27157
United States
Phone: 1 3367161795
Email: dpalaksh@wakehealth.edu

Abstract

Background: Health-related social needs are associated with poor health outcomes, increased acute health care use, and impaired chronic disease management. Given these negative outcomes, an increasing number of national health care organizations have recommended that the health system screen and address unmet health-related social needs as a routine part of clinical care, but there are limited data on how to implement social needs screening in clinical settings to improve the management of chronic diseases such as hypertension. SMS text messaging could be an effective and efficient approach to screen patients; however, there are limited data on the feasibility of using it.

Objective: We conducted a cross-sectional study of patients with hypertension to determine the feasibility of using SMS text messaging to screen patients for unmet health-related social needs.

Methods: We randomly selected 200 patients (≥18 years) from 1 academic health system. Patients were included if they were seen at one of 17 primary care clinics that were part of the academic health system and located in Forsyth County, North Carolina. We limited the sample to patients seen in one of these clinics to provide tailored information about local community-based resources. To ensure that the participants were still patients within the clinic, we only included those who had a visit in the previous 3 months. The SMS text message included a link to 6 questions regarding food, housing, and transportation. Patients who screened positive and were interested received a subsequent message with information about local resources. We assessed the proportion of patients who completed the questions. We also evaluated for the differences in the demographics between patients who completed the questions and those who did not using bivariate analyses.

Results: Of the 200 patients, the majority were female (n=109, 54.5%), non-Hispanic White (n=114, 57.0%), and received commercial insurance (n=105, 52.5%). There were no significant differences in demographics between the 4446 patients who were eligible and the 200 randomly selected patients. Of the 200 patients included, the SMS text message was unable to be delivered to 9 (4.5%) patients and 17 (8.5%) completed the social needs questionnaire. We did not observe a significant difference in the demographic characteristics of patients who did versus did not complete the questionnaire. Of the 17, a total of 5 (29.4%) reported at least 1 unmet need, but only 2 chose to receive resource information.

Conclusions: We found that only 8.5% (n=17) of patients completed a SMS text message–based health-related social needs questionnaire. SMS text messaging may not be feasible as a single modality to screen patients in this population. Future research should evaluate if SMS text message–based social needs screening is feasible in other populations or effective when paired with other screening modalities.

(JMIR Cardio 2024;8:e54530) doi:10.2196/54530
KEYWORDS
social determinants of health; health-related social needs; mobile health; health information technology; feasibility; mobile phone; SMS text messaging; message; pilot study; patients; patient; hypertension; screening

Introduction
Unmet health-related social needs, such as food insecurity and housing instability, are associated with impaired chronic disease management and worse health outcomes [1-5]. For example, people with hypertension who live in a food-insecure household are more likely to have worse diet quality and blood pressure control than people with hypertension who live in a food-secure household. Because of their negative impact, national organizations, such as the Centers for Medicare and Medicaid (CMS), have recommended that health systems integrate interventions to screen and address patients’ unmet social needs as a routine part of clinical care [6-9]. Although there has been growing investment by health systems to integrate these interventions, there are still limited data on how to most effectively implement screening in busy clinical settings [10,11]. Studies assessing the use of mobile tools (eg, tablets) and telephone-based screening identified barriers to these screening modalities [12-14]. Barriers to using these methods include that tablets are dependent on patients presenting in person to the clinic [12,15,16] and phone-based screening may add additional work for already busy clinical staff [14].

SMS text messaging could be an effective and efficient approach to assess patients for health-related social needs and allow for screening to occur outside of the direct patient encounter. However, prior studies have not used SMS text messaging to screen patients for health-related social needs. To fill this gap, our objective was to determine the feasibility and acceptability of using SMS text messaging to screen and assist patients with hypertension with health-related social needs. We were specifically interested in evaluating if patients would complete a SMS text message–based social risk questionnaire and if there were differences in demographics between patients who completed the questionnaire and those who did not.

Methods
Study Design and Population
We conducted a pilot cross-sectional study at Atrium Health Wake Forest Baptist Health (AHWFB) to assess the feasibility of using SMS text messaging to send a link to a web-based questionnaire to screen patients for health-related social needs. AHWFB is a large, integrated academic health system serving communities in Central and Western North Carolina. The system is comprised of a tertiary care hospital located in Winston-Salem, NC, 4 community hospitals, and >300 ambulatory practices that all use a single electronic health record (EHR; EpicCare). We identified eligible adult patients (≥18 years) with hypertension who were seen at an AHWFB primary care clinic in the previous 3 months (between November 2022 and February 2023). We only included patients who had been seen in the last 3 months to ensure they were still a patient at the clinic. We limited the sample to patients seen in an AHWFB internal or family medicine clinic (17 clinics) in Forsyth County, North Carolina to provide tailored information about local community-based resources (eg, food pantries). We also included these 17 clinics because they are in the process of integrating social risk screening into routine clinical care, but none of the 17 clinics had implemented a standardized screening process prior to or during the time period the study was conducted. Based on 2023 census estimates of people living in Forsyth County, 17.2% of the population are older than 65 years of age, 65.7% identify as non-Hispanic White, 27.7% as non-Hispanic Black, and 14.3% as Hispanic. A total of 14% of the population have a household income below the federal poverty level, 12.9% of the population are estimated to be uninsured, and 11.6% of households in the county are estimated to be food insecure. We recruited participants by taking a simple random sample of 200 patients from the 4446 eligible patients identified and sending them SMS text messages to the cell phone number included in the EHR. As there is no specific consensus on the sample size necessary to assess the feasibility of a pilot study, consistent with prior studies, we included 200 (~5% of the eligible population) patients [17,18].

Ethical Considerations
The Wake Forest University School of Medicine institutional review board reviewed and approved this study under the expedited review with a waiver of written informed consent (IRB00092658). The SMS text message included language to notify the participants that the questionnaire was part of a research study and that participation was voluntary. To maintain privacy and confidentiality, all participants’ responses to the social risk questionnaire and personal health and demographic data were stored in a password-protected file on the institution’s secure server. Only study team members had access to the data. The participants did not receive compensation for participation in the study.

SMS Text Messages
We developed the SMS text message–based on a detailed literature review of the social needs literature (Multimedia Appendix 1). The AHWFB digital communication committee also reviewed the SMS text messages. The committee includes patients, clinicians, hospital administrators, and members of the institutional review board. The committee reviews all SMS text messages that may be sent to patients for either research or clinical purposes at the institution, and they provide input on the wording of the messages. We also reviewed the SMS text messages with patients who were not included in the study to assess face validity and to provide additional input on the messages. The SMS text message included a link to a questionnaire with 6 questions from the CMS Accountable Health Communities Health-Related Social Needs Screening Tool [7]. The 6 questions included 2 questions about housing (including 1 about patients’ current housing situation and 1 about problems with housing), 2 questions about food insecurity, 1 question about transportation, and 1 question about use. We limited to questions regarding food, housing, transportation,
and utilities because there were local resources available to assist patients with these domains. The initial message was sent to the patient’s cell phone number listed in the EHR on March 14, 2023. All of the 4446 patients eligible had a phone number listed in the EHR. For those that did not respond, the same message was sent again 1 week later. Responses were documented in the EHR. The SMS text message and questionnaire were sent in English or Spanish based on the preferred language of the patient listed in the EHR. We used the standard scoring to identify patients who screened positive for a social need. The patients were identified as having housing instability if they provided a response other than “I have a steady place to live” to the first housing question or if they provided a response other than “None of the above” to the second question. Patients were identified as having food insecurity if they responded to either of the 2 questions with “sometimes true” or “often true.” Patients were identified as having a lack of transportation if they responded “yes” to the transportation question, and they were identified as having difficulty with utilities if they responded “yes” or “already shut off” to the utilities question.

For patients who screened positive for any of the social needs, they were asked if they would be interested in receiving information about local community resources. A list of resources was then sent by the system in a subsequent SMS text message to patients who were interested in receiving information about local community resources. The system used branching logic and only provided information on resources for the unmet need the patient reported (eg, food resources for those with food insecurity). Patients were asked if they would be willing to receive an additional message 1 month later to assess the acceptability of the process and if they used any of the information provided about community resources (Multimedia Appendix 1). Questions were based on the validated Acceptability of Intervention Measure [19].

**Statistical Analysis**

We obtained age, sex, race (White, Black, American Indian or Alaska Native, Asian Indian, Filipino, and other), ethnicity (Hispanic and non-Hispanic), insurance status (commercial or private, Medicaid, Medicare, uninsured, and other), and preferred language (English or Spanish) for all patients through data extraction from the EHR. Informed by the Reach, Effectiveness, Acceptability, Implementation, and Maintenance (RE-AIM) framework [20-22], feasibility was based on the reach of the screening or the proportion of patients who completed the social needs questionnaire. To understand if using a SMS text message–based social needs questionnaire could lead to disparities in who completes screening questions, we evaluated for differences in demographics between patients who completed the questions and those who did not use bivariate analyses. We used either the chi-square or Fisher exact test for categorical variables, and we used the Welch $t$ test for continuous variables to account for unequal sample sizes and variances. We considered an $\alpha$ of <.05 significant and all analyses were conducted using Stata 15.0 (StataCorp).

**Results**

Of the 200 patients randomly selected, the majority were females (n=109, 54.5%), non-Hispanic White (n=114, 57.0%), who received commercial or private health insurance (n=105, 52.5%), and had English listed as their preferred language (n=192, 96.0%). The mean age of the patients selected was 57.6 (SD 12.9) years of age.

Of the 200 patients, the SMS text message was unable to be delivered to 9 patients (either because the number listed was no longer working or was not a cell phone). A total of 17 (8.5%) patients completed the social needs questionnaire (Table 1). We did not find a significant difference in demographics between patients who did and those who did not complete the questionnaire. Of the 17 who completed the questionnaire, 5 (29.4%) reported at least 1 unmet social need, but only 2 chose to receive local resource information. One person completed the follow-up questionnaire and reported that they learned about new community resources through the process.
Table 1. Study patient characteristics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N=200)</th>
<th>Did not respond (n=183)</th>
<th>Responded (n=17)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>57.6 (12.9)</td>
<td>57.1 (13.0)</td>
<td>63.1 (11.6)</td>
<td>.05</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>.16</td>
</tr>
<tr>
<td>Male</td>
<td>91 (45.5)</td>
<td>86 (47.0)</td>
<td>5 (29.4)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>109 (54.5)</td>
<td>97 (53.0)</td>
<td>12 (70.6)</td>
<td></td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>.99</td>
</tr>
<tr>
<td>Non-Hispanic and White</td>
<td>114 (57.0)</td>
<td>104 (56.8)</td>
<td>10 (58.8)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic and Black</td>
<td>67 (33.5)</td>
<td>61 (33.3)</td>
<td>6 (35.3)</td>
<td></td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>1 (0.5)</td>
<td>1 (0.6)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Asian Indian</td>
<td>3 (1.5)</td>
<td>3 (1.6)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Filipino</td>
<td>1 (0.5)</td>
<td>1 (0.6)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>14 (7.0)</td>
<td>13 (7.1)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>.99</td>
</tr>
<tr>
<td>Hispanic, Latino, or Spanish</td>
<td>15 (7.5)</td>
<td>14 (7.7)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Not Hispanic, Latino, or Spanish</td>
<td>185 (92.5)</td>
<td>169 (92.4)</td>
<td>16 (94.1)</td>
<td></td>
</tr>
<tr>
<td>Health insurance, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>.17</td>
</tr>
<tr>
<td>Commercial</td>
<td>105 (52.5)</td>
<td>100 (54.6)</td>
<td>5 (29.4)</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>13 (6.5)</td>
<td>12 (6.6)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Medicare</td>
<td>64 (32.0)</td>
<td>55 (30.1)</td>
<td>9 (52.9)</td>
<td></td>
</tr>
<tr>
<td>Uninsured</td>
<td>11 (5.5)</td>
<td>10 (5.5)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>7 (3.5)</td>
<td>6 (3.3)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Language, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>.52</td>
</tr>
<tr>
<td>English</td>
<td>192 (96.0)</td>
<td>176 (96.2)</td>
<td>16 (94.1)</td>
<td></td>
</tr>
<tr>
<td>Spanish</td>
<td>8 (4.0)</td>
<td>7 (3.8)</td>
<td>1 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Food insecurity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>N/A</td>
<td>N/A</td>
<td>3 (17.7)</td>
<td>N/A</td>
</tr>
<tr>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>14 (82.4)</td>
<td>N/A</td>
</tr>
<tr>
<td>Living situation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I have a steady place to live</td>
<td>N/A</td>
<td>N/A</td>
<td>16 (94.1)</td>
<td>N/A</td>
</tr>
<tr>
<td>Prefer not answer</td>
<td>N/A</td>
<td>N/A</td>
<td>1 (5.9)</td>
<td>N/A</td>
</tr>
<tr>
<td>Problems in the home, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>N/A</td>
<td>N/A</td>
<td>16 (94.1)</td>
<td>N/A</td>
</tr>
<tr>
<td>Pests (eg, bugs, ants, or mice)</td>
<td>N/A</td>
<td>N/A</td>
<td>1 (5.9)</td>
<td>N/A</td>
</tr>
<tr>
<td>Lack of transportation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>14 (87.5)</td>
<td>N/A</td>
</tr>
<tr>
<td>Yes</td>
<td>N/A</td>
<td>N/A</td>
<td>1 (6.3)</td>
<td>N/A</td>
</tr>
<tr>
<td>Prefer not answer</td>
<td>N/A</td>
<td>N/A</td>
<td>1 (6.3)</td>
<td>N/A</td>
</tr>
<tr>
<td>Electric, gas, or water shut off, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>N/A</td>
<td>N/A</td>
<td>17 (100.0)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*aBivariate analysis comparing characteristics of patients who were did and did not respond to a SMS text message linked social needs questionnaire in March 2023; responses to the social needs questionnaire for the 17 participants are also included.

bN/A: not applicable.
Discussion

These results suggest that SMS text messaging may be inadequate when used as a single modality for screening patients for unmet health-related social needs in this population, as only 17 (8.5%) of patients completed the social needs questionnaire. Yet 29% (n=5) of patients who completed the questionnaire reported having at least 1 unmet social need. Given the growing investment in integrating social care interventions into health care delivery, understanding screening strategies that are both effective and those that may be less effective are important.

There are several possible explanations for the low response rate. First, patients could have concerns about completing the social risk questionnaire using a SMS text message–based link. Prior studies have found that there are multiple factors, such as trust in their provider and concern about disclosure of sensitive information, contributing to patients' acceptability of social needs screening [23-25]. Previous studies have also found that patients are more likely to complete social risk questionnaires and disclose sensitive information if they are screened using paper or tablets in the clinic, rather than being verbally asked [26-29]. Patients may be unable to have confidence in who is administering the questionnaire and have access to the results using SMS text messaging. We did not notify patients that they would be sent the SMS text message. Discussing with patients prior to sending the message or directly tying the message to an upcoming visit may result in higher screening completion rates. It is also possible that the majority of patients who received the message did not have a social need, so they did not see a benefit in completing the social risk questionnaire.

A second possibility for the low response rate is the wording of the message. We tried to gather input from multiple different stakeholders in developing the message, but patients may have either misunderstood the purpose of the SMS text message or were not interested in participating in a research study. A SMS text message coming directly from a patient's provider or clinic could yield different results and future research could randomize who sends the message. A third reason for the low response rate could be barriers to using the technology [30,31]. We had to embed the questionnaire as a link in the SMS text message rather than have the questions directly in the message. Barriers to accessing the link could include patients not having a smartphone, although more than 90% of people in the United States have a smartphone [32]. Even if patients had a smartphone, patients may not have had access to the internet on the device to access the link. Another barrier to using the technology could have been that people were concerned about accessing a link on their phone, because of concerns about privacy, or were unsure of how to access the link.

Despite the low response rate and the limitations, this study provides important information for clinical care. This is the first study to assess patients’ health-related social needs using SMS text messaging, and the response rate was lower than what has been seen in other SMS text messaging–based patient-reported outcomes studies [33,34]. Numerous national health care organizations have recommended that health systems address patients’ unmet social needs as a routine part of clinical care, and CMS will require that all adult patients admitted to the hospital be screened for health-related social needs beginning in 2024 [6-9]. Many health systems are in the process of implementing different approaches to screen patients for social needs. At least in this population, simply sending out a SMS text message with the social risk questionnaire may not be effective as a single modality to assess all patients for health-related social needs. Health systems and clinics may need to implement multiple modalities, such as using SMS text messaging, the patient portal, or tablets in the clinic, to effectively screen all patients. If health systems are still interested in using SMS text messaging, they may also want to consider varying when and how the messages are sent.

There are several limitations to this study that should be acknowledged. First, although we included patients seen in 17 different primary care clinics, the clinics were all located in the same county and part of the same academic medical center so the results may not be generalizable to other populations. Second, all of the messages were sent at the same time and day for every patient. Varying when the message is sent (ie, time of the day and proximity to a clinic visit), may yield different results. Third, the message was sent based on the preferred language listed in the EHR. It is possible that the language listed was not correct. Fourth, we limited this study to patients with a diagnosis of hypertension. Future studies in other patient populations could find different results. Fifth, as in other studies screening patients for social risks in clinical care settings, individuals who have a primary care provider or clinic may be different than individuals who do not (ie, more likely to have health insurance) [35]. The results of the social risk questionnaire may not be representative of the surrounding community. Sixth, the SMS text message was unable to be delivered to 9 patients based on the phone number included in the EHR. As populations who have been socially and economically disadvantaged are more likely to have disruptions in their phone service, future research should evaluate the reasons why the message was unable to be delivered.

In this study, we found that only 17 (8.5%) of the 200 randomly selected patients completed a SMS text message–based health-related social needs questionnaire. Despite the negative results, this study provides important information for clinics considering implementing social needs screening. Further research is needed to understand how to most effectively and efficiently implement social needs screening in a patient-centered approach.

Acknowledgments

DP is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under grant (K23HL146902). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
of Health. The funding organization has no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the study; and decision to submit the study for publication. DP reports personal fees from WellCare of North Carolina outside of the submitted work.

Data Availability
The data sets generated and analyzed during this study are not publicly available because they contain personal health information, but deidentified data sets are available from the corresponding author on reasonable request.

Conflicts of Interest
None declared.

Multimedia Appendix 1
Data and questions included in text messages.

References


**Abbreviations**

| AHWFBC | Atrium Health Wake Forest Baptist Health |
| CMS | Centers for Medicare and Medicaid |
| EHR | electronic health record |
| RE-AIM | Reach, Effectiveness, Acceptability, Implementation, and Maintenance |
Comparing the Efficacy of Targeted and Blast Portal Messaging in Message Opening Rate and Anticoagulation Initiation in Patients With Atrial Fibrillation in the Preventing Preventable Strokes Study II: Prospective Cohort Study

Alok Kapoor¹,², MS, MD; Parth Patel¹, BS; Soumya Chennupati¹, BS; Daniel Mbusa¹, BS; Hammad Sadiq¹, BS; Sanjeev Rampam¹, BS; Robert Leung¹,², MBA, MD; Megan Miller³, BS; Kevin Rivera Vargas³, BS; Patrick Fry⁴, BS; Mary Martin Lowe⁵, PhD; Christina Catalano⁴, MBA; Charles Harrison⁴, MD; John Nicholas Catanzaro⁴, MD; Sybil Crawford¹, PhD; Anne Marie Smith⁶, MBA

¹University of Massachusetts Chan Medical School, Worcester, MA, United States
²University of Massachusetts Memorial Health Care, Worcester, MA, United States
³College of Pharmacy, University of Florida, Jacksonville, FL, United States
⁴College of Medicine, University of Florida, Jacksonville, FL, United States
⁵Learning Advisors LLC, Chicago, IL, United States
⁶Heart Rhythm Society, Washington, DC, United States

Corresponding Author:
Alok Kapoor, MS, MD
University of Massachusetts Chan Medical School
55 N Lake Ave
Worcester, MA, 01655
United States
Phone: 1 9178564538
Email: alok.kapoor@umassmemorial.org

Abstract

Background: The gap in anticoagulation use among patients with atrial fibrillation (AF) is a major public health threat. Inadequate patient education contributes to this gap. Patient portal–based messaging linked to educational materials may help bridge this gap, but the most effective messaging approach is unknown.

Objective: This study aims to compare the responsiveness of patients with AF to an AF or anticoagulation educational message between 2 portal messaging approaches: sending messages targeted at patients with upcoming outpatient appointments 1 week before their scheduled appointment (targeted) versus sending messages to all eligible patients in 1 blast, regardless of appointment scheduling status (blast), at 2 different health systems: the University of Massachusetts Chan Medical School (UMass) and the University of Florida College of Medicine-Jacksonville (UFL).

Methods: Using the 2 approaches, we sent patient portal messages to patients with AF and grouped patients by high-risk patients on anticoagulation (group 1), high-risk patients off anticoagulation (group 2), and low-risk patients who may become eligible for anticoagulation in the future (group 3). Risk was classified based on the congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke, vascular disease, age between 65 and 74 years, and sex category (CHA²DS²-VASc) score. The messages contained a link to the Upbeat website of the Heart Rhythm Society, which displays print and video materials about AF and anticoagulation. We then tracked message opening, review of the website, anticoagulation use, and administered patient surveys across messaging approaches and sites using Epic Systems (Epic Systems Corporation) electronic health record data and Google website traffic analytics. We then conducted chi-square tests to compare potential differences in the proportion of patients opening messages and other evaluation metrics, adjusting for potential confounders. All statistical analyses were performed in SAS (version 9.4; SAS Institute).

Results: We sent 1686 targeted messages and 1450 blast messages. Message opening was significantly higher with the targeted approach for patients on anticoagulation (723/1156, 62.5% vs 382/668, 57.2%; P=.005) and trended the same in patients off
About 6 million Americans have atrial fibrillation (AF), with 12 million projected by 2050 [1-3]. AF accounts for 15% of ischemic strokes, resulting in permanent disability in 60% of cases and death in up to 20% [4]. The main approach to stroke prevention is anticoagulation. Although guidelines [5] and evidence exist to guide providers in prescribing anticoagulation, only about 60% of eligible patients receive anticoagulation, leading to a projected annual excess stroke rate of 100,000 [6,7]. Low adherence to this guideline results from a combination of not initiating anticoagulation when indicated and discontinuing anticoagulation prematurely. This is particularly true in patients of minority race and ethnicity, where anticoagulation use is lower and stroke rates are higher [8-13].

There are multiple barriers to initiating and persisting with anticoagulation. Access to specialists, socioeconomic status, and health literacy each represent a barrier [8]. The advent of patient portals makes electronic messaging an attractive, low-cost method to educate patients and prepare them for visits with their anticoagulation providers. While the electronic health record (EHR) patient portal is increasingly being used in health care to improve patient education, engagement, and health outcomes, responsiveness to this methodology for anticoagulation use in patients with atrial fibrillation is unknown.

A recent review suggests that patient education about anticoagulation through a mobile device, such as a smartphone or tablet, increases patient knowledge levels, medication adherence, and satisfaction and is associated with improved clinical outcomes [14]. EHR-based programs have also been identified as a valuable method to improve warfarin therapy, a type of anticoagulation, self-management for pediatric patients with congenital heart diseases [15]. Evaluating patient responsiveness to different portal-based messaging methods can help identify the optimal use of EHR patient portal tools to best support patients in managing their AF and anticoagulation.

In this study, we compare patient responsiveness to 2 approaches to patient portal messaging with the goal of directing patients to the Upbeat website [16] of the Heart Rhythm Society, which contains print and video information about AF and anticoagulation.

**Methods**

**Overview**

We previously published the protocol for our paper, which covered the methods used at UMass to send patient messages [17]. We will briefly summarize the pertinent elements of the methods for that messaging campaign. We will also include additional details regarding the parallel messaging intervention at the UFL.

**Study Design**

We conducted a prospective cohort study. We sent patients a message through MyChart (Epic Systems Corporation), the patient portal associated with Epic Systems (Epic Systems Corporation) EHR, introducing the study and the purpose of communication (Multimedia Appendix 1). The message contained a link (unique to each site) to educational materials housed on a professional society web page—that is, the Upbeat website produced by the Heart Rhythm Society (HRS)—as well as a link to a survey soliciting feedback about the educational materials (Multimedia Appendix 2). Essentially, we created 2 unique websites, (1 for each site) but with the same content and layout (clone copies). In the first approach, at the University of Massachusetts Chan Medical School (UMass), we tested targeted messaging by sending messages to patients through MyChart 1 week before an appointment with a cardiology provider or primary care provider. In the second approach, at the University of Florida College of Medicine-Jacksonville (UFL), we tested a blast messaging approach of sending a message to all eligible patients independent of an appointment. At UMass, we facilitated the message-sending process with a bulk communication tool available through Epic Systems. At UFL, we sent messages manually.

**Setting**

We included the cardiology and primary care practices of the UMass Memorial Health System located in central Massachusetts, as well as the patients within UFL’s ambulatory practices located in northern Florida and southern Georgia. Both sites used the Epic Systems EHR and the MyChart patient portal for the duration of the study. We sent messages to UMass patients from November 2021 until February 2022. At UFL, we sent all messages in November 2021.

**Participants**

We included patients aged 18 years or older with AF with active MyChart patient portal accounts and who had at least 1 office visit in the 12 months before the start of our messaging intervention in November 2021. At UMass, starting each workday from November 2021 to February 2022, we ran the Epic System’s Reporting Workbench that identified patients based on their having an appointment (office or tele-visit type) with a primary or cardiology care provider scheduled to take place within a week. At UFL, from November 2021 to...
December 2021, we identified patients based on a previously established registry of those patients with AF who had a visit with a primary or cardiology care provider in the previous year. At both sites, we grouped patients based on their anticoagulation status (eg, on or off anticoagulation) and congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, and sex scale (CHA₂DS₂-VASc) score. Specifically, group 1 included those at high risk (eg, CHA₂DS₂-VASc score of ≥2 for men and ≥3 for women) and currently on anticoagulation; group 2 included those at high risk and off anticoagulation; and group 3 included those at low risk (eg, CHA₂DS₂-VASc score <2 for men and <3 for women) and not on anticoagulation.

Outcomes, Variables, or Data Sources

Message Opening
We tracked message opening as the number of messages opened divided by the number of messages sent. To identify messages, we relied on Epic Systems clarity structured query language–based coding. Specifically, we collected all messages received from individual patients and then filtered them by messages sent by the study coordinators. Study coordinators did not send messages for other purposes, allowing us to only isolate study-related messaging.

Website Review
Using Google Analytics (Google LLC), we tracked the number of unique page views as the value representing the total number of unique sessions. As patients may have received more than 1 message throughout the study (corresponding to 2 separate visits or in the case of canceled and rescheduled visits), we selected the number of messages sent as the denominator. We then calculated the percentage of messages resulting in a unique page view, with the number of unique page views as the numerator and compared this across sites. We also compared the “bounce rate” across sites, which represents the percentage of all sessions on a site in which users only viewed a single page. Google documentation [18] notes that bounce rates should be interpreted within the context of a specific website’s purpose. Upbeat, the website our messages directed patients toward, has many links to educational resources regarding anticoagulation and AF. We consider navigation away from the landing page to indicate more patient engagement with these educational materials. Thus, having a lower bounce rate indicates higher engagement with the Upbeat website beyond the information presented on the landing page. Digital experience research indicates that a bounce rate of less than 40% is excellent [19], although the referenced source did not provide a specific bounce rate for health education websites, which may differ from other types of websites.

Survey-Based Outcomes
We compared survey responses across both messaging approaches and sites. For group 1 (high risk, on anticoagulation), the survey covered domains of discussions of personal stroke risk, history of anticoagulation use, and persistence. For group 2 (high risk, off anticoagulation), the survey covered discussions of personal stroke risk, the report by the patient of receiving a provider suggestion to take anticoagulation, and the reason for stopping anticoagulation for those with previous use. For group 3 (low risk, not on anticoagulation), the survey covered the likelihood of learning more about personal stroke risk, willingness to start anticoagulation, and reasons for anticoagulation hesitancy. We also asked all 3 groups of patients about their attitude toward the Upbeat website materials, including if the materials were understandable, useful, and something they would recommend to other patients. We collected responses on a 5-point Likert scale ranging from strongly disagree to strongly agree.

Anticoagulation Use After Messaging
We tracked anticoagulation use through medication and laboratory records from our EHR for the 3 months following the completion of our messaging program until May 2023. To be on anticoagulation, a patient had to have an active prescription for an anticoagulant updated at an office visit in the 12 months before the start of the messaging program in November 2021. Moreover, the prescription had to be consistent with a therapeutic dose to prevent strokes associated with AF. We assigned baseline status based on the presence or absence of an anticoagulation medication on the current medication list for a visit occurring in the 12 months before baseline. We also considered a patient to be on anticoagulation if they had an international normalized ratio value of 1.5 or higher recorded within 60 days of the date of the end of follow-up, following an example in the literature as well as the clinical threshold commonly observed to make decisions about surgery and anticoagulation reversal [20,21].

Independent Exposure
The independent exposure was the messaging approach used (targeted at UMass vs blast at UFL).

Other Exposures: Anticoagulation Outcome Only
We included stroke risk based on the CHA₂DS₂-VASc score, which is comprised of congestive heart failure, hypertension, age, diabetes, previous stroke, vascular disease, and gender. To adjust further for potential confounders of the association between anticoagulation use and message opening, we included demographics omitted in that score (ie, race, ethnicity, language preference, and primary insurance). Finally, we included chronic kidney disease and anemia. In general, we relied on the International Classification of Diseases, tenth edition codes for the presence of a comorbid condition. For chronic kidney disease, low platelet count, and anemia, we relied on laboratory data.

Analysis or Efforts to Address Bias, Study Size, and Statistical Methods
Although we did not calculate an effect size a priori for this study, in our previous work, we have typically attempted to find a 5% or greater increase in anticoagulation initiation. A 5% increase would correspond with the prevention of 5 strokes over 1 year at our sites and 5000 strokes per year in the United States. We derive these figures from a large national registry reporting stroke rates in patients with AF as well as other epidemiological studies [22,23].
Message Opening, Website Review, and Survey-Based Outcomes

We calculated a chi-square-based $P$ value comparing proportions of patients, or in the case of website site review, unique sessions, across messaging approaches or sites.

Anticoagulation Outcome

Among patients opening portal messages, we compared anticoagulation across the 2 messaging approaches. Specifically, we compared anticoagulation use 3 months after completion of messaging with both approaches for patients in group 1 and then separately for those in group 2. For this outcome, we excluded patients who did not have information to calculate baseline anticoagulation status (ie, visits within the past 12 months where anticoagulation status would have been updated) [12]. We did not impute missing anticoagulation status given the number of missing values and the unclear randomness of missingness as suggested in guidance from the literature [24]. To determine the significance of the difference in the percentage of anticoagulation use across message approaches, we calculated a chi-square-based $P$ value, comparing proportions of anticoagulation separately for group 1 and then again for group 2.

To address potential bias from the confounder of the difference in populations at the 2 different sites, we computed the adjusted percentage of patients on anticoagulation between messaging approaches. More specifically, we constructed a generalized logistic mixed model with anticoagulation status (on or off) as the dependent variable and messaging approach (targeted vs blast) as the independent variable. We also included a random effect for provider to account for potential clustering and several covariates to adjust for potential confounders of anticoagulation. Covariates included variables making it more likely to be on anticoagulation (eg, higher stroke risk expressed through the CHA$_2$DS$_2$-VASc score) as well as factors making it less likely to be on anticoagulation (eg, anemia, chronic kidney disease, and high BMI). We did this separately for groups 1 and 2.

We performed all calculations in SAS (version 9.4; SAS Institute). In Multimedia Appendix 3, we include the code used to conduct the analysis.

Ethical Considerations

At UMass, the institutional review board (IRB) approved this protocol with an implied consent process (ie, we argued consent would be implied by those choosing to review the website or answer our survey). We also provided patients with the opportunity to opt-out if they did not want us to use their information about message opening or anticoagulation use. At the time of analysis, all data were deidentified or anonymized by stripping real identifiers with a unique study identifier. All patients were informed before they provided implied informed consent. The UMass Chan IRB approved the waiver of documentation of written informed consent as the study was minimal-risk, appropriate confidentiality protections were to be exercised, and the waiver of consent would not adversely affect the rights and welfare of subjects. The authors designed the study and gathered and analyzed the data according to the Helsinki Declaration guidelines on human research. The research protocol used in this study was reviewed and approved by the UMass Chan IRB (H00021866). The authors did not use any form of AI in any portion of this study, including manuscript writing.

At UFL, the IRB exempted the study as quality improvement.

Results

Message Opening

We sent 1156 (UMass) and 668 (UFL) messages to group 1 patients, 438 and 632 messages to group 2 patients, and 92 and 150 messages to group 3 patients with the targeted and blast approaches, respectively. Cohort characteristics by group and messaging approach are described in Table 1.

Message opening was moderately high at both sites and across groups, with the highest opening rates in group 1 (723/1156, 62.5%) at UMass and group 3 (87/150, 57.3%) at UFL. Message opening in group 1 was significantly higher at UMass than at UFL (723/1156, 62.5% vs 382/668, 57.2%; $P=.005$). We did not find a statistically significant difference in message opening rates between the targeted (UMass) and blast (UFL) messaging approaches for group 2 (274/438, 62.6% vs 335/632, 53%; $P=.09$) and group 3 (52/92, 56.5% vs 86/150, 57.3%; $P=.22$).
Table 1. Key characteristics in patients receiving messages with targeted versus blast approach (percentages may not sum to 100 due to rounding).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Targeted messaging (University of Massachusetts)</th>
<th>Blast messaging (University of Florida)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group 1 (high risk on anticoagulation; n=1156), n (%)</td>
<td>Group 2 (high risk off anticoagulation; n=438), n (%)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>272 (23.5)</td>
<td>96 (21.9)</td>
</tr>
<tr>
<td>65-74</td>
<td>374 (32.4)</td>
<td>140 (32)</td>
</tr>
<tr>
<td>≥75</td>
<td>501 (43.3)</td>
<td>196 (44.8)</td>
</tr>
<tr>
<td>Missing</td>
<td>9 (0.8)</td>
<td>6 (1.4)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>436 (37.7)</td>
<td>186 (42.5)</td>
</tr>
<tr>
<td>Male</td>
<td>708 (61.2)</td>
<td>246 (56.2)</td>
</tr>
<tr>
<td>Missing</td>
<td>12 (1)</td>
<td>6 (1.4)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>18 (1.6)</td>
<td>4 (0.9)</td>
</tr>
<tr>
<td>Other</td>
<td>49 (4.2)</td>
<td>19 (4.3)</td>
</tr>
<tr>
<td>White</td>
<td>1080 (93.4)</td>
<td>414 (94.5)</td>
</tr>
<tr>
<td>Decline to answer, missing, or unknown</td>
<td>9 (0.8)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>44 (3.8)</td>
<td>14 (3.2)</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>1089 (94.2)</td>
<td>420 (95.9)</td>
</tr>
<tr>
<td>Decline to Answer</td>
<td>22 (1.9)</td>
<td>4 (0.9)</td>
</tr>
<tr>
<td>Unknown or missing</td>
<td>1 (0.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Language preference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>English</td>
<td>1109 (95.9)</td>
<td>419 (95.7)</td>
</tr>
<tr>
<td>Not English</td>
<td>47 (4.1)</td>
<td>19 (4.3)</td>
</tr>
<tr>
<td>Unknown or missing</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Website Review

Using Google Analytics, we observed that few patients reviewed the Upbeat website—80 and 76 unique page views ($P = .56$) at UMass and UFL, respectively. For those that did review the website, the number that interacted with only viewed a single page of the website, that is, the “bounce rate” across both sites was between 54% and 57%. While a bounce rate of 40% or less is generally considered good [19], the referenced source did not provide a specific bounce rate for health education websites, which may differ from other types of websites. Bounce rates are best understood in the context of a website’s purpose and type. The average bounce rate for an informational website and landing pages tends to be higher than other website types [25], thus our findings indicate moderately high engagement with the Upbeat website.

The average session duration was shorter at UFL than at UMass (83 seconds vs 148 seconds). Although we can conduct a statistical test for the average session duration, Google Analytics did not provide the distribution of individual times for each unique page viewer (Table S1 in Multimedia Appendix 4 [19,26-29] for the remaining comparisons).

Survey-Based Outcomes

From Group 1, 93 and 59 patients answered our survey using the targeted and blast messaging approaches, respectively. There was not a significant difference in patient reports of discussion with their provider about stroke risk, the duration of current anticoagulation use, or the frequency of missing doses of anticoagulation. Notably, forgetfulness and other reasons (apart from costs, side effects, or lack of benefit) comprise the majority of reasons for forgetting doses across messaging approaches. Most patients in both the targeted vs blast messaging groups strongly agreed or agreed that the materials from the HRS were easy-to-understand (68/82, 83% vs 13/15, 87%), were useful (69/82, 84% vs 14/15, 93%), as well as something they would recommend (71/83, 85% vs 14/15, 93%) without any of the differences reaching statistical significance (Table S2 in Multimedia Appendix 4 [27] for details).
From Group 2, a total of 9/25 patients answered our survey using the targeted and blast messaging approaches, respectively. More patients in the UMass group had discussed their stroke risk with their physician at UMass (16/25, 64% vs 3/9, 33%; \( P = .04 \)). Among the patients in the targeted approach, only 26% (6/25) reported concern about the risk of bleeding as a cause for stopping anticoagulation. Only 4 patients from the blast approach answered this item, limiting comparison. The majority of patients strongly agreed or agreed that the materials from the HRS were easy-to-understand and useful, as well as something they would recommend (also, comparisons were limited due to only 3 patients from the blast messaging group answering this item; Table S3 in Multimedia Appendix 4 [27]).

For group 3, we only had 2 responses from the targeted approach and 1 response from the blast approach and therefore did not conduct any further calculations or comparisons.

### Anticoagulation

For this outcome, we excluded patients for whom we did not have information to calculate baseline anticoagulation status (ie, visits within the past 12 months where anticoagulation status would have been updated) [12]. Among the included patients on anticoagulation (group 1) who opened messages, there were 636 and 285 from the targeted messaging and blast messaging approaches, respectively. Most patients reported race as White, with 91.8% (584/636) and 84.2% (240/285) under the targeted messaging and blast messaging approaches, respectively (Table 2).

The percentage of patients from group 1 on anticoagulation did not differ between targeted versus blast messaging approaches. By contrast, 11.9% (21/176) versus 3% (3/100; \( P = .01 \)) of patients from group 2 in targeted versus blast messaging were on anticoagulation at the end of follow-up (Table 3). This difference persisted after adjustment with an anticoagulation percentage of 9.3% versus 2.1% \( (P < .001; \) Table 3).
### Table 2. Key characteristics of patients opening messages with a targeted versus blast approach (percentages may not sum to 100 due to rounding).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Targeted messaging (University of Massachusetts; n=636), n (%)</th>
<th>Blast messaging (University of Florida; n=285), n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>60 (9.4)</td>
<td>9 (3.2)</td>
</tr>
<tr>
<td>65-74</td>
<td>200 (31.4)</td>
<td>80 (28.1)</td>
</tr>
<tr>
<td>≥75</td>
<td>376 (59.1)</td>
<td>196 (68.8)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>248 (39)</td>
<td>117 (41.1)</td>
</tr>
<tr>
<td>Male</td>
<td>388 (61)</td>
<td>168 (58.9)</td>
</tr>
<tr>
<td><strong>Race</strong>a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>9 (1.4)</td>
<td>28 (9.8)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>17 (2.7)</td>
<td>6 (2.1)</td>
</tr>
<tr>
<td>Other</td>
<td>17 (2.7)</td>
<td>11 (3.8)</td>
</tr>
<tr>
<td>White</td>
<td>584 (91.8)</td>
<td>240 (84.2)</td>
</tr>
<tr>
<td>Missing</td>
<td>9 (1.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Insurance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>62 (9.7)</td>
<td>21 (7.4)</td>
</tr>
<tr>
<td>Medicare</td>
<td>522 (82.1)</td>
<td>242 (84.9)</td>
</tr>
<tr>
<td>Medicaid</td>
<td>20 (3.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other or state health insurance exchange</td>
<td>32 (5)</td>
<td>7 (2.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>0 (0)</td>
<td>15 (5.3)</td>
</tr>
<tr>
<td><strong>Anemia</strong>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>359 (56.4)</td>
<td>146 (51.2)</td>
</tr>
<tr>
<td>No</td>
<td>269 (42.3)</td>
<td>131 (46)</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 (1.3)</td>
<td>8 (2.8)</td>
</tr>
<tr>
<td><strong>Chronic kidney disease</strong>c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>162 (25.5)</td>
<td>63 (22.1)</td>
</tr>
<tr>
<td>Stage 2</td>
<td>195 (30.7)</td>
<td>95 (33.3)</td>
</tr>
<tr>
<td>Stage 3</td>
<td>219 (34.4)</td>
<td>101 (35.4)</td>
</tr>
<tr>
<td>Stage 4 or 5</td>
<td>60 (9.4)</td>
<td>22 (7.7)</td>
</tr>
<tr>
<td>Missing</td>
<td>0 (0)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td><strong>BMI Group</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morbid obesityd</td>
<td>51 (8)</td>
<td>15 (5.3)</td>
</tr>
<tr>
<td>Not morbidly obese</td>
<td>585 (92)</td>
<td>270 (94.7)</td>
</tr>
<tr>
<td><strong>Anticoagulant use at baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>459 (72.2)</td>
<td>186 (65.3)</td>
</tr>
<tr>
<td>No</td>
<td>177 (27.8)</td>
<td>99 (34.7)</td>
</tr>
<tr>
<td><strong>Antiplatelet use</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>353 (55.5)</td>
<td>237 (83.2)</td>
</tr>
<tr>
<td>No</td>
<td>283 (44.5)</td>
<td>48 (16.8)</td>
</tr>
</tbody>
</table>

---

*a*Black includes Black of African American and multiracial, including Black or African American. Hispanic includes those individuals reporting Hispanic or Latino ethnicity. Asian includes White Hispanic. There were no individuals who reported Black race or Hispanic ethnicity. Other include Asian, Native American, Alaska Native, and others.
The main implication of this study is that targeted messaging was more effective than blast messaging in achieving message opening for those on anticoagulation. There was a trend toward increased message opening among patients off anticoagulation (274/438, 62.6% for the targeted approach versus 335/632, 53% for the blast approach). This increased message opening may have explained some anticoagulation starts, but replication at other sites would be helpful in drawing firm conclusions. Given the low rates of website reviews it is unlikely that it contributed to anticoagulation starts and would not be valuable to include in future programs, at least in the way we delivered it (as a simple website link). Education provided directly in the message or within the health portal is likely to be more effective than requesting patients to review external websites.

There are other implications for our findings. The best approach to messaging patients should also factor in local resources. Our approach to sending targeted messaging required the daily execution of a workbench report and subsequent filtering and transmission of portal messages. In the future, we anticipate that we could automate the manual steps and link the messaging approach that institutions and providers take when determining how to deliver messages to their patients.

Limitations
We acknowledge several limitations of this proposed study. Most notably, we did not randomly allocate patients to messaging approaches. Each site pursued the approach of their preference. Thereby, baseline differences in populations and provider practice patterns may have explained some of our findings. This is especially true for the outcomes of message opening.

Discussion
Principal Results
The message opening was significantly higher with the targeted approach for patients on anticoagulation. Subsequent website reviews were not different across approaches. Notably, 7.2% more patients off anticoagulation at baseline started anticoagulation with the targeted approach.

Comparison With Previous Work
Several published studies have examined the impact of portal messaging. Toscos et al [32] and Toscos et al [33] found that a multicomponent intervention that included sending portal messages led to higher AF knowledge and adherence in AF patients randomized to the intervention compared to controls. The authors only focused on patients who had already been prescribed anticoagulation and found higher rates of patient portal use, similar to what we found in terms of message opening in this patient group. Szilagyi et al [34] demonstrated a small increase in influenza vaccination rates (on the order of 1%-3%) for patients receiving portal messages versus those not receiving one, but the authors did not study the delivery of the message in targeted versus blast approaches as we did. By contrast, Halket et al [35] studied the use of targeted electronic portal messaging for hepatitis C screening. More specifically, they studied the effect of sending a patient portal message for patients having an appointment in the upcoming 6 months compared with sending this message to those without an upcoming visit. Compared to controls, they found that 10% more patients (59/227, 26% vs 52/318, 16.4%; \( P < .01 \)) underwent screening with the targeted approach. The authors do not further report the optimal timing within 6 months for sending a message. Presumably closer to the time of the visit would achieve the best results.

The main implication of this study is that targeted messaging was more effective than blast messaging in achieving message opening for those on anticoagulation. There was a trend toward increased message opening among patients off anticoagulation (274/438, 62.6% for the targeted approach versus 335/632, 53% for the blast approach). This increased message opening may have explained some anticoagulation starts, but replication at other sites would be helpful in drawing firm conclusions. Given the low rates of website reviews it is unlikely that it contributed to anticoagulation starts and would not be valuable to include in future programs, at least in the way we delivered it (as a simple website link). Education provided directly in the message or within the health portal is likely to be more effective than requesting patients to review external websites.

Table 3. Unadjusted and adjusted percentages of anticoagulation for 2 messaging approaches or sites stratified by group.

<table>
<thead>
<tr>
<th>Group</th>
<th>Unadjusted percentage on anticoagulation</th>
<th>Adjusted percentage on anticoagulation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targeted messaging (UMass(^a)), n (%)</td>
<td>Blast messaging (UFL(^b)), n, (%)</td>
</tr>
<tr>
<td>Group 1 (high risk, on anticoagulation at baseline)</td>
<td>438 (95.4)</td>
<td>179 (96.2)</td>
</tr>
<tr>
<td>Group 2 (high risk, off anticoagulation at baseline)</td>
<td>21 (11.9)</td>
<td>3 (3.0)</td>
</tr>
</tbody>
</table>

\(^a\)UMass: University of Massachusetts.
\(^b\)UFL: University of Florida.
\(^c\)Chi-square–based \( P \) value.
\(^d\)Only percentages are shown.

\(^e\)Value derived from generalized estimating equation adjusting for age, gender, BMI, patient race-ethnicity, insurance, CHA\(_2\)DS\(_2\)-VASc score, presence of anemia (ie, hemoglobin <13 g/dL for male candidates, <12 g/dL for female candidates, and level of chronic kidney disease).
opening and website review, where we did not have patient-level variables. For the anticoagulation outcome, we adjusted for known confounders of the use of anticoagulation, including demographics, stroke risk score, and bleeding risk factors (i.e., anemia and chronic kidney disease). Many other factors, including other indications for anticoagulation, type of anticoagulant, baseline health literacy, and computer literacy, may, however, have been different across our sites. In addition, because the site of care dictated the receipt of one versus the other messaging approach and we had limited information about the reason for receiving care at one versus the other site, we did not pursue propensity or other causal inference modeling approaches. Other institutional-based programs may have explained the increase with the targeted approach. A human-centered design approach has successfully overcome limitations in other messaging programs cited in the literature [32,36]. Oake et al [36] observed that an automated voice messaging response system for communicating anticoagulation testing and dosage schedules to patients led to improved anticoagulation monitoring. Another limitation was that we were not able to ascertain if patients read our message, only that our portal message was opened. In many cases, a family member will be opening the message. Website review and survey responses may be limited in the same way. Although education by proxy through a family member may lead to decisions to take anticoagulation or stay on it, we were not able to distinguish the discrete effect of direct versus proxy communication in the current study. Our results may also not generalize to non-White populations, which is significant given the lower adherence of non-Whites [8]. Lastly, it is important to note the impact of COVID-19 and the timing of the UFL messages on the project. UFL messages were sent out in December, with a follow-up in January. In addition to patients receiving holiday-related emails, COVID-19 was surging as well. It is unclear how these two variables may have impacted message opening.

Conclusion

In conclusion, message opening was significantly higher with the targeted approach for patients on anticoagulation. Subsequent website reviews were not different across approaches. More patients off anticoagulation at baseline started anticoagulation with the targeted approach. The best approach to messaging patients should also factor in local resources.

Acknowledgments

Funds were secured by the Heart and Rhythm Society through grants from the Bristol-Myers Squibb–Pfizer Alliance and Janssen. The funders had no role in the initiative’s design, implementation, interpretation, or reporting.

Data Availability

The data sets generated during and/or analyzed during this study are available from the corresponding author on reasonable request.

Authors’ Contributions

AK is responsible for the conceptualization, formal analysis, and project administration. AK, PP, SC, DM, HS, SR, RL, MML, KRV, PF, CC, CH, JNC, and SC were responsible for writing the manuscript. MML was responsible for project administration. SC was responsible for methodology and formal analysis. AM was responsible for project administration and funding acquisition.

Conflicts of Interest

AK has received research grant support from Pfizer through its Independent Grants for Learning and Change funding mechanism and from Bristol-Myers Squibb for Independent Medical Education Grants. More recently, he has received research grant support through a competitive process adjudicated and funded by the Bristol-Myers Squibb-Pfizer Alliance, which is formed by both Pfizer and Bristol-Myers Squibb. He has also been awarded a grant by Pfizer to examine conversations between patients and providers. HS, SR, and SC have also received research grant support from Bristol Meyers Squibb in the past 3 years (staff members or coinvestigators on the grants secured by AK). MML has received funding from and served on rheumatology and transthyretin amyloidosis research fellowship review panels for Pfizer. JNC has received research grant support from Bristol-Myers Squibb and Pfizer. All remaining authors have nothing to disclose.

Multimedia Appendix 1

Patient portal messages that were sent to patients in Groups 1, 2, and 3.

[PDF File (Adobe PDF File), 228 KB - cardio_v8i1e49590_app1.pdf]

Multimedia Appendix 2

Blank questionnaires that were completed by patients in Groups 1, 2, and 3.

[PDF File (Adobe PDF File), 102 KB - cardio_v8i1e49590_app2.pdf]
References


18. Bounce rate. Google Analytics. URL: https://support.google.com/analytics/answer/1009409?hl=en# text=About%20bounce%20rate&text=Bounce%20rate%20is%20single%20page%20request%20to%20%20Analytics%20server [accessed 2023-12-28]
19. What is a good bounce rate? And what’s a bad one? Fullstory Education Team. 2023. URL: https://www.fullstory.com/blog/what-is-a-good-bounce-rate/ [accessed 2023-12-28]


26. The difference between Google ads clicks, and sessions, users, entrances, pageviews, and unique pageviews in analytics. Google Analytics. URL: https://support.google.com/analytics/answer/1257084?hl=en#zz [accessed 2023-02-13]


Abbreviations

AF: atrial fibrillation
CHA2DS2-VASc: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex scale
EHR: electronic health record
HRS: Heart Rhythm Society
IRB: institutional review board
UFL: University of Florida College of Medicine-Jacksonville
UMass: University of Massachusetts Chan Medical School
Physical Activity, Heart Rate Variability, and Ventricular Arrhythmia During the COVID-19 Lockdown: Retrospective Cohort Study

Sikander Z Texiwala¹, MD; Russell J de Souza²,³, RD, ScD; Suzette Turner¹,⁴, BScN; Sheldon M Singh¹,⁵, MD

¹Schulich Heart Center, Sunnybrook Health Sciences, Toronto, ON, Canada
²Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
³Population Health Research Institute, Hamilton Health Sciences Corporation, Hamilton, ON, Canada
⁴Lawrence Bloomberg Faculty of Nursing, University of Toronto, ON, Canada
⁵Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

Corresponding Author:
Sheldon M Singh, MD
Schulich Heart Center
Sunnybrook Health Sciences
Room A222
2075 Bayview Ave
Toronto, ON, M4N 3M5
Canada
Phone: 1 416 480 6100 ext 86359
Fax: 1 416 480 5707
Email: sheldon.singh@sunnybrook.ca

Abstract

Background: Ventricular arrhythmias (VAs) increase with stress and national disasters. Prior research has reported that VA did not increase during the onset of the COVID-19 lockdown in March 2020, and the mechanism for this is unknown.

Objective: This study aimed to report the presence of VA and changes in 2 factors associated with VA (physical activity and heart rate variability [HRV]) at the onset of COVID-19 lockdown measures in Ontario, Canada.

Methods: Patients with implantable cardioverter defibrillator (ICD) followed at a regional cardiac center in Ontario, Canada with data available for both HRV and physical activity between March 1 and 31, 2020, were included. HRV, physical activity, and the presence of VA were determined during the pre- (March 1-10, 2020) and immediate postlockdown (March 11-31) period. When available, these data were determined for the same period in 2019.

Results: In total, 68 patients had complete data for 2020, and 40 patients had complete data for 2019. Three (7.5%) patients had VA in March 2019, whereas none had VA in March 2020 (P=.048). Physical activity was reduced during the postlockdown period (mean 2.3, SD 1.6 hours vs mean 2.1, SD 1.6 hours; P=.003). HRV was unchanged during the pre- and postlockdown period (mean 91, SD 30 ms vs mean 92, SD 28 ms; P=.84).

Conclusions: VA was infrequent during the COVID-19 pandemic. A reduction in physical activity with lockdown maneuvers may explain this observation.

(JMIR Cardio 2024;8:e51399) doi:10.2196/51399

KEYWORDS
implanted cardioverter defibrillator; heart rate variability; physical activity; lockdown; ICD; ventricular arrhythmias; defibrillator; implementation

Introduction

Increased ventricular arrhythmias (VAs) have been reported with acts of terror and environmental disasters [1,2]. The onset of the COVID-19 pandemic was associated with increased levels of stress [3]. Although one may have anticipated an increased rate of VA during this time, this was not borne in North America and Europe [4,5]. A mechanism to explain this has not been elucidated.

Patients with implantable cardioverter defibrillators (ICDs) are at risk for VA. ICDs contain sensors that can quantify the physical activity of a patient who has an ICD implanted. Acute
increases in physical activity can increase the risk of VA [6]. ICDs monitor the changes in the patient’s heart rate. Heart rate variability (HRV) summarizes the beat-to-beat changes in heart rate and reflects the balance between the sympathetic and parasympathetic nervous system. A reduction in HRV can occur during times of stress due to increased sympathetic activation. A reduction in HRV predicts VA [7]. Assessing the changes in physical activity and HRV may provide insight into the lack of increased VA observed during the onset of the COVID-19 lockdown.

Herein, we report the changes in physical activity and HRV in patients with ICD during the COVID-19 lockdown of March 2020 in Ontario, Canada.

**Methods**

**Study Cohort**

Sunnybrook Hospital is a regional cardiac center in Ontario, Canada. The Sunnybrook ICD clinical electronic medical record database (Paceart Optima System, version 1.8.269.0; Medtronic) was searched to identify all actively followed patients with ICD with data on physical activity and HRV in March 2020. As this was a retrospective observational study, patients were not actively recruited rather all patients with the available data were included in this retrospective cohort study.

**Study Periods**

Our study focused on the first month of the COVID-19 pandemic (March 2020). March 1-10, 2020, was designated as the prelockdown period and March 11-31, 2020, as the lockdown period. During the latter period, the World Health Organization declared the COVID-19 outbreak a pandemic (March 11), with a subsequent crash in North American stock markets (March 12) and a declaration of a state of emergency in the United States (March 13) and Ontario (March 17).

**VA, Physical Activity, and Heart Rate Variability**

ICDs record all VA. The presence of VA requiring an ICD therapy during the study period was documented. Patient physical activity is recorded when a patient moves at a rate above a minimum threshold of 2 miles per hour. ICDs quantify the amount of time spent moving above this rate. ICD algorithms determine HRV as the SD of the average sinus intervals over 5 minutes, averaged over 24 hours (288 periods). This time domain approach to determine HRV provides the best prognostic information [7]. As the knowledge of atrial activity is necessary to determine the HRV, it cannot be determined in patients who do not have a dual chamber ICD (ie, a device with an atrial lead). Furthermore, HRV cannot be determined in the presence of inherently irregular arrhythmia such as atrial fibrillation. As such, patients with a single chamber ICD and a history of atrial fibrillation were excluded from the study.

Physical activity and HRV during the study period were extracted using an open-source software tool (WebPlotDigitizer, version 4.4). To provide an estimate of the change in physical activity and HRV between the 2 study periods, the extracted daily values for physical activity and HRV were averaged over the pre- and lockdown periods. Where available, VA, physical activity, and HRV were obtained from March 1 to 31, 2019, to act as a control.

**Statistical Analysis**

Participant characteristics are presented as mean (SD) or counts (%). Chi-square testing was used to determine the differences in the percentage of patients experiencing VA during the study periods. Two-tailed paired t tests and analysis of covariance were used to compare HRV and physical activity between the 2 study periods.

Statistical analyses were performed using the statistical analysis system statistical software package (version 9.4; SAS Institute Inc). P values <.05 were considered statistically significant.

**Ethical Considerations**

The Sunnybrook Hospital research ethics board approved the study (study 1632). The requirement for patient consent was waived by the research ethics board. Data were collected in anonymously. There was no patient compensation for participation in this study.

**Results**

Of the 650 actively followed ICD patients, 485 did not have data on both physical activity and HRV, and 97 patients did not have follow-up during the COVID-19 pandemic. The final cohort comprised of 68 patients, 40 of whom had HRV and physical activity data for 2021 and 2020.

The average age of the cohort was 70 (SD 11) years and predominantly male (n=52, 77%). Half of the participants (n=34, 50%) had coronary artery disease, 40% (n=27) had ventricular tachycardia, and 37% (n=25) had a cardiac resynchronization device. Beta-blockers and antiarrhythmic drugs were used by 77% (n=52) and 24% (n=16) of the cohort, respectively.

No patient had a VA during the 2020 study period. Three (7.5%) patients experienced VA in 2019, all between March 11 and 30. Thus, there were fewer VA events in the lockdown period of 2020 compared to the equivalent time in 2019 (n=0, 0% vs n=3, 7.5%; P=.048).

Activity was reduced by approximately 12 minutes during the lockdown period of 2020 compared to the prelockdown period of 2020 (mean 2.1, SD 1.6 hours vs mean 2.3, SD 1.6 hours; P=.003). There was no difference in the average activity in the prelockdown period in 2020 compared to the equivalent dates in 2019 (mean 2.3, SD 1.6 hours vs mean 2.5, SD 1.7 hours; P=.06).

HRV was unchanged between the 2020 prelockdown and lockdown periods (mean 91, SD 30 ms vs mean 92, SD 28 ms; P=.84). HRV was similar in 2020 and 2019 (prelockdown: mean 89, SD 28 ms vs mean 90, SD 30 ms; P=.70 and lockdown: mean 86, SD 26 ms vs mean 90, SD 25 ms; P=.30).

**Discussion**

**Principal Findings**

This work supports prior publications highlighting a lack of increased VA with the onset of the COVID-19 pandemic. Our
research is hypothesis generating, which provides a possible mechanism to explain the lack of increased VA observed at the onset of the COVID-19 pandemic. It is speculated that a reduction in physical activity with lockdown maneuvers may have reduced the frequency of VA.

Lockdown maneuvers resulted in stay-at-home orders, closing of gyms or shopping centers, and working from home. These maneuvers, which were similar in Ontario and other jurisdictions, effectively reduced the physical activity of all individuals during this time period. Although small (~12 minutes), it is possible that the reduction in physical activity may have played a role in mitigating arrhythmic risk. For context, a reduction of 12 minutes is at a minimum equivalent to a reduction in walking 0.4 miles or 1000 steps a day. As we are not able to quantify the intensity of the activity, it is possible this reduction in activity could have been higher.

HRV is a marker of autonomic tone and a predictor of VA. We observed no clinically important or statistically significant change in HRV. This finding seems counterintuitive, given the reports of increased distress with the onset of the lockdown maneuvers [3]. We hypothesize that a number of factors may have mitigated additional reductions in HRV in this population. First, the use of beta-blockers was high (n=52, 77%) in this population. Prior work has demonstrated that beta-blockers can preserve autonomic balance in the setting of mentally stressful events [8]. Second, patients with ICD already have a high level of circulating catecholamines (evidenced by the depressed HRV even prior to the COVID-19 pandemic). The additional influence of external psychological stresses with the COVID-19 pandemic may not impact overall autonomic tone. Finally, we speculate that, unlike singular unexpected catastrophic events [8], the anticipation of lockdown measures may have lessened this psychological stress. This finding highlights the variable impact of different catastrophic events on the risk of VA.

Limitations to this work include the fact the data were derived from a single center with a relatively small number of patients. Second, the large number of exclusions may have resulted in a highly selected population limiting the applicability to other populations. Third, we limited our assessment to the early part of the pandemic, given the homogenous lockdown interventions and limited impact of lack of access to care during this early time. It is unclear whether these findings would persist into different waves of the pandemic. Finally, the findings were from Ontario, Canada, and may not apply to other jurisdictions with more severe COVID-19 outbreaks and interventions. The primary strength of this work is the precise measure of VA, physical activity, and HRV.

Conclusions

Physical activity was reduced in patients with ICD during the COVID-19 lockdown. Our observations may provide a possible mechanistic insight into lack of increased VA in patients with ICD during the COVID-19 pandemic. We suggest future work in larger patient populations and other jurisdictions to confirm our findings. Given the long-term benefits of physical activity, we also suggest future work by public health agencies to ensure the observed decline in physical activity at the onset of the COVID-19 pandemic is not sustained.

Acknowledgments

This work was supported by a generous donation from the Horgan Family and Sunnybrook Hospital Foundation.

Data Availability

The data sets generated and analyzed during this study are available from the corresponding author upon reasonable request.

Authors' Contributions

All authors contributed to the design of the work, acquisition, analysis, and interpretation of the data. SZT and SMS drafted the manuscript. All authors critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript. All authors are accountable for the accuracy and integrity of the work. No artificial intelligence assistive tools were used to generate any portions of this work.

Conflicts of Interest

None declared.

References


8. Huang JL, Chiou CW, Ting CT, Chen YT, Chen SA. Sudden changes in heart rate variability during the 1999 Taiwan earthquake. Am J Cardiol 2001;87(2):245-248, A9. [doi: 10.1016/s0002-9149(00)01331-x] [Medline: 11152854]

Abbreviations

- HRV: heart rate variability
- ICD: implantable cardioverter defibrillator
- VA: ventricular arrhythmia

©Sikander Z Texiwala, Russell J de Souza, Suzette Turner, Sheldon M Singh. Originally published in JMIR Cardio (https://cardio.jmir.org), 05.02.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study

Sigridur Björnsdottir¹, MD, PhD; Hildigunnur Ulfsdottir², MPH, MD; Elias Freyr Gudmundsson², BSc, MSc; Kolbrun Sveinsdottir³, MSc; Ari Pall Isberg², MSc; Bartosz Dobies², MSc; Gudlaug Erla Akerlie Magnusdottir², BSc; Thrudur Gunnarsdottir², PhD; Tekla Karlsdottir³, MD; Gudlaug Björnsdottir³,4, MSc; Sigurdur Sigurdsson³,4, PhD; Saemundur Oddsson², MD; Vilmundur Gudnason³,4, MD, PhD

¹Department of Endocrinology, Metabolism and Diabetes, Karolinska Institutet, Stockholm, Sweden
²Sidekick Health, Kopavogur, Iceland
³Icelandic Heart Association, Kopavogur, Iceland
⁴School of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Corresponding Author:
Sigridur Björnsdottir, MD, PhD
Department of Endocrinology, Metabolism and Diabetes
Karolinska Institutet
Solnavägen 1
Stockholm, 171 77
Sweden
Phone: 46 8 524 800 00
Email: sigridur.bjornsdottir@ki.se

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes.

Objective: This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life.

Methods: We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks.

Results: In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0.0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction.

Conclusions: The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants...
showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD.

**Trial Registration:** Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382

(JMIR Cardio 2024;8:e52576) doi:10.2196/52576

**KEYWORDS**
digital health program; nonalcoholic fatty liver disease; NAFLD; cardiometabolic health; digital therapeutics; liver; chronic; hepatic; cardiometabolic; cardiovascular; cardiology; weight; acceptability; digital health; metabolic syndrome; diabetic; diabetes; diabetics; type 2; BMI; lifestyle; exercise; physical activity; coaching; diet; dietary; nutrition; nutritional; patient education; coach; feasibility; fat; body composition

**Introduction**

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world [1]. NAFLD is defined as >5% fat in the liver (steatosis) among people who drink moderate amounts or no alcohol and have no other chronic liver diseases [2]. NAFLD reflects a spectrum of liver pathologies, ranging from simple steatosis to a more severe condition called nonalcoholic steatohepatitis (NASH), which includes inflammation and potential scarring of the liver [3]. The major comorbidities associated with NAFLD are central obesity, type 2 diabetes mellitus (DM), dyslipidemia, and metabolic syndrome [4]. The global prevalence of NAFLD is estimated to be 25% in the general population and the rising prevalence of NAFLD parallels that of obesity and type 2 DM, since NAFLD is a comorbidity in an estimated 55% of people with type 2 DM and in up to 80% of people with obesity [4-6]. Studies have shown that around 20% to 30% of people with NAFLD progress to NASH, with its consequent risks of liver scarring, cirrhosis, end-stage liver disease, and hepatocellular carcinoma [7]. Furthermore, NAFLD and NASH are associated with cardiovascular diseases, type 2 DM, and chronic kidney disease and pose a large burden on health care systems [8-10].

Growing evidence supports a common pathophysiological mechanism between metabolic syndrome and NAFLD and NASH, which often involves insulin resistance and dysfunctional adipose tissue [11]. Currently, no pharmacological treatment is approved for NAFLD or NASH, and, according to treatment guidelines, first-line therapy should focus on lifestyle improvement with the aim of 5% to 10% weight loss [12,13]. However, reaching these goals is often difficult, and there is a need to continue exploring optimal treatment modalities for individuals with NAFLD or NASH [14].

Sidekick Health, an Icelandic digital therapeutic company, has developed a digital health program (Sidekick-241 or SK-241) specifically designed for people with metabolic conditions and NAFLD. The 12-week program is delivered through a mobile app and aims to improve lifestyle and health outcomes by focusing on improving diet, increasing activity levels, and reducing stress through behavior change. In this prospective study, we evaluated the feasibility and potential clinical impact of the 12-week digital health program on liver and cardiometabolic health in individuals with metabolic conditions and NAFLD.

**Methods**

**Trial Design**

This was an open-label, single-arm, prospective study conducted between June and September 2022 in Iceland. The study included a 12-week digital health program delivered through the Sidekick app. Screening and preprogram and postprogram clinical assessments were carried out at the Icelandic Heart Association.

**Participants**

In total, 38 individuals aged between 18 and 80 years from an ongoing population-based cohort study (The REFINE-Reykjavik Study) at The Icelandic Heart Association and individuals followed at an endocrine outpatient clinic (the Reykjavik Heart Center) were invited to participate in the study [15]. People with at least one of the following risk factors were invited to participate: BMI >30, metabolic syndrome, or type 2 DM. Individuals with type 2 DM were only included if they were on a stable dose of antidiabetes medication for the last 90 days before screening. Eligible individuals had to have the capacity to give informed consent, understand verbal and written Icelandic, own and know how to operate a smartphone, and be willing and able to comply with the study program, all scheduled visits, and procedures.

The exclusion criteria were as follows: insulin use; known or self-reported cirrhosis; alcohol consumption over 14 units/week for men or over 7 units/week for women; self-reported hepatitis B, hepatitis C, human immunodeficiency virus, or autoimmune hepatitis; vitamin E intake of >400 IU/day unless stable for 12 weeks prior to baseline; taking medications associated with liver steatosis, such as steroids, methotrexate, tamoxifen, amiodarone, tetracycline, or valproic acid; self-reported pregnancy; participation in a weight loss program; or history of or any existing medical condition (eg, ongoing cancer treatment, severe cardiopulmonary or musculoskeletal disease); magnetic resonance imaging contraindications (eg, pacemakers, aneurysm clips), or stroke or myocardial infarction in the last 6 months that, in the opinion of the primary investigator, would interfere with evaluation of the study or affect the interpretation of the results of the study.

After obtaining informed consent, participants were screened for eligibility by study staff at the Icelandic Heart Association.
Screening for NAFLD

Individuals were screened to assess if they had liver steatosis with a noninvasive ultrasonography-based controlled attenuation parameter (CAP) assessment through a FibroScan device [16]. To avoid overestimation of steatosis, we used 2 probe sizes (medium and extra-large). Individuals who met the full inclusion and exclusion criteria and had a CAP score of >294 dB/m, which represents a high likelihood of >5% liver steatosis, were eligible for participation in the study [17]. Additionally, liver stiffness measurement (LSM) was performed with vibration-controlled transient elastography (VCTE) at screening and at the 12-week follow-up visit. Individuals with an LSM score >9.7 kPa, which represents moderate-to-severe liver fibrosis (grade F3-F4), were referred to a specialist for further evaluation [18]. All individuals with a CAP score >294 dB/m had a magnetic resonance imaging proton density fat fraction (MRI-PDFF) measurement at screening and at the 12-week follow-up visit. MRI-PDFF is considered an emerging biomarker for non-invasive hepatic steatosis assessment as it is accurate, precise, quantitative, and reproducible [19].

The Digital Health Program

The SK-241 digital health program was developed by a multidisciplinary group of experts, including a clinical psychologist, nutritionist, behavioral scientists, medical doctors, and nurses at Sidekick Health. The primary focus of the program was to reduce participants’ daily dietary carbohydrate consumption and improve their overall nutrition quality in small, achievable, and sustainable steps (eg, reducing added sugars and processed foods, prioritizing protein, and increasing vegetable consumption). A secondary focus was to increase daily activity levels, improve sleep quality and reduce stress. The user interface with example screenshots from the program is shown in Figure 1.

The program included short daily missions (defined as in-app tasks for the participant to complete) aimed at increasing knowledge about NAFLD and NASH and its contributing factors and improving participants’ lifestyles for better metabolic health. The daily missions included watching short educational videos, reading brief informational content, logging meals and beverages by taking a photo of the meal, assessing on a sliding scale how healthy the meal was, and evaluating hunger and satiety before and after the meal. Other missions involved practicing mindfulness and meditation and logging daily energy levels, stress, and sleep quality. The app also provided participants with in-app health coach support (by a live person, not artificial intelligence), which provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions as needed. The coaching element was active throughout the 12-week intervention period. Further details of the in-app content and missions are presented in Table 1 and Table S1 in Multimedia Appendix 1.

Figure 1. Example screens of the Sidekick app and the Sidekick-241 NAFLD program user interface. NAFLD: nonalcoholic fatty liver disease.
Table 1. The Sidekick-241 program content and descriptions of main missions.

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food journal</td>
<td>Participants were asked to log their meals at least 3 times per week each week. During week 2, individualized goals for gradually reducing carbohydrate intake throughout the program were set based on week 1 consumption.</td>
</tr>
<tr>
<td>Step counter</td>
<td>Participants could manually log their steps each day. Individualized goals for increasing steps were set for week 2 based on week 1 step counts.</td>
</tr>
<tr>
<td>QoL PROs (stress, sleep, energy)</td>
<td>Participants were prompted to log these measures 2 days per week on a 10-point visual-analog sliding scale.</td>
</tr>
<tr>
<td>Surveys</td>
<td>Questions about motivation levels, knowledge and attitudes relating to nutrition and physical activities were administered during weeks 1 and 2 and again during weeks 11 and 12. Questions about current food-related behaviors and potential NAFLD- or NASH-related symptoms were administered every 2 weeks.</td>
</tr>
<tr>
<td>Mindfulness</td>
<td>Participants were prompted to complete short mindfulness exercises regularly throughout the program and practice meditation 2 times per week from week 3 onwards.</td>
</tr>
<tr>
<td>Coaching</td>
<td>Feedback on weekly in-app activities was provided to participants, particularly on food logs and answers to the in-app surveys. Throughout the program, participants were also able to ask questions as needed and the coach would answer within 24 hours (weekends exempt).</td>
</tr>
</tbody>
</table>

aQoL: quality of life.
bPROs: patient-reported outcomes.

During the baseline visit, study staff assisted participants with downloading and installing the Sidekick app with the SK-241 program. A short web-based interview with the program’s health coach was offered to all participants during the first 2-3 weeks of the study to establish coach connection and accountability and to provide participants with an opportunity to ask questions. During the interview, the primary goals, main concepts, and the program’s approach to diet and weight management were explained. In addition, participants’ strengths and potential barriers to participation were discussed.

Outcome Measures and Covariates

Primary outcomes were the program’s feasibility and acceptability, as assessed by participant retention, engagement, and satisfaction after the 12-week study period. An active participant was defined as one completing at least 1 in-app mission or interacting with the health coach at least once per week. Retention was measured as the number of participants completing the 12-week program, which was defined as being active 9 of 12 weeks. Engagement was measured as the number of participants who were active during the whole 12-week period. Satisfaction with the program was assessed after program completion with the validated mHealth App Usability Questionnaire (MAUQ), which consists of 18 items and has a possible score of 0-7, with 7 being the highest potential score. The scoring can further be divided into 3 subscales reflecting ease of use (5 items), interface and satisfaction (7 items), and usefulness (6 items) [20]. In addition, detailed participant engagement with specific program features was analyzed.

Secondary outcomes were the program’s preliminary and potential clinical impact, as measured by weight loss, changes in liver fat, body composition, serum biomarkers, and other cardiometabolic risk factors (eg, blood pressure, waist and hip circumference, and step counts). Participants were assessed at baseline and at a 12-week follow-up visit for demographic information, anthropometric measures, medical history, medications, and adverse events. Liver fat content was measured and quantified at baseline and at 12 weeks using MRI-PDFF with a multiecho chemical shift–encoded gradient-echo sequence [21]. Body composition was assessed at baseline and at 12 weeks with a dual-energy X-ray absorptiometry [22]. Blood pressure was measured using an automatic blood pressure monitor. Blood samples were drawn at baseline and at the 12-week follow-up to measure complete blood count, alanine aminotransferase, aspartate aminotransferase, hemoglobin A1c (HbA1c), fasting glucose and insulin for the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-sensitivity C-reactive protein.

Participants were administered the following questionnaires via an electronic patient-reported outcome (PRO) system at baseline and at 12 weeks: the Depression, Anxiety and Stress Scale (DASS-21), the EuroQol-5 Dimension – 5-Level (EQ-5D-5L) index, and the 8-item Morisky Medication Adherence Scale (MMAS-8) [23-25].

For exploratory outcome analysis, study participants were divided into 2 groups depending on how engaged they were with the digital health program. Those using the app 5 or more days per week were defined as highly engaged compared with those using the app less than 5 days per week, and clinical outcomes were compared to assess a potential dose-response relationship.

Statistical Analysis

As this is a feasibility study, a formal sample size calculation was not performed. The researchers aimed for 30-40 participants as this was considered a sufficiently sized sample to obtain information on practical aspects of participants’ recruitment, in-app engagement, retention, and rates of acceptance.

Changes in clinical assessments and PROs from baseline to postprogram were calculated as the mean and SD for approximately normally distributed variables (normality was analyzed with the Shapiro-Wilk test) or as the median and IQR for variables that did not satisfy normality criteria. Categorical data were calculated as frequencies and percentages. To compare baseline and postprogram outcomes, paired t tests were computed for approximately normally distributed data. In case...
the normality assumption was not met, nonparametric tests were computed (Wilcoxon signed-rank tests). Unless otherwise specified, all statistical tests were performed at the 5% (2-sided) significance level. Statistical analysis was performed in Stata (StataCorp) and R (version 4.0.3; R Foundation for Statistical Computing).

All enrolled participants were included in the full analysis set. Missing data were imputed using the last observation carried forward provided that the participant was enrolled in the study and at least one of two measurements (baseline or follow-up) was collected. Moreover, missing baseline measurements in waist circumference, hip circumference, and low-density lipoprotein cholesterol were imputed for 1 participant using the next observation carried backward. The complete case analysis set included participants who attended both the baseline visit and the 12-week follow-up visit.

Ethical Considerations
This study was approved by the National Bioethics Committee of Iceland and the Data Protection Authority (22-075-VI). All participants provided informed consent before being enrolled in the study. All data was deidentified and analyzed in accordance with institutional protocols. Participants were given the option of seeking reimbursement for travel expenses not exceeding US $150 in total; no other compensation was provided. The study was registered at ClinicalTrials.gov under the trial identifier NCT05426382.

Results

Participant Characteristics
After screening and enrollment, 38 individuals were eligible to participate in the study (Figure 2). The median age of the participants was 59.5 (IQR 46.3-68.8) years, 23 (61%) were women and all were White (Table 2). Of the 38 participants, 17 (45%) had a university degree, none smoked, 34 (90%) had obesity (BMI >30), 19 (50%) had type 2 DM, 27 (71%) had hypertension, 15 (40%) had hypercholesterolemia, and 11 (29%) had a history of cardiovascular disease. Other common comorbidities included hypothyroidism (n=11, 29%), polycystic ovary syndrome (n=4, 11%), and gout (n=2, 5%). In total, 45% (n=17) of participants reported taking antidiabetic medication, 79% (n=30) antihypertensive medication, 37% (n=14) antilipidemic medication, and 37% (n=14) hypothyroid medication. Additionally, 74% (n=28) reported taking other medications, such as proton-pump inhibitors (n=11, 29%), anticoagulants (n=11, 29%), antidepressants (n=8, 21%), vitamin B_{12} (n=5, 13%), nonsteroidal anti-inflammatory medication (n=4, 11%), and antihistamines (n=4, 11%). During the 12-week study period, 5 (13%) participants reported medication changes: 3 (8%) started new medications (one received antibiotics, one received calcium channel blockers, and one vitamin B_{12}) and 2 (5%) reported dosage adjustments (one for diabetes medications and one for beta blockers and antidepressants).

Figure 2. Flowchart of study participants. MRI: magnetic resonance imaging; SK: Sidekick.
Table 2. Baseline characteristics of the study participants.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Participants (n=38)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>23 (61)</td>
</tr>
<tr>
<td>Men</td>
<td>15 (39)</td>
</tr>
<tr>
<td><strong>Age (years), median (IQR)</strong></td>
<td>59.5 (46.3-68.8)</td>
</tr>
<tr>
<td><strong>Ethnicity: White, n (%)</strong></td>
<td>38 (100)</td>
</tr>
<tr>
<td><strong>Work status, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Full-time</td>
<td>18 (47)</td>
</tr>
<tr>
<td>Part-time</td>
<td>5 (13)</td>
</tr>
<tr>
<td>Not in labor market</td>
<td>15 (39)</td>
</tr>
<tr>
<td>Pension</td>
<td>11 (29)</td>
</tr>
<tr>
<td>Disability</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Sick leave</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Unemployed</td>
<td>1 (3)</td>
</tr>
<tr>
<td><strong>Educational level, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>University degree</td>
<td>17 (45)</td>
</tr>
<tr>
<td>Trades or vocational school or equivalent</td>
<td>12 (32)</td>
</tr>
<tr>
<td>Primary education or less</td>
<td>6 (16)</td>
</tr>
<tr>
<td>Secondary or matriculate</td>
<td>3 (8)</td>
</tr>
<tr>
<td><strong>Smoking status, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Never smoked</td>
<td>20 (53)</td>
</tr>
<tr>
<td>Former smoker</td>
<td>18 (47)</td>
</tr>
<tr>
<td><strong>Comorbidities, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>19 (50)</td>
</tr>
<tr>
<td>BMI &gt;30</td>
<td>34 (89)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>15 (39)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>27 (71)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>11 (29)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>11 (29)</td>
</tr>
<tr>
<td>Polycystic ovary disease</td>
<td>4 (11)</td>
</tr>
<tr>
<td>Gout</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Other</td>
<td>23 (61)</td>
</tr>
</tbody>
</table>

**Retention and Engagement in the 12-Week Program**

Of the 38 participants, 34 (89%) completed the 12-week program, 29 (76%) were engaged during the whole study period, and 22 (58%) were highly engaged (defined as visiting the app at least 5 days per week) (Table 3). Engagement and retention in the app were similar between those younger or older than 60 years and between men and women (data not shown). Participants were active in-app on a median of 81 (IQR 45.8-84.0) of 84 days or 6.8 (IQR 4.6-7.0) days per week on average and completed an average of 6.9 (SD 2.9) daily missions. Over the course of the study, the health coach sent an average 23.5 (SD 10.3) messages to participants, while participants sent an average of 15.5 (SD 12.4) messages to the coach, who responded within 1.2 (SD 0.9) days. The median MAUQ score was 6.3 (IQR 5.8-6.7) of 7, suggesting high satisfaction with the program among participants.
Table 3. Overall retention, engagement, and satisfaction.

<table>
<thead>
<tr>
<th>Description</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retention(^a), n (%)</td>
<td>34 (89)</td>
</tr>
<tr>
<td>Engagement(^b), n (%)</td>
<td>29 (76)</td>
</tr>
<tr>
<td><strong>Satisfaction(^c) median (IQR)</strong></td>
<td></td>
</tr>
<tr>
<td>MAUQ(^d) total score</td>
<td>6.3 (5.8-6.7)</td>
</tr>
<tr>
<td>Ease of use (mean of MAUQ items 1 to 5)</td>
<td>6.4 (5.6-6.8)</td>
</tr>
<tr>
<td>Interface and satisfaction (mean of MAUQ items 6 to 12)</td>
<td>6.3 (5.9-6.9)</td>
</tr>
<tr>
<td>Usefulness (mean of MAUQ items 13 to 18)</td>
<td>6.0 (5.5-6.7)</td>
</tr>
<tr>
<td><strong>Exploratory engagement metrics</strong></td>
<td></td>
</tr>
<tr>
<td>Average active(^e) days per week (0-7), median (IQR)</td>
<td>6.8 (4.6-7.0)</td>
</tr>
<tr>
<td>Average total active days (0-84), median (IQR)</td>
<td>81 (45.8-84.0)</td>
</tr>
<tr>
<td>Average daily missions completed(^f), mean (SD)</td>
<td>6.9 (2.9)</td>
</tr>
<tr>
<td>Average daily missions assigned, mean (SD)</td>
<td>5.7 (0.49)</td>
</tr>
<tr>
<td>Participants who were active &gt;5 days every week, n (%)</td>
<td>22 (58)</td>
</tr>
<tr>
<td>Average number of messages sent by participants, mean (SD)</td>
<td>15.5 (12.4)</td>
</tr>
<tr>
<td>Average number of messages received by participants, mean (SD)</td>
<td>23.5 (10.3)</td>
</tr>
</tbody>
</table>

\(^a\)Retention was defined as participants who completed the program, being active for 9 of 12 weeks. Being active was defined as completing at least 1 in-app mission or interacting at least once in that week with the health coach.

\(^b\)Engagement was defined as participants who were active for the entire study period.

\(^c\)Satisfaction was measured using the MAUQ.

\(^d\)MAUQ: mHealth App Usability Questionnaire.

\(^e\)An active day was defined as a day in which the participant completed at least 1 in-app mission or interacted with the coach.

\(^f\)The participants receive daily assigned missions but also had the opportunity to complete additional missions within the app, thereby surpassing the number of assigned missions.

**Metabolic Parameters**

The mean weight loss was 3.5 (SD 3.7) kg (\(P<.001\)), or 3.2% (SD 3.4%) (Table 4). The median body fat percentage changed from 46.6% (IQR 39.4%-52.4%) to 44.3% (IQR 37.8%-52.2%) (\(P<.001\)) and the mean fat mass from 50.3 (SD 13.8) kg to 48.1 (SD 14.5) kg (\(P<.001\)). These improvements in body composition were accompanied by reduced MRI-PDFF liver fat values: in the full analysis set (n=38), the mean liver fat percentage significantly decreased from 12.3% (SD 7.1%) to 10.1% (SD 6.5%; \(P<.001\)), representing a mean relative change of 19.4% (SD 23.9%) (Table 4). In the complete case analysis set (n=34), mean liver fat was reduced from 12.4% (SD 6.9%) to 9.9% (SD 6.3%; \(P<.001\)) with a corresponding mean relative change of 21.6% (SD 24.2%).
Table 4. Differences in anthropometric, biochemical, and clinical measurements at baseline and after 12 weeks for the full analysis set (n=38).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 12</th>
<th>Change from baseline to week 12</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg), mean (SD)</td>
<td>110.0 (18.5)</td>
<td>106.5 (18.4)</td>
<td>3.5 (3.7)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Relative percentage weight change, mean (SD)</td>
<td>N/A</td>
<td>N/A</td>
<td>3.2 (3.4)</td>
<td>N/A</td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>37.6 (5.8)</td>
<td>36.4 (5.8)</td>
<td>1.2 (1.3)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Waist circumference (cm), mean (SD)</td>
<td>123.8 (12.2)</td>
<td>119.9 (12.2)</td>
<td>4.0 (5.1)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Hip circumference (cm), mean (SD)</td>
<td>125.1 (14.0)</td>
<td>123.2 (13.3)</td>
<td>1.8 (0.0 to 4.9)</td>
<td>.01d</td>
</tr>
<tr>
<td>Waist to hip ratio, median (IQR)</td>
<td>1.00 (0.95 to 1.03)</td>
<td>0.99 (0.92 to 1.03)</td>
<td>0.00 (–0.01 to 0.03)</td>
<td>.09d</td>
</tr>
<tr>
<td><strong>Liver assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver fat MRI-PDFF (%)</td>
<td>12.3 (7.1)</td>
<td>10.1 (6.5)</td>
<td>2.2 (2.9)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Liver fat MRI-PDFF relative change (%)</td>
<td>N/A</td>
<td>N/A</td>
<td>19.4 (23.9)</td>
<td>N/A</td>
</tr>
<tr>
<td>Liver stiffness measure (kPa), median (IQR)</td>
<td>6.4 (5.2 to 9.6)</td>
<td>6.6 (5.3 to 8.4)</td>
<td>0.2 (–0.3 to 1.6)</td>
<td>.11d</td>
</tr>
<tr>
<td>CAP score (dB/m), mean (SD)</td>
<td>343.6 (34.8)</td>
<td>310.3 (47.2)</td>
<td>33.3 (39.7)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td><strong>Body composition</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total body region fat (%)</td>
<td>46.6 (39.4 to 52.4)</td>
<td>44.3 (37.8 to 52.2)</td>
<td>0.9 (1.4)b</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Fat mass (kg), mean (SD)</td>
<td>50.3 (13.8)</td>
<td>48.1 (14.5)</td>
<td>2.2 (2.7)</td>
<td>&lt;.001a</td>
</tr>
<tr>
<td>Lean mass (kg), mean (SD)</td>
<td>56.3 (10.1)</td>
<td>55.6 (9.7)</td>
<td>0.7 (1.7)</td>
<td>.008a</td>
</tr>
<tr>
<td><strong>Blood pressure (mmHg), mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>141.4 (17.1)</td>
<td>135.4 (17.3)</td>
<td>6.0 (13.5)</td>
<td>0.009a</td>
</tr>
<tr>
<td>Diastolic</td>
<td>83.6 (7.4)</td>
<td>82.5 (7.4)</td>
<td>1.2 (7.7)</td>
<td>.36a</td>
</tr>
<tr>
<td><strong>Biochemical measures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>60.0 (56.0 to 66.8)</td>
<td>60.0 (54.3 to 64.0)</td>
<td>0.5 (–0.7 to 3.8)</td>
<td>.03d</td>
</tr>
<tr>
<td>S-glucose (mmol/L), median (IQR)</td>
<td>6.2 (5.3 to 7.4)</td>
<td>6.3 (5.4 to 6.9)</td>
<td>0.0 (–0.3 to 0.4)</td>
<td>.64d</td>
</tr>
<tr>
<td>S-insulin (µU/ml), median (IQR)</td>
<td>21.1 (16.4 to 27.9)</td>
<td>19.0 (13.0 to 25.0)</td>
<td>3.2 (0.0 to 5.4)</td>
<td>.003d</td>
</tr>
<tr>
<td>HOMA-IR (%)</td>
<td>5.8 (4.3 to 8.4)</td>
<td>4.8 (3.6 to 7.2)</td>
<td>0.4 (–0.2 to 2.1)</td>
<td>.02d</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L), mean (SD)</td>
<td>4.9 (1.3)</td>
<td>4.8 (1.2)</td>
<td>0.0 (–0.2 to 0.2)</td>
<td>&gt;.99d</td>
</tr>
<tr>
<td>LDL-C (%)</td>
<td>2.9 (1.1)</td>
<td>2.9 (1.1)</td>
<td>–0.1 (–0.3 to 0.1)</td>
<td>.18d</td>
</tr>
<tr>
<td>HDL-C (%)</td>
<td>1.11 (0.23)</td>
<td>1.12 (0.19)</td>
<td>–0.01 (0.12)</td>
<td>.56a</td>
</tr>
<tr>
<td>Triglycerides (mmol/L), median (IQR)</td>
<td>1.88 (1.35 to 2.45)</td>
<td>1.68 (1.21 to 1.90)</td>
<td>0.14 (0.00 to 0.47)</td>
<td>.003d</td>
</tr>
<tr>
<td>hs-CRP (mg/L), median (IQR)</td>
<td>3.0 (1.2 to 5.2)</td>
<td>2.5 (1.1 to 3.9)</td>
<td>0.1 (–0.1 to 0.7)</td>
<td>.14d</td>
</tr>
<tr>
<td>ALAT (IU/L), median (IQR)</td>
<td>21.4 (18.2 to 30.2)</td>
<td>23.2 (18.4 to 32.0)</td>
<td>0.0 (–6.8 to 2.8)</td>
<td>.37d</td>
</tr>
<tr>
<td>ASAT (IU/L), median (IQR)</td>
<td>20.8 (17.9 to 24.8)</td>
<td>22.3 (18.0 to 25.5)</td>
<td>0.4 (–2.5 to 2.5)</td>
<td>.53d</td>
</tr>
<tr>
<td>FIB-4 Index, median (IQR)</td>
<td>1.08 (0.78 to 1.34)</td>
<td>1.08 (0.75 to 1.21)</td>
<td>0.01 (–0.06 to 0.07)</td>
<td>.58d</td>
</tr>
</tbody>
</table>

a Analyzed with a paired t test.
b Percentage change calculated as the average over individual relative changes.
c N/A: not applicable.
d Analyzed with a Wilcoxon signed-rank test.
During the study, the distribution of steatosis levels changed. At baseline, the 10%-15% liver steatosis category had the highest frequency with 32% (n=12) of participants. At follow-up, the 5%-10% liver steatosis category had the highest frequency with 34% (n=13) of participants (Table 5). We additionally found a significant correlation between weight loss and absolute ($r=0.48$, $P=.004$) and relative ($r=0.72$, $P<.001$) liver fat changes measured by MRI-PDFF.

According to the FIB-4 data, 4 of the 38 participants were classified as having a high risk of fibrosis at baseline, of which 1 individual regressed to intermediate risk at the 12-week follow-up visit. Most participants (n=27, 71%) had a low risk of fibrosis at baseline according to the FIB-4. At the 12-week follow-up, this percentage had gone up to 79% (n=30).

Mean systolic blood pressure significantly decreased by 6.0 (SD 13.5) mmHg ($P=.009$), and this was not explained by changes in medication or medication adherence (Table 4). There was no significant difference in diastolic blood pressure.

Participants recorded on average 3085 (SD 2246) daily steps in the first week and 4664 (SD 3780) daily steps in the last week, representing a significant increase of 1579 steps per day ($P=.02$).

While participants’ average baseline fasting insulin and HOMA-IR levels indicated insulin resistance, we found a significant decrease in serum insulin levels (median 3.2, IQR 0.0-5.4 µU/ml; $P=.003$), HOMA-IR levels (median 0.4, IQR –0.2 to 2.1 mmol/L; $P=.02$), and HbA$_1$C levels (median 0.5, IQR –0.7 to 3.8 mmol/mol; $P=.03$) (Table 4), suggesting improved glycemic control. In addition, triglyceride levels significantly decreased by a median of 0.14 (IQR 0.00-0.47) mmol/L ($P=.003$), and median high-sensitivity C-reactive protein levels decreased from 3.0 (IQR 1.2-5.2) mg/L to 2.5 (IQR 1.1-3.9) mg/L ($P=.14$) (Table 4), representing improvements in those cardiovascular risk factors. We did not find any significant change in cholesterol levels, nor any significant changes in PRO scores of health-related quality of life, mental health, or medication adherence from preprogram to postprogram (Table 6).

<table>
<thead>
<tr>
<th>Liver fat category (%)</th>
<th>Participants at baseline, n</th>
<th>Participants at week 12, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>5-10</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>10-15</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>15-20</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>20-25</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>25-30</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

*Limits for the presented ranges correspond to values greater than or equal to for lower limits and less than for upper limits.*

Table 5. Distributions of liver fat percentage categories based on magnetic resonance imaging proton density fat fraction liver fat values at baseline and at the 12-week follow-up (n=38). All participants with >5% liver fat at baseline had stage 1 steatosis according to the standardized Nonalcoholic Steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease [26].
Table 6. Differences in patient reported outcomes (PROs) at baseline and after 12 weeks for the full analysis set (n=38).

<table>
<thead>
<tr>
<th>PROs</th>
<th>Baseline</th>
<th>Week 12</th>
<th>Change from baseline to week 12</th>
<th>P value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ-5D-5L index&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.8 (0.7 to 0.9)</td>
<td>0.9 (0.8 to 1.0)</td>
<td>0.0 (–0.1 to 0.0)</td>
<td>.36</td>
</tr>
<tr>
<td>EQ-5D-5L index</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DASS-21&lt;sup&gt;c&lt;/sup&gt;, median (IQR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total score (0 to 56)</td>
<td>5.5 (2.0 to 13.0)</td>
<td>6.0 (2.0 to 11.0)</td>
<td>0.0 (–2.0 to 2.0)</td>
<td>.95</td>
</tr>
<tr>
<td>Depression score</td>
<td>1.0 (0.3 to 4.5)</td>
<td>1.0 (0.0 to 3.0)</td>
<td>0.0 (0.0 to 1.0)</td>
<td>__&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anxiety score</td>
<td>1.0 (0.0 to 2.0)</td>
<td>1.0 (0.0 to 2.0)</td>
<td>0.0 (–0.7 to 1.0)</td>
<td>—</td>
</tr>
<tr>
<td>Stress score</td>
<td>3.0 (1.0 to 6.0)</td>
<td>3.0 (0.3 to 6.0)</td>
<td>0.0 (–1.0 to 1.0)</td>
<td>__&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>MMAS-8&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total score (0 to 8)</td>
<td>7.0 (6.8 to 8.0)</td>
<td>7.0 (6.8 to 8.0)</td>
<td>0.0 (–0.7 to 0.0)</td>
<td>.68</td>
</tr>
<tr>
<td>High adherence (=8), n (%)</td>
<td>14 (37)</td>
<td>15 (39)</td>
<td>N/A&lt;sup&gt;f&lt;/sup&gt;</td>
<td>—</td>
</tr>
<tr>
<td>Moderate adherence (6 to 7), n (%)</td>
<td>15 (39)</td>
<td>15 (39)</td>
<td>N/A&lt;sup&gt;f&lt;/sup&gt;</td>
<td>—</td>
</tr>
<tr>
<td>Low adherence (&lt;6), n (%)</td>
<td>9 (24)</td>
<td>8 (21)</td>
<td>N/A&lt;sup&gt;f&lt;/sup&gt;</td>
<td>—</td>
</tr>
</tbody>
</table>

<sup>a</sup> Analyzed with Wilcoxon signed-rank test.
<sup>b</sup> EQ-5D-5L index: EuroQol-5 Dimension – 5-Level index.
<sup>c</sup> DASS-21: Depression, Anxiety, and Stress Scale - 21 Items.
<sup>d</sup> Not available.
<sup>e</sup> MMAS-8: 8-item Morisky Medication Adherence Scale.
<sup>f</sup> N/A: not applicable.

Associations Between App Engagement and Clinical Outcomes

An exploratory analysis was performed to assess the relationship between participants’ in-app activity and their clinical outcomes. We found that participants who were highly engaged (visited the app at least 5 days per week) had greater weight loss and liver fat reduction (Table S2 in Multimedia Appendix 1) compared with those who were less engaged. In a complete case analysis, participants who were highly engaged (n=22) lost on average 5.1 (SD 3.8) kg and achieved a 27.5% relative reduction in liver fat, while those who were active on fewer than 5 days a week (n=12) lost on average 1.8 (SD 2.2) kg and achieved 10.8% relative reduction in liver fat. Moreover, highly engaged participants were significantly more likely to achieve a relative weight loss of at least 5% (<i>P</i>=.001) or 5% (<i>P</i>=.02) compared with those who were less engaged (Fisher exact tests). Taken together, these results suggest that higher engagement with the digital program may be associated with improved metabolic health.

Adverse Events

In total, 9 adverse events were reported, all of which were of mild to moderate intensity with no serious adverse events (Table S3 in Multimedia Appendix 1). No adverse events were considered to have a causal relationship to the digital health program, as assessed by the primary investigator.

Discussion

Principal Findings

This study demonstrated that the 12-week-long digital health program, SK-241, was feasible given its high retention, engagement, and satisfaction among people with NAFLD. Cardiometabolic health and liver-specific outcomes improved over the 12-week study period with a significant weight loss and reductions in fat mass, liver fat, systolic blood pressure, triglycerides, insulin, and HbA<sub>1c</sub> levels.

Digital behavioral programs can be effective at targeting weight loss among people with chronic conditions [27]. Increasing evidence shows that programs—whether digital or face-to-face—with a holistic approach can also be effective for people with NAFLD, where weight loss is a major component of disease management. A recent randomized controlled study from Singapore including 108 adults with NAFLD randomized either to lifestyle advice by a trained nurse or using a lifestyle mobile app in addition to receiving advice by a dietitian showed that the mobile app group had a 5-fold higher likelihood of achieving ≥5% weight loss compared with the control group at 6 months [28].

Previous studies suggest that digital solutions can be as effective as face-to-face behavioral change programs, but engagement with the digital program is an important component of efficacy [29]. Indeed, an important finding of this study was the correlation between participants’ in-app engagement and their clinical outcomes; this shows that maintaining engagement and interest is key to reaching the desired clinical improvements. Program engagement may be influenced by several factors, such as recruitment methods, participant characteristics, app design, and the level of support, such as coaching [30,31]. Coaching in particular may be essential to drive engagement as it encourages accountability and may increase motivation [30]. The regular contact that participants had with the coach in the SK-241 program may have contributed to the low attrition and high engagement in this study. Should larger implementation of this
intervention take place, then coaching would be an integral part, at least in the initial stages of the program.

Lifestyle interventions consisting of diet, exercise, and weight loss are recommended to individuals with NAFLD according to treatment guidelines [2]. The primary driver of NAFLD is overnutrition, which causes expansion of adipose deposits and macrophage infiltration into the visceral adipose tissue, creating a proinflammatory state that promotes insulin resistance [32,33]. The resulting imbalance in lipid metabolism leads to the formation of lipotoxic lipids that contribute to cellular stress, including oxidative stress, inflammasome activation, and apoptotic cell death [34,35]. Central obesity is also an important driver of insulin resistance and proinflammatory signaling [36].

In this 12-week study, the mean waist circumference was significantly reduced by 4.0 cm, and body weight by 3.2% on average; these are encouraging results, considering that a 3%-5% weight loss can lead to a reduction in hepatic steatosis [37]. In addition, we found a correlation between weight loss and MRI-PDFF liver fat fraction changes. This is in line with a previous report of greater weight loss leading to more significant improvements in liver histopathology, and studies have shown that a ≥30% relative decline in liver fat by MRI-PDFF is associated with histopathological improvements in NASH [38-40]. Participants in this study were able to decrease their waist circumference and body weight and had an average of around a 20% relative reduction in liver fat by MRI-PDFF, with a subset of participants achieving a 30% relative decline, which might lead to improved NAFLD and NASH histopathology. Despite the risk of progressive liver disease, the leading cause of death in people with NAFLD is cardiovascular disease [10]. This is likely due to risk factors that are shared between NAFLD and cardiovascular diseases, although it is unclear to what extent NAFLD has a direct causative role in the development of cardiovascular disease [41]. Therefore, it was important to see significant improvement in cardiovascular risk factors in our study, such as a decrease in systolic blood pressure, triglycerides, insulin, and HbA1c. The increased physical activity in our study as measured by the in-app step counter and the correlation between in-app activity and weight loss suggest that the digital program may successfully engage participants in behaviors that lead to more weight loss, which in turn may hypothetically improve liver function and glycemic control. Regular tracking of meals and physical activity and completing the in-app PROs may help people become more aware of their habits, while the education and the coach’s feedback and support may give them the necessary tools to change their behaviors. We did not find any significant changes in the PRO scores of health-related quality of life and mental health, which was most likely due to the short duration of the study and the small size of the cohort.

Furthermore, studies have shown that health care utilization and expenditure are particularly high among people with NAFLD and NASH [42,43]. Therefore, there is a great need for early identification and effective management of people with NAFLD to minimize the comorbidity burden and health care costs.

The fibrosis risk among study participants was assessed both with a VCTE FibroScan LSM and by calculating the FIB-4 index score from participants’ age and the serum alanine aminotransferase, aspartate aminotransferase, and platelet count. The results indicated that a few participants had an intermediate to high risk of having liver fibrosis (data not shown) and could be referred to as probable patients with NASH, thereby suggesting that the digital health program might be feasible for individuals with NASH in addition to those with NAFLD. However, both of these measurements have their limitations and need to be interpreted cautiously. VCTE can rule out advanced fibrosis but often leads to false positive results in NAFLD, while the FIB-4 score might overestimate fibrosis in populations older than 65 years and is considered to have a low positive predictive value for identifying advanced fibrosis [44,45].

Strengths and Limitations
A strength of this study was the high engagement and completion rate, as these are well known issues of digital health programs [46]. In addition, the holistic nature of the program, developed by a multidisciplinary team of experts and focused on multiple aspects of participants’ lifestyle, combined with the regular support provided by the coach, can be considered a strength. A further strength was the length of the program, which allowed sufficient time to assess meaningful changes in engagement and clinical outcomes.

Limitations of this study included the single-arm design, which limits the interpretation and generalizability of our findings. The lack of a control group made it difficult to directly infer the clinical benefit of digital program, thus the secondary outcomes relating to clinical efficacy should be interpreted with caution. The observed clinical improvements should also be interpreted in context with the short duration of the health program, as sustaining improvements can be challenging after short-term behavioral interventions. It should also be acknowledged that a seasonal increase in activity levels may have contributed to the observed changes, as the study began in early summer when people tend to be more physically active. Furthermore, all the participants were White and around 50% had a relatively high education level. Higher education level has been associated with a lower burden of traditional cardiovascular risk factors [47]. Previous studies have shown an association between socioeconomic status and NAFLD, where poverty seems to be a risk factor for developing NAFLD independent of other known risk factors, such as type 2 DM and obesity, and food insecurity is associated with developing NAFLD and advanced fibrosis [48]. Education and smoking status may have affected engagement with the digital health program and, therefore, the generalizability of these results to a wider population may be limited and future trials should recruit a more diverse group of participants to assess the efficacy of the program [49].

Conclusions
The 12-week-long digital health program was feasible for individuals with NAFLD, showing high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed and more engaged

https://cardio.jmir.org/2024/1/e52576

JMIR Cardio 2024 | vol. 8 | e52576 | p.125

(page number not for citation purposes)
participants showed greater improvements. This NAFLD digital health program could provide a new tool to improve health outcomes in people with NAFLD.

Acknowledgments
Judit Mészáros and Joanna McCarter provided medical writing and editing support. We would also like to thank the staff at the Icelandic Heart Association who helped with the study procedures, as well as the people who participated in the study. The study was funded by Sidekick Health. Use of the MMAS-8 is protected by US and international copyright laws. Permission for use is required. A Licensure agreement is available from: MMAR, LLC., www.moriskyscale.com.

Data Availability
The data sets generated or analyzed during this study are not publicly available due to restrictions in the informed consent form. Additional summary statistics will be provided upon on reasonable request.

Authors' Contributions
SB, HU, EFG, KS, TG, TK, SO, and VG contributed to conceptualization. SB, HU, EFG, KS, AI, BD, GEAM, TG, GB, SS, SO, and VG contributed to the methodology. SB, HU, EFG, AI, BD, SS, SO, and VG contributed to the investigation. SB and HU wrote the original draft. SB, HU, EFG, KS, AI, BD, GEAM, TG, TK, GB, SS, SO, and VG revised and edited the manuscript. SO acquired funding. SO and VG procured resources and supervised the study.

Conflicts of Interest
HU, EFG, AI, BD, KS, TK, GEAM, and TG are employed by Sidekick Health. SO is an employee and cofounder of Sidekick Health. SB received consultancy fees from Sidekick Health during the study period. SS, GB, and VG have no competing interests to declare.

Multimedia Appendix 1
Supplementary tables.
[DOCX File, 17 KB - cardio_v8i1e52576_app1.docx ]

References


49. Björnsdottir et alJMIR CARDIO 2024 | vol. 8 | e52576 | p.128https://cardio.jmir.org/2024/1/e52576

Abbreviations

CAP: controlled attenuation parameter
DASS-21: Depression, Anxiety, Stress Scale, 21 Items
DM: diabetes mellitus
EQ-5D-5L index: EuroQol-5 Dimension – 5-Level index
HbA1c: hemoglobin A1c
HOMA-IR: homeostatic model assessment for insulin resistance
Cognitive Behavioral Therapy for Symptom Preoccupation Among Patients With Premature Ventricular Contractions: Nonrandomized Pretest-Posttest Study

Björn E Liliequist¹, MSc; Josefina Särnholm¹, PhD; Helga Skuladóttir²,³, MD; Eva Ólafsdóttir²,³, RN; Brjánn Ljóttsson¹, PhD; Frieder Braunschweig²,³, MD, PhD

¹Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Stockholm, Sweden
²Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden
³Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

Corresponding Author:
Björn E Liliequist, MSc
Department of Clinical Neuroscience
Division of Psychology
Karolinska Institutet
Nobels väg 9
Stockholm, 171 65
Sweden
Phone: 46 08 524 800 00
Fax: 46 08 31 11 01
Email: bjorn.liliequist@ki.se

Abstract

Background: Premature ventricular contractions (PVCs) are a common cardiac condition often associated with disabling symptoms and impaired quality of life (QoL). Current treatment strategies have limited effectiveness in reducing symptoms and restoring QoL for patients with PVCs. Symptom preoccupation, involving cardiac-related fear, hypervigilance, and avoidance behavior, is associated with disability in other cardiac conditions and can be effectively targeted by cognitive behavioral therapy (CBT).

Objective: The aim of this study was to evaluate the effect of a PVC-specific CBT protocol targeting symptom preoccupation in patients with symptomatic idiopathic PVCs.

Methods: Nineteen patients diagnosed with symptomatic idiopathic PVCs and symptom preoccupation underwent PVC-specific CBT over 10 weeks. The treatment was delivered by a licensed psychologist via videoconference in conjunction with online text-based information and homework assignments. The main components of the treatment were exposure to cardiac-related symptoms and reducing cardiac-related avoidance and control behavior. Self-rated measures were collected at baseline, post treatment, and at 3- and 6-month follow-ups. The primary outcome was PVC-specific QoL at posttreatment assessment measured with a PVC-adapted version of the Atrial Fibrillation Effects on Quality of Life questionnaire. Secondary measures included symptom preoccupation measured with the Cardiac Anxiety Questionnaire. PVC burden was evaluated with 5-day continuous electrocardiogram recordings at baseline, post treatment, and 6-month follow-up.

Results: We observed large improvements in PVC-specific QoL (Cohen $d=1.62$, $P<.001$) and symptom preoccupation (Cohen $d=1.73$, $P<.001$) post treatment. These results were sustained at the 3- and 6-month follow-ups. PVC burden, as measured with 5-day continuous electrocardiogram, remained unchanged throughout follow-up. However, self-reported PVC symptoms were significantly lower at posttreatment assessment and at both the 3- and 6-month follow-ups. Reduction in symptom preoccupation had a statistically significant mediating effect of the intervention on PVC-specific QoL in an explorative mediation analysis.

Conclusions: This uncontrolled pilot study shows preliminary promising results for PVC-specific CBT as a potentially effective treatment approach for patients with symptomatic idiopathic PVCs and symptom preoccupation. The substantial improvements in PVC-specific QoL and symptom preoccupation, along with the decreased self-reported PVC-related symptoms warrant further investigation in a larger randomized controlled trial.

Trial Registration: ClinicalTrials.gov NCT05087238; https://clinicaltrials.gov/study/NCT05087238

https://cardio.jmir.org/2024/1/e53815

JMIR Cardio 2024 | vol. 8 | e53815 | p.130
Introduction

Premature ventricular contractions (PVCs) are a common type of cardiac arrhythmia with a prevalence of 69%-99.5% in the adult population [1,2]. PVCs are commonly asymptomatic but can result in mild to disabling symptoms due to palpitations, dyspnea, presyncope, and fatigue [3]. In the absence of structural heart disease or inherited ion channelopathies, PVCs are referred to as idiopathic and considered benign, although a high PVC burden may induce a cardiomyopathy in some patients [3,4]. Medical treatment with beta-blockers or nondihydropyridine calcium channel blockers can decrease the PVC burden and provide symptomatic improvement; however, this treatment is ineffective in a large portion of patients and may cause side effects. Catheter ablation is the most effective approach to abolish PVCs and has been emphasized in recent guidelines as the recommended first-line treatment for symptomatic idiopathic PVCs [5]. However, ablation may not be readily available or may be offered with some reservation owing to the risk of rare but potentially life-threatening complications and considerable costs [5]. Therefore, many patients with PVCs continue to live with persistent and debilitating symptoms.

Symptom preoccupation, which involves excessive attention to symptoms, fear of symptoms, and associated avoidance behavior, is related to increased symptom severity and low disease-specific quality of life (QoL) in other somatic conditions [6,7]. Studies of atrial fibrillation (AF) have shown that symptom preoccupation, rather than the objective arrhythmia burden, explains elevated symptom severity and impaired QoL [8,9]. However, few studies have investigated QoL in patients with PVCs [10], and the factors underpinning symptom severity and QoL in these patients are not well understood. Given the similar symptom presentation as that associated with AF, we hypothesized that symptom preoccupation is likely to play a role in the subjective symptom experience for patients with PVCs. We have defined symptom preoccupation in the context of cardiac arrhythmias (AF and PVCs) as the fear of experiencing and triggering cardiac-related symptoms, hypervigilance toward cardiac symptoms, persistent worry about complications, and arrhythmia-related avoidance of physical and social activities [11,12].

Cognitive behavioral therapy (CBT) has been found to be effective in reducing disability associated with both anxiety disorders [13] and somatic conditions where symptom preoccupation is prevalent [6,7,13]. In a series of clinical studies, Särmholm et al [11,12,14] developed AF-specific CBT (AF-CBT) targeting symptom preoccupation, which resulted in significant improvements in AF-specific QoL and self-reported symptom severity. Therefore, the purpose of this study was to further adapt and evaluate the AF-CBT protocol to target symptom preoccupation in patients with symptomatic idiopathic PVCs.

PVC-specific CBT (PVC-CBT) aims to break the cycle of cardiac-related fear and hypervigilance as well as arrhythmia-specific avoidance behavior and disability through repeated exposure to cardiac-related symptoms and situations that have been avoided due to fear, negative emotional responses, and apprehension of experiencing PVCs. We also aimed to investigate changes in the objective arrhythmia burden as measured with electrocardiogram (ECG), along with the role of symptom preoccupation as a potential mediator of the treatment effect on PVC-specific QoL.

Methods

Study Design

In this uncontrolled pilot trial, we used a pretest-posttest design with 3- and 6-month follow-ups. Self-rated measures were completed online using a secure web-based assessment tool and were collected at pretreatment, post treatment, and at 3- and 6-month follow-ups. The primary outcome and potential mediators were also collected weekly during treatment. The aim was to include 30 participants, yielding a power of 80% to detect at least a moderate increase in the main outcome measure, corresponding to an effect size of Cohen $d=0.65$. However, due to time constraints, we made a pragmatic decision to stop recruitment at 19 participants. This decision was based on the clinical impression of substantial improvements in the first 15 treated participants and experiences from the previous pilot study of AF-CBT, where large average improvement was observed in 19 participants [11].

Participants

Participants were recruited nationwide from Sweden by advertisement in social media and newspapers. To be eligible for the study, participants had to fulfill the following inclusion criteria: (1) 18-70 years old, (2) diagnosed with PVCs with impairing or bothering PVC-associated cardiac symptoms, (3) on medication in accordance with current guidelines [5], and (4) able to read and write in Swedish. Participants were excluded if they had (1) any structural heart disease, including previous myocardial infarction, heart failure with preserved or reduced left ventricular ejection fraction, valvular disease, or previous cardiac surgery; (2) other arrhythmia or severe medical illness; (3) were scheduled for ablation therapy or any other cardiovascular intervention; (4) any medical restriction to physical exercise; (5) severe psychiatric disorder, severe depression, or risk of suicide; or (6) alcohol dependency. All participants underwent cardiac and psychological assessments to ensure that eligibility criteria were met. Participants were asked not to engage in other psychological treatment and only make necessary changes in medication during study participation. Participants were recruited and treated between January 2021 and October 2021, and the last 6-month follow-up was conducted in April 2022.
Ethical Considerations

The Regional Ethics Review Board in Gothenburg approved the trial protocol (Dnr 2020–05809) and the study was registered on ClinicalTrials.gov (NCT05087238). The study was conducted in accordance with the Declaration of Helsinki and all respondents provided informed consent prior to their involvement in the study, wherein they were given detailed information regarding the study’s purpose, procedures, potential risks, benefits, and their rights as study participants. The informed consent form outlined these aspects clearly, and participants were given the opportunity to ask questions before agreeing to participate. All identifying data were stored on secure servers and data analysis was conducted on pseudonymized data. No compensation was given for participating. This study report adheres to the TREND (Transparent Reporting of Evaluations with Nonrandomized Designs) statement checklist for nonrandomized interventions [15]. The authors assure the completeness and accuracy of the data and adherence to the trial protocol.

Procedure

Applicants registered at the study’s secure webpage and completed an online screening, including informed digital consent, demographic questions, and medical history. Applicants also completed the Alcohol Use Disorders Identification Test [16], the 9-item Patient Health Questionnaire (PHQ-9) measuring depressive symptoms [17], the Atrial Fibrillation Effects on Quality of Life (AFEQT) questionnaire adapted for PVCs (primary outcome measure), and the Cardiac Anxiety Questionnaire (CAQ) [18]. The cardiac study nurse (EÖ) then screened the applicants’ medical records and conducted clinical telephone interviews to ensure that eligibility criteria were met. Eligible patients then underwent a structured telephone-based psychological assessment by a clinical psychologist. All clinical assessments and the cardiac parameters from the medical chart were reviewed by the study cardiologist (HS) before a decision on inclusion was made.

Intervention

The PVC-CBT intervention consisted of 10 weekly face-to-face sessions with a clinical psychologist (BEL) delivered via videoconference in conjunction with online text-based modules accessed through a secure web-based platform. All theoretical elements were presented verbally in sessions 1-4 and summarized in text-based form online together with homework assignments. This design allowed us to combine the flexibility of a face-to-face session with the scaffolding structure of the internet-based format. The clinical psychologist could consult the study cardiologist in cases of uncertainties regarding participants’ health. Due to technical shortcomings of the videoconference application, some of the weekly sessions were delivered by telephone and one participant received all sessions by telephone. The last 6 sessions focused on continuing working with the central elements of treatment presented in sessions 1-4. Participants were recommended to spend 30 minutes a day on the homework assignments. The treatment was based on the AF-specific CBT protocol [11,12,14] and adapted to patients with PVCs by authors BEL and JS.

The PVC-CBT was designed to target symptom preoccupation (ie, fear and hypervigilance toward cardiac-related symptoms and avoidance behavior) and included the following interventions: (1) education on PVCs and common psychological reactions to PVC symptoms, and the role of control and avoidance behavior in maintaining fear and hypervigilance of PVC symptoms; (2) interoceptive exposure to physical sensations similar to PVC symptoms by performing physical exercises such as increasing the heart rate and inducing palpitations by running on the spot or inducing dyspnea by excessive breathing to reduce the fear of symptoms and hypervigilance; (3) self-observation of cardiac symptoms, thoughts, feelings, and behavioral impulses to reduce fear and hypervigilance, serving as a form of interoceptive exposure technique; (4) in vivo exposure to avoided activities that were anticipated to elicit or potentially exacerbate PVC symptoms (such as vigorous exercise) or situations in which PVC symptoms are unwanted (such as engaging in leisure activities or driving); and (5) strategies on how to refrain from behaviors that serve to control symptoms, such as pulse checking, and how to handle worry when conducting exposure exercises. Participants were encouraged to combine interventions 2-5 to maximize the effect of exposure (ie, inducing dyspnea by excessive breathing [interoceptive exposure] before taking a walk alone in the woods [in vivo exposure]) and then using self-observation while experiencing symptoms instead of checking their pulse. Participants were also encouraged to view symptomatic episodes as opportunities to practice the skills acquired in treatment. The last module focused on (6) relapse prevention, including participants making their own plan for continuous practice of the acquired skills after the end of treatment. See Textbox 1 for an overview of the treatment.
Overview of the treatment plan in cognitive behavioral therapy for patients with premature ventricular contractions (PVCs).

**Education**
- Education on PVCs
- The role of cardiac-related fear, hypervigilance, and behavior on symptoms and quality of life
- Self-observation of cardiac-related symptoms, thoughts, feelings, and behavioral impulses

**Interoceptive exposure**
- Exposure to physical sensations associated with PVC symptoms

**In vivo exposure**
- Gradual exposure to avoided situations or activities that patients fear may elicit or aggravate PVC symptoms or where symptoms are unwanted
- Combining in vivo exposure with interoceptive exposure while refraining from control and safety behavior

**Relapse prevention**
- Prevention of relapse into control or avoidance behavior by identifying risk situations

**Assessments**

**Design**
All outcome measures were completed online, with no interference of study personnel, at pretreatment, post treatment, and at 3- and 6-month follow-ups, except when noted otherwise.

**Primary Outcome**
In the absence of a validated PVC-specific QoL measure, we used the AFEQT [19] as the primary outcome measure and adapted the questionnaire to PVCs (AFEQT-PVC). The AFEQT is a well-validated instrument for assessing self-reported AF-specific QoL in four domains: AF symptoms, impact on physical and social activities, medical treatment concerns, and satisfaction with AF treatment. The scale consists of 20 items with a total score ranging from 0 (severe AF symptoms and disability) to 100 (no AF symptoms and disability) [19]. The AFEQT has been shown to be sensitive to clinical change, with a change of 18.9 points corresponding to a meaningful improvement as assessed by a physician [19,20]. The original structure of the AFEQT questionnaire was preserved, only removing the last 6 items measuring satisfaction and concern with current medical treatment as these issues were not targeted in the study treatment. All other items were retained except for changing the wording relevant to AF to be relevant to PVCs (eg, “On a scale of 1 to 7, over the past 4 weeks, as a result of your extra heart beats, how much did the feelings below bother you?”). The AFEQT-PVC measures PVC-related QoL in the following domains: arrhythmia symptoms and impairment in physical and social activities. The adapted scale consists of 16 items (0-5), with a total score ranging from 0 (severe symptoms and disability) to 100 (no symptoms or disability).

**Secondary Outcomes**
Secondary outcome measures included the Symptoms Checklist (SCL), which consists of two subscales measuring the frequency and severity of arrhythmia-specific symptoms [21], and the CAQ, which was used to measure symptom preoccupation and consists of three subscales: (1) cardiac-related fear, (2) attention to cardiac-related symptoms, and (3) cardiac-related avoidance [18]. QoL was measured with the 12-item Short-Form Health Survey (SF-12), which contains two subscales measuring physical health-related QoL (PCS-12) and mental health-related QoL (MCS-12) [22]. To assess fear toward bodily symptoms, the Body Sensations Questionnaire (BSQ) [23] was used. Stress reactivity was measured with the Perceived Stress Scale (PSS-4) [24] and physical activity was measured with the Godin–Shephard Leisure Time Physical Activity Questionnaire (GSLTPAQ) [25]. Depressive symptoms were measured with the PHQ-9 [17] and general anxiety was measured with the General Anxiety Disorder scale (GAD-7) [26]. Treatment credibility was measured with the Credibility/Expectancy Scale [27] in the second week of treatment.

Patient satisfaction with the treatment was assessed with the Client Satisfaction Questionnaire (CSQ) [28] post treatment. Potential adverse events from treatment were assessed at post treatment and at 3- and 6-month follow-ups. Participants were instructed to report and rate the short- and long-term discomfort caused by the adverse event from 0 (did not affect me at all) to 3 (affected me very negatively) [6].

**ECG Measurements of Objective PVC Burden**
To assess changes in the objective PVC burden (number of PVCs per day), participants wore a three-channel ambulatory ECG patch (ePatch [29]) continuously for 5 days at pretreatment, post treatment, and at the 6-month follow-up. All participants contributed with three recordings except one participant who missed the 6-month follow-up recording. As a measure of the subjective experience of the PVC burden, participants were instructed to indicate symptoms by tapping a button on the patch recorder when experiencing symptoms of PVCs. The patch recorder was delivered via mail together with written instructions. The ECG data were analyzed by an experienced consultant using specialized software (Cardiologs; Cardiologs Technologies). The consultant was blinded to participant ID and assessment occasion.
Statistical Analysis

Linear mixed modeling was performed in Stata/IC 16.0 to analyze the change in the estimated mean for assessments from pretreatment to post treatment and from pretreatment to 3-month and 6-month follow-up, respectively. Effect sizes of within-group changes (Cohen $d$) were calculated as the mean change between the two compared time points (pretreatment to post treatment, pretreatment to 3-month follow-up, and pretreatment to 6-month follow-up) divided by each measure’s standard deviation at baseline. The 95% CIs for effect sizes were calculated in R [30] using bootstrapping with 5000 samples. Data were analyzed in an intention-to-treat design, meaning that all participants were included in the analyses regardless of treatment completion status.

The change in objective PVC burden and in the self-reported PVC burden (ie, indicating PVC symptoms) was analyzed using the ECG measurements from pretreatment to post treatment and from pretreatment to 6-month follow-up in Stata/IC 16.0. Profile analysis with a Poisson generalized estimation equation model and log-link function was used for the incidence rate of objective PVCs and self-reported PVCs by tapping the patch recorder device.

Mediation Analysis

The potential mediating effects of symptom preoccupation (CAQ) on the effect of the treatment on the primary outcome measure were analyzed in an exploratory mediation analysis using the weekly version of the AFEQT-PVC, only differing from the AFEQT-PVC in that participants were asked to recall a period of 1 week instead of 1 month. The mediation analyses were conducted based on the 10 weekly measurements collected during the treatment (ie, at the beginning of the first treatment week until the beginning of the tenth treatment week).

The three subscales (attention, avoidance, and fear) as well as the total score of the CAQ were included as indicators of symptom preoccupation. To control for nonspecific improvement, we used the weekly versions of PSS-4 (perceived stress) and GSLTPAQ (physical activity), which are not targeted in the CBT treatment, as competing mediators. The analyses were performed in line with the procedure described by Baron and Kenny [31] and further developed by Preacher and Hayes [32]. With the purpose of investigating to what extent the changes in outcome could be explained by changes in the mediators, we conducted both single mediator analyses, in which each mediator was tested separately, and multiple mediator analyses, in which we included all mediators to compete. This design allowed us to study the relative contribution of each mediator to the improvement on the outcome weekly AFEQT-PVC.

We hypothesized a gradual and linear improvement in outcome during treatment with an effect of treatment week on mediators and the outcome. Further, we expected an association between the mediators and outcome during treatment. Both the single and multiple mediation analyses were performed in three steps. First, the association between treatment week and the mediator(s) (ie, $a$-path) was estimated. Second, while controlling for treatment week, the association between the mediator(s) and weekly AFEQT-PVC (ie, $b$-path) over the course of the therapy was estimated. Third, the $ab$-product, which is the indirect or mediated effect (ie, the contribution of the change in the mediator on the effect of treatment week on the outcome), was calculated by multiplying the a- and b-path estimates for each mediator. In the second set of analyses, which included all mediators, the first step was conducted separately for each mediator as the dependent variable and the second step included all mediators as independent variables. To account for dependency between the weekly measurements, all analyses were based on linear mixed models, with random intercept 95% CIs for the indirect effects (ie, the $ab$-products) estimated using 5000 bootstrap replications of all analyses; the criterion for a statistically significant mediation effect was that the 95% CI did not contain zero [32].

Results

Sample

Table 1 displays the characteristics of the participants, and Figure 1 illustrates the participant flow through the trial. The included sample (N=19) predominantly comprised women (14/19, 74%). The mean age was 50.0 (SD 15.2) years and the self-reported mean time since the PVC diagnosis was 5 (SD 5.3) years.
Table 1. Characteristics of study participants at baseline (N=19).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>14 (74)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>50 (15)</td>
</tr>
<tr>
<td><strong>Employment status, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Employed</td>
<td>12 (63)</td>
</tr>
<tr>
<td>Retired</td>
<td>5 (26)</td>
</tr>
<tr>
<td>Self-employed</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Student</td>
<td>1 (5)</td>
</tr>
<tr>
<td><strong>Highest completed education, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Secondary</td>
<td>4 (21)</td>
</tr>
<tr>
<td>Tertiary</td>
<td>15 (79)</td>
</tr>
<tr>
<td>PVC\textsuperscript{a} duration (years), mean (SD)</td>
<td>5 (5)</td>
</tr>
<tr>
<td><strong>Current medication, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>11 (58)</td>
</tr>
<tr>
<td>Calcium-channel blocker</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>1 (5)</td>
</tr>
<tr>
<td>ACE\textsuperscript{b}/ARB\textsuperscript{c}</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Anticoagulation</td>
<td>1 (5)</td>
</tr>
<tr>
<td>SSRI\textsuperscript{d}</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Thyroid replacement therapy</td>
<td>3 (16)</td>
</tr>
<tr>
<td><strong>Medical disorders, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Obstructive sleep apnea</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>4 (21)</td>
</tr>
<tr>
<td><strong>Comorbid psychiatric conditions, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Any psychiatric condition</td>
<td>13 (68)</td>
</tr>
<tr>
<td>Depressed mood</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Excessive worry</td>
<td>4 (21)</td>
</tr>
<tr>
<td>Social anxiety</td>
<td>3 (16)</td>
</tr>
<tr>
<td>Panic attacks</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Agoraphobia</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Trauma-related stress symptoms</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Exhaustion symptoms</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Sleeping impairment</td>
<td>5 (26)</td>
</tr>
<tr>
<td>Previous psychological treatment, n (%)</td>
<td>13 (68)</td>
</tr>
</tbody>
</table>

\textsuperscript{a}PVC: premature ventricular contraction.  
\textsuperscript{b}ACEi: angiotensin converter-enzyme inhibitor.  
\textsuperscript{c}ARB: angiotensin receptor blocker.  
\textsuperscript{d}SSRI: selective serotonin reuptake inhibitor.
Treatment Activity
Mean session attendance was 9.6 (SD 1.9) sessions, ranging from 2 to 10 sessions. In total, 18 of the 19 participants (95%) were considered treatment completers, meaning that they completed at least 3 sessions and engaged in interoceptive and in vivo exposure exercises, and thus received the core components of the treatment. The one noncompleter attended 2 sessions. There were no missing self-assessment data at any assessment point, whereas one ECG measurement was missing at the 6-month follow-up.

Primary and Secondary Outcomes
Table 2 shows the scores for the continuous outcomes at all assessment points. We observed substantial improvements in PVC-specific QoL (AFEQT-PVC), with large within-group effect sizes at the pretreatment-to-posttreatment assessment. Furthermore, we observed large pretreatment-to-posttreatment reductions in the self-reported frequency (SCL frequency) and severity (SCL severity) of arrhythmia symptoms, and in symptom preoccupation as measured by the total CAQ score as well as on all three subscales of the CAQ: fear, avoidance, and attention. Large effect sizes were also observed for mental health–related QoL (MCS-12), bodily symptoms (BSQ), and depressive symptoms (PHQ-9). Moderate effect sizes were observed on self-perceived stress (PSS-4), general anxiety (GAD-7), and physical activity (GSLTPAQ). One participant (1/19, 5%) reported substantially higher levels of physical activity than the others, leading to a 7-fold increase in variance on the GSLTPAQ. This participant was deemed an outlier and removed from the outcome analysis. No significant effect was seen on the physical health–related QoL (PCS-12). Results for all measures were sustained at the 3- and 6-month follow-ups compared with baseline assessments, except for the PSS-4 score that was nonsignificant at 3-month follow-up.
Table 2. Continuous treatment outcome measures and mixed-effects regression model results.

<table>
<thead>
<tr>
<th>Measure and assessment time point</th>
<th>Mean (SD)</th>
<th>Change from pretreatment</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cohen $d^a$ (95% CI)$^b$</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AFEQT-PVC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>58.3 (13.8)</td>
<td>1.62 (1.07 to 2.28)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>80.7 (16.1)</td>
<td>1.64 (1.06 to 2.36)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>81 (17.5)</td>
<td>1.53 (0.92 to 2.18)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>79.5 (19.4)</td>
<td>1.53 (0.92 to 2.18)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>SC$^c$ frequency</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>19.6 (7.8)</td>
<td>1.39 (0.78 to 2.00)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>13 (7.2)</td>
<td>0.93 (0.51 to 1.33)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>12.3 (7.1)</td>
<td>0.94 (0.52 to 1.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>12.2 (8.0)</td>
<td>0.94 (0.52 to 1.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>SCL severity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>18.2 (6.4)</td>
<td>1.39 (0.78 to 2.00)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>10 (6.1)</td>
<td>1.29 (0.84 to 1.76)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>10 (6.1)</td>
<td>1.29 (0.84 to 1.76)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>9.9 (5.8)</td>
<td>1.30 (0.89 to 1.81)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>CAQ$^d$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>35.6 (9.2)</td>
<td>1.73 (1.27 to 2.38)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>19.6 (9.9)</td>
<td>1.73 (1.27 to 2.38)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>18.8 (8.5)</td>
<td>1.35 (0.94 to 1.87)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>19.7 (12.9)</td>
<td>1.71 (1.03 to 2.54)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>CAQ fear</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>16.5 (5.3)</td>
<td>1.22 (0.78 to 1.71)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>9.9 (5.3)</td>
<td>1.22 (0.78 to 1.71)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>9.3 (5.3)</td>
<td>1.22 (0.78 to 1.71)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>10.3 (6.4)</td>
<td>1.16 (0.67 to 1.78)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>CAQ avoid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>8.2 (4.9)</td>
<td>0.91 (0.5 to 1.41)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>3.9 (4.2)</td>
<td>0.91 (0.5 to 1.41)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>3.7 (3.9)</td>
<td>0.91 (0.5 to 1.41)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>3.7 (4.6)</td>
<td>0.91 (0.5 to 1.41)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>CAQ attention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>10.8 (2.5)</td>
<td>2.03 (1.36 to 2.97)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>5.7 (2.4)</td>
<td>2.03 (1.36 to 2.97)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>5.8 (2.8)</td>
<td>2.03 (1.36 to 2.97)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>5.8 (3.3)</td>
<td>2.03 (1.36 to 2.97)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>MCS-12$^e$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>37.8 (9.8)</td>
<td>1.03 (0.6 to 1.54)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Posttest</td>
<td>47.9 (9.5)</td>
<td>1.03 (0.6 to 1.54)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>47.0 (11)</td>
<td>0.94 (0.25 to 1.55)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>47.9 (10.8)</td>
<td>1.03 (0.39 to 1.62)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Measure and assessment time point</td>
<td>Mean (SD)</td>
<td>Change from pretreatment</td>
<td>P value</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------</td>
<td>--------------------------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohen $d^a$ (95% CI)$^b$</td>
<td></td>
</tr>
<tr>
<td><strong>PCS-12$^b$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>50.9 (8.3)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>52.5 (6.4)</td>
<td>0.18 (-0.4 to 0.5)</td>
<td>.26</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>50 (6.7)</td>
<td>0.11 (0.18 to 0.87)</td>
<td>.49</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>51 (7.5)</td>
<td>0.01 (-0.51 to 0.34)</td>
<td>.95</td>
</tr>
<tr>
<td><strong>BSQ$^d$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>35.3 (8.9)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>28.0 (8.7)</td>
<td>0.81 (0.34 to 1.46)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>26.0 (7)</td>
<td>1.04 (0.53 to 1.59)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>27.1 (8.5)</td>
<td>0.91 (0.44 to 1.63)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>PSS-4$^i$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>5.7 (3.2)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>4.2 (2.9)</td>
<td>0.50 (0.26 to 0.89)</td>
<td>.01</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>5.1 (3.5)</td>
<td>0.20 (-0.23 to 0.73)</td>
<td>.28</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>4.4 (2.9)</td>
<td>0.43 (0 to 0.95)</td>
<td>.02</td>
</tr>
<tr>
<td><strong>GLSTPAQ$^k$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>32.1 (24.1)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>49.3 (24.5)</td>
<td>0.71 (0.34 to 1.18)</td>
<td>.01</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>55.6 (42.2)</td>
<td>0.97 (0.49 to 2.28)</td>
<td>.001</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>53.4 (33.3)</td>
<td>0.88 (0.45 to 1.83)</td>
<td>.002</td>
</tr>
<tr>
<td><strong>PHQ-9$^l$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>5.8 (2.8)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>3 (2.6)</td>
<td>1.03 (0.58 to 1.52)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>3.8 (3.9)</td>
<td>0.71 (-0.27 to 1.32)</td>
<td>.02</td>
</tr>
<tr>
<td>6-month follow-up</td>
<td>3.8 (3.9)</td>
<td>0.73 (-0.06 to 1.34)</td>
<td>.01</td>
</tr>
<tr>
<td><strong>GAD-7$^m$</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretest</td>
<td>6.5 (3.2)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Posttest</td>
<td>4.2 (3.9)</td>
<td>0.73 (0.17 to 1.42)</td>
<td>.008</td>
</tr>
<tr>
<td>3-month follow-up</td>
<td>3.8 (3.4)</td>
<td>0.84 (0.24 to 1.47)</td>
<td>.003</td>
</tr>
</tbody>
</table>
ECG Analyses
The ECG analyses (Table S1 in Multimedia Appendix 1) did not show any significant change in the objective PVC burden at post treatment \((P=.87)\) or at 6-month follow-up \((P=.21)\). However, we observed a statistically significant decrease in self-reported PVC symptoms \((P=.006)\) as reported by tapping the patch-recorder symptom indicator when experiencing symptoms of PVCs at posttreatment assessment. These effects were sustained at 6-month follow-up \((P=.003)\).

Mediation Analysis
The potential mediators and outcomes were measured weekly for 9 consecutive weeks during treatment. We collected a mean number of 17.7 observations per week out of 19 possible observations, and no less than 16 for any week (week 5). Table S2 in Multimedia Appendix 1 shows the estimated indirect effects (ab-products) and their 95% CIs for the three mediators when tested separately and in competition in a multiple mediator model.

In the single mediator analysis, the following measures had statistically significant ab-products: CAQ fear \((0.64)\), CAQ attention \((1.01)\), and PSS-4 \((0.21)\). This indicated a mediating effect of both symptom preoccupation and stress sensitivity on the main outcome AFEQT-PVC. The effect of physical activity based on the GSLTPAQ \((-0.01)\) was not statistically significant, regardless of whether or not the outlying participant was included in the analysis. When allowing the measures to compete in explaining the change in outcome in AFEQT-PVC in a multiple mediator analysis, the ab-product of PSS-4 \((0.12)\) was statistically significant but substantially lower than that of the attention \((0.42)\) and avoidance \((0.80)\) subscales of the CAQ, which also remained statistically significant. The fear subscale of the CAQ \((0.14)\) was nonsignificant in the multiple mediator analysis.

Treatment Satisfaction
In total, 18 out of 19 participants (95%) reported that they were very satisfied (13/19, 68%) or satisfied (5/19, 26%) with the treatment. The mean score on the CSQ measure was 28.9 (SD 3.2) of a maximum 32 points, which indicated a high level of satisfaction with the treatment.

Changes in Medication and Cardiac Health
At post treatment, 4 of the 19 (21%) participants reported changes in their cardiac medication. Three participants quit using beta-blockers and one participant reported an increase in the use of beta-blockers. At the 6-month follow-up, 6 participants (32%) reported changes in cardiac medication; 1 (5%) quit using beta-blockers, 1 (5%) decreased the use of beta-blockers, and 4 (21%) increased their use of beta-blockers (including one participant who started using beta-blockers to treat hypertension rather than symptoms of PVCs). At 6-month follow-up, 1 (5%) participant had undergone invasive therapy (catheter ablation) and 1 (5%) participant reported slightly increased blood pressure. In addition, 1 (5%) participant had episodes of paroxysmal AF based on the analyses of the ECG data after the 6-month follow-up.

Adverse Events
At post treatment, among the 19 participants, 2 (11%) reported adverse events from engaging in the study. One of the participants (5%) reported increased stress and worry from participating in the study and rated the negative impact of this event as of mild severity (1 out of 3) at the time of the event as well as on the residual discomfort from the event. The other participant reported two adverse events during treatment consisting of elevated cardiac symptoms, rated as having the highest severity (3 out of 3) at the time of the events as well as on residual discomfort. No other adverse events were reported at the 3-month follow-up. At the 6-month follow-up, 1 (5%) participant reported an adverse event consisting of an episode of increased frequency of palpitations, rated as of medium severity at the time of the event (2 out of 3) and of mild severity on residual discomfort from the event (1 out of 3).
Discussion

Principal Findings

To our knowledge, this is the first study to evaluate the potential efficacy and feasibility of PVC-CBT for symptom preoccupation in patients with symptomatic idiopathic PVCs. Substantial improvements were found on the primary outcome measure AFEQT-PVC with respect to PVC-specific QoL and self-reported PVC symptoms. We also observed large reductions in cardiac-related fear and hypervigilance and avoidance behavior as measured by the CAQ. Furthermore, medium to large improvements were observed on all other secondary measures, except for the physical health domain of the SF-12, which remained unchanged. ECG analyses showed a significant reduction in self-reported PVC symptoms, although the objective PVC burden was unchanged. All posttreatment results were sustained at 3- and 6-month follow-ups, with high adherence and participant satisfaction and few adverse events reported. These results are comparable to the results for exposure-based AF-CBT delivered face to face [11] and via the internet [12,14] as well as for CBT for functional somatic disorders [6,7,33-35]. The exploratory mediation analyses indicated that symptom preoccupation had a mediating effect on the impact of PVC-CBT on PVC-specific QoL and self-reported PVC symptoms. These results are consistent with previous results of AF-CBT [12,14] and of CBT for other somatic conditions [36-38]. Sustained improvements in PVC-specific QoL (AFEQT-PVC) and self-reported PVC symptoms (SCL and tapping the ECG) were observed despite the lack of change in the objective PVC burden, providing support for further investigation on the proposed role of symptom preoccupation as a potential maintaining mechanism of symptom focus and impairment in PVCs.

The promising findings of this pilot study, with large improvements in the outcome measures, high treatment adherence, and reported satisfaction with treatment as well as the limited report of adverse events, encourage further research into the efficacy of CBT in patients with symptomatic PVCs. The use of videoconferencing and text-based material delivered online in this study enabled access to treatment for patients who do not otherwise benefit from current treatment regimens and for patients in rural areas. If the results of this study can be replicated in further studies, PVC-specific CBT may be made available to larger groups of patients, irrespective of their geographical location. In the future, as digital devices are available to larger groups of patients, irrespective of their geographical location. In the future, as digital devices are increasingly used in the detection and follow-up of patients with arrhythmias [39], online CBT may be combined with other telemedicine applications as part of a remote management strategy in patients with PVC or other arrhythmic conditions.

Limitations

There are several limitations to this study, which should be considered when interpreting the results. The within-group design with a lack of control group precludes deriving a firm conclusion as to whether the results are true effects of the intervention or caused by extraneous variables such as the passage of time, expectancy of improvement, or attention from a caregiver. Another limitation is the reliance on self-reported measures, which could raise validity concerns due to the subjective nature of self-reporting. Nevertheless, the use of self-reported outcomes of QoL in arrhythmia intervention research is endorsed [40]. All self-reported measures used in this study are well-validated, except for the main outcome measure (AFEQT-PVC), which has not been validated for the PVC population. Unfortunately, to our knowledge, there is no validated PVC-specific QoL questionnaire, and while the AFEQT is a well-validated measure for AF-specific QoL and patients with PVCs show a similar symptom presentation and arrhythmia-related disability to those of patients with AF, important aspects of QoL among patients with PVCs may not be adequately reflected by this measure. In addition, the ECG patch measurement period of 5 days may have been too short to measure the objective PVC burden accurately. A more reliable measure could have been obtained by using an implantable loop recorder. However, this was considered too intrusive for a secondary outcome measure. Inferences on generalizability are also limited by the small sample size and the skewed sex distribution with a majority of female participants (14/19, 74%). A possible selection bias may have been introduced due to recruitment mainly from advertisements on social media, which may affect the generalizability to patients in routine care. However, the treatment is designed for patients with symptom preoccupation who are willing to engage in psychological intervention and thus the selected recruitment approach may also have lowered the threshold for seeking treatment. A majority (13/19, 68%) of the participants had previous experience of psychological treatment, which may have made them more susceptible to the CBT treatment.

Conclusions

The main objective of this pilot study was to investigate the potential efficacy of PVC-CBT for patients with symptomatic idiopathic PVCs delivered by videoconference together with online text-based modules and homework assignments. The large improvements on PVC-specific QoL and the indication that the effect on PVC-specific QoL was mediated by reductions in symptom preoccupation suggest potential efficacy of exposure-based CBT targeting symptom preoccupation for this patient group. Randomized controlled trials are warranted to confirm our findings in larger patient samples.

Acknowledgments

Funding of this study was made possible by grants from Karolinska University Hospital. The funding organization did not exert any influence on the study design, execution, data analysis, or interpretation. All researchers were independent of the funders. The authors wish to express their gratitude to Professor Matteo Bottai at Karolinska Institutet for statistical consultation and analysis and to Elin Westberg for conducting the electrocardiogram analysis. Finally, we would like to thank the participants of the study for their time and effort.
Data Availability
The data sets generated during and/or analyzed during this study are not publicly available due to European Union law regulating sensitive personal data. Access to data requires approval from the Swedish Ethical Review Authority and data sharing agreement with Karolinska University Hospital.

Authors’ Contributions
BEL, JS, BL, FB, and HS were responsible for study supervision. BEL, JS, and BL carried out the statistical analysis. BEL drafted the manuscript, which was revised by all authors.

Conflicts of Interest
FB declares personal fees for trial committee participation and lectures by Medtronic, Biotronic, Biosense Webster, Impulse Dynamics, Novartis, Orion, Boehringer, and Pfizer. BL has coauthored a self-help book based on exposure-based cognitive behavior therapy for health anxiety that is available in the public marketplace. The other authors have no conflicts to declare.

Multimedia Appendix 1
Detailed results of the electrocardiogram (ECG; Table S1) and exploratory mediation (Table S2) analyses.

References


Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001 Sep;16(9):606-613 [FREE Full text] [doi: 10.1046/j.1525-1497.2001.016009060.x] [Medline: 11556941]


Amireault S, Godin G. The Godin-Shephard Leisure-Time Physical Activity Questionnaire: validity evidence supporting its use for classifying healthy adults into active and insufficiently active categories. Percept Mot Skills 2015 Apr 01;120(2):604-622. [doi: 10.2466/03.27.pms.120v1x7]


Abbreviations

AF: atrial fibrillation
AF-CBT: atrial fibrillation–specific cognitive behavioral therapy
AFEQT: Atrial Fibrillation Effects on Quality of Life
AFEQT-PVC: Atrial Fibrillation Effects on Quality of Life adapted to premature ventricular contraction
BSQ: Body Sensations Questionnaire
CAQ: Cardiac Anxiety Questionnaire
CBT: cognitive behavioral therapy
CSQ: Client Satisfaction Questionnaire
ECG: electrocardiogram
GAD-7: Generalized Anxiety Disorder scale
GSLTPAQ: Godin-Shepard Leisure Time Physical Activity Questionnaire
MCS-12: mental health–related quality of life subscale of the Short-Form Health Survey
PCS-12: physical health–related quality of life subscale of the Short-Form Health Survey
PHQ-9: 9-item Patient Health Questionnaire
PSS-4: Perceived Stress Scale
PVC: premature ventricular contraction
PVC-CBT: premature ventricular contraction–specific cognitive behavioral therapy
QoL: quality of life
SCL: Symptoms Checklist
SF-12: Short-Form Health Survey
TREND: Transparent Reporting of Evaluations with Nonrandomized Designs

©Björn E Liliequist, Josefin Särnholm, Helga Skúladóttir, Eva Öfalsdóttir, Brjánn Ljótsson, Frieder Braunschweig. Originally published in JMIR Cardio (https://cardio.jmir.org), 07.05.2024. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
Factors That Influence Patient Satisfaction With the Service Quality of Home-Based Teleconsultation During the COVID-19 Pandemic: Cross-Sectional Survey Study

Guangxia Meng¹, MSN; Carrie McAiney¹, PhD; Ian McKillop¹, PhD; Christopher M Perlman¹, PhD; Shu-Feng Tsao¹, PhD; Helen Chen¹, PhD
School of Public Health Sciences, University of Waterloo, Waterloo, ON, Canada

Corresponding Author:
Helen Chen, PhD
School of Public Health Sciences
University of Waterloo
200 University Ave W
Waterloo, ON, N2L 3G1
Canada
Phone: 1 519 888 4567 ext 42131
Email: helen.chen@uwaterloo.ca

Abstract

Background: Ontario stroke prevention clinics primarily held in-person visits before the COVID-19 pandemic and then had to shift to a home-based teleconsultation delivery model using telephone or video to provide services during the pandemic. This change may have affected service quality and patient experiences.

Objective: This study seeks to understand patient satisfaction with Ontario stroke prevention clinics’ rapid shift to a home-based teleconsultation delivery model used during the COVID-19 pandemic. The research question explores explanatory factors affecting patient satisfaction.

Methods: Using a cross-sectional service performance model, we surveyed patients who received telephone or video consultations at 2 Ontario stroke prevention clinics in 2021. This survey included closed- and open-ended questions. We used logistic regression and qualitative content analysis to understand factors affecting patient satisfaction with the quality of home-based teleconsultation services.

Results: The overall response rate to the web survey was 37.2% (128/344). The quantitative analysis was based on 110 responses, whereas the qualitative analysis included 97 responses. Logistic regression results revealed that responsiveness (adjusted odds ratio [AOR] 0.034, 95% CI 0.006-0.188; \(P<.001\)) and empathy (AOR 0.116, 95% CI 0.017-0.800; \(P=.03\)) were significant factors negatively associated with low satisfaction (scores of 1, 2, or 3 out of 5). The only characteristic positively associated with low satisfaction was when survey consent was provided by the substitute decision maker (AOR 6.592, 95% CI 1.452-29.927; \(P=.02\)). In the qualitative content analysis, patients with both low and high global satisfaction scores shared the same factors of service dissatisfaction (assurance, reliability, and empathy). The main subcategories associated with dissatisfaction were missing clinical activities, inadequate communication, administrative process issues, and absence of personal connection. Conversely, the high-satisfaction group offered more positive feedback on assurance, reliability, and empathy, as well as on having a competent clinician, appropriate patient selection, and excellent communication and empathy skills.

Conclusions: The insights gained from this study can be considered when designing home-based teleconsultation services to enhance patient experiences in stroke prevention care.

(JMIR Cardio 2024;8:e51439) doi:10.2196/51439

KEYWORDS

teleconsultation; secondary stroke prevention; telemedicine; service quality; patient satisfaction
Introduction

Secondary Stroke Prevention and Ontario Stroke Prevention Clinics

As of 2019, stroke was the second leading cause of disability worldwide for people aged >50 years, and it was the fourth leading cause of death in Canada from 2017 to 2019 [1,2]. The 36% decline in stroke mortality from 1990 to 2016 can be attributed to better prevention and management of stroke risks [3]. The INTERSTROKE study found that 90% of strokes are preventable owing to modifiable risk factors, including disease-related and behavioral lifestyle factors [4]. Secondary stroke prevention is crucial, as there is up to a 10% risk of recurrent stroke within 90 days of a transient ischemic attack (TIA) or minor stroke [5].

Approximately 80% of patients with minor stroke discharged from the emergency department in Ontario are referred to stroke prevention services [6]. Stroke prevention clinics provide rapid assessments, diagnostic tests, treatments, prevention, and education to reduce the risk of recurrent stroke [7]. Ontario’s 41 stroke prevention clinics are integral to publicly funded health systems [7]. Stroke prevention clinic services are associated with a 25% reduction in mortality [8].

Before the COVID-19 pandemic, stroke prevention care in Ontario was predominantly delivered through in-person consultations. A small percentage of rural and northern Ontario stroke prevention clinics used teleconsultation at local satellite clinics to address access challenges [9]. One stroke prevention clinic conducted a pilot project offering follow-up home video visits from August 2018 to September 2019 [10]. The video consultation produced higher patient satisfaction, was considered safe by physicians, and was shown to be cost-effective in reducing health care costs and patient expenses [10].

In this study, home-based teleconsultation was defined as a synchronous consultation between a clinical service provider and a patient in their home to provide diagnostic or therapeutic advice through telephone or videoconference [11]. Despite a handful of cases in which home-based teleconsultation was used for follow-up care, before the COVID-19 pandemic [10], Ontario stroke prevention clinics had never used home-based teleconsultation to conduct synchronous, interactive, in-home patient visits for new referrals. A survey of >3000 Canadians with stroke, heart disease, or vascular impairment conducted in the spring of 2021 showed that 80% of respondents had had a teleconsultation during the pandemic [12]. The effect of the rapid change from in-person visits to home-based teleconsultation during the COVID-19 pandemic on patients’ experiences was unknown. Patients with stroke are often older adults with multiple chronic conditions [13]. Older adults have lower telehealth service use overall [14]. The impact of service mode change on the older population of stroke prevention clinics needs further exploration.

Service Quality and Patient Satisfaction

Although the rapid transition to home-based teleconsultation may be a temporary response to the COVID-19 pandemic, it offers a significant opportunity to examine the service quality of home-based teleconsultation in stroke prevention clinics. Delivering safe, high-quality health services is the primary goal of health systems [15]. The literature’s definition of health care service quality is commonly described as including 2 aspects. One views health care service quality as characteristics and features that meet clinicians’ predetermined specifications and standards (such as professional or ethical standards); the other views it as characteristics and features that meet or exceed patients’ needs and expectations [16]. Patients often cannot accurately assess the internal service quality as they lack the medical knowledge to judge [17]; however, patient satisfaction with a medical service is the primary determinant of service quality [18]. Patient satisfaction is essential for and meaningful to delivering high-quality care [19].

Patient satisfaction is generally regarded as patients’ perception of care delivery as well as how their health needs have been addressed [20,21]. Patient satisfaction can be examined using direct and indirect indicators [21]. First, service quality can be measured by directly asking patients to rate their satisfaction with service quality via, for example, a single item with response options ranging from very dissatisfied to very satisfied [21]. However, the shortfall of single-item measurement is that we cannot evaluate or identify a specific aspect of service quality [21]. The alternative approach is to ask patients to rate their experience of different aspects of care, but this indirect measure has the weakness of preemptive assumptions about the determinants of service quality [21]. To obtain an accurate measurement of patient satisfaction, we applied direct and indirect measurements. We asked one question on global satisfaction and applied a theory-guided questionnaire to assess patient satisfaction.

Service Performance Model

As health care quality is multidimensional, we chose an appropriate service quality model (SERVQUAL) to assess patient satisfaction. Examples of existing health care SERVQUALs include the SERVQUAL [22] and its derivative service performance model (SERVPERF) [23], Total Quality Management [24], Health Quality Model [25], service quality for a public hospital [26], and hospital quality model [27]. The Health Quality Model, service quality for a public hospital, and hospital quality model are derivatives of the SERVQUAL model and assess the care quality of hospital inpatient services. The SERVQUAL and SERVPERF models include 5 dimensions: tangibles, reliability, responsiveness, assurance, and empathy [22]. SERVQUAL tends to measure the difference between one’s expectations and the actual performance of the service [22]. SERVPERF only focuses on the actual performance, and studies have shown that service quality is appropriately modeled using SERVPERF as an antecedent of satisfaction [23,28]. There are 22 service attributes listed within the 5 service dimensions of the SERVPERF model [29]. Textbox 1 presents each dimension and item in detail.
Textbox 1. Dimensions and items of the service performance model (adapted from Zeithaml et al [29]).

**Tangibles: facilities, equipment, and the presence of personnel**
- Up-to-date equipment
- Visually appealing physical facilities
- Neat-appearing employees
- Visually appealing materials associated with the service

**Reliability: ability to perform the promised service responsibly and accurately**
- The company keeps its promises to do something by a certain time
- The company shows a sincere interest in solving the customer’s problem
- The company performs the service right the first time
- The company provides its services at the time it promises to do so
- The company insists on error-free records

**Responsiveness: willingness to provide help and a prompt service to customers**
- Employees of the company tell customers exactly when services will be performed
- Employees of the company provide a prompt service to customers
- Employees of the company are always willing to help customers
- Employees of the company are never too busy to respond to customers

**Assurance: the knowledge and courtesy of employees and their ability to inspire trust and confidence**
- The behavior of employees of the company instills confidence in customers
- Customers of the company feel safe in their transactions
- Employees of the company are consistently courteous with customers
- Employees of the company have the knowledge to answer customers’ questions

**Empathy: caring and understanding, which a company provides or offers its customers in terms of its individualized and personalized attention**
- The company gives customers individual attention
- The company has operating hours convenient to all its customers
- Employees of the company give customers personal attention
- The company has the customers’ best interests at heart
- The employees of the company understand the specific needs of their customers

**Study Aims and Research Question**
Any new service model implementation should usually be well planned to improve user satisfaction; however, home-based teleconsultation at stroke prevention clinics was implemented without the usual planning. The rapid implementation could affect patients’ experiences. As a result, it is vital to evaluate patient satisfaction with the quality of the teleconsultation service they received during the COVID-19 pandemic by assessing satisfaction with various service dimensions to identify aspects of service quality that patients are and are not satisfied with. This study aimed to explore the factors affecting patient satisfaction. The research question was as follows: “What are the patient-identified factors influencing patients’ satisfaction with service quality in stroke prevention clinics’ home-based teleconsultation service?”

**Methods**

**Participants and Procedure**
We conducted a web-based or telephone survey of patients who had at least one home-based teleconsultation, either the initial or follow-up visit, at the stroke prevention clinics. The study sites were 2 stroke prevention clinics at 2 tertiary hospitals in Ontario, Canada. The study sample consisted of individuals who received at least one home-based teleconsultation at a stroke prevention clinic between January 1, 2021, and November 30, 2021. A convenience sampling technique was used as we invited patients who lived in their homes and self-participated in the stroke prevention clinic home-based teleconsultation service during the COVID-19 pandemic. Our exclusion criteria included (1) patients who lived in a long-term care home or group home and (2) patients with dementia who could not participate in home-based teleconsultations.
To minimize volunteer bias and increase the response rate, we applied various data collection techniques to capture participants with and without internet access. A web survey was used for patients with email addresses, whereas a telephone survey was used for patients without email addresses. The questionnaire was administered between May 17, 2021, and December 10, 2021.

We developed a telephone script for recruitment to explain the research project in lay terms. In total, 2 modified-duty nurses from one site and neurologists from another site who were not part of the research team obtained permission from patients to be contacted by the research team. The list of email addresses or telephone numbers of patients who gave permission was shared with the research team. Participants who chose a web-based survey received an email with a brief cover letter explaining the study’s purpose and their rights as study participants. Informed consent was via the web before accessing the questionnaire, and they were asked to click a box indicating that they agreed to complete the survey (Multimedia Appendix 1). Participants who chose a telephone survey received a mail-in cover letter, a consent form, and a copy of the survey (Multimedia Appendix 2).

**Ethical Considerations**

This study was reviewed by the research ethics boards of Southlake Regional Health Center and Mackenzie Health and was considered a continuous quality improvement project; thus, a full research ethics review was not required. This study was also reviewed by the University of Waterloo Office of Research Ethics (ORE 42686) and received ethical clearance.

**Measures**

Our study used SERVPERF to design a Likert-scale survey to assess patient satisfaction with home-based teleconsultation service quality in stroke prevention clinics. We acknowledge that patient satisfaction is subjective, with many determinants that may not be related to the SERVPERF model. The literature has indicated that patient satisfaction can be influenced by patient knowledge and expectations; therefore, other factors such as demographics (eg, age, gender, and education), clinical factors (eg, comorbidities, diagnosis, and number of visits), and experiences with teleconsultation can influence patient expectations [20,21]. We also included these factors in our survey. By considering other factors and applying direct and indirect measurements, we attempted to explore patient satisfaction using a holistic approach. The 18-item questionnaire used in our study was developed by referencing the telehealth service quality questionnaire developed by Yin et al [30] (see Multimedia Appendix 3 for a description).

The survey consisted of three components: (1) demographic, clinical, and telemedicine questions; (2) an 18-item Likert scale–based questionnaire measured on a 5-point scale, with 1 for strongly disagree and 5 for strongly agree; and (3) 6 open-ended follow-up questions (Multimedia Appendix 4). The demographic, clinical, and telemedicine independent variables were selected based on previous evidence from a literature review and clinical significance from a practice point of view [31]. We conducted a pilot study in March 2021 with 10 participants who had home-based teleconsultation from October 2020 to December 2020 and asked 6 additional questions about the survey content (Multimedia Appendix 5). Overall, patients were satisfied with the language and content of the survey, indicated in their feedback.

**Data Collection**

The web survey was conducted through a secured, password-protected REDCap (Research Electronic Data Capture; Vanderbilt University) website hosted at the University of Waterloo that supports research data collection [32]. Skype for Business (Skype Technologies) from the University of Waterloo, with recording and transcription functions, was set up for the research assistant to conduct the telephone survey.

**Statistical Analysis**

We applied quantitative and qualitative analysis to understand patient satisfaction. A binary outcome variable was defined as (1) a low-satisfaction group if the participants chose very unsatisfied, dissatisfied, and neither satisfied nor satisfied with the overall home-based teleconsultation service quality; and (2) a high-satisfaction group if the participants chose satisfied and very satisfied. We used SPSS for Windows (version 28.0.1; IBM Corp) for statistical analysis [33]. The Likert-scale questions were converted to numerical values. Using the item means, we generated each SERVPERF dimension score and an overall questionnaire score for each respondent’s survey. There were 10 demographic, 7 clinical, and 6 technical-related independent variables (see Multimedia Appendix 6 for the definitions). Chi-square tests were used to identify the statistical significance between the categorical independent and binary outcome variables. The point biserial correlation was calculated to identify the correlation between a continuous independent variable and the binary outcome variable. To test the internal reliability of our instrument, we calculated the Cronbach α. As we had a large number of independent variables under consideration, a forward selection model was most suitable [34]. We used statistically significant variables correlating to the binary outcome variable in the stepwise binary logistic regression model, with $P<.05$ considered significant.

We used NVivo (QSR International), a software developed to organize and support the analysis of qualitative data. GM coded the entire data set, and ST independently coded 10 random samples. The results were compared and reached an initial 87.1% agreement. Discrepancies were discussed, and conflicts were resolved after further clarification of the definition of the codes. We applied direct content analysis to understand the service quality of the teleconsultation under study [35]. We used the 5 service dimensions and their operational definitions as the initial coding categories [36]. Next, we read each transcript and identified and categorized all the text that appeared to represent the operational definition of the code [35]. Text not categorized using the initial coding scheme would be considered for a new code. We summarized the categories of the entire data set and then divided them into low- and high-satisfaction groups to explore positive and negative patient perceptions. We compared the differences between the 2 groups that could explain the quantitative analysis results [37].
Results

Participant Characteristics

The response rate was 35.9% (104/290) for the web-based survey and 44% (24/54) for the telephone survey. A total of 110 (n=86, 78.2% web and n=24, 21.8% telephone) surveys were included for quantitative analysis, and 97 (n=74, 76% web and n=23, 24% telephone) surveys were included for direct content analysis. Figures 1 and 2 show a flowchart summarizing the subsequent exclusion of cases from the original number participants to arrive at the final analysis. A total of 97.3% (107/110) of the participants used telephone consultations. The percentages of missing values (1% to 8%) for each Likert-scale question were insignificant (<20%); therefore, the mean of each item was used to replace the missing data [38].

Figure 1. Sample flowchart for the web-based survey.

![Flowchart]

- Patients gave permission to send email (N=319)
  - Excluded (n=29)
    - Duplicate respondent emails (n=13)
    - Invalid email address (n=14)
    - Declined to participate (n=2)
  - Valid survey emails sent (n=290)
    - Did not respond (n=186)
    - Survey responses (n=104)
      - Excluded (n=16)
        - Logged on, did not complete any items (n=9)
        - Only completed demographic information (n=7)
      - Survey response analysis for completeness (n=88)
        - Insufficient response to Likert-scale questionnaire (n=2)
        - Included in quantitative study (n=86)
      - Did not respond to open-ended questions (n=12)
      - Included in qualitative study (n=74)
The descriptive statistics of the demographic, clinical, and telemedicine variables are presented in Tables 1-3. Briefly, most of the participants (99/110, 90%) were aged ≥55 years, were retired (80/109, 73.4%) and married (76/110, 69.1%), lived with others (85/109, 78%), and lived within 20 km of where the stroke prevention clinic was located (77/110, 70%). Only a few participants (7/109, 6.4%) had an educational level lower than high school, and most (67/109, 61.5%) had a postsecondary education (Table 1). Regarding clinical factors, most participants had a stroke diagnosis (71/110, 64.5%) and self-identified as having only one stroke risk factor (74/110, 67.3%). Most patients were new (101/110, 91.8%) to the stroke prevention clinics (Table 2). Many participants had relatively less experience with health technology. Although most of them owned digital equipment for teleconsultation (79/109, 72.5%), many of them had never used patient portals (94/108, 87%) and telemedicine (92/108, 85.2%) before the COVID-19 pandemic (Table 3).
Table 1. Demographic characteristics of the patients included in the study (N=110).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total(^a)</th>
<th>Low satisfaction (n=26)</th>
<th>High satisfaction (n=84)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age group (y), n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.04(^b)</td>
</tr>
<tr>
<td>&lt;55</td>
<td>11 (10)</td>
<td>2 (7.7)</td>
<td>9 (10.7)</td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>18 (16.4)</td>
<td>3 (11.5)</td>
<td>15 (17.8)</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>25 (25.5)</td>
<td>4 (15.4)</td>
<td>24 (28.6)</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>40 (36.4)</td>
<td>16 (61.5)</td>
<td>24 (28.6)</td>
<td></td>
</tr>
<tr>
<td>≥85</td>
<td>13 (11.8)</td>
<td>1 (3.8)</td>
<td>12 (14.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.52</td>
</tr>
<tr>
<td>Female</td>
<td>49 (44.5)</td>
<td>13 (50)</td>
<td>36 (42.9)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>61 (55.5)</td>
<td>13 (50)</td>
<td>48 (57.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Distance (km), mean (SD)</strong></td>
<td>17.73 (16.52)</td>
<td>13.53 (11.65)</td>
<td>19.03 (17.61)</td>
<td>.31</td>
</tr>
<tr>
<td>1-20, n (%)</td>
<td>77 (70)</td>
<td>21 (80.8)</td>
<td>56 (66.7)</td>
<td></td>
</tr>
<tr>
<td>21-40, n (%)</td>
<td>21 (19.1)</td>
<td>4 (15.4)</td>
<td>17 (20.2)</td>
<td></td>
</tr>
<tr>
<td>&gt;40, n (%)</td>
<td>12 (10.9)</td>
<td>1 (3.8)</td>
<td>10 (13.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Education, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.52</td>
</tr>
<tr>
<td>Grade 8 or lower</td>
<td>7 (6.4)</td>
<td>0 (0)</td>
<td>7 (8.3)</td>
<td></td>
</tr>
<tr>
<td>High school</td>
<td>35 (32.1)</td>
<td>10 (40)</td>
<td>25 (29.8)</td>
<td></td>
</tr>
<tr>
<td>College</td>
<td>32 (29.4)</td>
<td>6 (24)</td>
<td>26 (31)</td>
<td></td>
</tr>
<tr>
<td>University</td>
<td>24 (21.8)</td>
<td>6 (24)</td>
<td>18 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Graduate school</td>
<td>11 (10)</td>
<td>3 (12)</td>
<td>8 (9.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Employment, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.68</td>
</tr>
<tr>
<td>Retired</td>
<td>80 (73.4)</td>
<td>20 (76.9)</td>
<td>60 (72.3)</td>
<td></td>
</tr>
<tr>
<td>Working</td>
<td>17 (15.6)</td>
<td>2 (7.7)</td>
<td>15 (18.1)</td>
<td></td>
</tr>
<tr>
<td>Unemployed</td>
<td>4 (3.7)</td>
<td>1 (3.8)</td>
<td>3 (3.6)</td>
<td></td>
</tr>
<tr>
<td>Self-employed</td>
<td>3 (2.8)</td>
<td>1 (3.8)</td>
<td>2 (2.4)</td>
<td></td>
</tr>
<tr>
<td>On disability</td>
<td>5 (4.6)</td>
<td>2 (7.7)</td>
<td>3 (3.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Marital status, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.42</td>
</tr>
<tr>
<td>Married</td>
<td>76 (69.1)</td>
<td>18 (69.2)</td>
<td>58 (69.1)</td>
<td></td>
</tr>
<tr>
<td>Divorced</td>
<td>11 (10)</td>
<td>4 (15.4)</td>
<td>7 (8.3)</td>
<td></td>
</tr>
<tr>
<td>Widowed</td>
<td>17 (15.5)</td>
<td>4 (15.4)</td>
<td>13 (15.5)</td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>6 (5.5)</td>
<td>0 (0)</td>
<td>6 (7.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Living arrangement, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.69</td>
</tr>
<tr>
<td>With others</td>
<td>85 (78)</td>
<td>21 (80.8)</td>
<td>64 (77.1)</td>
<td></td>
</tr>
<tr>
<td>Alone</td>
<td>24 (22)</td>
<td>5 (19.2)</td>
<td>19 (22.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Transportation, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td>.24</td>
</tr>
<tr>
<td>Drives</td>
<td>67 (65)</td>
<td>12 (54.5)</td>
<td>55 (67.9)</td>
<td></td>
</tr>
<tr>
<td>Relies on others</td>
<td>36 (35)</td>
<td>10 (45.5)</td>
<td>26 (32.1)</td>
<td></td>
</tr>
<tr>
<td>Use of a cane or walker (yes), n (%)</td>
<td>30 (27.5)</td>
<td>8 (30.8)</td>
<td>22 (26.2)</td>
<td>.57</td>
</tr>
<tr>
<td>Language barrier (yes), n (%)</td>
<td>10 (9.1)</td>
<td>6 (23.1)</td>
<td>4 (4.8)</td>
<td>.005(^c)</td>
</tr>
<tr>
<td><strong>Hearing impaired (yes), n (%)</strong></td>
<td>28 (25.5)</td>
<td>9 (34.6)</td>
<td>19 (22.6)</td>
<td>.22</td>
</tr>
<tr>
<td>Affecting phone conversations (yes)</td>
<td>14 (50)</td>
<td>6 (66.7)</td>
<td>8 (42.1)</td>
<td>.92</td>
</tr>
<tr>
<td><strong>Vision impaired (yes), n (%)</strong></td>
<td>33 (30)</td>
<td>8 (30.8)</td>
<td>25 (29.8)</td>
<td>.88</td>
</tr>
<tr>
<td>Variable</td>
<td>Total (n=110)</td>
<td>High satisfaction (n=84)</td>
<td>Low satisfaction (n=26)</td>
<td>P value</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>---------------</td>
<td>--------------------------</td>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Affecting the use of a screen (yes)</td>
<td>16 (50)</td>
<td>11 (45.8)</td>
<td>5 (26.9)</td>
<td>.41</td>
</tr>
<tr>
<td>The survey was consented to by the SDM</td>
<td>53 (49.1)</td>
<td>35 (41.7)</td>
<td>18 (69.2)</td>
<td>.01</td>
</tr>
<tr>
<td>Web survey (yes), n (%)</td>
<td>86 (78.2)</td>
<td>62 (73.8)</td>
<td>24 (92.3)</td>
<td>.046</td>
</tr>
</tbody>
</table>

Note that the percentages are based on denominators that vary from the overall sample size of 110 because of missing data.

Table 2. Clinical characteristics of the patients included in the study (N=110).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total, n (%)</th>
<th>Low satisfaction (n=26), n (%)</th>
<th>High satisfaction (n=84), n (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Had stroke diagnosis</td>
<td>71 (64.5)</td>
<td>17 (65.4)</td>
<td>54 (64.3)</td>
<td>.92</td>
</tr>
<tr>
<td>Had stroke residual deficits</td>
<td>27 (38)</td>
<td>9 (52.9)</td>
<td>18 (33.3)</td>
<td>.15</td>
</tr>
<tr>
<td>New referral</td>
<td>101 (91.8)</td>
<td>25 (96.2)</td>
<td>76 (90.5)</td>
<td>.36</td>
</tr>
<tr>
<td><strong>Number of stroke risk factors</strong></td>
<td></td>
<td></td>
<td></td>
<td>.40</td>
</tr>
<tr>
<td>0</td>
<td>14 (12.7)</td>
<td>3 (11.5)</td>
<td>11 (13.1)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>74 (67.3)</td>
<td>21 (80.8)</td>
<td>53 (63.1)</td>
<td></td>
</tr>
<tr>
<td>2-4</td>
<td>19 (17.3)</td>
<td>1 (3.8)</td>
<td>18 (21.4)</td>
<td></td>
</tr>
<tr>
<td>5-6</td>
<td>3 (2.7)</td>
<td>1 (3.8)</td>
<td>2 (2.4)</td>
<td></td>
</tr>
</tbody>
</table>

Note that the percentages are based on denominators that vary from the overall sample size of 110 owing to missing data.

Table 3. Telemedicine-related characteristics of the patients included in the study (N=110).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total, n (%)</th>
<th>Low satisfaction (n=26), n (%)</th>
<th>High satisfaction (n=84), n (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Used telephone</td>
<td>107 (98.2)</td>
<td>26 (100)</td>
<td>81 (97.6)</td>
<td>.42</td>
</tr>
<tr>
<td><strong>Number of stroke prevention clinic home-based teleconsultations</strong></td>
<td></td>
<td></td>
<td></td>
<td>.74</td>
</tr>
<tr>
<td>Once only</td>
<td>52 (47.3)</td>
<td>13 (50)</td>
<td>39 (46.4)</td>
<td></td>
</tr>
<tr>
<td>2-4 times</td>
<td>50 (45.5)</td>
<td>12 (46.2)</td>
<td>38 (45.2)</td>
<td></td>
</tr>
<tr>
<td>≥5 times</td>
<td>8 (7.3)</td>
<td>1 (3.8)</td>
<td>7 (8.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Patient portal use before the COVID-19 pandemic</strong></td>
<td></td>
<td></td>
<td></td>
<td>.71</td>
</tr>
<tr>
<td>Never</td>
<td>94 (85.5)</td>
<td>23 (92)</td>
<td>71 (85.5)</td>
<td></td>
</tr>
<tr>
<td>1-2 times</td>
<td>10 (9.1)</td>
<td>2 (8)</td>
<td>8 (9.6)</td>
<td></td>
</tr>
<tr>
<td>3-5 times</td>
<td>3 (2.7)</td>
<td>0 (0)</td>
<td>3 (3.6)</td>
<td></td>
</tr>
<tr>
<td>≥5 times</td>
<td>1 (0.9)</td>
<td>0 (0)</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td><strong>Telemedicine use before the COVID-19 pandemic</strong></td>
<td></td>
<td></td>
<td></td>
<td>.35</td>
</tr>
<tr>
<td>Never</td>
<td>92 (83.6)</td>
<td>21 (80.8)</td>
<td>71 (86.6)</td>
<td></td>
</tr>
<tr>
<td>1-2 times</td>
<td>7 (6.4)</td>
<td>2 (7.7)</td>
<td>5 (6.1)</td>
<td></td>
</tr>
<tr>
<td>3-5 times</td>
<td>6 (5.5)</td>
<td>1 (3.8)</td>
<td>5 (6.1)</td>
<td></td>
</tr>
<tr>
<td>≥5 times</td>
<td>3 (2.7)</td>
<td>2 (7.7)</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Previsit contact by the stroke prevention clinic (no)</td>
<td>94 (85.5)</td>
<td>24 (92.3)</td>
<td>70 (85.4)</td>
<td>.36</td>
</tr>
<tr>
<td>Owned digital equipment at home (yes)</td>
<td>79 (71.8)</td>
<td>19 (73.1)</td>
<td>60 (72.3)</td>
<td>.94</td>
</tr>
</tbody>
</table>

Note that the percentages are based on denominators that vary from the overall sample size of 110 owing to missing data.
Findings From the Quantitative Analysis

Overall, the instrument was reliable as the Cronbach’s reliability analysis of the SERVPERF questionnaire was .894 (Multimedia Appendix 7), which indicated an excellent level of reliability of the instrument [39]. The adjusted $R^2$ value was 0.76, indicating that the 5 SERVPERF dimensions could explain 76% of the variation in the global satisfaction score. The mean global satisfaction score was 2.5 (SD 0.65) for the low-satisfaction group and 4.40 (SD 0.49) for the high-satisfaction group. To examine the explanatory variables that were significantly associated with the binary outcome variable, consent from the substitute decision maker (SDM), language barrier, age group, survey method, and 5 service dimensions were entered into the final forward stepwise logistic regression model. The adjusted $R^2$ indicated that 69% of the variance could be explained in the final model. Table 4 illustrates that consent from the SDM (adjusted odds ratio [AOR] 6.59, 95% CI 1.45-29.93; $P=.01$) was positively associated ($\beta=1.89$) and the responsiveness (AOR 0.03, 95% CI 0.006-0.188; $P<.001$) and empathy (AOR 0.12, 95% CI 0.02-0.80; $P=.03$) dimensions were negatively associated ($\beta=-3.37$ for responsiveness; $\beta=-2.15$ for empathy) with dissatisfaction with the home-based teleconsultation service quality (Table 4). The odds of dissatisfaction for participants who consented to the survey through their SDM were 6.59 (95% CI 1.45-29.93) compared with those who consented themselves. Every one-unit increase in the responsiveness dimension score decreased the odds of dissatisfaction by 0.03 (95% CI 0.006-0.19) when other variables were held constant. Every one-unit increase in the empathy dimension score decreased the odds of dissatisfaction by 0.12 (95% CI 0.02-0.80) when other variables were held constant.

Table 4. The forward stepwise binary logistic regression model.

<table>
<thead>
<tr>
<th>Variable</th>
<th>$\beta$ (SE)</th>
<th>P value</th>
<th>AOR$^a$ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consent from SDM$^b$</td>
<td>1.89 (0.772)</td>
<td>.01$^c$</td>
<td>6.59 (1.45-29.93)</td>
</tr>
<tr>
<td>Responsiveness$^d$</td>
<td>-3.37 (0.867)</td>
<td>&lt;.001$^e$</td>
<td>0.03 (0.006-0.19)</td>
</tr>
<tr>
<td>Empathy$^f$</td>
<td>-2.15 (0.986)</td>
<td>.03$^c$</td>
<td>0.12 (0.02-0.80)</td>
</tr>
</tbody>
</table>

$^a$AOR: adjusted odds ratio.  
$^b$SDM: substitute decision maker. Consent from SDM indicates that the survey was answered with the help of an SDM.  
$^cP<.05$.  
$^d$Responsiveness is a service performance model dimension regarding the willingness to help customers and provide a prompt service.  
$^eP<.001$.  
$^f$Empathy is a service performance model dimension regarding providing individual care and attention to customers.

The significant characteristics of the participants who had their SDM sign the consent form and help them answer the survey are listed in Table 5. The participants whose SDM provided consent to help them answer the survey were more likely to answer a web-based survey ($\chi^2=15.6; P<.001$) and have a language barrier ($\chi^2=15.6; P<.001$), hearing impairment ($\chi^2=3.9; P=0.48$), or hearing that affected telephone conversations ($\chi^2=5.6; P<0.02$) and were less likely to drive ($\chi^2=7.0; P=.04$). Tangibles was the only statistically significant SERVPERF dimension ($P<.001$). The participants who consented through their SDM had a shorter travel distance, were older, and were more likely to have residual stroke symptoms.
Table 5. Comparison of variables between surveys for which consent was obtained from the substitute decision maker (SDM) and surveys for which consent was obtained from the patient themselves (difference of >15%).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Consent from SDM (n=53)</th>
<th>Consent from patient (n=57)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web-based survey, n (%)</td>
<td>50 (94)</td>
<td>36 (63)</td>
<td>&lt;.001b</td>
</tr>
<tr>
<td>Age (y), mean (SD)</td>
<td>73.75 (13.085)</td>
<td>70.60 (10.61)</td>
<td>.17</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>34 (64)</td>
<td>27 (47)</td>
<td>.08</td>
</tr>
<tr>
<td>Distance (km), mean (SD)</td>
<td>15.897 (16.525)</td>
<td>19.435 (16.48)</td>
<td>.26</td>
</tr>
<tr>
<td>Driving, n (%)</td>
<td>27 (55)c</td>
<td>40 (74)d</td>
<td>.04e</td>
</tr>
<tr>
<td>Language barrier, n (%)</td>
<td>10 (19)</td>
<td>0 (0)</td>
<td>&lt;.001b</td>
</tr>
<tr>
<td>Hearing impaired, n (%)</td>
<td>18 (34)</td>
<td>10 (18)</td>
<td>.048</td>
</tr>
<tr>
<td>Hearing impairment affecting phone conversations, n (%)</td>
<td>12 (67)f</td>
<td>2 (20)g</td>
<td>.02e</td>
</tr>
<tr>
<td>Residual stroke symptoms, n (%)</td>
<td>17 (49)b</td>
<td>10 (28)i</td>
<td>.07</td>
</tr>
<tr>
<td>Tangibles, mean (SD)</td>
<td>3.21 (0.83)</td>
<td>3.67 (0.61)</td>
<td>&lt;.001b</td>
</tr>
<tr>
<td>Reliability, mean (SD)</td>
<td>3.87 (0.82)</td>
<td>3.94 (0.56)</td>
<td>.68</td>
</tr>
<tr>
<td>Responsiveness, mean (SD)</td>
<td>3.76 (0.94)</td>
<td>3.76 (0.59)</td>
<td>.98</td>
</tr>
<tr>
<td>Assurance, mean (SD)</td>
<td>3.99 (0.78)</td>
<td>4.04 (0.53)</td>
<td>.68</td>
</tr>
<tr>
<td>Empathy, mean (SD)</td>
<td>3.75 (0.71)</td>
<td>3.96 (0.56)</td>
<td>.34</td>
</tr>
</tbody>
</table>

aConsent from SDM indicates that the survey was answered with the help of an SDM.
bP<.001.
cN=49.
dN=54.
eP<.05.
fN=18.
gN=10.
hN=35.
iN=36.

Findings From the Content Analysis

Overview

A total of 88.2% (97/110) of patients completed the open-ended questions in the survey, with 25% (24/97) in the low-satisfaction group and 75% (73/97) in the high-satisfaction group. Multimedia Appendices 8 and 9 list the dimensions and subcategories of positive and negative comments among patients with low and high satisfaction scores, respectively. Interestingly, the low- and high-satisfaction groups shared the same dissatisfied service dimensions (assurance, reliability, and empathy) and subcategories. Overall, missing clinical components, inadequate communication, administrative issues, and absence of personal connection were the significant concerns that affected patients’ perceived home-based teleconsultation quality at the stroke prevention clinics.

In contrast, the most satisfying service dimensions were assurance, empathy, and responsiveness among the high-satisfaction group. Overall, a competent clinician with effective communication skills and great empathy for patients is crucial for patient-perceived high-quality care in home-based teleconsultation. In addition, convenience, appropriateness to the patient’s situation, and timely consultation were important for high satisfaction with home-based teleconsultation.

Future Use of Home-Based Teleconsultation

Assessment of patient preference for future use of home-based teleconsultation under normal circumstances (after the COVID-19 pandemic) showed that 35% (33/95) of participants preferred not to use home-based teleconsultation. Most participants (18/23, 78%) in the low-satisfaction group preferred not to use home-based teleconsultation. In contrast, 56% (40/72) of participants in the high-satisfaction group were willing to use it, and 24% (17/72) indicated that they might use home-based teleconsultation for specific reasons. However, a minority of participants in the high-satisfaction group (15/72, 21%) still refused to use it in normal circumstances, with primary concerns of communication issues, lack of personal connection, and the belief in the superiority of in-person consultations.

Discussion

Principal Findings

Home-based teleconsultation as a form of telemedicine rapidly expanded in many health sectors in Canada during the...
COVID-19 pandemic owing to lockdowns and social distancing restrictions [31]. Since the COVID-19 pandemic, home-based teleconsultation has become essential in outpatient service delivery [40]. By April 2020, 77% of Ontario ambulatory visits were conducted using teleconsultation, a total of 77% of ambulatory visits were conducted using a virtual modality [41]. Nearly all (32/33, 97%) Ontario stroke prevention clinics that responded to a province-wide survey from June 2021 to July 2021 (response rate of 33/41, 80%) reported that they had adopted home-based teleconsultation as a service delivery mode in addition to in-person visits since the COVID-19 pandemic [42]. Patient satisfaction should be the priority in future virtual care development and adoption [43]. To our knowledge, this is the first study to use a service quality theoretical lens to assess patient satisfaction with home-based teleconsultation in outpatient stroke care during the pandemic. Many studies of patient surveys during the COVID-19 pandemic have found that most patients and clinicians reported positive experiences with teleconsultation at outpatient neurology services during the COVID-19 pandemic [31]. However, no study has investigated outpatient stroke prevention services or examined the service quality of home-based teleconsultation during the COVID-19 pandemic. The patient population of stroke prevention clinics and the disease characteristics differ from those of other chronic neurological diseases. For instance, patients at stroke prevention clinics have a unique mix of acuity (such as early identification of large vessel occlusion and cardiac source of embolism) and chronic disease management (eg, hypertension, dyslipidemia, diabetes, and lifestyle management), and most are older adults. Owing to health resource disparity, timely access to outpatient magnetic resonance imaging is not always feasible for minor strokes. When referred to stroke prevention clinics, patients with TIA have transient neurological symptoms, unremarkable brain images, and normal physical examinations. History taking is essential in patients with TIA. The unique patient population and characteristics may pose different challenges in home-based teleconsultation, especially for newly referred patients. Our study found that the participants who were older (mean age 72.12, SD 11.92 years) and mostly newly referred (101/110, 91.8%) and used the telephone modality (107/109, 98.2%) were satisfied with the home-based teleconsultation provided by the stroke prevention clinics during the COVID-19 pandemic. We identified patient-reported factors that affected their satisfaction with the service quality of home-based teleconsultation. Our study filled these research gaps.

Responsiveness was the most statically significant dimension in our quantitative results and is an influential factor for a positive experience. Convenience was the main subtheme of the responsiveness dimension in the high-satisfaction group. The patients in the low-satisfaction group tended to live closer to the stroke prevention clinics, with an average distance of 13.53 (SD 11.57) km, than those in the high-satisfaction group (mean 19.03, SD 17.61 km). Even though they were less likely to drive and had some communication barriers (more likely to have language barriers or hearing impairments), convenience was not a positive factor influencing their satisfaction. Our content analysis supported that convenience, by saving time, travel, and energy, influenced patients’ positive perceptions of the personal benefits of home-based teleconsultation during the pandemic [31]. Our findings were consistent with those of studies conducted before the COVID-19 pandemic [44]. A systematic review of digital experience also found that convenience is one of the motivating factors contributing to a positive digital patient experience [45]. The convenience of home-based teleconsultation is an influential factor in swaying patients’ satisfaction with service quality to the positive side and their preference for teleconsultation [31]. However, convenience is not equivalent to good quality of care. We need to consider the effect of convenience when assessing patients’ preferences and evaluating patient satisfaction with the service quality of home-based teleconsultation.

Second, the empathy dimension was a significant factor in both the quantitative and qualitative analyses. Dissatisfaction feedback in the empathy dimension was found in both the low- and high-satisfaction groups. Our study participants used mostly the telephone modality, where the lack of nonverbal cues may be associated with a profound concern about the lack of personal connection, which is the primary subcategory of the empathy dimension. As indicated by existing studies, the replacement of interpersonal connection and a lack of physical human contact are negatively associated with digital patient experiences [45]. The literature shows that empathy can have powerful effects on positive patient outcomes and satisfaction [46,47]. There is a concern that the digitalization of health care services could primarily lead to a decrease in the expression of empathy [46]. A study on patient satisfaction with tele-obstetric care found that a desire for personal connection via face-to-face interaction with a clinician was a critical motivation for selecting in-person versus teleconsultation care modalities [48]. Our findings are in line with those of the previous literature. The lack of personal connection in our content analysis could explain the negative relationship between the empathy dimension and dissatisfaction. An interesting finding from our content analysis was that even 98% (81/83) of the participants in the high-satisfaction group used the telephone modality; they expressed overwhelmingly more positive than negative comments (34 vs 12) on the empathy dimension. The clinician’s empathy skills may significantly enhance patient experiences even with a low-technology modality. Empathy skill training for clinicians, primarily through computer-mediated communications, is a key area to study in the future [46].

Third, although the assurance dimension was not found to be statistically significant between the low- and high-satisfaction groups, this was likely due to no real difference between the 2 groups. Our content analysis indicated that the assurance dimension was one of the most important SERVPERF dimensions in both the low- and high-satisfaction groups. The subcategories raised from the content analysis revealed that the patients’ concerns in the assurance dimension were the missing clinical components—especially physical examination—and inadequate communication. The view of the inferior quality of a remote examination among clinicians was dominant in outpatient neurology teleconsultation before the COVID-19 pandemic [49]. This is likely why most teleconsultations were performed for follow-up patients with chronic neurological diseases before the COVID-19 pandemic [50]. Compared with
before the COVID-19 pandemic, home-based teleconsultation has been widely used in both new and follow-up patients at home without the luxury of having a health care professional assisting a teleconsultation since the COVID-19 pandemic [31]. The lack of a physical examination and inadequate communication could impede the clinician’s ability to diagnose and formulate a treatment plan, especially for new patients [31]. In addition, the use of video is more challenging than the use of a telephone because of the rapid adaptation and lack of preparation. According to the Ontario stroke prevention clinic web survey, nearly half of the clinics use only the telephone [42]. Video consultations enable a certain degree of remote examination and may facilitate better communication, whereas telephone-only visits limit clinical assessment and communication. Telephone consultations lack body language and physical prompts, which could negatively affect the communication between the clinician and patient. However, most of the participants in our study used telephone consultations (107/110, 97.3%), and their overall satisfaction was high (3.9/5). Future studies could consider patient satisfaction when using a telephone-only modality for new referrals in this patient population under normal circumstances.

The appropriateness of patient selection is a critical factor in high-quality home-based teleconsultation from patients’ perspectives. Our statistical findings indicated that patients who required help from their SDM to consent and answer the survey were positively associated with dissatisfaction. The SDM may have chosen a web survey, as the participants had difficulty answering a telephone survey because of language barriers, hearing impairments, or communication difficulties from residual stroke symptoms (such as aphasia, apraxia, or mild cognitive impairment; Table 5). Moreover, the patients who needed their SDM to consent and help them answer the survey scored significantly lower in the tangibles dimension, which may indicate that the participants had low comfort levels with technology and technical difficulties even with the telephone modality. The consent from an SDM has many unknown characteristics and requires further exploration in future research.

Similarly, the analysis showed that there were no statistically significant differences in the reliability dimension between the low- and high-satisfaction groups. However, it is important to note that issues primarily related to administration, which fall under the reliability dimension, had a negative impact on both the low- and high-satisfaction groups. This possibility aligns with findings from a scoping review that the lack of proper administrative support has harmed clinicians’ teleconsultation satisfaction [31]. Our findings indicate that it also negatively affects patient satisfaction. Some of the low satisfaction may be due to the abrupt change to teleconsultation because of the COVID-19 pandemic and the lack of clinical and patient preparation. We know that some administrative problems are not unique to home-based teleconsultation, as they occur during in-person visits. Home-based teleconsultation may have increased the workload by keeping pace with the transitioning workflow among telephone, video, and in-person visits, contributing to the maladaptation of home-based teleconsultation

[51]. Establishing a new care pathway for home-based teleconsultation may streamline the administrative workflow.

The assurance, empathy, and reliability dimensions all had the most negative comments in both the low- and high-satisfaction groups, and the high-satisfaction group had the most positive remarks in the assurance and empathy dimensions in the content analysis, which showed a double-edged effect. This finding might indicate that different key subcategories have buffer effects on improving patient satisfaction with the service quality of home-based teleconsultation. This may reflect the advantage of using both quantitative and qualitative data to provide diverse types of information [37]. By comparing them side by side, the qualitative analysis may provide insights to explain the quantitative findings.

**The Future of Stroke Prevention Clinics’ Service Delivery Mode**

A combination of teleconsultation and in-person visits for outpatient stroke prevention care is the future. Our study showed that 45% (43/95) of participants were willing to use and 18% (17/95) would consider using home-based teleconsultation in future nonpandemic conditions. A study examining patient preference for telehealth for nonemergent health issues after the COVID-19 pandemic concluded that patients were generally willing to use video but preferred in-person visits [52]. A patient-centered service should be delivered by offering the patient a choice [20]. Virtual care provides an opportunity to design a health system that is actually patient-centered [43]. A combination of in-person visits and home-based teleconsultation—a hybrid care model—could best meet patient needs by improving efficiency and capacity without added risk [53,54].

Hybrid care should be sustainable in practice settings to ensure patient care quality, equity, and justice [53]. To avoid increasing the digital divide, a telephone may be favorable instead of video calls for older patients and those with a lower education or income and from racial and ethnic minority groups [55]. However, we should refrain from creating a 2-tiered health care system in which high-income individuals receive video consultations and low-income individuals receive phone consultations. Patients should receive the right care in the right setting, at the right time, and with the right mode; the cost of the service should be reduced; and the best clinical practice guidelines should be followed [56]. Hybrid care could be a balanced approach to achieving a high-performance health care system. Patients can choose the best model by considering flexible options, and clinicians can offer individualized recommendations for optimal care modalities [54].

**Limitations**

Our study has several limitations. First, the cross-sectional survey only provides a snapshot of a phenomenon and cannot determine the temporal relationship between the dependent and independent variables. Second, the participants in this study may not be generalizable to patients of other stroke prevention clinics in Ontario, notably in areas with different health resources such as urban versus very remote rural centers. In addition, the open-ended responses to the web survey were very
brief, limiting our ability to gain a deeper understanding of their experiences. Next, as we surveyed patients who had had a home-based teleconsultation within 6 months, recall bias is possible [57]. Only patients who had a home-based teleconsultation in January 2021 and February 2021 received the survey 4 to 5 months later; the following patients received their survey 2 and a half months after the home-based teleconsultation on average (range 1-3 months). In addition, there is potential nonresponse bias, as web surveys usually have a low response rate [57]. A meta-analysis comparing web survey response rates concluded that the average response rate for web surveys was approximately 11% [58]. Our web survey had a 35.9% (104/290) response rate, and the telephone survey yielded a 44% (24/54) response rate.

Overall, although our study may only reflect part of the concept of satisfaction with service quality because of its complexity, it provided substantial insights into areas for quality improvements from patients’ point of view. The literature suggests that patient satisfaction is a multidimensional concept that still needs to be fully defined. The patient satisfaction scores may reflect the demographic mix and clinical and psychological picture of the patients served by a medical service [59]. Our study attempted to use a theory-guided quantitative and qualitative analysis to reveal the relationship and explanation of such a complex phenomenon. Despite the problems of using patient satisfaction to assess service quality, its measurement provides unique information regarding the care process as seen through the patients’ eyes [59]. Patients still provide the best source of accurate information on the care they receive [60]. In the absence of choice in public-funded health care, our survey gave patients a voice to indicate their preferences [21].

Conclusions

Our findings highlighted 2 crucial service quality dimensions (responsiveness and empathy) that were negatively statistically significantly associated with patient dissatisfaction. Moreover, we identified that a survey consented to by an SDM was positively associated with dissatisfaction. In addition, there were 4 subcategories related to patient dissatisfaction (missing clinical activities, inadequate communication, administrative process issues, and absence of personal connection). We anticipate that appropriate patient selection, consideration of patient preferences, a streamlined home-based teleconsultation administrative workflow, and a competent clinician with communication and empathy skills are essential for achieving high satisfaction with home-based teleconsultation. These factors could be considered when designing home-based teleconsultation services to enhance patient experiences of stroke prevention care.

Acknowledgments

This work was supported by 2 stroke prevention clinics. The authors acknowledge especially Dr Courtney Scott, a neurologist, for helping with patient recruitment and Lorri Reynold, the director of Patient Experience, Professional Practice, and Research, for arranging personnel for patient recruitment. This work was also supported by the University of Waterloo, especially by Gaya Bin Noon, a master’s student at the School of Public Health Sciences of the University of Waterloo, who served as the research assistant for this study.

Data Availability

Data are available upon request from the authors.

Conflicts of Interest

GM is a clinical practitioner in one of the stroke prevention clinics but was not involved in patient contact during the research, including the recruitment and telephone interview processes.

Multimedia Appendix 1
Survey consent sheet for participants.
[DOCX File, 26 KB - cardio_v8i1e51439_app1.docx ]

Multimedia Appendix 2
Cover letter for mail-in package.
[DOCX File, 19 KB - cardio_v8i1e51439_app2.docx ]

Multimedia Appendix 3
The description of 18 items used in the service performance model questionnaire.
[DOCX File, 13 KB - cardio_v8i1e51439_app3.docx ]

Multimedia Appendix 4
[DOCX File, 24 KB - cardio_v8i1e51439_app4.docx ]
Multimedia Appendix 5
Six questions to check the clarity of the survey questions.
[DOCX File , 13 KB - cardio_v8i1e51439_app5.docx ]

Multimedia Appendix 6
Definitions of 10 demographic, 7 clinical, and 6 technical-related independent variables.
[DOCX File , 14 KB - cardio_v8i1e51439_app6.docx ]

Multimedia Appendix 7
Cronbach α reliability statistics and item-total statistics of the service performance model questionnaire.
[DOCX File , 14 KB - cardio_v8i1e51439_app7.docx ]

Multimedia Appendix 8
Positive and negative categories among patients with low global satisfaction.
[DOCX File , 17 KB - cardio_v8i1e51439_app8.docx ]

Multimedia Appendix 9
Positive and negative categories among patients with high global satisfaction.
[DOCX File , 18 KB - cardio_v8i1e51439_app9.docx ]

References


44. Fleischhacker CL. Patient satisfaction with telehealth services compared to in-office visits: a systematic literature review. Minnesota State University. 2020. URL: https://corncr.chnsn.edu/etds/982/ [accessed 2023-07-21]


**Abbreviations**

AOR: adjusted odds ratio  
REDCap: Research Electronic Data Capture  
SDM: substitute decision maker  
SERVPERF: service performance model  
SERVQUAL: service quality model  
TIA: transient ischemic attack
A Multidisciplinary Assessment of ChatGPT’s Knowledge of Amyloidosis: Observational Study

Ryan C King1, MD; Jamil S Samaan2, MD; Yee Hui Yeo2, MSc, MD; Yuxin Peng3, BS; David C Kunkel4, MD; Ali A Habib5, MD; Roxana Ghashghaei1, MD

1Division of Cardiology, Department of Medicine, University of California, Irvine Medical Center, Orange, CA, United States
2Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
3School of Mathematics and Statistics, Xi’an Jiaotong University, Xi’an, China
4GI Motility and Physiology Program, Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States
5Division of Neurology, University of California, Irvine Medical Center, Orange, CA, United States

Abstract

Background: Amyloidosis, a rare multisystem condition, often requires complex, multidisciplinary care. Its low prevalence underscores the importance of efforts to ensure the availability of high-quality patient education materials for better outcomes. ChatGPT (OpenAI) is a large language model powered by artificial intelligence that offers a potential avenue for disseminating accurate, reliable, and accessible educational resources for both patients and providers. Its user-friendly interface, engaging conversational responses, and the capability for users to ask follow-up questions make it a promising future tool in delivering accurate and tailored information to patients.

Objective: We performed a multidisciplinary assessment of the accuracy, reproducibility, and readability of ChatGPT in answering questions related to amyloidosis.

Methods: In total, 98 amyloidosis questions related to cardiology, gastroenterology, and neurology were curated from medical societies, institutions, and amyloidosis Facebook support groups and inputted into ChatGPT-3.5 and ChatGPT-4. Cardiology- and gastroenterology-related responses were independently graded by a board-certified cardiologist and gastroenterologist, respectively, who specialize in amyloidosis. These 2 reviewers (RG and DCK) also graded general questions for which disagreements were resolved with discussion. Neurology-related responses were graded by a board-certified neurologist (AAH) who specializes in amyloidosis. Reviewers used the following grading scale: (1) comprehensive, (2) correct but inadequate, (3) some correct and some incorrect, and (4) completely incorrect. Questions were stratified by categories for further analysis. Reproducibility was assessed by inputting each question twice into each model. The readability of ChatGPT-4 responses was also evaluated using the Textstat library in Python (Python Software Foundation) and the Textstat readability package in R software (R Foundation for Statistical Computing).

Results: ChatGPT-4 (n=98) provided 93 (95%) responses with accurate information, and 82 (84%) were comprehensive. ChatGPT-3.5 (n=83) provided 74 (89%) responses with accurate information, and 66 (79%) were comprehensive. When examined by question category, ChatGTP-4 and ChatGPT-3.5 provided 53 (95%) and 48 (86%) comprehensive responses, respectively, to “general questions” (n=56). When examined by subject, ChatGPT-4 and ChatGPT-3.5 performed best in response to cardiology questions (n=12) with both models producing 10 (83%) comprehensive responses. For gastroenterology (n=15), ChatGPT-4 received comprehensive grades for 9 (60%) responses, and ChatGPT-3.5 provided 8 (53%) responses. Overall, 96 of 98 (98%) responses for ChatGPT-4 and 73 of 83 (88%) for ChatGPT-3.5 were reproducible. The readability of ChatGPT-4’s responses ranged from 10th to beyond graduate US grade levels with an average of 15.5 (SD 1.9).
Conclusions: Large language models are a promising tool for accurate and reliable health information for patients living with amyloidosis. However, ChatGPT’s responses exceeded the American Medical Association’s recommended fifth- to sixth-grade reading level. Future studies focusing on improving response accuracy and readability are warranted. Prior to widespread implementation, the technology’s limitations and ethical implications must be further explored to ensure patient safety and equitable implementation.

(JMIR Cardio 2024;8:e53421) doi:10.2196/53421

KEYWORDS
amyloidosis; ChatGPT; large language models; cardiology; gastroenterology; neurology; artificial intelligence; multidisciplinary care; assessment; patient education; large language model; accuracy; reliability; accessibility; educational resources; dissemination; gastroenterologist; cardiologist; medical society; institution; institutions; Facebook; neurologist; reproducibility; amyloidosis-related

Introduction

Background
Amyloidosis is a rare, multisystem disease that comprises several subtypes including secondary amyloidosis, light chain amyloidosis, and ATTR (transthyretin amyloidosis), with the latter 2 being the most common but often underdiagnosed [1]. Light chain amyloidosis is diagnosed in 2500 to 5000 individuals annually in the United States, while the exact incidence of ATTR and secondary amyloidosis remains unknown due to challenges and delays in diagnosis stemming from a broad range of symptoms affecting multiple organ systems [2,3]. Diagnosing and caring for patients living with amyloidosis necessitate effective multidisciplinary collaboration between specialists in fields including but not limited to cardiology, gastroenterology, and neurology [4].

Due to amyloidosis being a rare disease, patients may be at risk for decreased health literacy regarding their condition. A notable scarcity of patient education materials (PEMs) exists for rare diseases compared to common ones, with one study showing nearly a 10-fold difference in the availability of PEMs related to rare diseases, which has been shown to adversely affect health outcomes [5]. According to the Centers for Disease Control and Prevention [6], improved health literacy could prevent up to 1 million hospitalizations annually and save US $25 billion in total health care costs.

ChatGPT (OpenAI), a large language model (LLM) powered by artificial intelligence released in late 2022, may be a powerful tool for improving the availability of accurate and readable information for rare and complex diseases like amyloidosis. Unlike traditional search engines, ChatGPT generates human-like text in a conversational format through an intuitive user interface. This is achieved with reinforcement learning from human feedback, wherein the model’s responses are refined through feedback loops to optimize responses [7]. With ongoing improvement and training using an extensive data set spanning diverse topics including medicine, ChatGPT’s accuracy and reliability in answering questions are expected to improve.

Prior Work
Prior studies have demonstrated ChatGPT’s impressive accuracy and reliability in answering clinical questions across multiple medical specialties [8-10]. One study found the model’s generated responses were significantly higher in both quality and empathy compared to physicians when answering medical questions posted to social media, further bolstering the dynamic nature of this technology [11]. In March 2023, ChatGPT-4, the successor to ChatGPT-3.5, was released and has demonstrated superior performance in answering clinical questions across multiple fields of medicine [12-15]. In addition to accuracy and reliability, the readability of ChatGPT’s responses is an active area of investigation. Several studies related to ophthalmology and endocrinology have revealed that responses by ChatGPT-4 often exceed the fifth- to sixth-grade reading level recommended by the American Medical Association (AMA) [16-18]. While the literature examining LLM responses to clinical questions is growing, studies examining rare diseases are limited. Furthermore, there are currently no studies examining ChatGPT’s ability in answering questions related to amyloidosis.

Aims of This Study
As with any emerging technology, rigorous evaluation of these models’ capabilities and limitations is essential to ensuring effective and safe implementation during their nascent stages before broad adoption by patients and providers. This study aims to build upon previous literature by using a multidisciplinary approach in assessing ChatGPT’s (1) accuracy in answering questions related to amyloidosis, particularly concerning cardiology, gastroenterology, and neurology; (2) reproducibility of responses; (3) readability; and (4) comparison of performance between ChatGPT-4 and ChatGPT-3.5.

Methods

Question Curation
A total of 98 amyloidosis-related questions were sourced from the frequently asked questions section of websites for professional medical societies and institutions. Questions from amyloidosis Facebook support groups were also incorporated to represent a more comprehensive patient perspective. Of these questions, 56 addressed general amyloidosis topics, while 42 were specific to cardiology (n=12), gastroenterology (n=15), and neurology (n=15). Each question was inputted twice into ChatGPT-4 (version updated on March 14, 2023) and ChatGPT-3.5 (version updated on February 9, 2023) except for neurology-related questions, which were only inputted into ChatGPT-4 due to reviewer availability. At the time of data collection, ChatGPT-4 required a paid monthly subscription. Furthermore, the models were without internet access, and their training data were limited to information prior to September 2021.

https://cardio.jmir.org/2024/1/e53421
Accuracy and Reproducibility

The accuracy of responses was assessed using the scale: (1) comprehensive, (2) correct but inadequate, (3) some correct and some incorrect, and (4) completely incorrect. Reproducibility was evaluated by categorizing each of the 2 responses of each question into those containing either no incorrect information (comprehensive and correct but inadequate) or those with incorrect information (some correct and some incorrect and completely incorrect). Questions that produced responses in different grading categories were deemed nonreproducible. Two independent reviewers (RG and DCK), board-certified in cardiology and gastroenterology with expertise in amyloidosis, assessed general amyloidosis questions and those of their respective specialties. Discrepancies in general question grading were resolved through discussion to reach a consensus. An additional reviewer (AAH), board-certified in neurology and specializing in amyloidosis, graded the neurology-specific responses for ChatGPT-4.

Readability

The readability of ChatGPT-4’s responses was also assessed using the Textstat library in Python (Python Software Foundation) and the Textstat readability package in R software (R Foundation for Statistical Computing). The readability level was quantified either as a readability index or by using a predicted grade level, the latter indicating the US educational grade, at which the responses are comprehensible.

Statistical Analysis

Categorical variables were presented as counts and percentages, while continuous variables were presented as means and SDs. Bivariate analysis consisted of Fisher exact test for categorical variables. Microsoft Excel (version 16.68; Microsoft Corp) was used for all statistical analysis.

Ethical Considerations

Since all responses and outputs from ChatGPT were publicly available, approval from the institutional review board was not sought, and no informed consent was required.

Results

In this study, ChatGPT’s responses were predominantly correct and also comprehensive (Table 1). Specifically, ChatGPT-4 (n=98) provided correct answers in 93 (95%) instances, with a notable 82 (84%) being graded as comprehensive. ChatGPT-3.5 (n=83) also performed well, delivering correct answers for 74 (89%) cases and comprehensive responses in 66 (79%) cases.
Table 1. Accuracy of responses by ChatGPT-3.5 and ChatGPT-4 to amyloidosis-related questions stratified by question subgroup.

<table>
<thead>
<tr>
<th>Question subgroup</th>
<th>ChatGPT-3.5</th>
<th>ChatGPT-4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall (n=83 for Chat GPT-3.5 and n=98 for Chat GPT-4)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>66 (79)</td>
<td>82 (84)</td>
</tr>
<tr>
<td>Correct but inadequate</td>
<td>8 (10)</td>
<td>11 (11)</td>
</tr>
<tr>
<td>Some correct and some incorrect</td>
<td>8 (10)</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Completely incorrect</td>
<td>1 (1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>General questions (n=56)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>48 (86)</td>
<td>53 (95)</td>
</tr>
<tr>
<td>Correct but inadequate</td>
<td>4 (7)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Some correct and some incorrect</td>
<td>4 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Completely incorrect</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Cardiology questions (n=12)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>10 (83)</td>
<td>10 (83)</td>
</tr>
<tr>
<td>Correct but inadequate</td>
<td>0 (0)</td>
<td>2 (17)</td>
</tr>
<tr>
<td>Some correct and some incorrect</td>
<td>2 (17)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Completely incorrect</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Gastroenterology questions (n=15)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>8 (53)</td>
<td>9 (60)</td>
</tr>
<tr>
<td>Correct but inadequate</td>
<td>4 (27)</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Some correct and some incorrect</td>
<td>2 (13)</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Completely incorrect</td>
<td>1 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Neurology questions (n=15)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>—a</td>
<td>10 (67)</td>
</tr>
<tr>
<td>Correct but inadequate</td>
<td>—</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Some correct and some incorrect</td>
<td>—</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Completely incorrect</td>
<td>—</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*aNot available.

When stratified by question category, both ChatGPT-4 and ChatGPT-3.5 excelled in general topics (n=56), where 53 (95%) and 48 (86%) of their responses, respectively, were comprehensive, though this difference was not statistically significant (P=.12). For cardiology, ChatGPT-4 was particularly accurate, correctly answering all 12 questions compared to ChatGPT-3.5’s 10 (83%) responses (P=.48). In gastroenterology (n=15), both models produced correct responses for 80% (n=12) of questions. However, their comprehensiveness varied slightly with ChatGPT-3.5 at 8 (53%) and ChatGPT-4 at 9 (60%). In neurology (n=15), ChatGPT-4’s responses were graded as comprehensive for 10 (67%).

Overall, ChatGPT-3.5 and ChatGPT-4 generated incorrect information in 9 of 83 (11%) and 5 of 98 (5%) responses, respectively. Notably, ChatGPT-3.5 produced 1 “completely incorrect” response regarding amyloidosis treatment of the gastrointestinal tract, involving the recommendation of probiotics and digestive enzymes (Multimedia Appendix 1). An example of a “some correct and some incorrect” response from ChatGPT-3.5 related to the management of atrial fibrillation in patients with amyloidosis. The model correctly described similar rate control and anticoagulation strategies for patients with amyloidosis having atrial fibrillation compared to those without amyloidosis but understated the prevalence of atrial fibrillation in ATTR. ChatGPT-4, on the other hand, did not produce any completely incorrect responses but did provide a response categorized as “correct but inadequate” by omitting autonomic symptoms in amyloidosis-related neuropathy. Regarding reproducibility, ChatGPT-4 showed a higher rate of 96 of 98 (98%) reproducible responses compared to 73 of 83 (88%) for ChatGPT-3.5 (Table 2).
Table 2. Reproducibility of responses by ChatGPT-3.5 and ChatGPT-4 to amyloidosis-related questions categorized by question subgroup.

<table>
<thead>
<tr>
<th>Question subgroup</th>
<th>Responses, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ChatGPT-3.5</td>
</tr>
<tr>
<td>Overall (n=83 for ChatGPT-3.5 and n=98 for ChatGPT-4)</td>
<td>73 (88)</td>
</tr>
<tr>
<td>General (n=56)</td>
<td>49 (88)</td>
</tr>
<tr>
<td>Cardiology (n=12)</td>
<td>10 (83)</td>
</tr>
<tr>
<td>Gastroenterology (n=15)</td>
<td>14 (93)</td>
</tr>
<tr>
<td>Neurology (n=15)</td>
<td></td>
</tr>
</tbody>
</table>

*Not available.

In terms of readability, ChatGPT-4’s responses varied but were consistently well above the AMA’s recommended fifth- to sixth-grade reading level. The Flesch–Kincaid Grade Level scale rated them between a high school sophomore and a graduate level, averaging at a college level (mean 15.5, SD 1.9; range 10.3-21.7; Table 3). The Flesch Reading Ease scores, on a scale of 0 to 100, averaged at 23.3 (SD 9.4), indicating a college graduate level of complexity. Additional readability metrics showed a broad range of scores, all with similar advanced reading levels: Simple Measure of Gobbledygook (range 12.8-20.2), Gunning Fog Index (range 14.3-24.2), Coleman-Liau Index (range 10.5-18.3), Automated Readability Index (range 9.9-24.3), FORCAST Grade Level (range 10.3-13.4), and Powers Sumner Kearl Grade (range 6.8-9.4).

Table 3. Readability of responses by ChatGPT-4 to amyloidosis-related questions.

<table>
<thead>
<tr>
<th>Readability metric</th>
<th>Score, mean (SD)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flesch Reading Ease</td>
<td>23.3 (9.4)</td>
<td>5.6-47.9</td>
</tr>
<tr>
<td>Flesch-Kincaid Grade Level</td>
<td>15.5 (1.9)</td>
<td>10.3-21.7</td>
</tr>
<tr>
<td>Simple Measure of Gobbledygook</td>
<td>16.7 (1.6)</td>
<td>12.8-20.2</td>
</tr>
<tr>
<td>Gunning Fog Index</td>
<td>19.1 (2.3)</td>
<td>14.3-24.2</td>
</tr>
<tr>
<td>Coleman-Liau Index</td>
<td>15.3 (1.4)</td>
<td>10.5-18.3</td>
</tr>
<tr>
<td>Automated Readability Index</td>
<td>15.6 (2.1)</td>
<td>9.9-24.3</td>
</tr>
<tr>
<td>FORCAST Grade Level</td>
<td>12.1 (0.53)</td>
<td>10.3-13.4</td>
</tr>
<tr>
<td>Powers Sumner Kearl Grade</td>
<td>8.2 (0.55)</td>
<td>6.8-9.4</td>
</tr>
</tbody>
</table>

Discussion

Principal Results

Literature examining ChatGPT’s knowledge regarding rare diseases, such as amyloidosis, is limited compared to that of more prevalent health conditions. In this study, we employed an interdisciplinary panel of amyloidosis experts from cardiology, gastroenterology, and neurology to evaluate the accuracy and reproducibility of ChatGPT-4’s and ChatGPT-3.5’s responses to amyloidosis-related questions. Furthermore, the readability of responses by ChatGPT-4 was examined. ChatGPT-4 and ChatGPT-3.5 produced comprehensive responses to 53 (95%) and 48 (86%) general questions, respectively. Incorrect information was found in 5 of 98 (5%) and 9 of 83 (11%) responses from ChatGPT-4 and ChatGPT-3.5, respectively (P=.17), with 1 of 83 (1%) ChatGPT-3.5 responses graded as completely incorrect. The models also provided high reproducibility in accuracy of responses overall, with ChatGPT-4 and ChatGPT-3.5 generating 96 of 98 (98%) and 73 of 83 (88%) reproducible responses, respectively. However, the readability of ChatGPT-4’s responses exceeded the AMA’s recommended fifth- to sixth-grade reading level for PEMs, with readability at a college reading level on average.

Comparison With Prior Work

Previous studies have shown ChatGPT’s impressive knowledge when assessing both common and rare diseases. The model has displayed extensive knowledge regarding cardiovascular disease prevention [8]. In more intricate scenarios such as clinical vignettes describing atrial fibrillation, congenital heart disease, and heart failure, its answers were assessed as predominantly reliable, valuable for patients, and crucially, not hazardous. Interestingly, many of these responses were favored over those generated by a standard Google search [19]. Similar results have been shown in several studies involving gastrointestinal-related topics such as cirrhosis, hepatocellular carcinoma, and bariatric surgery [9,10], with ChatGPT-4 demonstrating a significant improvement in knowledge compared to ChatGPT-3.5 [12,15]. Mehnen et al [13] demonstrated superior diagnostic precision of rare diseases by ChatGPT-4 compared to ChatGPT-3.5 as well. Our results showed comparable overall accuracy and reproducibility to previous studies, with both models generating consistent and reliable information. Although not meeting the level of significance as seen in prior research, ChatGPT-4 did generate fewer responses with incorrect information than ChatGPT-3.5 in this study.
The superior performance of ChatGPT-4 in prior studies may stem from multiple factors inherent to the design of each model. ChatGPT-4 was trained on a larger body of information, potentially exposing the model to a wider range of medical information. ChatGPT-4 has been reported to possess more advanced reasoning capabilities, allowing the model to better formulate explanations tailored to the input provided. Finally, the training of ChatGPT-4 may have provided the model with an advantage [14].

**Limitations of ChatGPT**

ChatGPT holds the potential to enhance clinical practice in the context of amyloidosis, but notable limitations exist. Chief among these is the undisclosed origin of ChatGPT’s primary training data set, paired with its inability to regularly provide citations for its responses. Directly referencing established medical sources would bolster its clinical credibility. Moreover, ChatGPT sometimes produces responses referred to as “hallucinations,” which are confident sounding, yet completely incorrect answers. The data set’s scope is further limited to information prior to September 2021 [7]. The quality of responses generated by ChatGPT is affected by the nature of the prompts inputted by the user. Prompt engineering has been shown to significantly alter the models’ output both in quality and comprehensiveness. Future studies would benefit from including the testing of different prompts and their effect on response output in the context of amyloidosis. Furthermore, concerted efforts in increasing patient and provider knowledge regarding prompt engineering may better facilitate the future effective use of these models. This study highlights the need for improvements in response readability to ensure equitable use of this technology across all patient populations. Similarly, other studies involving hypothyroidism in the setting of pregnancy and retinal surgery have also noted ChatGPT to produce information at a college reading level and beyond [17,18]. Furthermore, the majority of studies in the literature have examined the model’s performance in English, with a limited body of literature examining non-English languages [20-22]. More studies are needed to ensure the optimization of model performance across a wide range of languages.

**Ethical Implications**

Beyond model-specific challenges, ethical issues remain unresolved. Potential biases introduced during training could skew user outputs. Clinical research bias, such as the overrepresentation of White populations [23], might also persist within the model. There is a growing body of literature examining implicit bias in responses from LLMs with conflicting results [24-26]. Equitable access is another concern; lower socioeconomic groups might face barriers in accessing such technology due to hardware and internet constraints. Privacy is a further point of contention, though OpenAI’s option to disable chat history storage addresses some concerns [27]. Regulatory oversight, as suggested by the Food and Drug Administration, is paramount. The proposed regulation would align artificial intelligence health care tools with medical device standards, emphasizing repeated validation and testing at each stage of development [28]. Additionally, physician panels should advise technical developers, ensuring patient safety and prioritizing equitable, outcome-driven patient care.

**Strengths and Limitations of This Study**

This study’s strengths include being among the first in using a multidisciplinary approach to evaluate ChatGPT’s knowledge of amyloidosis. This holistic approach enabled a thorough assessment of ChatGPT’s abilities in addressing clinical queries related to amyloidosis, a rare disease necessitating advancements in health education, diagnostics, and management for improved patient outcomes. However, this study is not without its limitations. We relied on a single physician reviewer for specialty-specific responses, which is subjective and prone to bias. Research could bolster validity by engaging multiple reviewers within each specialty to minimize the potential for subjective bias. It would also be beneficial to include physicians specializing in hematology, oncology, and nephrology as reviewers due to their integral involvement in caring for patients with amyloidosis. Furthermore, we recommend including patients and all members of the health care team when reviewing the quality of responses. While we took a systematic approach when curating questions, our list may not comprehensively represent all potential patient questions related to amyloidosis.

**Conclusions**

ChatGPT delivered accurate and reliable responses to amyloidosis-related questions across general and specialty-specific questions. ChatGPT has the potential to serve as a supplemental tool in disseminating vital health education to patients in the future. However, the presence of some incorrect responses underscores the necessity of continued improvements and fine-tuning of future iterations prior to incorporation into clinical practice. Furthermore, improvement in the readability of responses is essential to ensuring equal access to this technology by all patients. We advocate for the use of this technology as an adjunct and not a replacement to care and advice provided by licensed health care professionals. In its current state, there are also limitations and ethical concerns that need to be resolved before the technology may be widely implemented in health care in a safe and equitable manner.

**Acknowledgments**

ChatGPT-4, the version updated on March 14, 2023, by OpenAI was used in the final editing process of this paper to improve readability.

**Data Availability**

The data sets generated and analyzed during this study are available from the corresponding author on reasonable request.
Conflicts of Interest

RG is a consultant for Pfizer, Alnylam, and AstraZeneca. None of the other authors have interests to disclose.

Multimedia Appendix 1
Examples of prompts with corresponding ChatGPT responses and reviewer accuracy grades.

References


Abbreviations
AMA: American Medical Association
ATTR: transthyretin amyloidosis
LLM: large language model
PEM: patient education material
Use of Machine Learning for Early Detection of Maternal Cardiovascular Conditions: Retrospective Study Using Electronic Health Record Data

Nawar Shara¹,², PhD; Roxanne Mirabal-Beltran³, PhD; Bethany Talmadge⁴, BS; Noor Falah¹, MS; Maryam Ahmad¹, BS; Ramon Dempers², MS; Samantha Crowatt⁴, BS; Steven Eisenberg⁴, MD; Kelley Anderson³, PhD

¹MedStar Health Research Institute, Hyattsville, MD, United States
²Georgetown-Howard Universities Center for Clinical and Translational Science, Washington, DC, DC, United States
³School of Nursing, Georgetown University, Washington, DC, United States
⁴Invarynt Inc, Roswell, GA, United States

Corresponding Author:
Roxanne Mirabal-Beltran, PhD
School of Nursing
Georgetown University
3700 Reservoir Road, NW
Washington, DC, 20057
United States
Phone: 1 2026873496
Email: rm1910@georgetown.edu

Abstract

Background: Cardiovascular conditions (eg, cardiac and coronary conditions, hypertensive disorders of pregnancy, and cardiomyopathies) were the leading cause of maternal mortality between 2017 and 2019. The United States has the highest maternal mortality rate of any high-income nation, disproportionately impacting those who identify as non-Hispanic Black or Hispanic. Novel clinical approaches to the detection and diagnosis of cardiovascular conditions are therefore imperative. Emerging research is demonstrating that machine learning (ML) is a promising tool for detecting patients at increased risk for hypertensive disorders during pregnancy. However, additional studies are required to determine how integrating ML and big data, such as electronic health records (EHRs), can improve the identification of obstetric patients at higher risk of cardiovascular conditions.

Objective: This study aimed to evaluate the capability and timing of a proprietary ML algorithm, Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology (HOPE-CAT), to detect maternal-related cardiovascular conditions and outcomes.

Methods: Retrospective data from the EHRs of a large health care system were investigated by HOPE-CAT in a virtual server environment. Deidentification of EHR data and standardization enabled HOPE-CAT to analyze data without pre-existing biases. The ML algorithm assessed risk factors selected by clinical experts in cardio-obstetrics, and the algorithm was iteratively trained using relevant literature and current standards of risk identification. After refinement of the algorithm’s learned risk factors, risk profiles were generated for every patient including a designation of standard versus high risk. The profiles were individually paired with clinical outcomes pertaining to cardiovascular pregnancy conditions and complications, wherein a delta was calculated between the date of the risk profile and the actual diagnosis or intervention in the EHR.

Results: In total, 604 pregnancies resulting in birth had records or diagnoses that could be compared against the risk profile; the majority of patients identified as Black (n=482, 79.8%) and aged between 21 and 34 years (n=509, 84.4%). Preeclampsia (n=547, 90.6%) was the most common condition, followed by thromboembolism (n=16, 2.7%) and acute kidney disease or failure (n=13, 2.2%). The average delta was 56.8 (SD 69.7) days between the identification of risk factors by HOPE-CAT and the first date of diagnosis or intervention of a related condition reported in the EHR. HOPE-CAT showed the strongest performance in early risk detection of myocardial infarction at a delta of 65.7 (SD 81.4) days.

Conclusions: This study provides additional evidence to support ML in obstetrical patients to enhance the early detection of cardiovascular conditions during pregnancy. ML can synthesize multiday patient presentations to enhance provider decision-making and potentially reduce maternal health disparities.
Introduction

All other high-income nations in the world have substantially lower maternal mortality rates compared to the United States [1]. Maternal mortality rates in the United States have increased over the past 30 years [1,2], increasing approximately 85% between 2018 and 2021 [3]. There were 23.8 and 32.9 maternal deaths in the US per 100,000 live births in 2020 and 2021, respectively [4], and although the United States has one of the highest health care spending rates [5], the projected trends of maternal mortality are anticipated to continue to rise. Racial and ethnic disparities in maternal mortality rates have not only persisted, but differences in rates have widened. Non-Hispanic Black (Black) women are significantly more likely to die of pregnancy-related causes than non-Hispanic White (White) women (69.9 and 26.6 deaths per 100,000 live births, respectively) [4]. Cardiovascular conditions (eg, cardiac and coronary conditions, hypertensive disorders of pregnancy, and cardiomyopathies) were the leading cause of maternal mortality between 2017 and 2019 (27.8%) [6]. Black women have higher rates of cardiovascular morbidity and mortality than women of other races and ethnicities [7].

Programs across the United States are integrating technology to mitigate increasing maternal mortality rates, and there is a growing body of literature reporting the use of machine learning (ML) to identify patients at increased risk for hypertensive disorders in pregnancy [8,9]. Hoffman et al [8] used ML to accurately predict maternal readmission due to the complications of hypertensive disorders. ML models have also shown promising results for predicting maternal risk of hypertensive disorders of pregnancy and other cardiovascular conditions [10-12], including improved prediction accuracy when gestational age, epidemiology, hemodynamics, and biochemistry data are incorporated [9]. However, a fundamental gap remains to identify pregnant individuals at higher risk of morbidity and mortality using the power of ML and big data including electronic health records (EHRs). Therefore, this study evaluated ML technology, specifically Invaryant’s Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology (HOPE-CAT), applied to a large health care system database, to enable early and effective risk identification of cardiovascular conditions associated with complications in pregnancy, including maternal morbidity and mortality.

Methods

Overview

This study was conducted using retrospective data of 32,409 obstetric patients sourced from the EHR of a large, US-based health care system with a documented birth between January 1, 2017, and December 31, 2020. This timeline was chosen to capture as many pregnancies as possible while considering factors related to when various EHR systems within MedStar Health were implemented.

Sample

For this study, patients were selected if they met inclusion criteria: patients between the ages of 18 and 40 years at the time of the index pregnancy–related visit and who had more than 1 pregnancy-related medical encounter. To ensure the richness of the data and adequate data points to test the ability of HOPE-CAT to assess a diagnosed condition in the EHR, patients were excluded if they had limited EHR data or a single pregnancy–related medical encounter (n=11,485) and if the initial encounter within the EHR was a birth with no corresponding pregnancy data (n=14,855). This resulted in a sample of 6069 patients for analysis.

HOPE-CAT

The ML risk assessment algorithm, HOPE-CAT, was trained via causal inference to analyze patient data and identify factors associated with the development of conditions leading to complications during pregnancy and postbirth. Clinical criteria were designated by clinical experts based on relevant literature and current standards in evaluating risk during pregnancy. Following an iterative training process, using anonymized EHRs, patient records were reviewed by HOPE-CAT on a simulated encounter-by-encounter basis. HOPE-CAT then surfaced and refined the most frequent indicators of risk within this patient population. Data analysis then validated findings against relevant data, and clinical experts then reviewed the training results and made necessary adjustments before final manual testing was conducted, and HOPE-CAT was deployed for this study. The risk factors assessed by HOPE-CAT are divided into 2 categories—static and variable (Textbox 1). Static risk factors are defined as those characteristics that do not change or change infrequently such as race, ethnicity, age, medical history, and family history. Variable risk factors are defined as characteristics that change more frequently, such as blood pressure, heart rate, and symptoms such as headache and shortness of breath.

Risk profiles were generated by patient encounters and included basic patient demographics (eg, patient ID number, age at visit, and race) and any surfaced risk factors (Textbox 1) that were noted in the patient’s record at the time of appointment. HOPE-CAT generated 2 types of risk profiles that quantify the risk factors recorded or identified in each visit: standard and high risk. High-risk, or red flag, profiles are defined as specific severe indicators or having 4 or more signs of risk present in a single encounter. Severe indicators that trigger a red flag, indicating greater risk compared to other parameters, include resting heart rate ≥120 bpm, systolic blood pressure ≥160 mm Hg, respiratory rate ≥30, oxygen saturation ≤94%, dyspnea, and orthopnea.
With this study, we primarily focused on validating the ability of the ML algorithm (HOPE-CAT) to identify pregnant individuals at high risk of cardiovascular disease within a retrospective data set. Therefore, the study design prioritized tracing outcomes for individuals flagged by the algorithm to assess its accuracy in predicting risk compared to diagnoses documented in medical records. For more extensive technical detail related to the development of HOPE-CAT, including data extraction, specifications of the computational systems, the development of the data set, and access to relevant systems, please see our previous work, Early Identification of Maternal Cardiovascular Risk Through Sourcing and Preparing Electronic Health Record Data: Machine Learning Study [10].

**Textbox 1.** Risk categories for maternal cardiovascular conditions; categories were divided into variable and static risk.

<table>
<thead>
<tr>
<th>Symptoms (variable risk): risk factors with no measurement scale specified were identified from the data by diagnosis codes as yes (present) or no (absent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Asthma, unresponsive to therapy</td>
</tr>
<tr>
<td>• Chest pain</td>
</tr>
<tr>
<td>• Dizziness or syncope</td>
</tr>
<tr>
<td>• Dyspnea (red flag risk)</td>
</tr>
<tr>
<td>• Headache, new or worsening</td>
</tr>
<tr>
<td>• Heart palpitations</td>
</tr>
<tr>
<td>• Orthopnea (red flag risk)</td>
</tr>
<tr>
<td>• Swelling of face or hands</td>
</tr>
<tr>
<td>• Tachypnea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physical findings (variable risk): risk factors with no measurement scale specified were identified from the data by diagnosis codes as yes (present) or no (absent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Basilar crackles in lungs</td>
</tr>
<tr>
<td>• Loud heart murmur</td>
</tr>
<tr>
<td>• Oxygen saturation $\leq 96%$ ($\leq 94%$ considered a red flag risk)</td>
</tr>
<tr>
<td>• Respiratory rate $\geq 24$ ($\geq 30$ considered a red flag risk)</td>
</tr>
<tr>
<td>• Resting heart rate $\geq 110$ beats per minute ($\geq 120$ beats per minute considered a red flag risk)</td>
</tr>
<tr>
<td>• Systolic blood pressure $\geq 140$ mm Hg ($\geq 160$ mm Hg considered a red flag risk)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical history (static risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age (continuous in years)</td>
</tr>
<tr>
<td>• Chronic hypertension existing prior to pregnancy</td>
</tr>
<tr>
<td>• Ethnicity</td>
</tr>
<tr>
<td>• History of chemotherapy</td>
</tr>
<tr>
<td>• History of complications in labor or birth</td>
</tr>
<tr>
<td>• History of heart disease</td>
</tr>
<tr>
<td>• Prepregnancy obesity (BMI $\geq 35$)</td>
</tr>
<tr>
<td>• Pregestational diabetes</td>
</tr>
<tr>
<td>• Race</td>
</tr>
<tr>
<td>• Substance use (eg, nicotine, cocaine, alcohol, and methamphetamines)</td>
</tr>
</tbody>
</table>

**Ethical Considerations**

Ethics approval was obtained from the Georgetown-MedStar institutional review board (STUDY00003534) and adhered to all appropriate ethical reviews and approvals, as per institutional guidelines. Institutional review board approval covered secondary analysis without additional consent. Data access, extraction, transfer, and anonymization procedures were reviewed by the institution’s data security team to ensure all necessary security requirements were implemented before the release of data. Data were deidentified before being transferred for analysis. All personal health information were removed, and patients were assigned a unique code to prevent reidentification; study identification numbers were known by a single member of the data team at the EHR institution to allow for any revalidation after original extraction. Events were also
deidentified to remove any comments or free-text entry fields that could potentially be identifiable. Adherence to institutional privacy and security policies ensured patient data were protected and secured throughout the project. As this was a secondary analysis, no compensation was provided.

Analysis

Within a virtual server environment created for this study, we systematically cleaned and standardized the EHR data (eg, organized and matched fields across tables and databases) before the deployment of an analysis by HOPE-CAT [10]. While the data set was sourced within a single health care system, standardization was necessary as data were sourced from multiple EHRs. Variables, however, were similarly defined across patients (eg, race, ethnicity, and preeclampsia). The EHR data were deidentified before analyses, enabling HOPE-CAT to truly analyze the data without consideration of race, ethnicity, or other variables that may lead to bias. Race, ethnicity, medical history, and family history were self-reported by patients and defined as recorded in the EHR.

HOPE-CAT was deployed to analyze patient data on an encounter-by-encounter basis, as in each visit and data collection on record were analyzed in the order of entry. Data from each encounter included patient demographics, physical findings, symptoms, and medical history and were analyzed by HOPE-CAT to identify changes and trends. In instances where HOPE-CAT detected any sign of risk, based on the training criteria, a risk profile was generated for the given patient and encounter [10]. Due to the nature of the available data, it was not possible to determine whether a patient’s pregnancy was their first. Each pregnancy was analyzed in isolation, and risk profiles were only compared to outcomes within that individual pregnancy.

Following full analysis by HOPE-CAT, patient risk profiles were linked to any outcomes of cardiovascular pregnancy conditions and complications, specifically preeclampsia and eclampsia, cardiomyopathy, myocardial infarction (MI), heart failure, acute kidney disease and failure, cerebral infarction, pulmonary embolism, venous thromboembolism, and HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Once a risk profile was identified and linked with a patient’s outcomes as stated in the EHR, a difference was calculated based on the date of the risk profile compared to the date of diagnosis or intervention recorded in the patient’s records. For example, if HOPE-CAT detected a risk that indicated a patient may be experiencing symptoms of preeclampsia on day 114 and the patient’s EHR data showed a diagnosis of preeclampsia on day 142, the difference would be 28 days. In-depth manual reviews were conducted by retrieving the relevant data against the results of HOPE-CAT and then cross-checking and tabulating each result. The tabulated information was further cross-checked by the independent quality team.

Results

Of the 6069 patients analyzed by HOPE-CAT, 5238 patients had 1 or more risk factors (Figure 1). A total of 1716 (32.8%) red flag risk profiles were identified among patients with 1 or more risk factors. Of the 1716 red flag risk profiles developed, HOPE-CAT identified risk profiles for 620 patients who could be matched with outcomes of interest in the patient’s diagnosis and intervention (medication) data. There were patients in the final subset for which HOPE-CAT identified risk of cardiovascular conditions after a diagnosis was made (ie, the delta was a negative number). These patients were included for accurate representation.

Following the identification of all resulting risk profiles, 16 patients who were identified by HOPE-CAT in duplicate (eg, risks that tracked to 2 different outcomes) were combined. This resulted in a final sample of 604 patients for whom available records of diagnoses or interventions could be compared against and linked with the identified risk profiles.

The majority of the final sample self-identified as Black (n=482, 79.8%) and between the ages of 20 and 34 years (n=509, 84.4%; Table 1). Twenty-one patients had 2 pregnancies recorded during the study period.

Preeclampsia was the most common condition diagnosed in our sample (n=547, 90.6%), followed by thromboembolism (n=16, 2.7%) and acute kidney disease or failure (n=13, 2.2%; Table 2).

The average delta for the final subset of 604 patients was 56.8 (SD 69.7) days between when HOPE-CAT pinpointed risk factors during a patient’s visit and the first date of diagnosis or intervention of a related condition in the patient’s record. For patients who were diagnosed with preeclampsia, HOPE-CAT identified risk factors an average of 60.2 (SD 90.9) days earlier than the time point indicated in the records. Patients with a diagnosis of MI were identified with risk factors for MI on average 65.7 (SD 81.4) days earlier than the first reported date of diagnosis. For patients whose pregnancy experience resulted in cerebral infarction (n=4, 0.7%), the delta was 42.3 days. Of these 604 patients, 19 (3.1%) experienced 2 or more tracked conditions (eg, preeclampsia with acute kidney failure and peripartum cardiomyopathy).
Figure 1. Flow diagram showing sample selection process for HOPE-CAT (Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology) analysis.

Table 1. Participant demographics of race, ethnicity, and age in years (N=604).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Values, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Race</strong></td>
<td></td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Black</td>
<td>482 (79.8)</td>
</tr>
<tr>
<td>White</td>
<td>86 (14.2)</td>
</tr>
<tr>
<td>None of the above or unknown race</td>
<td>34 (5.6)</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>7 (1.2)</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td>597 (98.8)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
</tr>
<tr>
<td>18-19</td>
<td>1 (0.17)</td>
</tr>
<tr>
<td>20-34</td>
<td>509 (84.4)</td>
</tr>
<tr>
<td>35-40</td>
<td>94 (15.6)</td>
</tr>
</tbody>
</table>

*aSelf-identification as reported in the electronic health record.

Table 2. Patient subset by condition identified in the electronic health record, including delta (N=604).

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Patients, n (%)</th>
<th>Delta mean (SD) (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preeclampsia</td>
<td>547 (90.6)</td>
<td>60.2 (90.9)</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td>16 (2.7)</td>
<td>15.3 (37.7)</td>
</tr>
<tr>
<td>Acute kidney disease and failure</td>
<td>13 (2.2)</td>
<td>25.1 (43.2)</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>10 (1.7)</td>
<td>13.9 (43.9)</td>
</tr>
<tr>
<td>Eclampsia</td>
<td>9 (1.3)</td>
<td>46.2 (58.3)</td>
</tr>
<tr>
<td>HELLP&lt;sup&gt;b&lt;/sup&gt; syndrome</td>
<td>7 (1.2)</td>
<td>34.0 (34.8)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>5 (0.8)</td>
<td>13.6 (13.2)</td>
</tr>
<tr>
<td>Cerebral infarction</td>
<td>4 (0.7)</td>
<td>42.3 (36.8)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>3 (0.5)</td>
<td>65.7 (81.4)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Percentage of patients does not add to 100 as some patients had multiple conditions.

<sup>b</sup>HELLP: hemolysis, elevated liver enzymes, and low platelets.
Discussion

Principal Findings

In this study, high-risk cardiovascular conditions in pregnancy were identified earlier than determined by a health care provider by leveraging Invaryant’s HOPE-CAT ML technology to surface signals and trends in patients’ medical records. HOPE-CAT enabled early and effective screening of potential risks from cardiovascular disease an average of 56.8 (SD 69.7) days earlier than the first date of diagnosis or intervention of a related condition as documented in the EHR.

Cardiovascular disease is the leading cause of death for women in the United States, and overall, US women experience challenges in cardiovascular care, with notable underdiagnosis and late presentations, making it less likely for them to receive appropriate treatments [13]. Black women, specifically, experience cardiovascular disease at a higher rate than White women [14,15] and are also significantly more likely to die of pregnancy-related causes [4]. Pregnancy-related disorders are not only associated with complications during pregnancy, but they also portend future cardiometabolic and long-term cardiovascular-related morbidity [13]. Implicit racial biases contribute to these health inequities, resulting in increased maternal morbidity and mortality when Black women with valid and important health concerns are dismissed [16]. Enabling early and effective screening for pre-existing comorbidities and early identification of risk with enhanced technological applications, like HOPE-CAT, independent of patient characteristics and descriptors or provider bias [17], has the potential to mitigate factors leading to racial biases [18]. Screening is imperative to promote optimal cardiovascular health to generate appropriate referrals and collaborations among health care specialties [19]. Cardio-obstetrics teams have demonstrated some promising outcomes in women with known cardiovascular disease, and early identification may facilitate the inclusion of patients who are pregnant into these multidisciplinary care teams in a timely manner [20].

HOPE-CAT also offers an important clinical tool for providers to enhance the early detection and intervention of cardiovascular disease in pregnancy by facilitating the delivery of care based on trends and synthesis of data over time rather than only the current presentation of the patient at a single visit. The ability to create risk profiles dependent on patient presentation and independent of provider recall may improve the accuracy of disease identification and promote changes in provider recommendations, monitoring, treatment, referrals, and even patients’ self-monitoring and awareness of risk. Importantly, HOPE-CAT generates a risk profile based on multiple factors that are routinely collected in prenatal visits. This approach has been argued to be superior to prediction models that require information not routinely collected [21] or to “static and single-class conventional prediction methods” in the detection of hypertensive disorders in pregnancy and post partum [9]. A real benefit of HOPE-CAT lies in its deployment in areas with limited resources and providers without obstetrical specializations. Early identification of pregnant individuals at high risk for cardiovascular disease would allow more prompt referral to high-risk clinics and specialist care.

Finally, identifying and treating cardiovascular diseases early in a pregnancy can alleviate stress on health care systems including decreasing costs of hospitalization and urgent care, and more importantly, decreasing the risk of morbidity and mortality among expecting mothers. Maternal mortality affects a country’s economic well-being. The total cost of US maternal mortality in 2019 was estimated to be US $32.3 billion from birth to the child reaching their fifth birthday [22]. In the United States, maternal mortality has been rising since 2000, even with respect to gross domestic product and health expenditure per capita [23]. It should be noted that while ML technology is a valuable tool for providers in the care of birthing persons resulting in decreased costs in the long term, the possibility exists that there could be additional short-term costs related to testing and interventions [8].

Comparison With Prior Work

Our retrospective study adds to the body of research exploring the use of ML in clinical practice by leveraging the power of EHR data to evaluate HOPE-CAT’s early identification of cardiovascular risk. This study also adds to the limited ML research in the field of obstetrics. A review conducted between 2000 and 2018 including 386 studies reporting on the use of ML in clinical practice found only 10 studies focused specifically on the field of obstetrics and gynecology [24]. Another systematic review analyzed publications on the use of ML application in obstetrics and gynecology core discipline journals and found only 19 publications between 2000 and 2020 [25].

In obstetrics, ML has successfully been used to determine the clinical parameters most useful for predicting preeclampsia and hypertensive disorders of pregnancy [12,26,27]. Our study provides additional evidence to support the use of ML in the field of obstetrics. Unlike prior work, our purpose was not to determine which parameters were most predictive but rather how soon HOPE-CAT could determine risk, based on an iterative, encounter-by-encounter basis [28]. Specifically, this study offers a novel tool for monitoring cardiovascular risk during pregnancy using real-time trends, thereby assisting health care professionals in the provision of perinatal care for high-risk patients. Consistent with earlier inquiries on the deployment of ML within obstetrics, our ML model has undergone technical validation [10]. Nonetheless, the imperative remains for further research to establish the clinical validity of the model.

Limitations

This study had several limitations. Complete EHRs were not always available for proper analysis and we did not have complete access to patients’ full health history [29]. Compared other studies applying ML to big data [27], we relied on EHRs and did not include other types of unstructured data (eg, clinical notes) in this analysis. This may have created limitations when interpreting results. In order to optimize the performance of HOPE-CAT, several steps were required to clean and standardize the data set due to sourcing from multiple EHRs. This does not negate the validity or capability of the ML
technology but does describe the nonstandardized, noninteroperable nature of EHRs data in the present day. The retrospective nature of our study was limited to data available within the health system’s EHRs and has been identified as a limitation in many prior studies using ML [24]. However, the advantage of retrospective data is that it allows for in-depth manual reviews. The data for this study were collected between January 1, 2017, and December 31, 2020. An overlap with the COVID-19 pandemic may have resulted in skewed data; pregnant individuals may have been reluctant to seek care or faced additional barriers to accessing care in 2020, which may have resulted in delayed diagnosis of complications. Additionally, analysis by race, ethnicity, or age was not possible with our sample, and thus we may have failed to capture important differences, such as whether the average delta may have been different by ethnicity, race, or age. Finally, this study was conducted within 1 health care system, and the results may not be generalizable to a different demographic or setting.

Conclusions
The findings from this study provide the foundation for future work to evaluate ML prospectively, in vivo, in the real-world setting, and longitudinally during current pregnancies and to inform future pregnancies, postpartum events, and overall cardiovascular health. Future ML may integrate multiple data sources including unstructured data using natural language processing, wearables, remote patient monitoring devices (eg, blood pressure), and symptom surveys. Additionally, the integration of factors related to social determinants of health may inform solutions to advance health equity and address the increasing US maternal mortality rates that show widening disparities associated with race and ethnicity. To facilitate the reversal of this trend, it is imperative that risk identification occurs earlier in the pregnancy trajectory to allow for increased monitoring and referral to more specialized care [30] and that ML technology is leveraged to support maternal health screening in routine appointments. The results from this study of ML through HOPE-CAT provide foundational evidence to develop solutions to mitigate the harmful impacts of pregnancy and improve maternal health for all.

Acknowledgments
We would like to acknowledge the following individuals who contributed to this work and manuscript: Sarah McGaughey and John Katial. RMB was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award KL2TR001432. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data Availability
The data sets generated and analyzed during this study are available from the corresponding author upon reasonable request.

Conflicts of Interest
None declared.

References


15. Davis SK, Gebreab S, Quarells R, Gibbons GH. Social determinants of cardiovascular health among Black and White women residing in stroke belt and buckle regions of the South. Ethn Dis 2014;24(2):133-143 [FREE Full text] [Medline: 24804357]


Abbreviations

- bpm: beats per minute
- EHR: electronic health record
- HELLP: hemolysis, elevated liver enzymes, and low platelet
- HOPE-CAT: Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology
- MI: myocardial infarction
- ML: machine learning
The Effect of an AI-Based, Autonomous, Digital Health Intervention Using Precise Lifestyle Guidance on Blood Pressure in Adults With Hypertension: Single-Arm Nonrandomized Trial

Jared Leitner¹, MS; Po-Han Chiang¹, PhD; Parag Agnihotri², MD; Sujit Dey¹, PhD

¹Electrical and Computer Engineering Department, University of California, San Diego, La Jolla, CA, United States
²Department of Medicine, University of California, San Diego, La Jolla, CA, United States

Corresponding Author:
Jared Leitner, MS
Electrical and Computer Engineering Department
University of California, San Diego
9500 Gilman Dr
La Jolla, CA, 92093
United States
Phone: 1 8587220467
Email: jjleitne@ucsd.edu

Abstract

Background: Home blood pressure (BP) monitoring with lifestyle coaching is effective in managing hypertension and reducing cardiovascular risk. However, traditional manual lifestyle coaching models significantly limit availability due to high operating costs and personnel requirements. Furthermore, the lack of patient lifestyle monitoring and clinician time constraints can prevent personalized coaching on lifestyle modifications.

Objective: This study assesses the effectiveness of a fully digital, autonomous, and artificial intelligence (AI)–based lifestyle coaching program on achieving BP control among adults with hypertension.

Methods: Participants were enrolled in a single-arm nonrandomized trial in which they received a BP monitor and wearable activity tracker. Data were collected from these devices and a questionnaire mobile app, which were used to train personalized machine learning models that enabled precision lifestyle coaching delivered to participants via SMS text messaging and a mobile app. The primary outcomes included (1) the changes in systolic and diastolic BP from baseline to 12 and 24 weeks and (2) the percentage change of participants in the controlled, stage-1, and stage-2 hypertension categories from baseline to 12 and 24 weeks. Secondary outcomes included (1) the participant engagement rate as measured by data collection consistency and (2) the number of manual clinician outreaches.

Results: In total, 141 participants were monitored over 24 weeks. At 12 weeks, systolic and diastolic BP decreased by 5.6 mm Hg (95% CI −7.1 to −4.2; P<.001) and 3.8 mm Hg (95% CI −4.7 to −2.8; P<.001), respectively. Particularly, for participants starting with stage-2 hypertension, systolic and diastolic BP decreased by 9.6 mm Hg (95% CI −12.2 to −6.9; P<.001) and 5.7 mm Hg (95% CI −7.6 to −3.9; P<.001), respectively. At 24 weeks, systolic and diastolic BP decreased by 8.1 mm Hg (95% CI −10.1 to −6.1; P<.001) and 5.1 mm Hg (95% CI −6.2 to −3.9; P<.001), respectively. For participants starting with stage-2 hypertension, systolic and diastolic BP decreased by 14.2 mm Hg (95% CI −17.7 to −10.7; P<.001) and 8.1 mm Hg (95% CI −10.4 to −5.7; P<.001), respectively, at 24 weeks. The percentage of participants with controlled BP increased by 17.2% (22/128; P<.001) and 26.5% (27/102; P<.001) from baseline to 12 and 24 weeks, respectively. The percentage of participants with stage-2 hypertension decreased by 25% (32/128; P<.001) and 26.5% (27/102; P<.001) from baseline to 12 and 24 weeks, respectively. The average weekly participant engagement rate was 92% (SD 3.9%), and only 5.9% (6/102) of the participants required manual outreach over 24 weeks.

Conclusions: The study demonstrates the potential of fully digital, autonomous, and AI-based lifestyle coaching to achieve meaningful BP improvements and high engagement for patients with hypertension while substantially reducing clinician workloads.

Trial Registration: ClinicalTrials.gov NCT06337734; https://clinicaltrials.gov/study/NCT06337734

doi:10.2196/51916
Introduction

Background

High blood pressure (BP), or hypertension, is one of the most prevalent chronic diseases in the world [1]. Hypertension affects 48% (approximately 120 million) of adults in the United States, and 78% (approximately 93 million) of the cases are uncontrolled (ie, BP≥130/80 mm Hg) [2]. Hypertension is a major risk factor for stroke and acute myocardial infarction [3] and remains a large public health challenge with an extra cost of US $2000 per year per hypertension patient, resulting in an additional US $131 billion in annual health care costs in the United States [4]. The American College of Cardiology and American Heart Association’s clinical practice guidelines define hypertension as systolic BP (SBP)≥130 mm Hg or diastolic BP (DBP)≥80 mm Hg, consistently over time [5]. A large-scale analysis of 48 randomized clinical trials showed that a 5–mm Hg reduction in SBP lowered the risk of major cardiovascular events by 10% [6], highlighting the importance of developing new strategies to achieve hypertension control at scale. Hypertension management typically begins with home monitoring of BP to gain a more accurate estimate of a patient’s BP within their usual, daily routine [7]. However, self-monitoring without additional support is not associated with lower BP or better control [8-10]. Lifestyle management in conjunction with self-monitoring is effective in controlling BP as lifestyle factors (eg, activity, sleep, diet, and stress) have a substantial impact on BP [11-14]. Even for patients taking antihypertensive medication, lifestyle management can enhance medication efficacy, leading to better BP control [15]. Traditionally, lifestyle management involves patients with hypertension visiting their primary care physician (PCP) and receiving guidance on lifestyle modifications that are generally known to improve BP. However, due to time constraints related to workload, physicians are often unable to optimally counsel patients on lifestyle modifications or personalize their guidance [16,17]. Due to insufficient guidance and the lack of feedback in between clinic visits, patients may implement some of these changes; however, patient engagement and compliance are generally suboptimal for achieving control. To improve patient engagement, new digital health technologies and remote patient monitoring programs have been developed for hypertension care [18-21]. These programs typically provide patients with remote monitoring devices (eg, BP cuffs and activity trackers) and match patients with health coaches. BP and lifestyle data collected from remote monitoring devices allow health coaches to view trends and make personalized recommendations to patients. However, these approaches do not consider the individual impact of lifestyle factors on BP, which may vary across individuals due to physiological differences. Furthermore, the reliance on health coaches is highly time and resource intensive, resulting in a high operating cost, which significantly limits scalability [22].

Objectives

To address the challenges of poor patient engagement due to generic, insufficient guidance and limited scalability of care due to human coaching models, we propose an artificial intelligence (AI)–driven, autonomous, precise lifestyle coaching program for patients with hypertension. The intervention platform consists of a monitoring system that ingests lifestyle and BP data and builds personalized machine learning (ML) models to determine the individual impact of different lifestyle factors on BP. On the basis of the lifestyle impact analysis, the system autonomously provides precise lifestyle recommendations delivered to a patient’s smartphone that enable patients to focus on specific aspects of their lifestyle that have the greatest associations with their BP. While the platform autonomously engages patients, it is clinician supervised and notifies clinicians of critical BP readings. In our previous study [23], we enrolled 38 participants who were prehypertensive or had stage-1 hypertension (SBP between 120 and 139 mm Hg or DBP between 80 and 89 mm Hg) and demonstrated that 75% of the participants receiving the intervention were able to achieve a controlled BP (<130/80 mm Hg) after 16 weeks of engagement. However, the limitations of the previous study [23] are as follows: (1) the participants were not provided with an interactive mobile app for the delivery of our precise lifestyle recommendations, (2) the small number of participants did not enable rigorous evaluation, and (3) the study did not consider patients with stage-2 hypertension who can potentially benefit more from lifestyle management.

This study aims to evaluate the effectiveness of our AI-based, precise lifestyle guidance coaching program in helping patients with stage-2 hypertension achieve BP control and demonstrate the platform’s scalability. The primary study objectives are to evaluate the change in BP and the percentage change of participants in different BP categories (controlled, stage-1 hypertension, and stage-2 hypertension) over time (baseline, 12 weeks, and 24 weeks). Secondary objectives include assessing participant engagement as measured by consistency of data collection and interactions with our mobile app and determining the number of manual clinician interventions, as defined by the escalation rules set for the study, to assess the potential scalability of our approach.

Methods

Recruitment

This study was performed in collaboration with the University of California, San Diego Health’s Population Health Services Organization (PHSO). Participants were enrolled on a rolling basis from November 2021 to February 2023. The inclusion criteria required participants to have stage-2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg per the American College of Cardiology and American Heart Association’s 2017 guidelines [5]) based on their most recent clinical measurements and to be fully ambulatory (ie, not requiring an assistive device to view trends and make personalized recommendations to patients. However, these approaches do not consider the individual impact of lifestyle factors on BP, which may vary across individuals due to physiological differences. Furthermore, the reliance on health coaches is highly time and resource intensive, resulting in a high operating cost, which significantly limits scalability [22].
such as a cane, wheelchair, or walker). In addition, participants were required to be aged ≥18 years at enrollment, be English speaking, and own an Android or iPhone (Apple Inc) smartphone. The trial was designed in a fully remote manner so that participants could participate entirely from home. The PHSO care team aggregated a list of patients who met the inclusion criteria and sent a recruitment flyer via bulk message using the Epic MyChart (Epic Systems Corporation) messenger. The flyer introduced the study and instructed patients to email the study team if they were interested in participating. After contacting the study team, eligible patients were asked to complete an electronic informed consent form. Patients who consented were sent a Fitbit Inspire 2 (Fitbit Inc) and a Bluetooth-enabled Omron Silver (Omron Corporation) BP monitor to collect their lifestyle and BP data for up to 6 months. Each shipment included instructions for self-onboarding, which described the steps to set up and connect the devices to the patient’s mobile phone. Patients who already owned a Fitbit or Apple Watch (Apple Inc) had the option to use their device instead of receiving one from the study team. Patients who required an extra-large cuff were provided an iHealth Ease (iHealth Labs Inc) BP monitor instead of an Omron Silver.

**Ethical Considerations**

This study (protocol #181405) was reviewed and approved by the University of California, San Diego’s Human Research Protections Program, which operates Institutional Review Boards. All participants in this study provided informed consent, which included the collection of their data and the provision of study results derived from their individual data. The confidentiality and privacy of participants were ensured by assigning a deidentified code to each patient. While participants were not offered monetary compensation, those without a BP monitor or wearable device were provided with these devices. The study was registered at ClinicalTrials.gov (NCT06337734).

**Study Design and Data Collection**

We collected data from each participant using a Fitbit or Apple Watch, Omron or iHealth wireless BP monitor, and the study’s questionnaire mobile app. Participants were asked to wear their Fitbit or Apple Watch as often as possible, including during sleep, and take 1 to 2 BP measurements per day, in the morning (8 AM-10 AM) or evening (7 PM-9 PM). We provided participants with instructions on how to take accurate resting BP readings [24] and asked that they take 3 consecutive readings during each morning and evening session. This resulted in 1 to 2 sets of 3 measurements per day, and the average of the 3 measurements was used as the final value for each session. Participants synced their BP data to the Omron or iHealth mobile app and their Fitbit data to the Fitbit mobile app; subsequently, the data were automatically uploaded to the Omron, iHealth, or Fitbit clouds. These data were retrieved remotely through the application programming interfaces (APIs) provided by Omron, iHealth, and Fitbit. Data from the Apple Watch were synced with the study mobile app and uploaded via a custom API to our server. In addition, participants completed a daily questionnaire using our study mobile app that asked about their stress, mood, and dietary choices over the past 24 hours. These questions were developed in collaboration with physicians on our team. The diet questions are tailored to measure information relevant to hypertension, including alcohol, red meat, fruits or vegetables, and salt consumption [25]. The details of the questionnaire are described in our previous study [23]. In addition, we asked participants to complete a study experience survey that asked them to rate the difficulty level of completing the study tasks, how useful they found the recommendations, and their experience using the app. These responses were collected through the mobile app and used to assess participant experience. Figure 1 describes the system architecture and data transmission.

Wrist-worn activity and sleep trackers have been widely used in health-related research studies [26], and devices such as Fitbits and Apple Watches have been shown to accurately measure parameters such as step count, heart rate, and sleep duration [27,28]. Fitbits and Apple Watches include an optical heart rate monitor and a 3-axis accelerometer. The devices use these sensors to calculate various health parameters, including lifestyle and vitals measurements. Lifestyle factors include activity (eg, steps, walking and running speed, and active time), sleep timing (eg, sleep duration, bedtime, and uptime), and sleep stages (ie, deep, light, rapid eye movement, and awake). These lifestyle factors are used as part of the intervention, in which we use ML techniques to determine which of the factors have the greatest association with a participant’s BP and base our guidance on this analysis.
Figure 1. Architecture of data transmission. Participant data were collected from Bluetooth-enabled blood pressure (BP) monitors, wearable devices, and a mobile app–based questionnaire. Data were uploaded through the respective application programming interfaces (APIs) to our app server, where the individualized analysis was carried out before delivering recommendations to participants.

Description of the Intervention

The intervention is intended to support participants’ daily efforts to improve BP and overall cardiometabolic function by facilitating behavioral changes that target physical activity, sleep hygiene, stress management, and dietary choices most relevant to their BP. The intervention platform uses remotely collected lifestyle and BP data to provide personalized, precise, and proactive lifestyle coaching using AI to participants with hypertension. The system integrates the data described in the previous section into a combined data set for each participant. Each participant’s personal data set consists of lifestyle features (eg, step count, sleep duration, and salt consumption) that are time aligned with their BP measurements, which serve as the labels for training the ML model. Therefore, each participant’s data set is used to train a personal ML model that can predict BP using the participant’s lifestyle data as input. With this trained model, the intervention system can determine how different aspects of lifestyle affect the participant’s BP. On the basis of the model’s determination of the lifestyle factors’ impact, the system generates precise lifestyle recommendations. Each lifestyle factor is mapped to a corresponding lifestyle recommendation that was designed with physicians on our team to be consistent with evidence-based clinical guidelines. Furthermore, prior studies have demonstrated that these recommendations, such as increasing step count [29,30], improving sleep quality [31,32], managing stress [33], and reducing salt consumption [34,35], can result in BP reduction. The objective of these precise lifestyle recommendations is to encourage participants to concentrate on 1 aspect of their lifestyle at a time, focusing on the factor that has the greatest association with their BP based on the underlying relationship between their BP and lifestyle factors. We describe the AI-based intervention platform in more detail in our previous study [23].

Participants received weekly lifestyle recommendations based on their data and personalized analytics, which continuously evolved over time. These recommendations were delivered to participants via programmable text messages using the Twilio API (Twilio Inc) service [36] and were displayed in the study mobile app. Each text message included a summary of the participant’s BP progression for the current week in addition to the lifestyle recommendation. Figure 2 displays examples of these weekly lifestyle recommendations provided in the study app. In addition, patients completed a midweek check-in on the app, which asked whether they could follow each recommendation (yes or no) and to rate the recommendation difficulty on a scale from 1 to 5.

The system includes a safety mechanism to involve clinician intervention in the case of critically high or low BP readings. Critically high BP was defined as SBP>180 mm Hg or DBP>110 mm Hg, and critically low BP was defined as SBP<90 mm Hg or DBP<60 mm Hg [5]. After a critical reading, participants received a text message asking them to remeasure their BP and prompting them to seek assistance or call their medical provider if they were experiencing certain symptoms (eg, chest pain and severe headache). After 2 critical readings in a row, an escalation notification was sent to the PHSO care team via email for manual outreach. To avoid notification fatigue, we limited the number of critically high or low BP notifications sent to the care team to 1 notification per week for a patient.
Primary Outcomes: BP Change and Population Hypertension Control

The first primary outcome was the change in SBP and DBP from baseline to 12 weeks and 24 weeks. A participant’s baseline BP was calculated as the average of their readings during the first week of the study. The 12th- and 24th-week BPs were a participant’s average reading during that week of the study plus 1 week and minus 1 week. We included BP measurements from 1 week before and after to get a more representative result. For example, the 12-week value was the average of all readings from weeks 11 to 13. As previously mentioned, a 5–mm Hg reduction in SBP can lower the risk of major cardiovascular events by 10% [6]. This motivated us to determine the percentage of participants who experienced >5–mm Hg reduction in SBP at 12 weeks and 24 weeks. To assess this, we calculated the percentage of participants who were in the controlled, stage-1 hypertension, and stage-2 hypertension categories at baseline, 12 weeks, and 24 weeks. Using these percentages, we determined the percentage change from baseline to 12 weeks and 24 weeks.

Secondary Outcomes: Participant Engagement and Clinician Intervention

A secondary outcome measured participant engagement as determined by the consistency of data collection and interactions with our mobile app. The 3 main tasks participants were asked to complete included measuring BP, syncing their wearable device, and answering the mobile app questionnaire. As a result, we used these 3 tasks as our measure of engagement and calculated the percentage of participants completing each of these tasks each week. A participant was marked as engaged for a given week if they provided a BP reading, synced their wearable device data, and answered the questionnaire at least once during the week.
Another secondary outcome was the number of times participants were escalated to the PHSO care team for manual follow-up. The objective of this outcome was to determine the care team’s time and resource requirements to implement the intervention and assess the scalability of our approach. The condition for care team intervention was 2 critical BP readings in a row, as previously described.

**Statistical Analysis**

Descriptive statistics (eg, mean, SD, and percentage) were calculated to describe the demographic and baseline clinical characteristics of the enrolled study population. We compared the characteristics between subgroups based on their baseline BP classification.

Change in SBP and DBP from baseline to 12 weeks and 24 weeks was analyzed using a 2-tailed paired Student t test with the level of statistical significance set to \( P < .05 \). Furthermore, 95% CIs were calculated for these changes. Baseline and follow-up BP data were normally distributed. The McNemar nonparametric test was used to examine the change in the proportion of participants in the controlled, stage-1, and stage-2 BP range from baseline to 12 weeks and 24 weeks. The McNemar test is used to determine if there is a statistically significant difference in proportions between paired data. We conducted all statistical analyses with Python 3.9 (Python Software Foundation) using the NumPy, Pandas, and SciPy libraries.

**Results**

**Feasibility Outcomes: Recruitment, Adherence, and Participant Experience**

Participants were enrolled on a rolling basis from November 2021 to February 2023. Figure 3 details the recruitment numbers and participant flow through the study. A total of 274 patients responded to the Epic MyChart recruitment message by contacting our team and expressing interest. In total, 164 patients consented to join the study, out of which 141 (86%) were onboarded and started collecting data. There was a 9.2% (13/141) dropout rate from the start of the study to 12 weeks and a 20.3% (26/128) dropout rate from 12 weeks to 24 weeks. The reasons for participants withdrawing from the study included receiving new medical diagnoses (eg, cancer diagnosis), achieving a healthy BP, family emergencies, and other personal reasons. For the 141 participants who onboarded, Table 1 compares the characteristics between subgroups based on baseline BP classifications. The average age of participants was 57.5 (SD 13.9) years, and 44% (62/141) of the participants were female. For participants who had stage 2 hypertension at baseline, the average baseline BP was 141.9/89.4 mm Hg. In total, 83.7% (118/141) of the participants reported that they were taking antihypertensive medication at the beginning of the study.

As previously described, we asked participants each week to rate the difficulty of the recommendations they received on a scale from 1 to 5 and indicate whether they could follow each recommendation. This was done to assess compliance and the perceived difficulty of the recommendations. The histogram of difficulty ratings, divided into Yes and No responses, is shown in Multimedia Appendix 1. Recommendations were followed 63.64% (721/1133) of the time and not followed 36.36% (412/1133) of the time. The average difficulty rating for recommendations that were followed was 1.97, indicating lower difficulty, whereas the average for those not followed was 3.67, indicating higher difficulty. Evidently, there is a negative correlation between the perceived difficulty of a recommendation and its likelihood of being followed. We also tracked the number of unique recommendations each patient was sent. Out of the 37 unique recommendations, patients received an average of 9.4 (25%) unique recommendations each. The maximum number of unique recommendations is shown in Figure 4. The median and IQR suggest a distribution close to normal. The maximum number of unique recommendations received by a single patient was as high as 21. These statistics demonstrate a broad range of recommendations given to the patients, covering various aspects of lifestyle.

An additional feasibility outcome we evaluated was participant experience as measured by responses to a study experience survey. As previously mentioned, this survey asked patients to rate the difficulty level of completing the study tasks, how useful they found the recommendations, and their experience using the app. Multimedia Appendix 2 presents the distribution of participant responses to these 3 questions. In total, 70 participants responded to the survey. In total, 61% (43/70) of the participants responded that the study tasks were “easy” or “very easy” to incorporate into their daily routine, 51% (36/70) of the participants found the personalized recommendations to be “useful” or “very useful” compared to generic recommendations, and 86% (60/70) of the participants rated the app experience as “good” or “great.”
Figure 3. Flow of participants through the study. Adults with hypertension were enrolled from the University of California, San Diego Health between November 2021 and February 2023 into a single-arm nonrandomized trial. BP: blood pressure.

Table 1. Participant demographics and characteristics grouped by baseline BP\(^a\) (N=141).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Baseline BP category</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (N=141)</td>
</tr>
<tr>
<td></td>
<td>Controlled (n=38)</td>
</tr>
<tr>
<td></td>
<td>Stage 1 (n=48)</td>
</tr>
<tr>
<td></td>
<td>Stage 2 (n=55)</td>
</tr>
<tr>
<td>Age (y), mean (SD)</td>
<td>57.5 (13.9)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>62 (44)</td>
</tr>
<tr>
<td>Weight (lb), mean (SD)</td>
<td>175.8 (48.4)</td>
</tr>
<tr>
<td>Baseline SBP(^b) (mm Hg), mean (SD)</td>
<td>131.9 (11.5)</td>
</tr>
<tr>
<td>Baseline DBP(^c) (mm Hg), mean (SD)</td>
<td>82.9 (9.0)</td>
</tr>
<tr>
<td>Taking hypertension medication, n (%)</td>
<td>118 (83.7)</td>
</tr>
</tbody>
</table>

\(^a\)BP: blood pressure.

\(^b\)SBP: systolic blood pressure.

\(^c\)DBP: diastolic blood pressure.
Figure 4. Distribution showing the number of unique recommendations sent to each patient. Patients received an average of 9.4 unique recommendations each.

BP Outcomes

For assessing BP outcomes, we used data from the 128 and 102 participants who completed 12 and 24 weeks in the study, respectively. Table 2 details the change in BP from baseline to 12 weeks. Across all participants, there was a statistically significant change of $-5.6$ mm Hg (95% CI $-7.1$ to $-4.2$; $t_{127}=7.6; P<.001$) in SBP and $-3.8$ mm Hg (95% CI $-4.7$ to $-2.8$; $t_{127}=7.7; P<.001$) in DBP after 12 weeks. Notably, 45.3% (58/128) of the participants achieved a clinically meaningful SBP drop of $\geq 5$ mm Hg after 12 weeks. Table 3 details the change in BP from baseline to 24 weeks. For the participants who completed 24 weeks in the study, there was a statistically significant change of $-8.1$ mm Hg (95% CI $-10.1$ to $-6.1$; $t_{101}=8.1; P<.001$) in SBP and $-5.1$ mm Hg (95% CI $-6.2$ to $-3.9$; $t_{101}=8.4; P<.001$) in DBP. In total, 58.8% (60/102) of the participants achieved a clinically meaningful SBP drop of $\geq 5$ mm Hg after 24 weeks.

Table 2. Comparison of average BP$^a$ change at 12 weeks for different participant subgroups based on baseline BP (n=128).$^b$

<table>
<thead>
<tr>
<th>BP and subgroup</th>
<th>Participants, n (%)</th>
<th>Change in BP at 12 weeks, $\Delta$mean (SD; 95% CI)</th>
<th>$t$ test (df)</th>
<th>$P$ value</th>
<th>$\geq 5$–mm Hg reduction in SBP$^c$ at 12 weeks, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>128 (100)</td>
<td>$-5.6$ (8.1; $-7.1$ to $-4.2$)</td>
<td>7.6 (127)</td>
<td>&lt;.001</td>
<td>58 (45.3)</td>
</tr>
<tr>
<td>Controlled</td>
<td>31 (24.2)</td>
<td>$-3.6$ (5.2; $-5.5$ to $-1.6$)</td>
<td>3.7 (30)</td>
<td>.001</td>
<td>11 (35)</td>
</tr>
<tr>
<td>Stage 1</td>
<td>46 (35.9)</td>
<td>$-2.6$ (7.2; $-4.8$ to $-0.5$)</td>
<td>2.5 (45)</td>
<td>.02</td>
<td>14 (30)</td>
</tr>
<tr>
<td>Stage 2</td>
<td>51 (39.8)</td>
<td>$-9.6$ (9.2; $-12.2$ to $-6.9$)</td>
<td>7.3 (50)</td>
<td>&lt;.001</td>
<td>33 (65)</td>
</tr>
<tr>
<td>DBP$^d$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>128 (100)</td>
<td>$-3.8$ (5.5; $-4.7$ to $-2.8$)</td>
<td>7.7 (127)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
<tr>
<td>Controlled</td>
<td>31 (24.2)</td>
<td>$-1.6$ (3.8; $-3.0$ to $-0.2$)</td>
<td>2.3 (30)</td>
<td>.03</td>
<td>N/A</td>
</tr>
<tr>
<td>Stage 1</td>
<td>46 (35.9)</td>
<td>$-3.1$ (4.4; $-4.4$ to $-1.7$)</td>
<td>4.7 (45)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
<tr>
<td>Stage 2</td>
<td>51 (39.8)</td>
<td>$-5.7$ (6.7; $-7.6$ to $-3.9$)</td>
<td>6.2 (50)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
</tbody>
</table>

$^a$BP: blood pressure.

$^b$For participants with stage-2 hypertension at baseline, SBP and DBP changed by $-9.6$ mm Hg and $-5.7$ mm Hg, respectively, after 12 weeks.

$^c$SBP: systolic blood pressure.

$^d$DBP: diastolic blood pressure.

$^e$N/A: not applicable.
Participants with a baseline BP classified as stage-2 hypertension had the greatest change in BP and the greatest percentage of participants achieving a clinically meaningful SBP drop after 12 and 24 weeks. For these participants, SBP and DBP improved by 17.2 mm Hg (95% CI −9.6 to 8.1 mm Hg, respectively) and 7.9 mm Hg and 8.1 mm Hg, respectively, after 24 weeks. This means that 63% (32/51) of the patients with stage-2 hypertension at baseline moved into lower BP categories after 12 weeks. For those who completed 24 weeks in the study, the percentage in the controlled range increased by 26.5% from 27.5% (28/102) to 53.9% (55/102; McNemar $\chi^2=2.0$, P<.001) after 12 weeks. This means that 73% (27/37) of the patients with stage-2 hypertension at baseline moved into lower BP categories after 24 weeks. Note that the percentage changes for the stage-1 hypertension category from baseline to 12 weeks and 24 weeks were not statistically significant at the P=.05 level. The smaller change in the stage-1 hypertension population is due to a cascading effect where the number of patients moving from stage 1 to stage 2 was offset by the number of patients moving out of stage 1 and into the controlled BP category. For example, from baseline to 24 weeks, 18 participants moved from stage 2 to stage 1, and 17 participants moved from stage 1 to the controlled category.

Another primary outcome we assessed was the percentage change of participants in different BP categories from baseline to 12 weeks and 24 weeks. Tables 4 and 5 detail this analysis. For participants completing 12 weeks in the study, the percentage of participants in the controlled range increased by 17.2% from 24.2% (31/128) to 41.4% (53/128; McNemar $\chi^2=3.0$, P<.001). The percentage of participants with stage 2 hypertension decreased by 25% from 39.8% (51/128) to 14.8% (19/128; McNemar $\chi^2=4.0$, P<.001) after 12 weeks. This means that 63% (32/51) of the patients with stage-2 hypertension at baseline moved into lower BP categories after 12 weeks. For those who completed 24 weeks in the study, the percentage in the controlled range increased by 26.5% from 27.5% (28/102) to 53.9% (55/102; McNemar $\chi^2=2.0$, P<.001), and the stage-2 percentage decreased by 26.5% from 36.3% (37/102) to 9.8% (10/102; McNemar $\chi^2=3.0$, P<.001). This means that 73% (27/37) of the patients with stage-2 hypertension at baseline moved into lower BP categories after 24 weeks. Note that the percentage changes for the stage-1 hypertension category from baseline to 12 weeks and 24 weeks were not statistically significant at the P=.05 level. The smaller change in the stage-1 hypertension population is due to a cascading effect where the number of participants moving from stage 2 into stage 1 was offset by the number of patients moving out of stage 1 and into the controlled BP category. For example, from baseline to 24 weeks, 18 participants moved from stage 2 to stage 1, and 17 participants moved from stage 1 to the controlled category.

### Table 3. Comparison of average BP change at 24 weeks for different participant subgroups based on baseline BP (n=102).^b^  

<table>
<thead>
<tr>
<th>BP and subgroups</th>
<th>Participants, n (%)</th>
<th>Change in BP at 24 weeks, mean (SD; 95% CI)</th>
<th>t test (df)</th>
<th>P value</th>
<th>≥5-mm Hg reduction in SBP^e^ at 24 weeks, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SBP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>102 (100)</td>
<td>−8.1 (10.1; −10.1 to −6.1)</td>
<td>8.1 (101)</td>
<td>&lt;.001</td>
<td>60 (58.8)</td>
</tr>
<tr>
<td>Controlled</td>
<td>28 (27.5)</td>
<td>−3.9 (8.6; −7.1 to −0.8)</td>
<td>2.6 (27)</td>
<td>.02</td>
<td>14 (50)</td>
</tr>
<tr>
<td>Stage 1</td>
<td>37 (36.3)</td>
<td>−5.2 (8.0; −7.9 to −2.5)</td>
<td>3.9 (36)</td>
<td>&lt;.001</td>
<td>17 (46)</td>
</tr>
<tr>
<td>Stage 2</td>
<td>37 (36.3)</td>
<td>−14.2 (10.6; −17.7 to −10.7)</td>
<td>8.2 (36)</td>
<td>&lt;.001</td>
<td>29 (78)</td>
</tr>
<tr>
<td><strong>DBP^d^</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>102 (100)</td>
<td>−5.1 (6.0; −6.2 to −3.9)</td>
<td>8.4 (101)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
<tr>
<td>Controlled</td>
<td>28 (27.5)</td>
<td>−1.9 (4.3; −3.6 to −0.2)</td>
<td>2.3 (27)</td>
<td>.03</td>
<td>N/A</td>
</tr>
<tr>
<td>Stage 1</td>
<td>37 (36.3)</td>
<td>−4.4 (4.7; −6.0 to −2.8)</td>
<td>5.7 (36)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
<tr>
<td>Stage 2</td>
<td>37 (36.3)</td>
<td>−8.1 (6.9; −10.4 to −5.7)</td>
<td>7.0 (36)</td>
<td>&lt;.001</td>
<td>N/A</td>
</tr>
</tbody>
</table>

^a^BP: blood pressure.  
^b^For participants with stage-2 hypertension at baseline, SBP and DBP changed by −14.2 mm Hg and −8.1 mm Hg, respectively, after 24 weeks.  
^c^SBP: systolic blood pressure.  
^d^DBP: diastolic blood pressure.  
^e^N/A: not applicable.

---

### Table 4. Change in the percentage of participants in different BP^a^ categories from baseline to 12 weeks (n=128).^b^  

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>Population at baseline, n (%)</th>
<th>Population at 12 weeks, n (%)</th>
<th>12-week difference, n (%)</th>
<th>McNemar $\chi^2$ (df)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled</td>
<td>31 (24.2)</td>
<td>53 (41.4)</td>
<td>22 (17.2)</td>
<td>3.0 (1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Stage 1</td>
<td>46 (35.9)</td>
<td>56 (43.8)</td>
<td>10 (7.8)</td>
<td>20.0 (1)</td>
<td>.02</td>
</tr>
<tr>
<td>Stage 2</td>
<td>51 (39.8)</td>
<td>19 (14.8)</td>
<td>−32 (−25)</td>
<td>4.0 (1)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

^a^BP: blood pressure.  
^b^The percentage of participants with stage-2 hypertension decreased by 25% from 39.8% to 14.8% after 12 weeks.
Table 5. Change in the percentage of participants in different BP\textsuperscript{a} categories from baseline to 24 weeks (n=102)\textsuperscript{b}.

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>Population at baseline, n (%)</th>
<th>Population at 24 weeks, n (%)</th>
<th>24-week difference, n (%)</th>
<th>McNemar $\chi^2$ (df)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled</td>
<td>28 (27.5)</td>
<td>55 (53.9)</td>
<td>27 (26.5)</td>
<td>2.0 (1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Stage 1</td>
<td>37 (36.3)</td>
<td>37 (36.3)</td>
<td>0 (0)</td>
<td>N/A\textsuperscript{c}</td>
<td>N/A</td>
</tr>
<tr>
<td>Stage 2</td>
<td>37 (36.3)</td>
<td>10 (9.8)</td>
<td>~27 (~26.5)</td>
<td>3.0 (1)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

\textsuperscript{a}BP: blood pressure.

\textsuperscript{b}The percentage of participants with stage-2 hypertension decreased by 26.5% from 36.3% to 9.8% after 24 weeks.

\textsuperscript{c}N/A: not applicable.

Participant Engagement

We assessed participant engagement based on the percentage of active participants completing the program tasks each week. Figures 5-7 show the weekly percentage of active patients measuring their BP, syncing their wearable device, and answering the questionnaire during the 24 weeks, respectively.

We set an engagement goal of 90% for the study, which is represented by the red dashed lines in the figures. The average BP measurement engagement rate was 93% (SD 4.3%), and this rate was >90% for 19 (79%) out of 24 weeks. The average wearable syncing engagement rate was 94% (SD 2.4%), and this rate was >90% for 21 (88%) out of 24 weeks. The average questionnaire engagement rate was 88% (SD 4.9%), and this rate was >90% for 10 (42%) out of 24 weeks.

Figure 5. Percentage of active participants measuring their blood pressure (BP) during the 24 weeks.
Clinician Intervention
For the 128 participants completing 12 weeks in the study, an escalation notification was sent to the care team 8 times. There were 3.9% (5/128) unique patients who required manual outreach during the first 12 weeks. For the 102 patients completing 24 weeks in the study, an escalation notification was sent to the PHSO care team 11 times. There were 5.9% (6/102) unique patients who required manual outreach during the 24 weeks.

Discussion
Principal Findings
This study aims to assess the effectiveness of a fully digital, autonomous, and AI-based lifestyle coaching program in achieving BP control and high engagement among adults with hypertension. The key components of this program included detailed lifestyle data collection via both wearables and questionnaires and weekly lifestyle recommendations based on personalized, AI-based analytics delivered via a mobile app. The guidance supported the participant’s daily efforts to improve BP through behavioral changes that targeted physical activity, sleep hygiene, stress management, and dietary choices. Specifically, the program provided weekly guidance based on associations between lifestyle data and BP uncovered using ML and asked the participants to focus on the lifestyle factor with the greatest association. The precise lifestyle recommendations enabled participants to focus on the most relevant aspect of their lifestyle as opposed to receiving general guidance. Our intervention approach aligns with the Fogg Behavioral Model, which states that 3 elements (ability, motivation, and prompts)
are essential for behavior change [37]. By directing participants to focus on 1 lifestyle behavior at a time, the intervention simplified compliance and therefore increased the ability of the participants to adhere to the recommendations. This targeted strategy likely bolstered participants’ motivation, as they could clearly see how specific lifestyle modifications directly influenced their BP. Each recommendation was delivered via a text message and prompted the user to take specific action. Furthermore, each recommendation was sent with a motivational message regarding their BP progress. We believe that this combination of personalized advice, ease of compliance, and motivational reinforcement contributed to our high engagement and improved BP outcomes.

We assessed multiple feasibility outcomes, including enrollment rate, adherence, and participant experience. In total, 59.9% (164/274) of the patients who initially expressed interest in joining the program ended up enrolling. Furthermore, although patients were recruited based on their last clinical BP reading, which required an SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg (stage-2 hypertension), many participants were not in the stage-2 range at baseline. Possible reasons for this include white coat hypertension [38] or that between the time of their last clinical BP reading and their enrollment in the study, they may have started taking BP medication or changed their diet. To improve the enrollment rate and ensure that patients who enroll have stage-2 hypertension, a new recruitment strategy is required. This new strategy could involve recruiting patients through PCP referrals. We hypothesize that this will increase the take-up rate due to increased trust from the more personal nature of the referral [39]. Furthermore, for the patients who are referred to the study, their PCPs would be instructed not to start the patients on any new BP medication or lifestyle intervention before the study, except in critical cases. This would help ensure patients joining the study are indeed in the stage-2 hypertension category. Another feasibility outcome we assessed was participant experience. While most participants (43/70, 61%) found the study tasks easy to incorporate into their daily routine, a few (3/70, 4%) found it difficult. These included difficulty in measuring BP due to work schedules and travel, caregiving responsibilities, and equipment and syncing issues. To address these challenges, the intervention should be more context aware and adapt the program tasks and recommendations based on patients’ circumstances. For example, a patient who works a night shift should not be asked to measure their BP at the same time or be given the same sleep recommendations as a patient who works during the day. Context-aware interventions would enhance the patient experience and increase the engagement rate.

Participants experienced a statistically significant decrease of 8.1 mm Hg and 5.1 mm Hg in SBP and DBP, respectively, after 24 weeks. Furthermore, this improvement was more pronounced in participants who started the program with stage-2 hypertension, achieving a 14.2 mm Hg and 8.1 mm Hg reduction in SBP and DBP, respectively. Reducing BP holds clinical significance not only for individuals with stage 2 hypertension but also for those with elevated BP or stage 1 hypertension. This is clinically meaningful as lower SBP values have been associated with progressively reduced risks of stroke, major cardiovascular events, and cardiovascular as well as all-cause mortalities [40]. In addition to BP improvement, the study demonstrates the intervention’s ability to maintain sustained engagement. However, the engagement rate dropped during the last 4 weeks potentially because the participants whose BP had improved through the program may have reduced their engagement as they did not feel the urgent need. In this study, the participant tasks remain consistent; however, participants may find it useful if the requirements are adaptive based on their health condition and preferences. It is worthwhile to design a dynamic mechanism that can adjust the extent and frequency of patient requirements based on the intervention progress. Both the BP and engagement results are achieved with minimal clinician intervention, primarily due to the autonomous nature of the intervention, demonstrating the potential scalability of this approach for hypertension management.

The observed BP improvement results from this study are comparable to those from clinician-led hypertension management programs [18–21]. The 3-month intervention program presented in the study by Wilson-Anumudu et al [18] combined lifestyle counseling with hypertension education, guided home BP monitoring, and support for taking medications and was led by either a registered nurse or certified diabetes care and education specialist. Patients with stage-2 hypertension who participated in this program experienced a 10.3 mm Hg and 6.5 mm Hg reduction in SBP and DBP, respectively, after 3 months. In the study by Milani et al [20], the 3-month digital intervention involved patients measuring their BP at least once per week and corresponding with pharmacists and health coaches to cocreate their treatment plan by choosing among various lifestyle modifications (eg, reducing dietary sodium) and medication options (eg, switching to generics or lower cost options). Patients with stage-2 hypertension participating in this program experienced a 14.0 mm Hg and 5.0 mm Hg reduction in SBP and DBP, respectively, after 3 months. Both interventions presented in the studies by Wilson-Anumudu et al [18] and Milani et al [20] assigned participants a designated hypertension coach who would provide lifestyle education and recommendations. These previous studies [18,20] primarily attribute their BP outcomes to the program’s support led by health professionals who interpreted BP data and supported lifestyle change. While health coach–based programs can produce meaningful BP improvements, the reliance on health coaches is highly time and resource intensive. Consequently, these approaches have limited scalability and accessibility as an individual health coach can only engage and care for a limited number of patients at a time. In contrast, our results demonstrate that a fully digital, AI-based lifestyle coaching program can produce clinically meaningful BP improvements comparable to those of programs led by health professionals. There is also potential for our approach to be used in conjunction with health coach–based programs. Under such a framework, our AI-based interactions and learnings from the patients can extend the reach of health coaches and provide them with more detailed insights about lifestyle factors impacting patients.

**Study Limitations and Future Directions**

As this was a single-arm nonrandomized study, it was not possible to conduct a causal analysis due to the lack of a control
group. In addition, regression to the mean is another limitation as participants with initially high BP values may naturally converge toward the average over time. Therefore, to conduct causal analysis and account for regression to the mean, a randomized controlled trial may be conducted to draw stronger conclusions in a future study. To gain additional insights into the effectiveness of the program, we can randomize patients into different treatment arms by providing different versions of the program. This could include varying the frequency or content of the lifestyle recommendations across the different treatment arms. Furthermore, we could investigate which lifestyle interventions, for example, increasing steps or improving sleep hygiene, result in greater BP improvements. With careful design, we can create a multiarm trial to investigate optimal engagement strategies and recommendations for different types of patients. Another limitation of this study is selection bias as the participants self-selected to enroll after receiving the recruitment flyer. To address this, we plan to recruit patients through PCP referrals. PCPs will refer their patients with high cardiovascular risk, who can benefit from our intervention. As previously mentioned, we hypothesize that this will increase the take-up rate due to increased trust from the more personal nature of the referral [39]. In addition, there is a need for a longer follow-up period as behavioral interventions can show improved outcomes during the first 6 months and then recidivism during the next 6 months. Finally, we did not collect socioeconomic data (eg, occupation, education, and income) from participants, preventing an analysis of how socioeconomic status impacts the program outcomes. In our future research, we will consider socioeconomic factors when analyzing the impact of the intervention. This analysis is imperative to ensure that the use of digital technologies does not contribute to an increased digital divide in health care and that all patients have equal access to high-quality health care [41,42].

Conclusions

To address the challenges of poor patient engagement due to generic, nonpersonalized lifestyle guidance and limited scalability of care due to human coaching models, we propose an AI-driven, autonomous, precise lifestyle coaching program for patients with hypertension. Patients who enrolled in the program experienced a significant improvement in BP. The program maintained a high engagement rate with minimal intervention from the care team. As the burden of hypertension increases globally, the necessity to develop new strategies to achieve hypertension control at scale is greater than ever. An AI-based, autonomous approach to hypertension-related lifestyle coaching can increase scalability and accessibility to effective BP management, ultimately improving the cardiovascular health of our community.

Acknowledgments

The research reported in this paper was supported by the Jacobs Family Endowed Chair fund for SD. The authors would like to thank Brian Khan for his clinical guidance during the study. The authors would like to thank Melissa Gellman, Russell Shimada, and Victoria Harris from the University of California, San Diego Health Population Health Services Organization for their support during the study.

Data Availability

The data sets generated and analyzed during this study are not publicly available due to restrictions in the informed consent form.

Conflicts of Interest

JL, PHC, and SD are cofounders of CIPRA.ai Inc, a start-up company formed out of the University of California, San Diego, which has licensed the intervention technology presented in this paper. PA reports no conflict of interest.

Multimedia Appendix 1

Histogram showing the number of recommendations adhered to based on their difficulty rating. The average difficulty rating for recommendations that were followed was 1.97, indicating lower difficulty, whereas the average for those not followed was 3.67, indicating higher difficulty. [PNG File, 109 KB - cardio_v8i1e51916_app1.png]

Multimedia Appendix 2

Participants’ responses to the study experience survey. This survey asked patients to rate the difficulty level of completing the study tasks, how useful they found the recommendations, and their experience using the app. [PNG File, 59 KB - cardio_v8i1e51916_app2.png]

References

2. Hypertension cascade: hypertension prevalence, treatment and control estimates among US adults aged 18 years and older applying the criteria from the American College of Cardiology and American Heart Association’s 2017 hypertension guidelines.


Abbreviations
AI: artificial intelligence
API: Application Programming Interface
BP: blood pressure
**DBP:** diastolic blood pressure  
**ML:** machine learning  
**PCP:** primary care physician  
**PHSO:** Population Health Services Organization  
**SBP:** systolic blood pressure

---

Edited by A Mavragani; submitted 24.08.23; peer-reviewed by Y Jeem, J Cheng, P Washington; comments to author 14.11.23; revised version received 29.01.24; accepted 09.04.24; published 28.05.24.

Please cite as:  
Leitner J, Chiang PH, Agnihotri P, Dey S  
The Effect of an AI-Based, Autonomous, Digital Health Intervention Using Precise Lifestyle Guidance on Blood Pressure in Adults With Hypertension: Single-Arm Nonrandomized Trial  
JMIR Cardio 2024;8:e51916  
URL: https://cardio.jmir.org/2024/1/e51916  
doi:10.2196/51916  
PMID:38805253

© Jared Leitner, Po-Han Chiang, Parag Agnihotri, Sujit Dey. Originally published in JMIR Cardio (https://cardio.jmir.org), 28.05.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.